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Abstract	
Background:	Vertical	GBS	transmission	is	the	prerequisite	for	early-onset	disease.	Disease	
protection	is	associated	with	maternally-derived	anti-GBS	antibody.	This	study	investigates	
the	correlation	between	serotype-specific	functional	antibody	in	cord	sera	and	
maternal/infant	GBS	colonisation,	as	a	surrogate	marker	of	GBS	colonisation	and	thus	
disease	protection.		
Methods:	750	Gambian	mother/infant	pairs	were	followed	to	day	60-89	postpartum.	
Maternal/infant	GBS	colonisation	was	determined	by	culture	and	polymerase	chain	reaction.	
Cord	and	infant	serum	were	collected	for	functional	antibody	concentrations,	analysed	by	
flow	cytometry.		
Results:	Maternal	colonisation	was	33.7%;	serotype	(ST)	V	was	most	prevalent.	Functional	
antibody	concentration	was	lower	in	colonised-	than	in	non-colonised	mother/infant	pairs	at	
birth	(STIa	(p<0.001),	STII	(p<0.001),	STIII	(p<0.001)	and	STV	(p<0.001)).	Mother-
colonised/infant-non-colonised	pairs	had	significantly	lower	functional	antibody	
concentration	than	non-colonised	mother/infant	pairs	against	STIa	(p=0.001),	STII	(p=0.001),	
STIII	(p<0.001)	but	not	STV	(p=1.0).	Persistently	colonised	infants	had	lower	functional	
antibody	concentration	than	non-colonised	infants	against	STII	(p=0.04)	and	STV	(p=0.01).	
Reduced	infant	colonisation	risk	was	associated	with	functional	antibody	concentration	
above	the	75th	centile	against	STIa	(p<0.001),	STII	(p<0.001),	STIII	(p=0.01)	and	STV	
(p<0.001).	A	ST-dependent	threshold	was	observed	above	which	infants	were	non-colonised	
at	birth.	
Conclusions:	Higher	concentrations	of	functional	maternally-derived	antibodies	are	
associated	with	a	decreased	risk	of	GBS	colonisation	in	infants	up	to	day	60-89	of	life.	
Enhancing	maternally-derived	antibody	concentrations	through	vaccination	may	reduce	
infant	colonisation	and	so	reduce	the	risk	of	GBS	disease.		
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Chapter	1	-	Background	
1.1.	General	Introduction	
Globally,	neonatal	mortality	remains	unacceptably	high,	with	little	change	in	
the	death	rate	in	the	first	28	days	of	life,	despite	reductions	in	under-5	mortality	of	
up	to	50%	since	1990.(1)	In	2014,	neonatal	deaths	accounted	for	44%	of	all	deaths	in	
children	under	5	with	neonatal	infection	accounting	for	over	a	third	of	all	deaths.(1)	
(Figure	1).		
Figure	1	-	Causes	of	neonatal	mortality	as	a	proportion	of	all	under-5	mortality	
	
Adapted	from	World	Health	Organisation,	Every	Newborn	2015(1)	and	Waters	et	al.	2011(2)		pie	chart	
demonstrates	%	of	neonatal	deaths,	first	pull	out	indicates	causes	of	neonatal	deaths,	second	pull	out	
indicates	main	causes	of	neonatal	sepsis/meningitis	and	pneumonia.	
	
Group	B	Streptococcus	(GBS)	remains	the	leading	cause	of	neonatal	mortality	
in	the	United	Kingdom	(UK)	(0.5/1000	live	births)(3)	and	the	United	States	of	
America	(USA)	(0.34-0.37/1000	live	births)(4),	with	long-term	adverse	
neurodevelopmental	outcomes	in	up	to	50%	of	survivors.(5)	In	low-	and	middle-
income	countries,	little	is	known	about	the	role	of	GBS	in	these	deaths.(6)	
GBS	 acquisition	 occurs	 through	 vertical	 transmission	 in	 15%-50%	 of	 infants	
born	to	a	vaginally/rectally	colonised	mother.	Maternal	colonisation	is	a	prerequisite	
Group	B	Streptococcus	
Escherischeria	coli	
Staphylococcus	aureus	
Streptococcus	pneumoniae	
Klebsiella	species	
Pseudomonas	species	
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for	early	onset	(EO)	and	a	risk	factor	for	late	onset	(LO)	disease.(4,	7)	EO-GBS	disease	
can	be	prevented	by	intrapartum	antibiotics	(IAP)	and,	in	a	number	of	resource-rich	
countries	 EO-GBS	 disease	 has	 become	 significantly	 less	 common	 following	 the	
introduction	of	IAP	strategies.(4,	8)	These	strategies	include	both	universal	and	risk-
based	screening	of	pregnant	women.	In	the	United	States	of	America	(USA)	women	
over	35	weeks	of	pregnancy,	or	those	 in	 labour	prior	to	35	weeks	are	screened	for	
GBS	and	if	GBS	is	identified	they	are	offered	high	dose	intravenous	benzylpenicillin	in	
labour.(7)	This	strategy	is	thought	to	be	the	reason	for	the	rapid	decline	in	EO-GBS	
disease	 and	 GBS-associated	 mortality	 since	 the	 first	 introduction	 of	 guidelines	 in	
1996.	 However,	 there	 is	 much	 debate	 about	 the	 efficacy	 of	 IAP	 protection	 and	 a	
recent	 Cochrane	 review	 found	 high	 levels	 of	 potential	 bias	 in	 studies	 reporting	
efficacy	of	IAP	as	an	intervention	to	reduce	GBS	disease.(9)	Whilst	the	report	found	
evidence	for	a	reduction	in	EO-GBS	disease,	there	was	no	evidence	of	a	reduction	in	
all	cause	or	GBS-associated	mortality	or	LO-GBS	disease.(9)	The	United	Kingdom	(UK)	
National	 Screening	 Committee	 examined	 the	 evidence	 for	 the	 prevention	 of	 GBS	
disease	 and,	 in	 contrast	 to	 the	 USA,	 recommended	 that	 routine	 screening	 of	 all	
pregnant	women	should	not	be	 the	part	of	UK	antenatal	 care.(3)	 In	 resource-poor	
countries	 IAP	 use	 poses	 additional	 logistical	 and	 financial	 problems	 and	 is	 poorly	
implemented.(10,	11)	
A	maternal	vaccine	would	be	effective	in	preventing	EO-	and	LO-GBS	disease	
via	 placental	 anti-GBS	 antibody	 transfer,	 as	 well	 as	 protecting	 the	mother	 against	
puerperal	 GBS	 sepsis.	 There	 are	 several	 capsular	 polysaccharide	 (CPS)	 conjugate	
vaccine	candidates	for	maternal	vaccination	in	development	to	prevent	both	EO-	and	
LO-GBS	disease.	These	CPS-conjugate	vaccines	 include	serotypes	(STs)	 Ia,	 Ib	and	III,	
	 18	
based	on	epidemiological	data	from	the	UK,	USA	and	South	Africa.(12,	13)	However,	
several	 obstacles	 exist	 in	moving	 the	most	 advanced	 vaccine	 into	 phase	 III	 clinical	
trials.	The	first	is	that,	given	the	relative	rarity	of	GBS	disease	in	Europe	and	the	USA,	
large	numbers	of	 infants	would	need	to	be	recruited	to	determine	vaccine	efficacy	
(at	an	 incidence	rate	of	1/1000	live	births	 it	 is	estimated	that	60,000	infants	would	
be	required	to	show	an	effective	vaccine).	Secondly,	there	is	practically	no	evidence	
outside	 of	 the	 USA,	 Europe	 and	 South	 Africa	 regarding	 disease-causing	 and	
colonising	 STs.	 This	 poses	 additional	 dilemmas	 in	 establishing	 vaccine	 efficacy	 in	
those	areas	of	the	world	where	the	burden	of	neonatal	 infection	is	highest.	Finally,	
obstacles	exist	in	determining	what	concentration	of	antibody	is	required	to	protect	
the	infant	for	the	duration	of	the	at-risk	period	(first	three	months	of	life),	as	there	
are	 currently	 no	 internationally	 recognised	 standards	 from	 which	 to	 interpret	
individual	study	results.	
As	 colonisation	 is	 the	 prerequisite	 for	 EO-GBS	 disease,	 this	 thesis	 seeks	 to	
introduce	 studies	 that	 attempt	 to	 address	 the	 efficacy	 of	 maternal	 antibody	 in	
reducing	 and	 eliminating	 colonisation	 in	 the	 infant	 by	 determining	 the	 functional	
antibody	concentration	that	prevents	infant	colonisation.		
	
1.2.	Group	B	Streptococcus	
GBS	is	a	Gram-positive	bacterium	that	causes	invasive	infection	and	can	be	
fatal	to	both	mothers	and	their	infants.(4,	11)	GBS	are	oxidase-negative,	catalase-
negative	cocci	occurring	in	chains	and	are	facultative	anaerobes	that	are	
serologically	classified	on	the	basis	of	cell	wall	polysaccharide	antigens.(14)	GBS	is	an	
encapsulated	bacterium	and	to	date	10	STs	have	been	identified.(15)	GBS	can	
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colonise	the	vagina,	rectum	and	the	intestines	of	pregnant	women	and	can	be	
vertically	transmitted	to	their	neonates	during	delivery.	Up	to	30%	of	women	carry	
GBS	in	the	vagina	or	rectum	without	it	causing	problems	or	symptoms.(8,	16,	17)	
However,	GBS	may	cause	fatal	infections	including	meningitis,	sepsis	and	pneumonia	
throughout	the	neonatal	period.(18,	19)		Vaginal	colonisation	in	labour	is	the	major	
risk	factor	for	neonatal	GBS	disease.		
1.2.1.		Global	epidemiology	of	invasive	GBS	disease	
GBS	invasive	disease	has	two	forms,	EO,	within	six	days	of	life,	which	
commonly	presents	as	pneumonia	or	sepsis	and	LO,	which	presents	after	day	six,	
often	with	meningitis	and	focal	infections	(4).		
1.2.1.1.	GBS	in	high-income	countries	
In	the	USA	and	Europe,	GBS-STs	causing	invasive	disease	are	predominantly	
ST	Ia,	Ib,	II,	III	and	V.(8,	20)	EO-GBS	disease	is	due	to	several	STs	(Ia,	Ib,	II,	III	and	V	in	
70%	of	cases)	while	LO-GBS	disease	is	predominantly	due	to	STIII.(20)	Since	the	
introduction	of	IAP	in	the	USA	rates	of	EO-GBS	disease	have	declined	from	1.7	per	
1000	live	births	in	the	1990s	to	0.34-0.37	per	1000	live	births	in	2014	(Figure	2).(4)	
However,	over	the	same	time	period	IAP	has	had	little	effect	on	LO-GBS	disease	
(Figure	2).	
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Figure	2	-	Incidence	of	early-	and	late-onset	invasive	GBS	disease	in	the	USA	
	
Active	Bacterial	Core	surveillance	areas	1990-2014	and	activities	for	prevention	of	GBS	disease	
(adapted	from	Active	Bacterial	Core	Surveillance	2015)(21).		Blue	line=	early	onset	disease,	purple	
line=late	onset	disease	
	
1.2.1.2.	GBS	in	low	and	middle-income	countries	(LMIC)	
Although	 the	 epidemiology	 of	 GBS	 in	 high-income	 countries	 is	 well	
documented,	its	contribution	to	the	burden	of	neonatal	infection	in	LMIC	has	proven	
more	 difficult	 to	 assess.(10)	 Six	 studies	 from	 five	 countries	 (Malawi,	 South	 Africa,	
Kenya,	Nigeria,	Zimbabwe)(22-27)	report	estimates	of	invasive	neonatal	disease	with	
an	overall	pooled	disease	rate	of	4%	of	neonatal	infection	(95%	CI	1-6).	Estimates	of	
LO-GBS	disease	in	LMIC	range	from	1-4	per	1000	live	births.(28)	Three	studies	report	
STs	 of	 disease-causing	 isolates	 (22,	 24,	 26)	 and	 a	 random	 effects	 meta	 analysis	
demonstrated	 GBS	 ST	 III,	 Ia	 and	 V	 accounted	 for	 84%	 of	 EO-	 and	 96%	 of	 LO-GBS	
disease	in	African	countries,	although	high	heterogeneity	(I2	of	99.7%)	prevents	any	
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extrapolation	of	the	data	to	other	populations	(Figure	3).	Conversely,	Asian	studies	
have	reported	a	much	lower	incidence.(29-31)	
Figure	3	-	Random	effects	meta-analysis	of	percentage	of	GBS	disease	caused	by	
GBS	ST	Ia,	III	and	V	in	African	countries	2000-2015	
	
Berkely	et	al.	 included	all	 children	admitted	with	 fever	between	August	1998	and	Juiy	2002;	Gray	et	al.	 included	all	children	
with	a	positive	blood	culture	for	GBS	between	May	2004	and	June	2005;	Madzinvandiha	et	al.	included	all	positive	GBS	cultures	
identified	 in	 the	 laboratory	between	January	2004	and	December	2008	as	part	of	a	prospective	cohort	 trial	of	chlorhexidine	
wash	in	labour	to	prevent	GBS	disease.	All	studies	used	BACTEC	automated	blood	culture	systems	to	identify	positive	cultures	
followed	by	latex	agglutination	to	identify	GBS.	
	
Under-identification	 and	 under-reporting	 of	 cases	 and	 deaths	 appears	 very	
likely	 in	 some	study	 settings,	especially	where	 it	 is	difficult	 to	access	healthcare.	A	
substantial	 proportion	 of	 births	 in	 sub–Saharan	 Africa	 (42-65%),	 India	 (53%)	 and	
Bangladesh	(85%)	 for	example,	occur	outside	health	 institutions.	 In	contrast,	South	
Africa,	which	 reports	 one	 of	 the	 highest	 incidences,	 also	 has	 a	 high	 proportion	 of	
hospital-based	births	(89%).(28)	Despite	GBS	colonisation	rates	in	the	Gambia	in	the	
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late	 1990’s	 of	 22%(17),	 in	 a	 separate	 study,	Mulholland	 et	 al.	 (1999)	 reported	 no	
neonatal	GBS	disease.(32)	However,	this	study	excluded	neonates	dying	before	day	
two	of	life	-	a	number	of	whom	may	have	succumbed	to	GBS	disease.	These	fatalities	
would	result	in	inaccurate	measures	of	EO-GBS	disease	incidence.		
1.2.2.	Global	epidemiology	of	colonising	GBS	
To	estimate	 the	 true	burden	of	GBS	disease,	 it	may	be	useful	 to	determine	
the	maternal	colonisation	rate	by	country,	as	maternal	colonisation	is	the	main	risk	
factor	 for	 EO-GBS	 disease.	 In	 contrast	 to	 GBS	 invasive	 disease	 incidence	 studies,	
maternal	 GBS	 colonisation	 studies	 reported	 similar	 colonisation	 rates	 to	 those	 of	
high-income	 countries	 (Middle	 East/North	 Africa,	 22%;	 Asia/Pacific,	 19%;	 Sub-
Saharan	 Africa,	 19%;	 India/Pakistan,	 12%;	 and	 Americas,	 14%)	 (33)	 and	 European	
pooled	incidence	of	21.3%.(16)	It	is	important	to	note	that	there	is	some	variation	in	
colonising	GBS	STs	by	geographical	region	with	GBS	ST	Ia,	III	and	V	most	prevalent	in	
the	USA	and	Europe,	GBS	STIII	and	V	in	African	countries	with	GBS	STIII,	V	and	VIII	in	
Asia.(34)	(Figure	4)	
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Figure	4	-	Differences	in	global	colonising	serotypes	
A. Percentage	of	pregnant	women	by	country	colonised	with	STs	Ia,	Ib,	III	
	
B.	Percentage	of	pregnant	women	by	country	colonised	with	STII	&	V	
	
C. Percentage	of	women	colonised	with	other	STs	(IV,	VI,	VII,	VIII,	NT)	
	
Adapted	from	Ippolito	et	al	(2010)(34).	Size	of	circles	represent	increasing	percentage	of	associated	colonising	STs.	
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1.2.2.1.	Epidemiology	of	colonising	GBS-STs	in	Africa	
A	literature	search	of	all	African	studies	that	reported	colonising	GBS	STs,	
used	carefully	defined	microbiology	methods	and	included	selective	culture	media,	
identified	four	colonisation	studies,	two	from	South	Africa(12,	26),	one	from	
Gambia(17)	and	one	from	Zimbabwe.(25)	All	studies	identified	reported	colonisation	
rates	of	GBS	in	pregnant	women	on	at	least	one	occasion.	Colonisation	rates	in	
pregnant	women	varied	between	African	countries	(22%	in	Gambia	to	30.9%	in	
South	Africa).(12,	17)	In	a	random	effects	meta-analysis	overall	colonisation	rate	was	
26%	(CI	21-31%),	although	data	were	quite	heterogeneous	(I2=85%).	Colonising	GBS	
ST	prevalence	also	varied	between	countries	with	GBS	STs	Ia,	III	and	V	most	common	
in	South	Africa	and	Zimbabwe	(South	Africa:	Ia	(39%),	III	(33%)	and	V	(12%);	
Zimbabwe:	III	(42%),	V	(37%)	and	Ia	(11%).(12,	25)%)).(12,	25)	The	only	West	African	
Study	(from	the	Gambia)	indicated	STV	predominance	(38%)	followed	by	II	and	I	with	
low	GBS	STIII	(6%).(17)	Overall,	random	effects	meta	analysis	of	colonising	GBS	STs	in	
African	studies	demonstrated	predominance	of	GBS	STIa	(30%	CI	15-44),	followed	by	
III	(26%	CI	2-50),	V	(22%,	CI	1-43)	II	(16%	CI	1-31)	with	low	prevalence	of	STIb	(5%	CI	
3-8).		
	
1.3.	Disease	pathogenesis	in	GBS	infection	
EO-GBS	infection	may	occur	intrapartum	by	inhalation	of	the	GBS	bacteria	as	
the	infant	passes	through	the	birth	canal	or	ascending	transmission	following	
premature	rupture	of	the	mother’s	membranes	prior	to	labour.(35)	The	GBS	is	then	
able	to	multiply	in	the	amniotic	fluid	and	colonise	the	foetal	skin	and	mucous	
membranes.(35,	36)	It	is	also	thought	that	GBS	at	high	enough	inoculum	may	cross	
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the	placenta,	possibly	explaining	why	some	infants	born	by	caesarian	section	may	
also	develop	EO-GBS	disease.(37)	EO-GBS	disease	presents	within	24	hours	in	90%	of	
cases(38),	primarily	due	to	aspiration	into	the	infant	lungs	causing	pneumonia	and	
subsequent	septicaemia	in	27-87%	of	cases.(39)	LO-GBS	disease	may	occur	from	
postnatal	exposure	to	GBS	or	via	breast	milk	and	presents	up	to	three	months	of	age,	
most	commonly	as	meningitis	in	40-60%.(4,	10,	40)		
1.3.1.	GBS	colonisation	of	maternal	rectum	and	vagina	and	cellular	invasion	
The	first	step	in	the	pathogenesis	of	GBS	infection	is	the	ability	of	the	bacteria	
to	adhere	to	mucosal	surfaces	and	compete	with	normal	flora.	Various	studies	have	
demonstrated	that	GBS	can	efficiently	adhere	to	the	vaginal	and	rectal	mucosal	
surfaces	(41),	placenta	(42),	respiratory	epithelium	(43,	44)	and	blood-brain-
barrier.(41,	45)	Following	adherence	to	epithelial	cells,	three	mechanisms	have	been	
determined	for	GBS	that	facilitate	host	cell	invasion,	subsequent	systemic	
dissemination	and	the	ability	to	cross	the	blood-brain-barrier:	intracellular	invasion,	
cytolytic	injury	and	induction	of	host	inflammatory	responses	(Figure	5).(46)	The	
process	involves	the	ability	of	GBS	to	mediate	host-cell	reactions	and	to	interfere	
with	innate	immune	clearance	mechanisms	via	a	combination	of	surface	and	
secreted	virulence	factors	that	are	described	in	more	detail	below.	
1.3.1.1.	Surface	Proteins	that	aid	GBS	adherence	and	cellular	
invasion	
In	order	to	maintain	colonisation	and	cell	invasion	in	the	presence	of	the	host	
immune	response,	GBS	appears	to	have	developed	a	series	of	adaptations	to	its	
surface	proteins	that	aid	epithelial	adherence,	promote	cellular	invasion	and	prevent	
complement	deposition.	Alpha	C	protein	(ACP),	GBS	immunogenic	bacterial	adhesion	
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(BibA),	pili,	Fibrinogen-binding	proteins	A	and	B	(FbsA/B),	serine-rich	domain	repeat	
protein	1	(Srr1),	laminin-binding	protein	(Lmb),	pneumococcal	adhesion	and	
virulence	protein	A	(PavA)	and	lipoteichoic	acid	(LTA)	mediate	GBS	binding	to	the	cell	
surface	and	fibrinogen	and	fibronectin	in	the	extracellular	matrix	(ECM)	and	enhance	
cellular	invasion	(Figure	5).(47)	
GBS	secretes	hyaluronate	lysase,	which	causes	damage	to	placental	tissue	
that	may	promote	EO-GBS	disease.(48)	Lung	epithelial	cell	damage	is	thought	to	be	
caused	by	β-haemolysin/cytolysin,	which	results	in	interleukin	8	(IL8)	secretion	
causing	further	cellular	damage	and	invasion	of	lung	cells.(49)	This	mechanism	is	
inhibited	by	human	surfactant	and	therefore	may	be	why	there	is	increased	risk	of	
GBS	disease	observed	in	premature	infants	who	are	known	to	be	surfactant-
deficient.(50)	It	is	also	possible	that	GBS	is	able	to	enter	epithelial	cells	by	
endocytosis	and	transcytosis,	which	can	enable	GBS	to	cross	the	blood-brain	barrier	
causing	subsequent	meningitis.(51,	52)		
1.3.1.2.	Hypervirulence		
A	substantial	proportion	of	LO-GBS	meningitis	is	thought	to	be	associated	
with	GBS	STIII.(53)	There	are	a	limited	number	of	GBS	STIII	clonal	complexes.	The	
main	sequence	type	(st)	associated	with	neonatal	meningitis	is	st-17	and	it	is	
therefore	designated	as	"the	hypervirulent	clone".	A	novel	surface	protein	found	on	
st-17	(hypervirulent	GBS	adhesion,	HvgA)	has	been	implicated	in	more	efficient	
adherence	to	epithelial	cells	and	microvascular	endothelial	cells	such	as	those	of	the	
blood-brain-barrier.	This	protein	may	contribute	to	the	evolution	of	GBS	meningitis	
in	neonates.(54)	
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1.3.2.	Interference	with	opsonophagocytosis	
Polymorphonuclear	lymphocyte	(PMN)-mediated	killing	is	critical	in	the	host	
defense	against	GBS.(55)	For	effective	killing,	the	organism	needs	to	be	opsonised	
with	complement	and	specific	antibody.	Complement	deposition	is	critical	for	
opsonophagocytosis	of	GBS.(55)	In	the	case	of	GBS,	several	secreted	and	surface	
factors	interact	to	impair	the	classical	and	alternative	complement	pathway,	thus	
impairing	uptake	by	PMN	and	intracellular	killing.	
1.3.2.1.	The	GBS	capsular	polysaccharide	(CPS)	
Human	isolates	of	GBS	express	a	CPS,	a	major	virulence	factor	that	helps	the	
microorganism	evade	opsonophagocytosis.(56)	Isolates	of	GBS	can	be	divided	into	
ten	CPS	STs	(Ia,	Ib,	II,	III,	IV,	V,	VI,	VII,	VIII,	IX),	each	antigenically	and	structurally	
unique.	In	1974,	Baker	et	al.	demonstrated	that	while	all	GBS	STs	were	capable	of	
causing	neonatal	infection,	GBS	STIII	isolates	were	significantly	increased	amongst	
infants	with	GBS	meningitis.(57)		
The	CPS	of	GBS	is	poorly	immunogenic,	especially	GBS	STIII,	and	aids	bacterial	
evasion	by	masking	surface	proteins.	All	GBS	STs	contain	a	terminal	sialic	acid	
molecule,	similar	to	mammalian	host	cell	sialic	acid	that	impairs	surface	deposition	
of	opsonically	active	complement	C3	on	the	bacterial	surface	blocking	the	alternative	
complement	pathway.(58)	
1.3.2.2.	Surface	proteins	that	interfere	with	complement	deposition	
In	addition	to	aiding	cellular	adhesion	and	invasion,	surface	proteins	have	
been	implicated	in	the	ability	of	GBS	to	evade	opsonisation	with	complement.	Three	
routes	can	activate	the	complement	pathway:	the	classical	pathway,	the	lectin	
binding	pathway	and	the	alternative	pathway	that	differ	in	their	effector	
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mechanisms	and	pathways	of	activation.	The	final	common	pathway	is	the	cleavage	
of	C3	to	form	C3b	that	attaches	to	the	bacteria	surface.	Regulation	of	complement	is	
tightly	controlled	by	factor	I,	factor	H	and	C4b	binding	protein.	Several	proteins	on	
the	surface	of	GBS	have	been	implicated	in	inactivation	or	evasion	of	the	
components	of	these	complement	pathways.	For	example,	in	the	absence	of	C5a-
peptidase,	which	cleaves	C5a	(a	chemoattractant	of	neutrophils,)	lower	levels	of	
neutrophils	were	found	both	in	in	vitro	models	(59)	and	in	neonatal	disease.(35)	C5a	
peptidase	is	produced	by	most	GBS	STs	and	is	therefore	a	potential	target	against	
which	a	vaccine	could	be	directed.	When	conjugated	with	GBS	STIII	in	a	CPS	protein-
conjugate	vaccine	it	induced	antibody	responses	that	are	cross	protective	in	mice	for	
other	GBS	STs.(60)	However,	C5a	peptidase	is	not	expressed	by	GBS	STV	(61),	
limiting	its	use	where	GBS	STV	is	most	prevalent.		Additionally,	a	recently	discovered	
complement	inhibitory	protein	(CIP)	was	found	to	inhibit	both	the	classical	and	lectin	
binding	pathway	but	not	the	alternative	pathway.(62)	
Surface	proteins,	such	as	α-	and	β-proteins	(present	on	GBS	ST	Ia,	Ib,	II	and	V)	
are	also	thought	to	mediate	complement	deposition.	Although	a	definitive	role	for	
these	proteins	in	the	promotion	of	virulence	is	as	yet	unclear,	β-protein	may	bind	to	
the	crystallised	portion	of	IgA	at	mucosal	surfaces	and	to	protein	factor	H,	required	
for	complement	C3b	deposition.(58)	Maruvada	et	al	describe	a	streptococcal	
histidine	triad	(SHT)	surface	protein	present	in	GBS	STIII	that	also	binds	factor	H.(63)	
This	may	account	for	the	ability	of	GBS	STIII	to	bind	to	factor	H	in	the	absence	of	the	
β-protein.	
Other	surface	proteins	such	as	BibA	(which	binds	to	C3b	and	inhibits	the	
classical	complement	pathway),	Lmb	and	cell	surface	protease	((CspA),	which	binds	
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to	ECM	fibrinogen)	reduce	complement	deposition	onto	the	bacterial	surface.(47)	
Figure	5	outlines	the	GBS	capsule	and	surface	proteins	involved	in	evasion	of	innate	
immunity.	
	
Figure	5	-	The	GBS	capsule,	surface	proteins	and	secreted	toxins	
	
ABC	–	ATP-binding	cassette;	AMP	–	antimicrobial	peptide;	BibA	–	Group	B	Streptococcus	immunogenic	
bacterial	adhesion	A;	CIP	–	complement	inhibitory	protein,	CspA	–	cell	surface	protease	A;	FbsA	–	
fibrinogen-binding	protein;	Lmb	–	laminin-binding	protein;	PavA-	pneumococcal	adhesion	and	
virulence	protein	A;	PbP	–	penicillin-binding	protein;	pilB	–	pilus	protein	island	B;	SHT	–	streptococcal	
histidine	triad;	SodA	–	superoxide	dismutase.	
		
1.3.2.3.	Secreted	toxins	that	cause	local	inflammation	and	interfere	
with	phagocytic	killing	
GBS	secretes	a	variety	of	toxins	and	virulence	factors	(invasins),	promoting	an	
inflammatory	response	that	may	account	for	the	rapid	progression	of	GBS	disease	in	
neonates.		
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Once	phagocytosis	has	occurred,	GBS	is	further	able	to	prevent	killing	by	
neutralising	the	result	of	the	phagocyte	oxidative	burst.	GBS	has	both	an	
endogenous	supply	of	glutathione(64)	and	secretes	the	enzyme	superoxide	
dismutase	A	(SodA)	(65)	to	neutralise	superoxide	ions.	GBS	also	secretes	a	carotinoid	
pigment	that	is	genetically	similar	to	β-haemolysin/cytolysin	that	is	able	to	neutralise	
the	effective	of	superoxides.(66)		
The	activity	of	antimicrobial	peptides	(AMP)	may	be	suppressed	by	GBS	due	
to	D-alanine	residue	in	the	GBS	cell	wall	that	reduces	the	surface’s	negative	charge	
and	thus	affinity	to	cationic	peptides	such	as	AMPs.	Penicillin	binding	protein	(PbP)	in	
the	GBS	cell	surface	additionally	enhances	resistance	to	AMP	secreted	by	
phagocytes.	Pilus	protein	island	B	(pilB)	is	thought	to	prevent	AMP-mediated	killing	
and	increase	resistance	to	macrophages	and	neutrophils.(47)		
	
1.4.	The	role	of	breast	milk	in	late-onset	GBS	infection	
It	has	been	suggested	that	GBS	typically	colonises	the	infant’s	oropharyngeal	
mucosa	 through	 contact	 with	 maternal	 vaginal/rectal	 secretions	 at	 the	 time	 of	
birth.(67)	However,	Butter	and	De	Moor	also	demonstrated	 infant	nasopharyngeal	
colonisation	at	 the	 same	 time	as	GBS	was	cultured	 from	the	mother’s	breast	milk,	
suggesting	 this	 as	 another	mechanism	 of	 acquisition.(68)	 Despite	 this	 finding,	 the	
majority	of	breastfed	infants	of	mothers	colonised	with	GBS	do	not	develop	LO-GBS	
disease	 (69),	 even	after	proven	GBS	mastitis	 and	 several	months	of	breastfeeding.	
Breast	milk	 is	 known	 to	 have	many	 protective	 properties,	 including	 antibody	 that	
should	protect	infants	from	both	EO-	and	LO-GBS	disease.(40)	
Therefore,	 there	appears	 to	be	a	contradiction	between	 the	possibility	 that	
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breast	milk	might	 cause	 LO-GBS	 disease	 in	 some	 infants	 yet	 protects	 the	majority	
from	acquiring	GBS	disease.	The	mechanisms	by	which	GBS	 is	 transmitted	 through	
breast	milk,	or	how	breast	milk	may	protect	from	infection,	are	not	fully	understood.	
This	knowledge	gap	may	partly	result	from	the	fact	that	breast	milk	of	GBS-colonised	
mothers	is	not	routinely	screened,	even	in	donor	breast	milk	in	neonatal	breast	milk	
banks.(70)	It	is	however	important	to	understand	what	factors	in	breast	milk	may	be	
involved	 in	either	protection	 from	disease	or	 transmission	of	GBS	 infection.	This	 is	
especially	true	for	premature	infants	who	are	a	high-risk	group	and	in	LMICs	where	
breastfeeding	is	the	only	sustainable	infant	feeding	option.	
	
1.5.	GBS	vaccine	development	
Various	monovalent	and	trivalent	vaccines	have	undergone	clinical	trials	
since	the	early	1970’s.	Here	I	describe	the	developments	leading	up	to	the	proposed	
phase	III	trial	of	the	current	pentavalent	CPS-protein-conjugate	vaccine.		
1.5.1.	Animal	Studies	
Three	decades	of	research	have	been	spent	assessing	the	immunogenicity,	
safety	and	effectiveness	of	GBS	vaccine	formulations	in	animal	and	healthy	human	
models.	Studies	of	CPS	protein-conjugate	vaccines	against	GBS	ST	Ia	and	Ib	(71)	
identified	protection	from	invasive	disease	in	mouse	pups.	Similar	findings	were	
present	for	monovalent	GBS	ST	II	(72),	III	(73-77)	and	V	(78)	vaccines	and	a	
tetravalent	vaccine	(79)	with	good	in	vitro	opsonophagocytosis	mediated	by	
neonatal	mouse	serum	following	maternal	vaccination.	These	mouse-neonatal	
challenge	models	have	also	been	useful	to	observe	the	concentration	and	function	of	
transplacentally	acquired	antibody.(76,	77)	Additionally,	animal	models	have	served	
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to	derive	protective	concentrations	of	antibody	that	would	possibly	confer	
protection	from	invasive	disease.(73-77)		
1.5.2.	Human	Studies	
Originally,	GBS	vaccine	development	was	based	on	a	CPS	vaccine.	However,	
the	CPS	vaccine	was	poorly	immunogenic	with	GBS	ST	Ia	and	III,	especially	if	women	
had	low	pre-immunisation	antibody	concentrations	and	less	than	60%	of	pregnant	
women	developed	an	antibody	response	post-vaccination.(80)	A	protein-conjugate	
vaccine	against	GBS	overcomes	the	poor	immunogenicity	of	the	GBS-CPS	by	inducing	
a	T-cell	dependent	immune	response.(81)		
Monovalent	tetanus-toxoid	conjugate	vaccines	to	GBS	ST	Ia,	Ib	(82),	II,	III	(83)	
and	V	have	been	tested	in	healthy,	non-pregnant	women.	Maximal	antibody	
responses	to	all	GBS	STs	peaked	at	4-8	weeks	post-vaccination	with	antibody	
persistence	between	26-52	weeks	post-vaccination.(84)	The	tetanus-toxoid	
conjugate	GBS	vaccine	against	STIII	has	also	been	tested	in	a	small	sample	of	
pregnant	women	between	30-32	weeks	gestation.	In	this	study,	infants	were	found	
to	have	lower	geometric	mean	concentration	(GMC)	of	antibody	at	one	month	and	
two	months	than	at	birth	(50%	and	30%	respectively),	although	opsonophagocytosis	
was	observed	up	to	two	months	of	age.(85)	
1.5.3	Surface	protein	vaccines		
CPS-	conjugate	vaccines	are	not	without	their	drawbacks	and	some	have	
argued	that	there	is	increased	risk	of	interaction	with	other	vaccines	and	possible	
impairment	of	vaccine	responses	when	conjugate	vaccines	are	used.	There	is	also	
the	possibility	of	the	emergence	of	non-vaccine	GBS	STs	following	vaccination	
containing	limited	GBS	STs,	as	seen	with	Streptococcus	pneumoniae	(86)	and	a	loss	of	
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natural	boosting	due	to	decreased	exposure	to	GBS	in	vaccinated	women	if	the	
vaccine	has	an	impact	on	maternal	colonisation.	A	further	limitation	to	the	
development	of	a	CPS-protein	conjugate	vaccine	is	the	lack	of	global	GBS	ST	data.	It	
is	likely	that	a	multivalent	CPS-protein	conjugate	vaccine	will	be	needed.	However,	
without	epidemiological	data	about	colonising	and	disease-causing	GBS	STs,	the	
applicability	of	a	single	global	vaccine	to	different	epidemiological	settings	remains	
unclear.		
One	way	of	overcoming	these	limitations	would	be	to	develop	a	surface	
protein	vaccine.	The	ideal	surface	protein	candidate	would	be	one	present	on	the	
surface	of	all	GBS	STs	such	as	the	pilus	proteins	or	ACP	and	resistance	to	proteases,	
immunity,	group	B	(Rib)	proteins.	A	phase	I	trial	of	an	ACP-Rib	protein-only	vaccine,	
which	could	protect	against	up	to	95%	of	GBS	isolates	is	currently	underway	in	
Northern	Ireland	(Neostrep	2015).(87)	
The	use	of	genomics	to	identify	candidate	proteins	has	revolutionised	vaccine	
development	in	the	past	ten	years.	Work	such	as	that	at	the	GlaxoSmithKline	(GSK,	
formerly	Novartis)	laboratories	in	Siena	has	identified	four	proteins	that	are	common	
to	GBS	disease	causing	STs:	the	pilus	proteins	(88,	89)	and	the	Sip	protein.(90)	It	has	
been	suggested	that,	by	extrapolating	the	data	from	mouse	models,	pilus	proteins	
could	protect	against	94%	of	GBS	strains.(89)		
	
1.6.	Neonatal	Immunity	and	GBS	
1.6.1.	Neonatal	immune	response	
The	physiological	demands	placed	on	the	neonatal	immune	system	include:	
to	protect	against	infection;	avoid	harmful	Th1	responses	that	would	induce	an	
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alloimmune	reaction	between	mother	and	infant	and	mediate	the	transition	to	
extra-uterine	life	and	colonisation	with	microorganisms	on	the	skin	and	
gastrointestinal	tract.(91,	92)	The	bias	towards	Th2	responses	(81,	91)	means	that	
the	neonatal	B	cells	do	not	respond	optimally	to	the	GBS	CPS	and	therefore	little	
antibody	is	produced	to	neutralise,	opsonise,	induce	phagocytosis	or	activate	
complement,	all	vital	steps	in	preventing	GBS	disease.	
1.6.2.	Neonatal	T-	and	B-Cell	responses	
Although	infant	immune	responses	are	present	at	birth,	early	life	responses	
are	thought	to	be	weaker	and	of	shorter	duration	than	mature	immune	responses,	
leaving	infants	vulnerable	to	infections	in	the	absence	of	stimulation	through	
vaccination(93).	Infant	vulnerability	to	encapsulated	bacteria	such	as	GBS	is	mainly	
due	to	a	failure	to	generate	T-cell	independent	B	cell	responses	to	bacterial	
polysaccharides.(94)	These	responses	mature	over	time,	but	remain	limited	in	
children	under	18-24	months	of	age.	(95-98)	Neonates	have	reduced	marginal	zone	
macrophages	that	are	required	for	antigen	recognition	and	subsequent	antibody	
production,	which	reduces	B	cell	activation	resulting	in	fewer	plasma	cells(99).	The	
reduction	in	plasma	cell	numbers	is	also	associated	with	decreased	plasma	cell	
survival,	which	may	also	be	why	there	is	limited	antibody	persistence	following	
antigen	challenge	and	limited	immune	memory(93).	Additionally,	neonatal	B	cells	
express	lower	levels	of	CD40	and	other	co-stimulatory	molecules,	which	limits	the	
response	of	the	neonatal	immune	system	to	CD40L	and	IL10	expressed	by	T	
cells(100).	(Table	1)	In	addition	to	T-cell	functional	and	structural	immaturity,	infants	
are	deficient	in	IL-1	and	tumour	necrosis	factor	α	(TNFα)	that	are	needed	to	optimise	
responses	to	CPS.(101,	102)	
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Table	1	-	Characteristics	of	neonatal	B	cell	responses	compared	to	healthy	adults	
(adapted	from	Siegrist	and	Aspinall)(93)	
	
Cell	type	 Characteristics	
Naive	B	cells	
	
Decreased	expression	of	cell-surface	receptors	(CD21,	
CD40,	CD80,	CD85)	
Plasma	cells	 Limited	IgG	responses	to	protein	antigens	below	12	months	
of	age	
Limited	IgG	responses	to	most	CPS	below	18-24	months	of	
age	
Limited	persistence	of	IgG	antibodies	below	12	months	of	
age	
Memory	B	cells	
	
Effective	memory	B-cell	priming	at	and	before	birth	
Progressive	diversified	IgG	repertoire	
Limited	affinity	maturation	below	4-6	months	of	age	
	
The	neonatal	adaptive	immune	response	is	impaired	during	early	life,	with	
lower	peak	antibody	levels,	affinity	and	concentration	of	IgG2	(the	predominant	
subclass	associated	with	opsonisation	of	the	bacterial	CPS	compared	to	healthy	
adults.(92,	103,	104)	
1.6.3.	The	role	of	complement	in	innate	immunity	to	GBS	
The	complement	cascade	can	be	activated	by	the	classical,	alternative	or	
mannose	binding	lectin	(MBL)	pathways	as	outlined	above.	Binding	of	the	fragment	
crystalline	(Fc)	portion	of	IgM	and	IgG	antibody	to	the	C1q	component	of	C1	
activates	the	classical	pathway	whilst	MBL	binds	directly	to	the	bacterial	surface	in	
the	absence	of	antibody	forming	a	C1-like	complex	that	initiates	the	MBL	pathway.	
The	alternative	pathway	is	activated	when	Factor	B	binds	to	circulating	C3b	directly	
to	the	bacterial	surface,	resulting	in	C3	convertase.	Common	to	all	three	pathways	is	
the	cleavage	of	C3	to	C3a	and	C3b.	C3a	is	a	potent	chemoattractant.	C3b	binds	to	cell	
surface	complement	receptors	or	via	C3	convertase	to	form	C5	convertase	to	
enhance	opsonisation	of	GBS.	GBS	opsonisation	with	complement	results	in	
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phagocytosis	without	antibody.	However,	once	antibody	binds	to	Fc	receptors	signal	
activity	between	complement	receptors	increases	and	phagocytosis	increases	
exponentially.(105)	Thus,	both	antibody	and	complement	play	a	role	in	immunity	to	
GBS	infection,	posing	unique	challenges	for	the	neonate.	
1.6.3.1.	Neonatal	complement	defects	
Several	factors	impair	the	neonatal	complement-mediated	immune	response	
to	GBS,	including	suboptimal	concentration	of	neonatal	complement.(106,	107)	As	
complement	is	vital	for	the	opsonisation	of	GBS	STIII(108),	this	lack	of	complement	
during	the	neonatal	period	contributes	to	increased	infant	susceptibility	to	disease.	
Infant	B	cells	express	less	CD21	(complement	receptor	2)	compared	to	adults,	which	
limits	the	neonatal	response	to	the	GBS	CPS-complement	complex.(81,	106,	109)		
The	antibody-complement	interaction	is	also	impaired,	with	neonates	being	
unable	to	fully	activate	the	alternative	complement	pathway	in	the	absence	of	
antibody	against	STIII.(55,	108)	However,	there	may	be	differences	between	GBS	STs	
and	the	ability	of	the	CPS	to	activate	the	alternative	complement	pathway,	as	it	has	
been	found	that	GBS	STIa	does	not	need	antibody	to	activate	complement.(110,	111)	
Taken	together	the	relative	lack	of	complement	and	functional	deficits	exacerbate	
the	inadequate	neonatal	immune	response	to	CPS	bacteria	such	as	GBS.	
	
1.7.	The	importance	of	maternal	antibody	in	GBS	disease	protection	
To	consider	maternal	antibody	as	a	means	of	protection	from	neonatal	
disease	is	not	a	new	concept.	Mothers	in	the	Faroe	Islands	who	survived	measles	
virus	in	1846	were	found	to	have	infants	who	did	not	contract	the	disease	(112)	and	
mothers	who	had	received	the	vaccinia	vaccine	in	1879	had	infants	who	did	not	
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contract	smallpox	(113),	demonstrating	the	benefit	of	passive	protection	in	the	form	
of	maternally-derived	antibody.	The	World	Health	Organisation	(WHO)	now	
recommends	maternal	vaccines	in	pregnancy	for	tetanus,	pertussis	and	inactivated	
influenza	virus.	Additional	vaccines	such	as	pneumococcal	and	meningococcal	
polysaccharide	vaccines,	inactivated	polio,	hepatitis	A	and	hepatitis	B	are	also	
considered	safe	during	pregnancy.(114)	
The	 importance	 of	 maternally-derived	 antibody	 in	 preventing	 GBS	 disease	
was	first	demonstrated	over	30	years	ago	by	the	 increased	risk	of	 infant	disease	 in	
infants	 born	 to	 women	 with	 negligible	 anti-GBS	 antibody	 concentrations.(115)	
Studies	have	shown	that	human	sera	containing	a	high	concentration	of	CPS-specific	
antibody	promoted	efficient	opsonisation	and	phagocytosis	in-vitro	and	affirmed	the	
importance	of	CPS	GBS	ST-specific	antibodies	in	disease	protection.(116)	
1.7.1.	Placental	antibody	transfer	
Studies	comparing	maternal	and	foetal	antibody	concentrations	demonstrate	
that	 anti-GBS	CPS	antibody	 is	 transferred	with	a	high	degree	of	 efficiency	after	30	
weeks	gestation.(117)		
Neonatal	IgG	antibody	is	found	to	be	higher	at	birth	than	in	the	mother	
indicating	active	transfer	across	the	placenta.(118-120)	IgG	binds	to	the	placenta	via	
receptors	to	the	Fc	portion	of	the	antibody	and	these	receptors	can	be	saturated	if	
maternal	concentrations	are	very	high.(121)	Several	studies	have	demonstrated	
significant	negative	correlations	between	maternal	concentrations	of	IgG	and	
placental	transfer	ratios	for	both	total	IgG	and	specific	IgG	against	viruses,	LPS	and	
other	antigens.(122-124)	Problems	with	placental	transfer	of	antibody	may	also	
occur	with	high	maternal	antibody	concentrations	such	as	the	
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hypergammaglobulinaemic	state	found	in	human	immunodeficiency	virus	(HIV)	
infected	women.(125,	126)	African	studies	have	reported	lower	cord/maternal	
placental	transfer	ratios	of	total	IgG	compared	to	the	UK	which	may	reflect	the	
comparatively	high	concentrations	of	maternal	antibody	in	African	populations	(113,	
122,	127),	possibly	due	to	increased	pathogen	exposure	in	African	women.(113)	
Maternal	age,	weight,	parity,	and	type	of	delivery	do	not	influence	placental	
antibody	transfer.(128)	
Therefore,	the	difference	in	invasive	disease	prevalence	between	the	Gambia	
and	resource	rich	settings	could	also	be	due	to	higher	concentrations	of	
transplacentally	acquired	protective	antibody.	Suara	et	al.	(1998)	reported	high	
mean	maternal	GBS	STIII	antibody	concentrations	in	women	that	could	account	for	
the	relative	rarity	of	GBS	STIII	GBS-disease	in	The	Gambia	(GMC)	1.1	±	
0.5μg/mL).(129)	
1.7.1.1.	Subclasses	of	IgG	and	placental	transfer	
There	are	several	reports	of	reduced	placental	transfer	of	antibody	to	
encapsulated	bacteria,	for	example	IgG1	antibodies	to	H.	influenzae	type	b	are	
transferred	in	greater	amounts	than	IgG2.(130)	This	is	concerning	as	IgG2	is	the	
predominant	IgG	subclass	required	for	protection	against	encapsulated	bacteria.	
Compared	to	IgG1	and	IgG3,	IgG2	is	often	detected	in	lower	amounts	in	cord	blood	
than	in	maternal	blood	and	IgG2	shows	less	affinity	for	the	FcRn	receptor.(131,	132)	
It	is	therefore	vital	that	not	only	is	total	antibody	concentration	high	but	also	that	
sufficient	amounts	of	IgG2	cross	the	placenta	to	provide	effective	antibody-mediated	
killing	to	prevent	GBS	disease.			
Lower	total	antibody	concentrations	for	GBS	ST	Ia	and	III	have	been	
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demonstrated	in	GBS-infected	infants,	including	lower	IgG	subclasses,	especially	
IgG2.(125,	133-135)	As	the	functional	IgG	response	against	GBS	STIII	is	mainly	due	to	
opsonisation	with	the	IgG2	subclass,	it	is	possible	that	the	deficient	transfer	of	this	
antibody	to	the	foetus	is	a	reason	for	enhanced	susceptibility.(136)	
	
1.8.	Maternal	antibody	and	maternal	vaccination		
Boosting	naturally-acquired	antibody	through	maternal	vaccination	is	a	useful	
strategy	 in	neonatal	disease	prevention,	as	neonatal	vaccination	would	not	protect	
infants	 from	 EO-GBS	 disease.	 The	 past	 30	 years	 have	 been	 spent	 in	 developing	 a	
vaccine	to	be	given	in	pregnancy	to	elicit	high	levels	of	functional,	GBS	ST-specific	IgG	
that	 would	 cross	 the	 placenta	 and	 protect	 neonates	 from	 disease.(137,	 138)	 It	 is	
estimated	 that	 a	 pentavalent	 vaccine	 containing	GBS	 STs	 Ia,	 Ib,	 II,	 III	 and	V	would	
cover	94-100%	of	invasive	isolates	globally	and	a	trivalent	vaccine	that	would	cover	
87%	 of	 invasive	 disease	 (ST	 Ia,	 Ib	 and	 III)(13,	 116).	 The	 development	 of	 other	
candidates	continues.		
1.8.1.	Conundrums	in	measuring	vaccine	efficacy	
Whilst	the	vaccine	study	data	highlighted	in	section	1.4.	are	encouraging,	 in	
order	 to	 assess	 vaccine	 efficacy	 in	 preventing	 neonatal	 disease,	 antibody	
concentrations	must	be	determined	that	confer	protection	from	disease.	However,	
determining	a	protective	antibody	concentration	is	not	easily	achieved,	as	protective	
antibody	 concentrations	 vary	 by	 organism	 (116),	 by	 GBS	 ST	 (139,	 140)	 and	 the	
assessment	of	immunogenicity	varies	by	research	methods.(116,	139)		
The	 association	 between	 GBS	 ST-specific	 capsular	 antibody	 concentrations	
and	 invasive	GBS	disease	 in	 newborns	was	 initially	 characterised	 in	 1976	by	Baker	
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and	 colleagues.(115)	 In	 the	 majority	 of	 subsequent	 studies	 lower	 GBS	 ST-specific	
capsular	 antibodies	were	 found	 in	 infants	with	 EO-	 and	 LO-GBS	 disease	 compared	
with	 controls.(141,	 142)	 Different	 specific	 antibody	 concentrations	 that	 could	 be	
associated	with	 protection	 from	disease	 have	 been	 defined	 in	 different	 studies	 as	
well	as	for	different	GBS	STs	(Table	2).	In	a	meta-analysis	undertaken	to	compare	the	
proportions	 of	 cases	 and	 controls	 with	 antibody	 levels	 ≥2	 μg/mL,	 the	 odds	 of	
invasive	 GBS	 disease	 was	 6.56	 (95%	 CI:	 2.10–20.55)	 and	 2.38	 (95%	 CI:	 1.20–4.70)	
times	greater	in	infants	whose	mothers	had	antibody	levels	<2	μg/mL	for	GBS	STs	III	
and	Ia,	respectively.(143)	A	threshold	of	1	μg/mL	has	also	recently	been	proposed	as	
a	 correlate	 of	 protection	 against	 disease	 caused	 by	 GBS	 STs	 Ia	 and	 III.(116)	
Thresholds	 are	 much	 higher	 in	 other	 large	 studies	 including	 the	 DEVANI	 project,	
based	on	European	sera	(144),	but	there	has	been	significant	controversy	regarding	
appropriate	methods	 to	 be	 used	 to	measure	 the	 antibody	 in	 order	 to	 derive	 such	
thresholds	 reliably.(145)	A	 recent	study	 from	South	Africa	suggested	that	maternal	
concentrations	of	>3μg/mL	for	GBS	STIa	and	>1μg/mL	for	GBS	STV	were	associated	
with	 significantly	 reduced	 maternal	 colonisation	 with	 these	 GBS	 STs	 (Table	 2).	
Further,	 the	 authors	 suggested	 that	 the	 opsonophagocytosis	 killing	 (OPkA)	 titre	
correlated	more	strongly	with	decreased	rectovaginal	acquisition	of	GBS,	 indicating	
the	 need	 for	 both	 a	 quantitative	 and	 a	 functional	 assessment	 of	 antibody	 when	
estimating	 protection.(146)	 Interpretation	 of	 all	 of	 these	 results	 is	 difficult	 due	 to	
differences	 in	 methods	 and	 the	 lack	 of	 available	 standardised	 reference	 sera.	 A	
standardised	approach	to	establish	antibody	concentration	and	function	and	its	role	
in	reducing	maternal	colonisation	and	neonatal	disease	is	urgently	required	in	order	
to	achieve	licensure	of	any	future	vaccines	based	on	immunogenicity	criteria.(147)		
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Table	2	-	Proposed	protective	antibody	concentrations	for	GBS	ST	Ia,	III	and	V	
Author	 Country	 Year	
of	
Study	
Method	of	
antibody	
assessment	
Proposed	
protective	
concentration		
OR/RR	(95%	CI)	of	
disease	protection	
Baker	et	al	(116)	 USA	 1998-
1999	
ELISA	 STIa,	STIII,	and	
STV	
≥1μg/mL		
	
OR:	if	Antibody	
≥0.5μg/mL:		
STIa:	0.11	(0.01-0.74)		
III:	0.09	(0.00-0.72)	
V:	0.29	(0.01-3.10)	
Edwards	et	
al(148)		
USA	 1979	 OPkA	 STIII	≥10μg/mL	 2.0	log10	reduction	in	
CFU/mL	compared	to	
antibody	deficient	sera	
Baker	et	al(83)		 USA	 2003	 OPkA	 STIII	≥1μg/mL	 >1.0	log10	reduction	in	
CFU/mL	
Baltimore	(149)	 USA	 1981	 RABA	 STIII	
≥2μg/mL		
	
	
Feldman	(141)	 UK	 1990	 ELISA	 STIII	
≥2μg/mL		
	
GMC	of	STIII	lower	in	
GBS	disease	cases	
Klegerman(142)	 USA	 1983	 ELISA	 STIa	
≥1μg/mL		
	
GMC	of	STIII	lower	in	
GBS	disease	cases	
Lin	(140)	 USA	 2001	 ELISA	 STIII	
≥10	μg/mL	
	
OR:	
0.09	(0.01-0.78)	
Lin	(139)	 USA	 2004	 ELISA	 STIa	
≥5	μg/mL	
	
OR:	
0.12	(0.02–0.93)	
DEVANI	
study(144)	
Europe	 2014	 ELISA	 STIa	≥5	μg/mL	
STIII	≥10	μg/mL	
No	correlate	
for	STV	
	
Kwatra(150)*	 South	
Africa	
2015	 Fluorescence	
based	micro-
bead	
immunosorbent	
assay	
	
≥3	μg/mL	STIa		
≥3	μg/mL	STIII		
≥1	μg/mL	STV	
OR:	
STIa	:	0.91	(0.68-1.21)	
STIII:	0.47	(0.26-0.84)	
STV:	0.39	(0.15-1.01)	
Dangor(151)	 South	
Africa	
2015	 Fluorescence	
based	micro-
bead	
immunosorbent	
assay	
STIa	≥6	μg/mL	
STIII	≥3	μg/mL	
	
Used	Bayesian	modelling	
to	impute	the	degree	of	
protection	based	on	
specific	threshold	
	GBS=Group	B	Streptococcus;	ELISA=enzyme-linked	immunoabsorbent	assay;	OPkA=opsonophagocytosis	killing	assay;	
RABA=radioantigen	binding	assay;	DEVANI=design	of	a	vaccine	to	immunize	neonates	against	GBS	through	a	durable	maternal	
immune	response;	ST=serotype;	OR=odds	ratio;	RR=risk	ratio;	CFU/mL=colony-forming	units	per	millilitre;	GMC=geometric	mean	
concentration.		
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1.9.	Assays	used	to	predict	immunity	to	GBS	disease	
A	 major	 barrier	 to	 the	 conduct	 of	 efficacy	 trials	 -	 which	 would	 have	 to	
measure	prevention	of	invasive	neonatal	GBS	disease	as	the	primary	endpoint-	is	the	
large	sample	size	required,	as	described	above.	As	an	alternative,	a	vaccine	could	be	
licenced	 based	 on	 immunogenicity	 data,	 if	 a	 threshold	 of	 protective	 antibody	was	
defined.		
An	 enzyme-linked	 immunoabsorbent	 assay	 (ELISA)	 measures	 antibody	
concentrations	and	has	been	used	in	the	majority	of	vaccine	studies	to	date	in	order	
to	estimate	the	antibody	concentration	required	to	reduce	the	risk	of	GBS	disease.	
However,	an	antibody	ELISA	does	not	provide	information	on	the	functional	ability	of	
the	antibody	 to	neutralise	GBS.	Therefore,	an	ELISA	alone	may	not	be	 sufficient	 in	
predicting	 functional	 immunity	 from	GBS	 infection.(143)	A	possible	 solution	 to	 this	
may	 be	 the	 development	 of	 an	 effective	 functional	 antibody	 assay	 that	 could	 be	
used	 as	 an	 in	 vitro	 correlate	 of	 protection.	 An	 example	 of	 this	 is	 the	
opsonophagocytosis	killing	assay	(OPkA)	(148,	152),	which	mimics	the	in	vivo	process	
of	 the	 killing	 of	 the	 bacterium	 by	 host	 effector	 cells	 following	 opsonisation	 by	
specific	antibodies.	Passive	protection	of	mice	by	sera	 from	adults	 immunised	with	
GBS	CPS-based	vaccines	has	been	shown	to	correlate	with	high	functional	antibody	
titres	measured	by	OPkA.(149,	153)	However,	OPkA	assays	are	laborious	to	perform	
and	 require	 large	 volumes	 of	 test	 sera.	 Reliance	 on	 human	 donor	 phagocytes	
introduces	 an	 extra	 variable,	 though	 this	 can	 be	 addressed	 with	 the	 use	 of	 the	
human	 phagocytic	 cell	 line	 human	 promyelocytic	 leukaemia	 cells	 (HL-60).(154)	 An	
OPkA	that	measures	the	uptake	of	fluorescently-labelled	bacteria	by	flow	cytometry	
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could	potentially	 substitute	 for	a	 conventional	OPkA	 requiring	cumbersome	colony	
counts.(155)	 A	 fluorescence	 opsonophagocytosis	 assay	 (fOPA)	 has	 also	 been	
developed	that	measures	both	the	uptake	of	bacteria	and	the	oxidative	burst	activity	
of	 the	 HL-60	 cells	 in	 a	 96-well	 format.(156)	 For	 large	 seroepidemiological	 studies	
however,	 both	 the	 OPkA	 and	 fOPA	 are	 still	 too	 laborious	 and	 require	 too	 much	
serum	 volume	 from	each	 vaccinee.	 This	 is	 a	 critical	 issue	 in	 studies	where	 sample	
volume	 is	 at	 a	 premium,	 such	 as	 in	 neonatal	 studies.	 Other	 assays,	 including	 an	
antibody-mediated	 complement	 C3b/iC3b	 deposition	 assay	 (125)	 have	 been	
developed	 that	 are	 less	 labour	 intensive	 and	 less	 variable	 as	 they	 do	 not	 rely	 on	
human	phagocytes	and	require	small	serum	volumes.		
	
1.10.	Conclusion	
Since	there	are	geographical	differences	in	GBS	ST	distribution,	the	potential	
global	effectiveness	of	GBS	vaccines	currently	in	development	is	unknown.		In	
particular,	there	are	no	recent	GBS	ST-specific	data	from	West	Africa	in	order	to	
predict	the	potential	local	impact	of	a	maternal	vaccine.	The	effect	of	GBS	ST-specific	
antibody	transfer	to	the	infant	and	subsequent	antibody	function	on	infant	
colonisation,	and	the	natural	history	of	antibody	in	infant	blood	have	not	been	
evaluated	but	are	important	for	future	vaccination	strategies.	The	work	presented	in	
this	thesis	aims	to	address	both	of	these	gaps	in	knowledge.	
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Chapter	2	–		Hypotheses,	aims	and	objectives	
2.1.	Hypotheses	
1.	 GBS	 colonisation	 in	 The	Gambia	 is	 predominantly	 due	 to	 ST	 Ia,	 Ib,	 III	 and	 V	
(addressed	in	specific	aim	1);		
2.	 GBS	 ST-specific	 maternally-derived	 antibody	 in	 cord	 blood	 is	 inversely	
associated	with	GBS-colonisation	in	infants	(addressed	in	specific	aim	2);	
3.	Higher	levels	of	GBS	ST-specific	antibody	in	infants	are	associated	with	better	
ability	to	kill	GBS	in	vitro,	representing	a	laboratory	surrogate	for	protection	from	
disease	(addressed	in	specific	aim	3).	
	
2.2.	Aims	
Specific	Aim	1:	To	describe	the	ST-specific	prevalence	of	GBS	colonisation	in	women	
and	their	infants	in	a	field	setting	in	the	Gambia;	
We	postulate	that	ST	prevalence	of	GBS	colonisation	in	Gambian	women	and	their	
infants	is	similar	to	other	African	countries	and	thus	that	a	pentavalent	vaccine	
candidate	would	provide	more	than	80%	coverage	of	circulating	GBS	isolates.		
Specific	Aim	2:	To	examine	the	relationship	between	maternal	GBS	ST-specific	
antibody	and	GBS	colonisation	in	neonates;	
We	postulate	that	increased	concentration	of	anti-GBS	ST-specific	antibody	
will	reduce	infant	colonisation	at	birth	and	that	infants	with	higher	concentration	of	
anti-GBS	antibody	at	birth	will	have	reduced	risk	of	GBS	colonisation	at	six	days	and	
up	to	day	60-89	of	life.		
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Specific	Aim	3:	To	develop	an	opsonophagocytosis	assay	and	correlate	the	results	to	
the	 complement	 deposition	 assay	 in	 order	 to	 determine	 if	 a	 concentration	 of	
antibody	exists	above	which	an	infant	is	no	longer	colonised	with	GBS.	
We	 postulate	 that	 higher	 concentrations	 of	 antibody	 bound	 to	 complement	
determine	 infant	 colonisation	 by	 promoting	 increased	 opsonophagocytic	 killing.	 It	 is		
anticipated	that	there	will	be	an	antibody	threshold	above	which	an	infant	is	no	longer	
GBS	 colonised	 and	 that	 this	 threshold	 can	 be	 used	 as	 a	 marker	 of	 protection	 from	
colonisation	and	thus	disease.		
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Chapter	3	-	Materials	and	Methods		
In	this	Chapter,	I	describe	how	I	addressed	the	specific	aims	of	the	project,	
including	study	setting,	design,	participant	sensitisation	and	recruitment	and	the	
laboratory	assays	and	data	analysis	techniques	used.		
	
3.1.	Field	study	set	up,	sensitisation	and	recruitment	
3.1.1.	Study	setting	
The	Gambia	is	a	low-income	country	with	an	annual	birth	rate	of	43.1/1000	
population,	neonatal	mortality	rate	of	28/1000	live	births	(157)	and	neonatal	sepsis	
rate	of	4.42/1000	live	births.(32)	The	study	occurred	at	two	sites	in	urban	costal	
Gambia:	the	antenatal	clinic	(ANC)	at	Faji	Kunda	Hospital,	and,	in	order	to	increase	
recruitment	following	successful	Wellcome	Trust	Clinical	Research	Training	
Fellowship	funding	from	1st	September	2014,	at	the	ANC	at	Jammeh	Foundation	for	
Peace	Hospital	(JFPH).	Together	these	two	hospitals	have	approximately	12,500	
births	annually	and	were	selected	as	they	reflect	the	antenatal	care	usually	available	
to	Gambian	women.	All	women	were	provided	with	serological	testing	for	HIV	and	
malaria	antigen	during	pregnancy	prior	to	recruitment.	If	participants	were	HIV	
positive	at	screening,	they	were	referred	for	specialist	ongoing	care.	
3.1.2.	Ethical	considerations	
The	Medical	Research	Council	(MRC)	Scientific	Coordinating	Committee	and	
the	Gambian	Government/MRC	Joint	Ethics	Committee	gave	ethical	approval	for	the	
study	on	1st	September	2013	(SCC	1350).	An	amendment	was	added	on	1st	August	
2014	prior	to	recruitment	roll	out	to	JFPH	(Appendix	1).	
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3.1.3.	Consent	
Informed	consent	to	enter	the	study	was	sought	from	mothers	on	behalf	of	
their	infants	and	from	the	mothers	themselves.	A	field	worker	fluent	in	both	English	
and	the	mother’s	local	language	(e.g.	Mandinka,	Wolof,	Fula,	Jolla)	undertook	
informed	consent.	Pregnant	women	were	encouraged	to	discuss	with	their	partners	
for	their	agreement.	If	there	was	disagreement	between	the	partners,	the	mother	
was	deemed	ineligible	for	study	entry.	All	consent	forms	were	designed	according	to	
standards	set	by	MRC	and	were	approved	by	the	Gambian	Government/MRC	Joint	
Research	Ethics	Committee	(Appendix	2).	
3.1.4.	Funding	
This	research	was	funded	by	a	Wellcome	Trust	Institutional	Strategic	Support	
Fund	grant	(year	1)	and	a	Wellcome	Trust	Clinical	Research	Training	Fellowship	and	
an	Al	Thrasher	Foundation	Award	(Years	2&3).	The	positive	control	sera	and	the	
bacteria	used	for	the	opsonophagocytosis	assays	were	kindly	donated	by	Prof.	Carol	
Baker,	Professor	of	Pediatric	Infectious	Diseases,	Baylor	College	of	Medicine,	
Houston,	Texas,	USA	.	The	bacteria	used	for	the	flow	cytometric	assays	were	kindly	
donated	by	Prof.	Androulla	Efstratiou,	Professor	of	Microbiology,	Public	Health	
England,	Colindale,	UK.	
3.1.5.	Study	Design	
This	 work	 represents	 a	 prospective	 cohort	 study	 of	 pregnant	 women	
attending	 ANC	 in	 the	 Banjul	 area	 of	 The	 Gambia	 and	 their	 infants	 (0-89	 days)	 for	
assessment	 of	 GBS	 colonisation	 and	 GBS	 ST-specific	 antibody	 in	 cord	 and	 infant	
serum	 at	 two	 time	 points:	 birth	 and	 day	 60-89	 (See	 Figure	 6	 for	 study	 design).	
Mothers	were	sensitised	at	32	weeks	of	pregnancy	and	screened	for	eligibility.		
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All	eligible	mothers	knew	their	HIV	status	either	by	early	antenatal	blood	test	
result	 or	 by	 rapid	 test	 at	 32	 weeks.	 HIV-positive	 mothers	 were	 excluded	 from	
enrolment	because	of	 the	effect	of	HIV	on	 the	maternal	 immune	system.	Mothers	
were	required	to	give	birth	at	one	of	the	health	facilities.	Rectovaginal	swabs	were	
taken	 in	 labour	 for	maternal	 GBS	 colonisation	 and	 cord	 blood	 sample	 at	 birth	 for	
functional	 antibody	 testing.	 Infant	 nasopharyngeal	 and	 rectal	 swabs	 and	maternal	
breast	 milk	 for	 culture	 were	 taken	 on	 day	 one	 (birth),	 day	 six	 and	 day	 60-89.	 A	
venous	blood	sample	for	antibody	concentration	was	taken	from	infants	at	day	60-
89.		
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Figure	6	-	Study	design	
	
3.1.6.	Recruitment	
If	these	women	fulfilled	the	eligibility	criteria	they	were	encouraged	to	
discuss	with	their	partners.	Follow	up	occurred	within	six	days	of	initial	contact	for	
written	consent.	Screening	and	recruitment	took	place	between	1st	January	2014	
and	31st	December	2014.	Mothers	were	approached	to	complete	a	screening	
questionnaire	and	the	infant	checked	for	any	abnormalities	requiring	medical	
intervention.	Women	and	infants	were	recruited	until	the	sample	size	of	750	women	
was	reached.	Infants	were	followed	up	at	home	until	day	six	and	then	asked	to	
return	to	clinic	when	the	infant	was	60-89	days	old	for	final	follow	up	visit	and	
vaccinations.	If	an	infant	died	during	the	study	a	verbal	autopsy	was	carried	out	to	
assess	the	potential	cause	of	death.		
Pregnant	Women	>32/40	
Incl:	Breas8eeding,	>18yrs,	low	risk	pregnancy,	HIV	negaDve,	no	
Abx	<4wks	prior	to	delivery,	infant	>2kg	
Excl:	congenital	malformaDons,	<32	weeks,	maternal	HIV,	
planning	to	travel	
Day	0		
Maternal	and	infant	swabs,		
4-5mL	cord	blood,	1-2	mL	colostrum	
consent	
Day	6-7		
4-5mL	breast	milk,	infant	swabs	
Day	60-90	
4-5mL	Breast	milk,	infant	swabs,	
	2-3mL	serum	
	 50	
3.1.7.	Inclusion/Exclusion	criteria	
Inclusion	criteria:		- Breastfeeding	women		- age	18-45	years	- pregnancy	over	32	weeks	gestation		- deemed	low	risk	singleton	pregnancy	(no	evidence	of	pre-eclampsia,	
cardiomyopathy,	maternal	gestational	diabetes,	placenta	praevia,	twin	
pregnancy).	- giving	birth	in	the	Banjul	area	- infants	birthweight	≥2kg	- remaining	in	the	Banjul	area	for	first	90	days	postpartum	- Healthy	infants	over	32	weeks	of	gestation	assessed	by	Ballard	score.		
Exclusion	criteria:		- Women	planning	to	move	from	the	area	within	3	months	postpartum	- congenital	abnormalities	- infants	requiring	neonatal	resuscitation	or	transfer	to	a	neonatal	unit	- extremely	preterm	infants	(under	32	weeks	gestation)	- known	maternal	HIV	infection	
3.1.8.	Demographic	and	clinical	information	
Background	demographic	and	maternal	clinical	information	was	obtained	at	
screening	including:	HIV	status,	haemoglobin	concentration,	use	of	medication	and	
vaccination	in	pregnancy,	ethnic	origin,	gravida,	number	of	previous	still	
births/spontaneous	abortions,	number	of	living	children,	maternal	weight,	blood	
pressure,		illnesses	during	pregnancy,	number	of	antenatal	attendances,		maternal	
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education	level,	diet,	compound	location,	type	of	cattle	at	the	compound,	midwife	
or	traditional	birth	attendant	delivery,	clinical	attendances	for	other	reasons.(158)	
Infant	clinical	information	was	obtained	at	birth	and	at	each	follow	up	visit	(See	
Appendix	3	for	example	case	report	form).	Each	child	was	issued	with	a	Gambian	
Maternal	and	Child	Health	Record	including	details	of	illnesses	and	anthropometry,	
which	were	reviewed	at	each	visit.	The	Gambia	follows	the	WHO	vaccination	
schedule	and	children	receive	Bacille	Calmette	Guerin	(BCG),	Hepatitis	B	vaccine	
(HBV)	and	oral	polio	virus	(OPV)	at	birth	and	Pentavalent	Diptheria,	Tetanus,	
Pertussis,	HBV,	H.	influenzae	(DTP-HBV-Hib),	OPV,	Pneumococcal	conjugate	vaccine	
13	valent	(PCV13)	and	rotavirus	vaccines	at	2,	3	and	4	months.	As	the	vaccine	supply	
chain	was	sometimes	uncertain	in	West	Africa	at	the	time	of	the	study,	all	study	
participants	received	their	vaccinations	in	the	study	clinic	at	follow	up.		All	study	
subjects	receiving	vaccines	were	provided	with	contact	information	and	asked	to	
contact	the	study	team	if	there	were	any	adverse	reactions	following	vaccination.		
3.1.9.	Sample	collection	
The	participant’s	perineum	was	wiped	with	surgical	spirit	and	then	
rectovaginal	swabs	(Copan,	UK)	were	collected	in	skim-milk	tryptone,	glucose	
glycerol	(STGG)	medium	on	presentation	to	labour	ward	by	the	midwifery	and	field	
nursing	team.	Cord	blood	(4-5mL)	was	collected	using	sterile	technique	before	
separation	of	the	placenta	using	sterile	needle	and	syringe	in	serum	separator	tubes	
(BD,	UK).	Colostrum	and	breast	milk	were	collected	by	hand	expression	with	the	help	
of	the	nursing	staff.	Both	breasts	were	wiped	with	an	alcohol	wipe	prior	to	
expression.	Infant	nasopharyngeal	(calcium	alginate	swabs,	Sterilin,	UK)	and	rectal	
swabs	(Copan,	UK)	in	STGG	were	collected	by	the	field	nursing	team.	Detailed	
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standard	operating	procedures	were	developed	for	this	purpose	(See	Appendix	4).	
Infant	venous	blood	(2-3mL)	was	collected	using	sterile	technique	into	serum	
separator	tubes	(BD,	UK)	using	sterile	needle	and	syringe	at	clinic	at	day	60-89.	
Swabs	and	cord	blood	were	kept	at	4°C	and	transported	to	the	clinical	microbiology	
laboratories	within	six	hours.	The	swab	samples	were	vortexed	and	separated	into	
two	aliquots	(one	containing	the	original	swab)	and	stored	at	-70	°C.	The	serum	
samples	were	centrifuged	for	ten	minutes	at	2200	rpm	to	separate	the	serum	and	
then	separated	into	1mL	aliquots	prior	to	freezing	at	-70°C.	Breast	milk	samples	were	
centrifuged	at	3200	rpm	for	30	minutes	to	separate	whey	and	lipid	layer.	The	lipid	
layer	was	removed	using	a	sterile	scalpel	and	stored	separately	in	1mL	aliquots	of	
whey	at		-70°C.	
	
3.2.	Microbiological	and	molecular	quantification	of	GBS	colonisation	
3.2.1.	Media	preparation	
3.2.1.1.	Skim-milk	tryptone	glucose	glycerol	(STGG)	–	transport	and	
storage	medium	
To	make	the	STGG,	3g	of	Oxoid	(Oxoid	UK)	tryptone	soya	broth,	0.5g	Glucose	
and	2g	skim	milk	powder	was	added	to	10mL	glycerol	and	100mL	double	distilled	
water	and	vortexed	briefly.	The	resulting	suspension	was	then	dispensed	in	1	mL	
aliquots	into	1.5mL	SARSTED®	(Sarstedt,	Germany)	cryotubes	and	autoclaved	for	10	
minutes	at	121°C.	The	suspension	was	cooled	and	refrigerated	(4-8°C)	until	use.	Each	
new	batch	was	tested	for	sterility	prior	to	use.	
3.2.1.2.	Preparation	of	Todd–Hewitt	Broth	(THB)		
To	make	the	THB,	36.4g	of	Todd-Hewitt	broth	(Oxoid,	UK)	was	dissolved	in	
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200mL	of	distilled	water	and	then	made	up	the	volume	to	1L.	The	suspension	was	
sterilised	at	115°C	for	10	minutes	and	stored	at	4°C	until	required.	Sterility	and	
performance	were	checked	weekly	using	standard	culture.	
3.2.1.3.	Preparation	of	Colombia-Colistin-Nalidixic	Acid	enrichment	
media	(CCNA)	
Ellner	et	al.	(159)	developed	a	selective	Staphylococcal/Streptococcal	
medium,	made	by	adding	colistin	and	nalidixic	acid	antibiotic	supplements	to	
Columbia	Agar	Blood	Base	(CCNA).	The	CCNA	inhibits	Streptococcus	albus,	
Micrococcus	species,	Proteus,	Klebsiella	and	Pseudomonas	species	allowing	
unrestricted	growth	of	Staphylococcus	aureus,	haemolytic	streptococci	and	
enterococci.	
For	each	1L	of	medium,	39g	of	dehydrated	Colombia	agar	base	(Oxoid,	UK)	
was	added	to	1L	of	distilled	water	(as	per	manufacturer’s	instructions)	and	mixed	
until	dissolved.	The	solution	was	then	autoclaved	at	121°C	for	15	minutes	and	cooled	
to	45-50°C.	Once	the	solution	had	cooled	sufficiently	15mg	nalidixic	acid	and	10mg	
colistin	were	reconstituted	in	10mL	95%	ethanol	and	added	together	with	50mL	of	
defibrinated	sheep	blood	(5%)	with	mixing.	The	resulting	agar	was	then	poured	into	
90mm	diameter	petri	plates	to	a	depth	of	4mm	and	allowed	to	set.	The	CCNA	plates	
were	refrigerated	at	4-8°C	until	use.	Prior	to	use	the	plates	were	dried	in	the	oven	at	
50°C	for	10	minutes.		
NOTE:	Blood	agar	plates	were	made	in	the	same	manner	but	without	the	addition	of	
nalidixic	acid	and	colistin.	Quality	control	and	performance	were	undertaken	weekly.		
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3.2.2.	Isolation	of	GBS	from	swabs	and	breast	milk	from	culture		
3.2.2.1.	Pre-culture	
The	protocol	was	adapted	from	the	Public	Health	England	(PHE)	protocol	for	
the	pre-incubation	of	swabs	in	enrichment	broth	prior	to	plating	on	solid	media	to	
enhance	the	yield	of	GBS.(160)	Swab	and	breast	milk	samples	were	processed	within	
seven	days	of	collection	in	batches	of	100.	For	swabs,	the	aliquots	that	did	not	
contain	the	original	swab	tip	were	thawed	on	wet	ice	and	transported	to	the	
microbiology	laboratory.	Samples	were	vortexed	for	10-20s	and	100μL	of	vortexed	
specimen	was	transferred	to	2.5mL	THB	for	24	hours	pre-culture	at	37°C	in	5%	CO2	
incubator.	Breast	milk	was	thawed,	vortexed	and	100μL	added	to	THB	as	for	swabs.	
After	pre-incubation,	the	THB	was	aliquoted	into	1mL	vials	and	stored	at	-70°C	for	
further	processing.	
3.2.2.2.	Serial	dilutions	
After	pre-incubation,	the	THB-sample	suspension	was	briefly	vortexed,	then	
100μL	of	THB-sample	suspension	was	added	to	900μL	of	THB	to	create	a	1:10	
dilution	in	a	cryovial.	Two	further	dilutions	of	1:100	and	1:1000	suspensions	were	
made	for	each	sample.		
3.2.2.3.	Plating	samples	
A	CCNA	plate	was	divided	into	four	segments	and	10μL	of	neat	suspension	
and	each	of	the	three	dilutions	were	dispensed	into	each	of	the	four	quadrants	and	
incubated	overnight	at	37°C	in	5%	CO2.	From	the	primary	plate,	presumptive	beta	
haemolytic	streptococcus	colonies	were	streaked	onto	a	blood	agar	plate	and	
reincubated	at	37°C	in	5%	CO2	for	24	hours.	Beta	haemolytic	streptococci	appeared	
	 55	
colourless	or	grey,	about	2mm	in	diameter	with	or	without	a	zone	of	beta-
haemolysis	surrounding.		
3.2.2.4	Catalase	test	
As	Staphylococcal	species	can	reduce	diatomic	oxygen	to	hydrogen	peroxide	
(H2O2)	or	superoxide	before	converting	H2O2	back	to	oxygen	and	water	using	
catalase,	the	catalase	test	enables	differentiation	between	Streptococcus	and	
Staphylococcal	species.	
A	drop	of	H2O2	was	pipetted	to	a	glass	slide	and	a	colony	of	the	test	organism	
was	added.	The	droplet	was	observed	for	the	evolution	of	O2	gas	bubbles.	If	O2	gas	
bubbles	were	seen,	the	catalase	test	was	considered	to	be	positive.	All	specimens	
that	were	catalase	test	negative	were	identified	by	Lancefield	grouping	using	
Streptex®	(Oxoid,	UK).	Growth	was	semi-quantified	from	the	1:1000	dilution	as:		
sparse,	≤103	colony-forming	units	(CFU)/mL;	average,	>103	&	<	105	CFU/mL;	or	
abundant,	≥105	CFU/mL.		
3.2.2.5.	Lancefield	grouping	
Streptex®	(Oxoid,	UK),	a	commercially	available	rapid	latex	agglutination	test	
system,	was	used	in	the	qualitative	detection	and	identification	of	the	Lancefield	
groups	of	Streptococci.		
Following	the	second	24-hour	incubation,	one	colony	of	presumed	
Streptococci	was	vortexed	in	70μL	phosphate	buffered	saline	(PBS)	(pH	7.4)	and	
incubated	for	10	minutes	as	per	manufacturer’s	instructions.	One	drop	(10uL)	of	a	
solution	containing	polystyrene	latex	particles	to	each	of	the	Lancefield	Groups	(A,	B,	
C,	D,	E,	F,	G)	was	added	with	10μL	of	presumptive	positive	solution	to	a	reaction	card	
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and	incubated	for	2	minutes.	A	clear	area	of	latex	agglutination	within	two	minutes	
indicated	a	positive	test.		
3.2.2.6.	Storage	of	positive	GBS	isolates	
Once	the	GBS	was	identified	by	latex	agglutination,	one	or	more	colonies	
from	the	confirmed	CCNA	plate	were	streaked	as	a	lawn	onto	a	blood	agar	plate.	The	
growth	was	examined	for	purity	after	overnight	incubation.	Ten	colonies	of	GBS	
were	harvested	using	a	sterile	loop	into	STGG	broth	for	storage	at	-70°C	for	future	
whole	genome	sequencing	and	ten	colonies	were	harvested	into	PBS	for	real-time	
(Rt)	(quantification)	and	gel-based	(serotyping)	polymerase	chain	reaction	(PCR)	and	
stored	at	-70°C.	
3.2.3.	GBS	Quantification	by	real-time	polymerase	chain	reaction	(Rt-PCR)	
3.2.3.1.	PCR	optimisation	
As	sample	collection	involved	the	use	of	plain	swabs	and	calcium	alginate	
swabs	the	first	ten	samples	collected	of	each	swab	type	that	tested	positive	on	
culture	for	GBS	were	tested	using	Rt-PCR	to	determine	whether	the	calcium	alginate	
in	the	nasopharyngeal	swabs	might	inhibit	the	magnesium	in	the	PCR-mastermix	
solution.	As	the	PCR	results	were	concordant	with	the	culture	results	I	continued	to	
use	calcium	alginate	swabs	for	nasopharyngeal	swab	collection	as	these	swabs	were	
readily	available	in	the	Gambia.	
3.2.3.2.	Nucleic	acid	extraction	
A	1mL	suspension	of	GBS	in	PBS	from	the	positive	isolates	was	thawed	on	
wet	ice,	then	boiled	in	a	water	bath	for	20	minutes	and	cooled	to	room	temperature	
to	release	the	deoxyribonucleic	acid	(DNA)	for	extraction.	Following	boiling,	the	
samples	were	vortexed	briefly	and	300μl	of	the	positive	suspension	was	added	to	an	
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equal	volume	of	lysis	solution	[300μl	AL	buffer	(Qiagen,	Germany),	30μl	proteinase	K	
(Sigma-Aldrich,	USA)],	and	incubated	for	10	min	at	56°C.	Following	incubation,	300μl	
of	pure	ethanol	was	added	and	the	samples	vortexed	before	DNA	was	purified	using	
DNeasy	Tissue	kit	(Qiagen,	Germany)	as	per	manufacturers’	instructions	and	eluted	
in	a	volume	of	100μl.	Two	200μl	aliquots	of	the	purified	DNA	solution	were	stored	at	
-70°C	for	PCR.	
3.2.3.3.	Rt-PCR	
The	Christie,	Atkinson,	Munch,	Peterson	factor	B	(CAMP	factor	B;	cfb)-gene	
was	used	as	the	target	with	primers	as	described	in	Diaz	et	al	(161)	and	a	TaqMan®	
(Thermoscientific,	UK)	probe.	Primers	and	probes	are	outlined	in	Table	3.	Rt-PCR	was	
performed	using	a	LightCycler	(Roche,	Switzerland).	The	following	PCR	conditions	
were	applied:	0.5	mM	primer,	0.2	mM	probe,	2.0	mM	MgCl2,	0.05	mM	dH2O	(2μl	
template	in	a	final	volume	of	50μl),	22.5μL	Mastermix	(Roche),	2.5mL	sample	DNA.	A	
cycle	threshold	(Ct)	value	of	40	was	used	as	the	lower	limit	of	quantification	for	
positive	fluorescence	detection	signal	of	target	amplification.	Two	positive	controls	
and	six	negative	controls	were	included	in	all	runs.	Purified	DNA	from	a	known	GBS	
strain	was	used	as	positive	control	in	a	dilution	corresponding	to	1x107	bacterial	
genomes.	We	used	sterile	water	as	a	negative	control.	Each	isolate	was	tested	in	
duplicate.	
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Table	3	-	Sequences	of	primers	and	probes	and	cycling	conditions	for	Rt-	and	gel-
based	PCR	
PCR	Target	 GenBank	
accession	
number	
Sequence	of	primers	and	probes	 Cycling	Conditions	 Reference	
Cfb	 X72754	 Primer	1:	ATC	CTG	AGA	CAA	CAC	TGA	CA	
(position	263–282)	
Primer	2:	TTG	CTG	GTG	TTT	CTA	TTT	TCA	
(position	340–320)	
TaqMan	probe:		
6-FAM–ATC	AGA	AGA	GTC	ATA	CTG	
CCA	CTT	C–TAMRA	(position	293–317)	
50	°C	(2	min);	95°C	
(10	mins);	45	cycles	
of	95°C	(15	s),	60	°C	
(60	s)	
Diaz	(161)		
CpsI-Ia-6-7-F	
CpsI-6-R	
CpsI-7-R	
CpsI-F	
cpsL-R	
cpsG-F	
cpsG-R	
cpsG-2-3-6-R	
cpsN-5-F	
cpsN-5-R	
cpsJ-8-F	
cpsJ-8-R	
cpsJ-2-4-F	
cpsJ-2-R	
cpsJ-4-R	
cpsI-7-9-F	
cpsI-9-R	
cpsJ-Ib-F	
cpsJ-Ib-R		
AB028896	
AF337958	
AB028896	
AF163833	
AB028896	
AF163833	
AB028896	
AF163833	
AB028896	
AF337958	
AB050723	
AB050723	
AF163833	
AF349539	
AB050723	
AY375363	
AF355776	
AB050723	
AY376403	
GAATTGATAACTTTTGTGGATTGCGATGA	
CAATTCTGTCGGACTATCCTGATG	
TGTCGCTTCCACACTGAGTGTTGA	
CAATCCTAAGTATTTTCGGTTCATT	
TAGGAACATGTTCATTAACATAGC	
ACATGAACAGCAGTTCAACCGT	
ATGCTCTCCAAACTGTTCTTGT	
TCCATCTACATCTTCAATCCAAGC	
ATGCAACCAAGTGATTATCATGTA	
CTCTTCACTCTTTAGTGTAGGTAT	
TATTTGGGAGGTAATCAAGAGACA	
GTTTGGAGCATTCAAGATAACTCT	
CATTTATTGATTCAGACGATTACATTGA	
CCTCTTTCTCTAAAATATTCCAACC	
CCTCAGGATATTTACGAATTCTGTA	
CTGTAATTGGAGGAATGTGGATCG	
AATCATCTTCATAATTTATCTCCCATT	
GCAATTCTTAACAGAATATTCAGTTG	
GCGTTTCTTTATCACATACTCTTG		
95	°C	(15	min);	35	
cycles	of	95°C	(60	
s),	54	°C	(60	s),	72°C	
(2	min);	72°C	(10	
min).		
Imperi	
(162)		
	
3.2.3.4.	Standard	Curve	
In	order	to	determine	the	quantity	of	GBS	DNA	corresponding	to	the	
recorded	Ct	value	from	the	Rt-PCR,	a	standard	curve	was	developed	using	a	GBS-
positive	sample	of	known	bacterial	genome	concentration	of	1x107.	The	positive	
isolate	was	diluted	to	1:10,	1:100,	1:1,000	and	1:10,000	concentrations	
corresponding	to	bacterial	genome	concentrations	of	106,	105,104,	103	to	give	a	five	
point	standard	curve	of	known	concentrations.	The	results	were	then	input	into	a	
four-parameter	logistical	regression	curve	using	the	following	formula:	
F(x)	=	((A-D)/(1+((x/C)^B)))	+	D	
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Where	F(x)	is	the	unknown	concentration,	A=minimum,	B=slope,	C=inflection,	
D=maximum.	
3.2.3.5.	Multiplex	PCR	and	post-reaction	electrophoresis	for	GBS	
serotyping.	
The	cps	genes	for	each	of	the	GBS	STs	were	used	as	the	target	with	primers	
and	probes	described	by	Imperi	et	al.(162)	Primers	are	outlined	in	Table	3.	PCR	was	
performed	using	a	Thermocycler	(Roche).	The	following	PCR	conditions	were	
applied:	0.5	mM	primers	cps	1-6-7-F,	cps-G-R,cps-G-2-3-6-R,	cpsJ-8-F,	cpsJ-8-R,	cpsI-
7-9-F;	0.3	mM	primers	cpsI-6-R,	cpsI-7-R,	cpsL-F,	cpsL-R,	cpsG-F,	cpsN-5-F,	cpsN-5-R,	
cpsJ-2-4-F,	cpsJ-2-R,	cpsJ-4-R,	cpsI-9-R,	cpsJ-Ib-F,	cpsJ-Ib-R,	0.05	mM	dH2O	(3.1μl	
template	in	a	final	volume	of	50μl),	12.5μL	Mastermix	(Roche),	2.5mL	sample	DNA.			
A		10μL	sample	of	each	PCR	product	was	mixed	with	2μL	loading	buffer	and	
10µL	of	the	resulting	sample	with	15µL	of	50-bp	ladder	(cat#	70538-3)	were	then	
pipetted	in	a	1.5%	(wt./vol.)	high	resolution	agarose-1000	gel	(Life	Technologies,	UK)	
and	analysed	by	horizontal	electrophoresis	at	100V	for	90	minutes.	By	using	GBS	
reference	strains	representing	all	recognized	GBS	STs,	ultraviolet	(UV)	
transillumination	of	the	amplified	products	on	the	agarose	gel	showed	a	two	or	
three	band	pattern,	specific	and	characteristic	of	each	GBS	ST	(Figure	7).	As	an	
internal	positive	control,	a	688	base	pairs	band	corresponding	to	the	amplification	of	
a	conserved	fragment	of	the	cpsL	gene	was	used.	As	a	negative	control,	sterile	water	
was	added	instead	of	DNA	to	the	template.	Each	isolate	was	tested	in	duplicate.	
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Figure	7	-	Gel	electrophoresis	of	the	multiplex	PCR	amplification	products	
	
	Direct	analysis	of	amplicon	size	and	band	pattern	allowed	the	determination	of	the	molecular	STs	of	
the	GBS	reference	strains	used:	lane	1:	NCTC	11078	(A909,Ia);	lane	2:	NCTC	8187	(H36B,	Ib);	lane	3:	
NCTC	11079	(18RS21,	II);	lane	4:	ATCC	BAA-22	(M781,	III);	lane	5:	CNCTC	1/82	(IV);	lane	6:	ATCC	BAA-
611	(2603,	V);	lane	7:	strain	Prague	118754	(VI);	lane	8:	Prague	4/89	(7271,	VII);	lane	9:	NCTC	9828	
(M9,	VIII);	lane	10:	strain	ISS5611	(IX).	Lanes	11-21	samples.	M1:	molecular	marker	50	bp	Step	Ladder	
(Promega);	M2:	molecular	marker	1	kb	plus	DNA	Ladder	(Life	Technologies).	
	
3.3.	Functional	immunoassay	methods	
3.3.1.	Bacteria	
GBS	strains	H092040676	(Ia),	H090820125	(Ib),	H092120162	(III)	H090320548	
(II)	and	H091780506	(V)	were	used	in	the	immunological	assays.	Starting	from	the	
GBS	strain	master	seed,	1mL	of	frozen	culture	was	removed	from	the	-70°C	freezer	
to	a	class	II	microbiological	safety	cabinet	and	allowed	to	thaw	at	room	temperature.	
10μL	of	stock	suspension	was	then	streaked	onto	5%	horse	blood	Colombia	agar	
plates	using	a	sterile	inoculating	loop	and	incubated	at	37°C	in	5%	CO2	overnight.	The	
growth	from	the	whole	plate	was	then	transferred	using	a	sterile	inoculating	loop	to	
10mL	of	THB	and	the	optical	density	at	600nm	(OD	600nm)	was	determined.	The	
6	x	Nega(ve	controls	 Ia	 Ib	 II	 III	 IV	 V	 VI	 VII	VIII	 IX	 S1	 S2	 S3	 S4	 S5	 S6	 S7	 S8	 S9	 S10	S11	
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OD600nmwas	used	to	calculate	the	volume	of	inoculum	to	be	added	to	50mL	of	THB	in	
an	Erlenmeyer	non-baffled	shake-flask	to	obtain	a	final	pre-incubation	OD600nm		of	
0.1.	The	resulting	inoculum	was	incubated	at	37°C	with	shaking	at	180	rpm	until	a	
final	OD600nm	of	1.0	was	reached.	The	aim	was	to	achieve	mid-log	phase	culture	
growth	(1.5-2	hours).	At	this	point	100μL	of	culture	was	serially	diluted	1:10	to	10-6.	
100μL	from	each	dilution	was	spread	onto	the	horse	blood	Colombia	agar	plates	and	
incubated	overnight	at	37°C	in	5%	CO2.	Colonies	were	counted	for	each	plate	and	
averaged.	The	total	viable	count	for	each	GBS	ST	was	then	calculated	using	the	
dilution	factor	and	expressed	as	CFU/mL.	Following	growth	the	bacteria	were	split	
into	two	25mL	flasks	and	centrifuged	at	3060g	for	five	minutes.	The	supernatant	was	
discarded	and	the	remaining	pellets	were	each	suspended	in	10mL	of	PBS.	These	
suspensions	were	centrifuged	at	3060g	for	five	minutes	and	the	supernatant	
discarded	subsequently.	The	pellets	were	re-suspended	in	9.5mL	of	PBS	and	500μL	of	
40%	formaldehyde,	giving	a	final	formaldehyde	concentration	of	2%.	These	
suspensions	were	incubated	at	room	temperature	for	one	hour.	Following	
incubation	the	killed	cultures	were	vortexed	to	break	up	any	remaining	cocci	in	
chains.	To	test	for	viability	10μL	of	each	suspension	was	streaked	onto	a	horse	blood	
Colombia	agar	plate	and	incubated	overnight	at	37°C	in	5%	CO2.	Once	total	killing	
was	confirmed	the	suspensions	were	aliquoted	into	1mL	volumes	and	stored	at		
-20°C	until	use.	An	OD	600nm	was	taken	for	each	suspension	and	used	to	calculate	the	
bacteria	required	for	each	assay.		
3.3.2.	IgG	surface-binding	assay	(IBA)	
Surface	deposition	of	ST-specific	antibody	was	measured	on	the	surface	of	
formaldehyde-fixed	GBS	using	a	flow	cytometric	assay	performed	in	96-well	
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microtitre	plates.		This	assay	is	the	first	step	developed	to	assess	functional	antibody	
activity	as	it	measures	antibody	binding	to	the	surface	of	whole	GBS	but	not	
antibody-mediated	complement	deposition	(described	below).	Briefly,	2µl	of	each	
test	serum	was	added	to	198µl	of	ST	Ia,	Ib,	II,	III	or	V	GBS	bacteria	at	5.14	x	107	
CFU/mL	in	blocking	buffer	(BB)	(1%	bovine	serum	albumin	(BSA)	in	PBS).	This	was	
incubated	at	25°C	for	30	minutes	with	shaking	(900	rpm),	then	centrifuged.	
Supernatant	was	removed	and	the	pellet	washed	twice	with	200µl	of	BB.	Alexa	
Fluor®	488	Goat	Anti-Human	IgG	(heavy	and	light)	(Life	Technologies)	(1:500)	in	BB	
was	added	and	samples	incubated	for	20	minutes	at	4°C,	before	being	washed	twice	
more	with	BB	and	analysed	by	flow	cytometry.	
3.3.3.	Complement	deposition	assay	(CDA)		
	The	initial	CDA	methods	have	been		described	previously.	(125,	163,	164)	5µl	
heat-inactivated	test	serum	was	added	to	the	relevant	wells	of	a	standard	U-bottom	
96-well	microtitre	plate,	followed	by	35µl	fixed	bacteria	at	a	concentration	of	
5.14x106	in	PBS	1%	BSA	and	10µl	IgG-depleted	human	plasma.(165)	Samples	were	
incubated	at	37°C	for	seven	minutes	with	shaking	at	900rpm,	centrifuged	at	3060g	
for	five	minutes	and	each	well	washed	with	200µl	PBS	1%	BSA,	centrifuged	again	and	
the	pellets	re-suspended	in	200µl	rabbit	anti-C3c-	fluorescein	isothiocyanate	(FITC)	
[Abcam,	UK	(1:500	dilution	in	PBS	1%	BSA)]	and	incubation	continued	at	4°C	for	20	
minutes.	The	plate	was	centrifuged	at	3060g	for	five	minutes	and	each	well	washed	
twice	with	200µl	PBS	1%	BSA,	and	finally	centrifuged	again	and	the	pellets	re-
suspended	in	200µl	PBS	1%	BSA.	The	plates	were	stored	in	the	dark	at	4°C	until	
analysed	by	flow	cytometry.	(Figure	8)	
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Figure	8	-	Summary	of	complement	deposition	assay	
	
	
3.3.4.	Flow	cytometry	
Assays	were	analysed	using	a	Beckman	Coulter	Cyan	flow	cytometer	
equipped	with	a	Cytek	96-well	microtitre	plate	reader.	Protocols	were	initially	set-up	
to	analyse	profiles	of	bacterial	events	using	bacteria	only	control	samples	and	the	
bacteria	identified	on	the	cytometer	by	the	forward	scatter	(FS),	measuring	the	size	
of	the	cell,	and	side	scatter	(SS),	measuring	the	granularity	and	internal	structural	
complexity.	An	analysis	‘gate’	was	drawn	around	the	population	of	interest	(single	
and	diplococci)	and	a	relevant	histogram	plot	created	to	analyse	the	fluorescence	
given	off	by	the	bacterial	population.	For	each	sample,	10,000	individual	events	were	
analysed	for	fluorescence	and	a	horizontal	gate	was	drawn	to	include	10%	of	the	
bacteria	plus	conjugate	control	sample	population	for	IBA	or	10%	of	the	bacteria	plus	
conjugate	plus	complement	control	sample	population	for	the	CDA.		A	fluorescence	
intensity	(FI)	was	calculated	for	each	sample,	which	involved	the	multiplication	of	the	
percentage	of	bacteria	moving	into	the	horizontal	gate	(%-gated),	by	the	mean	
fluorescence	of	that	population	(X-mean).	The	result	was	expressed	as	the	average	FI	
(average	FI	taken	for	duplicate	test	samples)	of	the	test	serum	sample	minus	the	
average	FI	of	the	bacteria	plus	conjugate	only	control	for	IBA,	expressed	as	FI-C	or	
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bacteria	plus	conjugate	plus	complement	control	for	the	CDA,	expressed	as	FI-C’	
(Figure	9).	
3.3.5.	Opsonophagocytic	killing	assay	(OPkA)	
The	following	methods	are	adapted	from	the	GSK	vaccine	research	laboratories	
standard	operating	practice	for	opsonophagocytosis	killing	assay.(156)	
3.3.5.1.	Bacteria	
For	the	OPkA,	GBS	strains	515	02/2012(Ia),	H36Ib	08/2013	(Ib),	COH1	
11/2013	(III)	5401	10/2013	(II)	and	CJBIII	03/2009	(V)	were	grown	up	to	an	OD	of	1.0	
dispersed	in	10%	glycerol	in	1mL	aliquots	into	cryo-vials	for	flash	freezing	in	a	95%	
ethanol	dry	ice	bath	and	stored	at	-70°C	until	use.	Bacteria	were	enumerated	by	
viable	count	on	CCNA	and	incubated	at	37°C	in	5%	CO2	overnight	before	counting.	
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Figure	9	–	Flow	diagram	of	calculation	for	fluorescence	intensities	
	
Diagram	outlines	gating	of	bacterial	population,	followed	by	gating	to	include	10%	of	the	bacteria	plus	complement	control	followed	by	calculation	of	the	fluorescence	index	
and	then	subtracting	the	complement	only	control	to	give	a	final	value	FI-C’	for	the	test	sample.		SS=side	scatter;	FS=forward	scatter;	FITC=fluorescein	isothiocyanate;	
FI=fluorescence	intensity;	Bac=bacteria;	FI-C’=FI-complement	control.	
	
10%	of	bacteria	plus	complement	control	
%nBac	
FI=%nBac	x	mean	FITC	 FI-C’=FI-FI	of	complement	only	control	
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3.3.5.2.	Phagocytes	
HL-60	cells	(CCL240;	American	Type	Culture	Collection,	Manassas,	VA,	USA)	
were	maintained	in	Roswell	Park	Memorial	Institute	(RPMI)	1640	medium	(without	
phenol	red;	Gibco)	supplemented	with	20%	fetal	bovine	serum	(LabTech)	and	1%	L-
glutamine	(Gibco).	The	cells	were	subcultured	daily	to	maintain	the	cell	density	
between	1×105	and	1×106	cells	mL−1.	The	cells	were	differentiated	into	granulocytes	
in	the	same	medium	containing	0.8%	(vol/vol)	N,N-dimethylformamide	(DMF;	Sigma)	
for	5	days.	
	 	 3.3.5.3.	OPkA	protocol	
Prior	to	use,	a	1mL	vial	of	bacteria	was	thawed	at	room	temperature,	diluted	
in	9mL	of	PBS	and	centrifuged	at	1800g	for	10	minutes.	The	pellet	was	resuspended	
in	1mL	of	PBS,	diluted	1:10,	1:20,	1:30	and	1:40	in	Hanks	Buffered	Salt	Solution	
(HBSS)	containing	phenol	red	(HBSS-red)	and	then	diluted	1:2	in	HBSS-red	plus	10%	
normal	rabbit	serum	(Sigma-Aldrich	USA).		
100µl	heat-inactivated	test	sera	diluted	1:3	with	HBSS-red	were	added	to	the	
relevant	wells	of	a	standard	U-bottom	96-well	microtitre	plate	and	a	five	step	
serodilution	preformed	by	transferring	50μL	serum	into	50μL	HBSS-red.	12.5μL	of	
each	dilution	was	then	dispensed	into	a	second	96-well	microtitre	plate,	followed	by	
25µl	fixed	bacteria	at	a	concentration	of	5.x105	CFU/mL	in	HBSS-red,	75μL	HL60	cells	
at	a	concentration	of	2.6	x	107	cells/mL	and	12.5µl	human	complement.	Samples	
were	incubated	at	37°C	for	1	hour	with	shaking	at	600rpm	in	a	Thermomixer	
(Eppendorf,	Germany).	Two	positive	controls	and	six	negative	controls	were	added	
to	each	plate.	The	following	negative	controls	were	used:	two	wells	with	bacteria,	
complement	and	phagocytes	but	without	human	serum;	two	wells	with	bacteria,	
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positive	control	serum	and	complement	but	without	phagocytes	and	two	wells	with	
bacteria,	serum,	phagocytes	and	heat	inactivated	complement.	Before	and	after	the	
one	hour	incubation,	(T0	and	T60),	each	reaction	was	diluted	in	sterile	water	(1:100	at	
T0	by	adding	25μL	of	reaction	to	225μL	sterile	water	,	1:20	and	1:200	at	T60	by	adding	
25μL	to	25μL	of	water	and	then	25μL	of	the	resultant	solution	to	225μL	water	(1:20)	
and	repeating	this	(1:200)).	10μL	of	each	dilution	was	subsequently	plated	by	tilt	
method	onto	CCNA	plates	and	incubated	overnight	at	37°C	in	5%	CO2.	The	following	
day	colonies	on	the	T0	and	T60	plates	were	counted	using	an	automated	colony	
counter.	The	opsonophagocytic	activity	was	determined	as	the	mean	log10	reduction	
in	GBS	CFU/mL	after	60	minutes	of	incubation	at	37°C	compared	to	T0	(LogT0-LogT60).	
The	OPkA	titre	was	expressed	as	the	reciprocal	serum	dilution	leading	to	50%	killing	
of	bacteria:	
killing(%)=[(mean	CFU/mL	T0-mean	CFU	T60)/mean	CFU/mL	T0]100	
	
3.4.	Sample	size	calculation	
Hypothesis	 1:	GBS	 ST-specific	maternal-derived	 antibody	 in	 serum	determines	GBS-
colonisation	in	infants;	
Based	 on	 estimates	 from	 the	 pilot	 study	 of	 100	 women	 in	 The	 Gambia	 which	
established	a	 colonisation	 rate	of	 approximately	24%,	50%	 transfer	of	 colonisation	
from	mother	to	infant	(12%	infants	colonised)	and	6%	prevalence	of	GBS	STIII	(lowest	
GBS	ST	found	in	original	study),(17)	a	sample	size	of	750	women	would	be	required	
to	give	180	colonised	women/90	colonised	infants	and	at	least	10	women/5	infants	
colonised	with	GBS	STIII	and	570	non-colonised	women.	10	mothers	for	each	GBS	ST	
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would	give	80%	power	 to	detect	a	 correlation	of	70%	or	greater	between	GBS	ST-
specific	antibody	and	colonisation.	
Hypothesis	2:	Higher	levels	of	GBS	ST-specific	antibody	in	infants	are	associated	with	
better	 ability	 to	 kill	 GBS	 in-vitro	 and	 this	 represents	 a	 laboratory	 surrogate	 for	
protection	from	disease;	
Based	 on	 the	 pilot	 study,	 all	 infants	 were	 expected	 to	 be	 seropositive.	 Thus	 150	
samples	would	give	over	90%	statistical	power	 to	compare	antibody	concentration	
to	IBA/CDA/OPkA	assays.	
Hypothesis	3:	GBS	colonisation	in	The	Gambia	is	predominantly	due	to	ST	Ia,	III	and	V	
Using	 the	 sample	 size	 of	 150	 colonised	 mothers	 calculated	 for	 hypothesis	 1,	 the	
standard	 error	 and	 95%	 confidence	 intervals	 (CI)	 were	 calculated	 for	 GBS	 ST	
prevalence	 between	 6-40%.	 For	 a	 GBS	 ST	 prevalence	 predicted	 for	 GBS	 STIII,	 a	
sample	size	of	150	colonised	mothers	would	allow	us	to	detect	6%	prevalence	of	this	
GBS	ST	with	a	standard	error	of	1.8%.	Table	4	outlines	the	standard	error	and	95%	
CIs	calculated.	
Table	4	-	Standard	error	and	95%	CIs	for	different	GBS	ST	prevalence	
Prevalence	 Standard	Error	 95%	CI	
6%	 0.018	 2.4-9.6%	
10%	 0.023	 5.4-14.6%	
20%	 0.030	 14-26%	
30%	 0.035	 23-37%	
40%	 0.038	 32.6-47.4%	
	
3.5.	Clinical	data	management	and	statistical	analysis	
A	study-specific,	password	protected	relational	Filemaker	Pro	database	(Filemaker	
Inc.	version	10.0v3)	was	developed	to	collect	clinical	and	demographic	data.	All	
personal	identifiers	were	excluded	from	the	database	and	all	study	participants	were	
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assigned	a	unique	patient	identification	number.	STATA	version	12	(	StataCorp	2013)	
and	GraphPad	Prism	version	6.0	(GraphPad	Software	Inc,	La	Jolla,	California)	were	
used	for	statistical	analysis.		Additional	statistical	support	was	sought	from	Fiona	
Warburton	at	Public	Health	England	who	verified	all	my	statistical	calculations	once	I	
had	completed	the	analysis.	
3.5.1.	Epidemiological	analyses	
Descriptive	statistics	were	calculated	which	included	the	prevalence	of	colonisation	
at	individual	time	points	expressed	as	a	proportion	of	the	total	number	of	
participants.	To	determine	the	individual	risk	factors	for	maternal	and	infant	
colonisation	logistic	regression	was	performed;	analysis	of	variance	(ANOVA)	was	
used	for	the	single	variable	analyses	of	the	transmission	dynamics	at	birth.	Adjusted	
odds	ratios	(AOR)	were	then	calculated	using	variables	from	the	single	variable	
analysis	with	a	p-value	<0.2	using	a	backwards-stepwise	regression	procedure.	The	
log-rank	test	was	used	to	examine	differences	in	duration	of	colonisation	between	
GBS	STs.	Assuming	that	the	vertical	transmission	rate	is	50%	(4)	I	calculated	observed	
vs.	expected	statistics	for	risk	of	infant	colonisation	by	GBS	ST.	For	comparison	
between	our	study	and	the	previous	study	conducted	in	the	Gambia	in	1994	(17),	I	
calculated	95%	CIs	of	the	prevalence	of	GBS	colonisation	in	both	studies.	If	the	CIs	
did	not	overlap	then	the	prevalence	of	colonisation	was	interpreted	as	statistically	
different.	
3.5.2.	Antibody	analyses	
Details	of	the	flow	cytometric	analyses	are	outlined	in	3.3.4.		
Due	to	the	skewed	distribution	of	the	GBS	ST-specific	FI-C’	values,	log	
transformations	were	required	to	conform	to	regression	assumptions.	Potential	
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differences	in	antibody	concentrations	between	colonised	and	non-colonised	
mothers	and	infants	were	evaluated	by	Student's	t	test	after	log	transformation	of	
data.	I	compared	four	groups	(mother	colonised/infant	non-colonised;	mother	
colonised/infant	colonised;	mother	non-colonised/infant	colonised	and	neither	
mother	nor	infant	colonised)	using	ANOVA	following	log-transformation	of	data.	
Comparison	of	log-transformed	serum	FI-C’	values	at	birth	(cord	blood)	and	at	60-89	
days	was	performed	using	a	paired	t	test.	To	determine	which	variables	were	
independently	associated	with	the	acquisition	of	GBS,	logistical	regression	was	used.	
Deming	regression	(166)	was	used	to	determine	the	correlation	between	bacterial	
concentration	and	cord	and	infant	antibody	concentration.	Deming	regression	is	an	
errors-in-variable	model	that	is	an	extension	of	linear	regression.	It	takes	into	
account	possible	errors	in	both	the	x	and	y-axis.	To	ascertain	the	relationship	
between	cord/infant	GBS	ST-specific	functional	antibody	response	and	the	covariates	
maternal	age	and	infant	sex,	I	used	multiple	linear	regression.	Missing	data	were	
excluded	from	analysis.	For	all	comparisons,	p<0.05	was	considered	to	be	significant.		
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Chapter	4	–	Epidemiological	study	
4.1.	Introduction	
In	the	African	setting,	information	on	GBS	colonisation	and	disease	
prevalence	remains	sparse.(6)	Maternal	colonisation	is	the	leading	risk	factor	for	
both	EO-	and	LO-GBS	disease(4),	yet	in	LMIC	little	is	known	about	other	risk	factors	
that	may	affect	not	only	maternal	colonisation	but	also	transmission	from	mother	to	
child.	Limited	knowledge	about	maternal	or	infant	colonising	GBS	STs	in	African	
countries	indicate	that	GBS	STV	may	be	important	as	both	a	colonising	and	invasive	
disease	ST	(12,	26),	similar	to	the	USA	in	the	1990s.(167)	
An	example	of	this	is	the	study	by	Suara	et	al	(1994)	undertaken	in	the	
Gambia,	which	examined	GBS	colonisation	in	pregnant	women	and	their	infants	and	
demonstrated	prevalence	of	maternal	colonisation	of	22%	(30/136	mothers)	and	
13%	in	their	infants	with	GBS	STV	the	predominating	ST.(17)	However,	interpreting	
this	data	is	difficult,	as	selective	media	was	not	used	to	isolate	GBS.	Hence,	there	was	
the	potential	for	overgrowth	of	other	gut	microflora	in	this	study	that	may	have	led	
to	an	underestimation	of	GBS	colonisation	in	this	population.	Additionally,	sampling	
was	limited	to	the	vagina.	We	now	know	that	rectovaginal	sampling	gives	the	highest	
yield	for	GBS.(168)		
Whilst	the	main	purpose	of	the	study	was	to	determine	the	role	of	antibody	
in	prevention	of	colonisation	with	GBS,	the	description	of	the	study	cohort	and	
comparison	with	other	African	studies	is	valuable.	Additionally,	detailed	
characterisation	of	the	cohort	is	essential	in	order	to	understand	the	dynamics	of	
transfer	from	mother	to	child	and	factors	that	may	affect	antibody	concentration	in	
this	population	and	is	indeed	a	strength	of	this	study.		
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This	Chapter	describes	the	study	cohort	including	demographics	and	risk	
factors	for	GBS	colonisation	and	transfer	from	mother	to	child.	Further,	in	this	
Chapter	I	describe	the	prevalence	of	colonising	GBS	STs	in	Gambian	women	and	their	
infants	from	delivery	to	day	60-89	and	the	effect	of	different	risk	factors	on	
colonisation	over	the	entire	study	period.		
	
4.2.	Study	design	and	participants	
The	study	took	place	between	1st	January	2014	and	31st	December	2014	in	
two	government	health	centres	as	described	in	Chapter	3.	The	results	of	this	study	
have	been	published	and	all	figures	and	tables	are	reproduced	from	Le	Doare	et	al	
(2016)	unless	otherwise	indicated.(158)	
Field	workers	explained	the	purpose	of	the	study	to	eligible	participants	in	
their	local	language	(Mandinka,	Wolof,	Fula,	Jola,	Mangago)	and	each	participant	
received	an	information	sheet	and	was	asked	to	sign	an	informed	consent	form,	or	in	
case	of	illiteracy,	the	information	sheet	and	consent	form	were	read	to	the	
participant	in	local	language	and	the	participant	asked	to	provide	a	thumb-print	to	
confirm	their	consent	and	the	consent	form	was	then	countersigned	by	an	impartial	
witness	(Appendix	2).	The	study	was	approved	by	the	Joint	Gambian	
Government/Medical	Research	Council	Research	Ethics	Committee,	SCC	1350	prior	
to	field	activities	(Appendix	1).	
Following	recruitment,	demographic	and	clinical	data	were	collected	from	each	
participating	mother	(Appendix	3).	Since	HIV	is	a	potential	confounding	factor	for	
immune	response,	each	mother	was	offered	a	confirmatory	HIV	test	prior	to	
enrolment.	Women	found	to	be	HIV	positive	were	referred	for	specialist	ongoing	
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care.	All	sick	infants	were	also	offered	an	HIV	test	and	had	blood	cultures	and	
malaria	films	taken	as	part	of	routine	care.	Further	information	about	recruitment	is	
outlined	in	3.1.6.	If	an	infant	died	during	the	study	a	verbal	autopsy	was	carried	out	
to	assess	the	potential	cause	of	death(169).	
	
4.3.	Methods	
The	microbiological	methods	used	for	this	part	of	the	study	are	outlined	in	
Chapter	3.	The	primary	outcome	was	prevalence	of	GBS	ST-specific	colonisation	in	
mothers	and	in	infants	at	birth,	six	days	and	days	60-89	using	microbiological	culture	
and	molecular	techniques.	Secondary	outcomes	were	detection	of	GBS	in	breast	
milk;	infant	acquisition	and	loss	of	GBS	colonisation	during	the	study	follow	up	
period	and	infant	GBS	disease	(sample	obtained	from	sterile	site),	as	ascertained	by	
positive	microbiological	culture	and	confirmatory	PCR.	Infant	GBS	disease	was	
defined	as	infant	presenting	with	features	of	systemic	sepsis	or	meningitis	
(tachycardia,	tachypnoea,	irritability,	poor	feeding	with	or	without	fever)	and	a	
positive	blood	culture	(eligible	infants	had	1-2mL	of	blood	taken	using	aseptic	
technique	and	cultured	in	a	paediatric	blood	bottle	in	a	BACTEC	machine).	Swabs	
were	considered	negative	if	no	GBS	was	evident	by	culture	and	PCR	and	positive	if	
GBS	was	found	on	culture	and	PCR.	If	swabs	were	negative	on	culture	but	positive	on	
PCR,	conventional	PCR	was	performed	to	determine	GBS	ST.	If	the	second	PCR	
resulted	in	the	identification	of	a	GBS	ST	the	samples	were	deemed	positive.	If	no	
GBS	ST	was	identified	or	the	DNA	did	not	amplify,	samples	were	deemed	negative.			
	 74	
4.3.1.	Data	analysis	approach	
Descriptive	statistics	were	calculated,	which	included	the	prevalence	of	
colonisation	at	individual	time	points	expressed	as	a	proportion	of	the	total	number	
of	participants.	Logistical	regression	was	also	performed	for	univariate	analyses	such	
as	individual	risk	factor	and	maternal	colonisation	status;	ANOVA	was	used	for	the	
univariate	analyses	of	the	transmission	dynamics	at	birth.	AORs	were	then	calculated	
using	variables	from	the	univariate	analysis	with	a	p-value	<0.2	using	backwards-
stepwise	logistic	regression.	The	log-rank	test	was	used	to	examine	differences	in	
duration	of	colonisation	between	GBS	STs.	Further	details	can	be	found	in	section	
3.6.1.	Assuming	an	expected	breast	milk	colonisation	rate	similar	to	the	observed	
maternal	rectovaginal	colonisation	rates	of	8.4%	(STIa),	6.8%	(STIb),	16.5%	(STII),	
10.1%	(STIII)	and	54.9%	(STV)	observed	vs.	expected	statistics	for	breast	milk	
colonisation	were	calculated	by	GBS	ST.	For	comparison	between	our	study	and	the	
study	conducted	in	1994,	95%	CIs	for	both	studies	were	calculated.		
	
4.4.	Demographics	
A	total	of	750	mothers	and	their	infants	were	recruited	to	the	study.	All	
mothers	met	the	inclusion	criteria	except	one,	who	was	admitted	to	hospital	on	day	
three	postpartum	severely	unwell	and	subsequently	tested	positive	for	HIV-1,	
despite	a	negative	test	at	20	weeks	gestation.	She	and	her	infant	were	referred	to	
routine	clinical	services	for	further	management	and	samples	excluded	from	further	
analysis.	Of	the	remaining	eligible	women	and	infants,	723	completed	the	day	six	
visit	(median	age	at	follow	up	8	days,	interquartile	range	(IQR)	7-9)	and	684	
completed	60-89	day	follow	up	(median	age	at	follow	up	62	days,	IQR	60-63).	The	
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main	reasons	for	not	completing	follow	up	were:	30	women	moved	out	of	area,	21	
women	whose	partners	were	not	in	agreement	with	continued	study	participation	
left	the	study,	one	postnatal	HIV	infection,	five	declined	for	other	reasons	and	nine	
infants	died	during	the	follow	up	period.	All	infants	were	exclusively	breastfed	for	
the	duration	of	the	study.	Participant	flow	diagram	and	demographic	characteristics	
of	mother-infant	pairs	are	outlined	in	10	and	Table	5.	
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Table	5	-	Mother	and	infant	demographics	and	odds	ratios	of	maternal	GBS	
colonisation	at	delivery	
	 Total	 Colonised	 Non-colonised	 p-value	 OR	(95%	CI)	
Maternal	Age	yrs.	 <20	 110	 40	 70	 0.78	 1	
	 20-24	 262	 81	 181	 	 0.78	(0.5-1.3)	
Mean:	25	(IQR	18-41)	 25-29	 203	 71	 132	 	 0.94	(0.6-1.5)	
	 30+	 175	 61	 114	 	 0.99	(0.6-1.7)	
	Ethnicity	 Mandinka	 315	 115	 200	 0.38	 1	
	 Wolof	 108	 36	 72	 	 0.9	(0.5-1.4)	
	 Fula	 126	 45	 81	 	 1	(0.6-1.5)	
	 Jola	 118	 33	 85	 	 0.7	(0.4-1.0)	
	 Other	 81	 23	 58	 	 0.7	(0.4-1.2)	
	 Missing	 2	 1	 1	 	 	
Maternal	Weight	(kg)	 <50	
50-70	
70-90	
>90	
27	
424	
148	
145	
7	
128	
61	
56	
20	
296	
87	
91	
0.03	
	
1	
1.2	(0.5-3.0)	
2.0	(0.8-5.0)	
1.8	(0.7-4.4)	
	 Missing	 6	 3	 3	 	 	
Maternal	illness	in	pregnancy	 Yes	
No	
Missing	
128	
504	
118	
45	
165	
43	
83	
339	
75	
0.32	 1	
1.1	(0.7-1.7)	
Maternal	Hb	below	10g/dL	 No	
Yes	
99	
651	
42	
211	
57	
440	
0.04	 1	
0.5	(0.3-0.9)	
Maternal	antibiotics	in	early	
pregnancy	
No	
Yes	
Missing	
505	
128	
117	
166	
44	
74	
339	
84	
43	
0.74	 1	
1.1	(0.7-1.6)	
Gravida	 1	 208	 67	 141	 0.44	 1	
Median:	2	(IQR	1-4)	 2-4	 370	 121	 249	 	 1	(0.7-1.5)	
	 5+	 169	 63	 116	 	 1.3	(0.8-2.0)	
	 Missing	 3	 1	 2	 	 	
Parity	 0-1	 212	 68	 144	 0.59	 1	
Median:	1	(IQR	0-4)	 2-4	 468	 164	 304	 	 1.1	(0.8-1.6)	
	 5+	
Missing	
67	
3	
20	
1	
47	
2	
	 1.1	(0.7-1.7)	
Living	children	 0	 230	 80	 150	 0.17	 1	
Median:	1	(IQR	0-3)	 1-4	 465	 155	 311	 	 0.9	(0.7-1.3)	
	 5+	 53	 17	 36	 	 0.9	(0.5-1.7)	
	 Missing	 2	 2	 0	 	 	
Spontaneous	abortion	 0	 649	 213	 436	 0.09	 1	
Median	1(IQR	0-2)	 1	 53	 20	 33	 	 1.2	(0.7-2.2)	
	 2+	 14	 7	 7	 	 1.5	(0.8-2.7)	
	 Missing	 34	 16	 18	 	 	
Stillbirths	 0	
1	
2+	
641	
75	
28	
207	
29	
15	
434	
46	
13	
0.05	 1	
0.9	(0.4-2.1)	
3.6	(1.2-10.5)	
	 Missing	 6	 2	 4	 	 	
Number	of	ANC	visits	 1	
2+	
303	
447	
85	
168	
218	
279	
0.01	 1	
1.5	(1.1-2.1)	
Attendance	by	midwife	or	TBA	 Midwife	
TBA	
Missing	
436	
254	
60	
168	
67	
37	
268	
187	
23	
0.001	 1	
0.5	(0.4-0.8)	
Birth	Season	 Dry	Cool	
Dry	Hot	
Wet	
280	
175	
295	
55	
85	
113	
225	
90	
18	
0.001	 1	
3.9	(2.5-5.9)	
2.5	(1.7-3.7)	
Infant	Sex	 Male	 369	 122	 247	 0.59	 1.1	(0.8-1.5)	
	 Female	 381	 131	 250	 	 	
Birth	Weight	(kg)	 2.0-3	 260	 73	 187	 0.04	 1	
	 3.1-4	 464	 169	 295	 	 1.5(1.1-2.0)	
	 >4.0	 26	 						11	 15	 	 1.9	(0.8-4.3)	
Gest.	Age	at	birth	(wks.)	 <34		 56	 18	 38	 0.03	 1	
	 34-37	 231	 83	 148	 	 0.7	(0.4-1.1)	
	 38+	 463	 152	 311	 	 1.1	(0.7-1.7)	
IQR	=	inter-quartile	range;	ANC=antenatal	clinic;	TBA=traditional	birth	attendant	
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Figure	10	-	Study	flow	diagram	
	
The	recruitment	process	at	each	stage	of	the	field	study	with	reasons	for	exclusion	or	loss	to	follow	up.	
Loss	to	follow-up	was	3.6%	at	end	of	day	6	and	8.8%	by	the	end	of	3	months	of	life.		APH	=	antepartum	
haemorrhage,	PPH	=postpartum	haemorrhage,	LBW=low	birth	weight	(<2kg).	
14428	Antenatal	visit	
6024	hospital	deliveries	
353	maternal	
complicaqons:	
Obstructed	labour	22,	APH	
36,	PPH	30,	Preeclampsia	
213,	eclampsia	52,	
maternal	death	77	
5671	healthy	women	
	2010	Neonatal	
complicaqons:	.	LBW	1090,	
prematurity	773,	sqllbirths	
106,	neonatal	death	41	
3661	eligible	mothers	and	
infants	
750	mothers	and	infants	at	
birth	
723	arended	day	6	
684	arended	day	60-89	
39	loss	to	follow	up:		
6	infant	deaths,	12	
partners	no	longer	in	
agreement,	5	declined,	16	
moved	away	
27	loss	to	follow	up:		
14	women	moved	away,	3	
infants	died,	9	partners	did	
not	agree,	1	postnatal	HIV	
infecqon	
8404	out-of	hospital	
deliveries	
	 78	
4.5.	Antibiotic	treatment	in	pregnancy	
Over	the	course	of	the	study,	77	women	received	antibiotics	during	
pregnancy:	34	for	urinary	tract	infection;	10	for	pneumonia;	14	for	vaginal	discharge;	
nine	for	malaria	and	10	for	non-malarial	fever.	Of	these,	73	women	received	
amoxicillin	(median	time	prior	to	delivery	42	days	[IQR	18-63	days]);	16	received	
antimalarial	therapy	(median	38	[IQR	31-41])	and	three	received	erythromycin.	In	
the	three	months	of	follow	up,	51	infants	required	antibiotic	therapy:	34	received	
ampicillin	and	gentamicin	for	presumed	neonatal	sepsis	(median	18	days	old	[IQR	4-
34]);	ten	received	amoxicillin	or	cloxacillin	for	skin	infections	(median	20	days	[IQR	
10-58]);	seven	received	other	antibiotics	(median	18	days	[IQR	11-23].	
	
4.6.	Prevalence	and	risk	factors	for	maternal	colonisation	
The	overall	prevalence	of	rectovaginal	GBS	colonisation	at	delivery	was	33.7%	
(253	women).	In	univariate	analysis	maternal	weight	≥50kg,	maternal	haemoglobin	
<10g/dL,	more	than	one	previous	stillbirth,	more	than	one	ANC	visit,	midwife	
delivery,	delivery	during	the	dry	hot	or	wet	season	and	gestation	under	34	weeks	
were	associated	with	increased	risk	of	GBS	colonisation	(Table	5).	In	adjusted	
analysis,	maternal	haemoglobin	<10g/dL,	history	of	more	than	one	previous	
stillbirth,	attendance	at	delivery	by	a	midwife	rather	than	a	traditional	birth	
attendant	(TBA)	and	giving	birth	during	the	dry	hot	or	wet	season	were	associated	
with	increased	odds	of	maternal	GBS	colonisation	at	delivery	(Table	6).		
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Table	6	-	Multivariable	analysis:	risk	factors	for	maternal	GBS	colonisation	at	time	
of	delivery	
	 AOR	(95%	CI)	 p-value	
Maternal	Weight	(kg)	 <50	
50-70	
71-90	
>90	
1	
1.0 (0.4-1.6)	
1.7	(0.6-4.5)	
1.4	(0.3-4.7)	
	
0.96	
0.30	
0.68	
Number	of	ANC	visits	 1	
2+	
1	
1.3	(0.9-1.8)	
	
0.16	
Maternal	Hb	above	10g/dL	 No	
Yes	
1	
0.7	(0.4-0.9)	
	
0.04	
Attendance	by	midwife	or	TBA	 Midwife	 1	 	
	 TBA	 0.6	(0.4-0.9)	 0.03	
Previous	Stillbirths	 0	
1	
2+	
1	
0.9	(0.4-2.0)	
5.4	(1.6-18.0)	
	
0.86	
0.009	
Birth	Season	 Dry	Cool	
Dry	Hot	
Wet	
1	
2.0	(1.3-3.1)	
1.8	(1.2-2.7)	
	
0.004	
0.008	
	ANC	=antenatal	clinic,	Hb=haemoglobin;	TBA	=	traditional	birth	attendant;	AOR=adjusted	odds	ratio	
	
4.7.	GBS	colonisation	dynamics	at	birth	
There	were	253	colonised	mothers	and	186	colonised	infants	at	birth,	of	
whom	146	were	born	to	colonised	women	(57.0%).	Table	7	describes	the	number	of	
colonised	infants	at	birth,	day	six	and	at	day	60-89	according	to	colonisation	site.	
Figures	11	and	12	demonstrate	colonisation	dynamics	at	each	time	point.	
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Table	7	-	Dynamics	of	colonisation	by	site	and	time	point	(%total)	
Birth	n=750;	253	colonised	mothers	
(%total)	
	
Mother	and	infant	colonised	 146	(19.5%	total;	57.7%	born	to	colonised	mothers)	
Infants	colonised,	mothers	non-colonised	 40	(5.3)	
Total	colonised	infants	 186	(24.8)	
Mothers	colonised,	infants	non-colonised	 107	(14.3)	
Neither	mother	nor	infant	colonised	 457	(60.9)	
Site	of	colonisation	at	birth	n=186	(%	colonised	infants)	
Nasopharyngeal	and	rectal	 96	(51.6)	
Rectal	only	 68.	(36.6)	
Nasopharyngeal	only	 22	(11.8)	
Site	of	colonisation	day	6-9;	n=722		(%	of	the	181	colonised	infants)	
Nasopharyngeal	and	rectal	 57	(31.5)	
Rectal	only	 95	(52.5)		
Nasopharyngeal	only	 29	(16.0)	
Site	of	colonisation	day	60-89;	n=684	(%	the	94	colonised	infants)	
Nasopharyngeal	and	rectal	 11	(11.7)	
Rectal	only	 57	(60.6)	
Nasopharyngeal	only	 26	(27.7)	
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Figure	11	-	Infant	GBS	colonisation	status	over	time	
	
Bars	represent	percentage	of	infants	colonised/uncolonised	at	each	of	the	time	points;	blue	bar=birth,	
red	=	day	6	compared	to	birth	and	green	=	day	60-89	compared	to	day	6.	N=750	at	birth;	n=723	at	day	
6	and	n=684	at	day	60-89.			
	
Figure	12	-	Breast	milk	colonisation	over	time	
	
Bars	represent	percentage	of	breast	milk	colonised/uncolonised	at	each	of	the	time	points;	blue	
bar=colostrum	on	day	1,	red	=	day	6	compared	to	colostrum	and	green	=	day	60-89	compared	to	day	
6.	N=750	at	birth;	n=723	at	day	6	and	n=684	at	day	60-89.			
	
Compared	to	mother/infant	pairs	who	were	both	non-colonised	at	birth,	
mother/infant	pairs	were	more	likely	to	both	be	colonised	if	mother’s	weight	was	
75%	
25%	
69%	
5%	
20%	
6%	
71%	
6%	
9%	
14%	
0%	
10%	
20%	
30%	
40%	
50%	
60%	
70%	
80%	
remain	uncolonised	 New	colonisaqon	 Remained	colonised	 colonisaqon	lost	
%
	c
ol
on
is
ed
	
90%	
10%	
83%	
9%	
2%	
6%	
76%	
13%	
2%	
9%	
0%	
10%	
20%	
30%	
40%	
50%	
60%	
70%	
80%	
90%	
100%	
remain	uncolonised	 New	colonisaqon	 Remained	colonised	 colonisaqon	lost	
%
	c
ol
on
is
ed
	
	 82	
above	70kg,	infants	were	born	at	less	than	37	weeks,	born	during	the	dry	hot	or	wet	
seasons,	mothers	with	more	than	one	previous	stillbirth,	mothers	attending	ANC	
more	than	once,	infants	delivered	by	midwives,	infants	born	with	a	birth	weight	
below	3.1kg	or	receiving	breast	milk	colonised	with	GBS.	(Table	8)	
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Table	8	-	Characteristics	of	mother/infant	pairs	according	to	colonisation	status	at	
birth	
	 Total		 M+I+	 M+I-	 M-I+	 M-I-	 p-value	
Maternal	weight	(kg)	
<50	
50-70	
70-90	
90+	
Missing	
	
27	
424	
148	
145	
6	
	
2	
74	
36	
32	
3	
	
5	
54	
25	
23	
0	
	
4	
21	
3	
9	
3	
	
16	
275	
84	
81	
0	
	
0.04	
Stillbirths	
0	
1	
2+	
Missing	
	
641	
75	
28	
6	
	
119	
20	
5	
2	
	
87	
9	
10	
1	
	
32	
6	
2	
0	
	
403	
40	
11	
3	
	
	
0.03	
Number	of	ANC	visits	
1	
2+	
	
303	
447	
	
58	
88	
	
27	
80	
	
15	
25	
	
203	
254	
	
	
0.002	
Midwife	delivery	
TBA	
Missing	
436	
254	
60	
108	
29	
9	
60	
38	
9	
20	
12	
8	
248	
175	
34	
<0.001	
Season	
Dry	Cool	
Dry	Hot	
Wet	
	
280	
175	
295	
	
22	
66	
58	
	
33	
19	
55	
	
17	
3	
20	
	
208	
87	
162	
	
	
<0.001	
Birth	weight	(kg)	
2.0-3	
3.1-4	
>4.0	
	
260	
464	
26	
	
44	
95	
7	
	
29	
74	
4	
	
20	
18	
2	
	
167	
277	
13	
	
0.02	
Gestation	(weeks)	
<34	
34-37	
38+	
	
56	
231	
463	
	
13	
57	
76	
	
5	
26	
76	
	
4	
12	
24	
	
34	
136	
287	
	
0.04	
Breast	milk	colonised	
Yes	
No	
Missing	
	
64	
600	
86	
	
31	
101	
14	
	
18	
77	
12	
	
7	
31	
2	
	
8	
391	
58	
	
<0.001	
Spontaneous	abortion	
0	
1	
2+	
Missing	
	
649	
53	
14	
34	
	
121	
14	
7	
11	
	
92	
6	
1	
0	
	
31	
4	
0	
5	
	
405	
29	
6	
18	
0.09	
Ethnicity	
Mandinka	
Wolof	
Fula	
Jola	
Other	
Missing	
	
315	
108	
126	
118	
81	
2	
	
63	
23	
28	
21	
11	
0	
	
52	
13	
17	
12	
12	
1	
	
23	
8	
2	
3	
4	
0	
	
177	
64	
79	
82	
54	
1	
0.10	
Maternal	Hb	<10g/dL	
No	
Yes	
	
99	
651	
	
24	
122	
	
18	
89	
	
2	
33	
	
55	
403	
0.11	
Maternal	Age	
<20	
20-24	
25-29	
30+	
	
110	
262	
203	
175	
	
23	
43	
46	
34	
	
17	
38	
25	
27	
	
2	
19	
11	
8	
	
68	
162	
121	
106	
0.96	
Mother	ill	
Yes	
No	
Missing	
	
128	
504	
118	
	
24	
97	
25	
	
21	
68	
18	
	
3	
25	
12	
	
80	
314	
63	
0.48	
Maternal	antibiotics	in	pregnancy	
No																																																						505	
Yes																																																				128	
	
99	
23	
	
92	
24	
	
0	
0	
	
314	
81	
	
0.91	
Gravida	
1	
2-4	
5+	
Missing	
	
208	
370	
169	
3	
	
39	
67	
39	
1	
	
28	
54	
25	
0	
	
13	
17	
10	
0	
	
128	
232	
95	
2	
0.44	
Parity	
0-1	
2-4	
5+	
Missing	
	
212	
468	
67	
3	
	
39	
96	
10	
1	
	
29	
68	
10	
0	
	
13	
24	
3	
0	
	
131	
280	
44	
2	
0.94	
Living	children	
0	
1-4	
5+	
Missing	
	
230	
465	
53	
2	
	
43	
94	
7	
2	
	
37	
61	
9	
0	
	
14	
25	
1	
0	
	
136	
285	
36	
0	
0.66	
Infant	Sex	
Male	
Female	
	
369	
381	
	
72	
74	
	
50	
57	
	
23	
17	
	
224	
233	
0.71	
M+I+=mother	and	infant	colonised;	M+I-=mother	colonised,	infant	non-colonised;	M-I+=mother	non-colonised,	infant	colonised,	
M-I-=neither	mother	nor	infant	colonised;	TBA	=	traditional	birth	attendant;	ANC=antenatal	clinic;	Hb=haemoglobin.	
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In	adjusted	analysis,	compared	to	mother/infant	pairs	who	were	both	non-
colonised	at	birth,	mother/infant	pairs	were	more	likely	both	to	be	colonised	if	birth	
occurred	in	the	dry	hot	or	wet	seasons,	infants	were	born	to	mothers	with	one	or	
more	previous	stillbirths	or	abortions,	or	infants	born	before	34	weeks	gestation.		
Compared	to	mother/infant	pairs	where	neither	was	colonised,	mother/infant	pairs	
where	the	mother	was	colonised	but	not	the	infant	were	more	likely	if	the	mother	
had	had	more	than	one	previous	stillbirth,	or	if	the	mother	gave	birth	during	the	wet	
season.	Infant	colonisation	in	the	absence	of	maternal	colonisation	(n=40)	was	
associated	with	gestation	before	34	weeks.	(Table	9)	
Most	notably,	compared	to	mother/infant	pairs	at	birth	where	both	
remained	non-colonised,	infants	born	to	mothers	who	had	GBS	cultured	in	their	
breast	milk	were	significantly	more	likely	to	be	colonised	with	GBS.	(Table	9)	
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Table	9	-	Multivariable	analysis	of	maternal/infant	pairs	by	GBS	colonisation	status	
at	time	of	delivery	
	 M+I+*	
OR	(95%	CI)	
M+I-*	
OR	(95%	CI)	
M-I+*	
OR	(95%	CI)	
Season	
Dry	Cool	
Dry	Hot	
Wet	
	
1	
8.3	(3.9-17.6)	
3.5	(1.8-6.8)	
	
1	
1.8	(0.8-3.9)	
2.3	(1.3-4.3)	
	
1	
0.4	(0.1-1.4)	
1.1	(0.5-2.5)	
Breast	milk	colonised	
Yes	
No	
	
21.0	(8.6-51.3)	
1	
	
11.5	(4.5-
29.4)	
1	
	
7.5	(2.0-27.5)	
1	
Gestation	(weeks)	
<34	
34-37	
38+	
	
1	
0.9	(0.9-1.0)	
0.4	(0.2-1.0)	
	
1	
1.0	(0.9-1.1)	
0.5	(0.3-1.6)	
	
1	
0.9	(0.8-1.0)	
0.9	(0.8-1.0)	
Midwife	delivery	
TBA	
1	
0.9	(0.5-1.6)	
1	
1.0	(0.6-1.8)	
1	
0.6	(0.2-1.3)	
Number	of	antenatal	clinic	
visits	
1	
2+	
	
	
1	
1.1	(0.7-1.9)	
	
	
1	
1.2	(0.8-2.1)	
	
	
1	
1.3	(0.6-2.8)	
Stillbirths	
0	
1	
2+	
	
1	
2.5	(1.0-8.7)	
2.4	(0.9-4.1)	
	
1	
2.0	(1.0-4.7)	
2.2	(0.9-	2.1)	
	
1	
1.4	(0.3-5.9)	
ND	
Spontaneous	abortion	
0	
1	
2+	
	
1	
0.9	(0.5-1.4)	
1.2	(1.1-2.3)	
	
1	
0.8	(0.3-2.1)	
0.3	(0.0-2.2)	
	
1	
1.0 (0.2-5.5)	
2.0 ND	
Gravida	
1	
2-4	
5+	
1	
1.0 (0.9-1.0)	
1.0	(0.5-2.0)	
1	
1.1	(0.6-2.0)	
0.8	(0.4-1.8)	
1	
1.0	(0.8-1.2)	
0.8	(0.3-2.3)	
M+I+=mother	and	infant	colonised;	M+I-=mother	colonised,	infant	non-colonised;	M-I+=mother	non-
colonised,	infant	colonised,	M-I-=neither	mother	nor	infant	colonised;	TBA=traditional	birth	
attendant.*M-I-	base	group,	adjusted	odds	ratios	are	compared	to	this	group.	
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4.8.	GBS	colonisation	dynamics	at	day	six	and	day	60-89	
Infants	born	to	colonised	mothers	remained	at	increased	risk	of	colonisation	
up	to	day	six	if	born	during	the	dry	hot	season,	but	not	at	day	60-89.	These	infants	
also	had	increased	risk	of	colonisation	if	born	before	34	weeks	gestation	at	both	six	
days	and	day	60-89.	A	birth	weight	over	3.1kg	was	associated	with	a	decreased	risk	
of	colonisation	at	both	time	points	after	birth.	(Table	10).	
The	association	between	breast	milk	colonisation	and	infant	colonisation	
remained	significant	up	to	89	days	regardless	if	GBS	was	isolated	in	the	maternal	
rectovaginal	tract	at	delivery	or	not.	(Table	10)	
Infants	born	to	non-colonised	mothers	had	an	increased	risk	of	being	GBS	
colonised	on	day	six	if	born	during	the	wet	season	and	up	to	89	days	if	born	during	
the	dry	hot	season.	These	data	suggest	that	infant	colonisation	is	most	prevalent	
during	the	wet	season	in	this	setting	as	infants	born	during	the	dry	hot	season	would	
be	60-89	days	of	age	during	the	wet	season	(Table	10).		
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Table	10	-	Univariate	analysis	of	infant	GBS	colonisation	dynamics	over	time	
compared	to	birth	
	
Mother	GBS	colonised	at	delivery	
Birth		
OR	(95%	CI)	
Day	6		
OR	(95%	CI)	
day	60-89		
OR	(95%	CI)	
Birth	Season	 Dry	Cool	
Dry	Hot	
Wet	
1	
4.6	(2.2-9.7)	
1.4	(0.7-2.8)	
0.2	(0.1-0.6)	
1.9	(1.0-4.1)	
0.7	(0.3-1.5)	
0.1	(0.0-0.4)	
0.6	(0.2-1.3)	
0.3	(0.1-0.7)	
Living	Children	 0	
1-4	
5+	
1	
0.9	(0.5-1.6)	
0.9	(0.3-2.6)	
0.5	(0.3-0.9)	
0.4	(0.2-0.7)	
0.6	(0.2-1.8)	
0.2	(0.1-0.4)	
0.1	(0.0-0.3)	
0.2	(0.0-0.9)	
Gestation	at	birth	(wks.)	 <34	
34-37	
38+	
1	
0.9	(0.3-2.4)	
0.4	(0.1-1.0)	
0.4	(0.1-1.4)	
0.3	(0.1-0.9)	
0.2	(0.1-0.5)	
ND	
0.2	(0.1-0.7)	
0.0	(0.0-0.1)	
Infant	Weight	(kg)	 2.0-3	
3.1-4.0	
>4.0	
1	
1.2	(0.4-3.8)	
0.6	(0.1-2.3)	
0.5	(0.2-1.0)	
0.7	(0.3-0.9)	
0.3	(0.1-0.7)	
0.1	(0.0-0.3)	
0.1	(0.1-0.3)	
0.1	(0.0-0.6)	
BM	colonised	 Yes	
No	
0.9	(0.5-1.7)	
1	
0.4	(0.2-0.8)	
0.4	(0.3-0.6)	
0.3	(0.1-0.7)	
0.1	(0.1-0.2)	
Infant	Sex																																	Male	
																																																		Female	
1	
0.7	(0.4-1.2)	
0.4	(0.3-0.7)	
0.4	(0.2-0.6)	
0.1(0.1-0.3)	
0.1(0.1-0.3)	
Mother	not	GBS	colonised	at	delivery	 	 	 	
Birth	Season	 Dry	Cool	
Dry	Hot	
Wet	
1	
1	
2.1	(0.8-6.0)	
1.4	(0.5-4.3)	
1.3	(0.3-5.3)	
4.1	(1.6-10.5)	
0.8	(0.2-2.8)	
4.7	(1.7-13.5)	
0.2	(0.0-1.9)	
Living	Children	 0	
1-4	
5+	
1	
1.0 (0.3-2.9)	
2.0 0.8	(0.1-7.1)	
1.8	(0.5-5.7)	
2.2	(0.8-5.9)	
1	
1.7	(0.5-5.6)	
0.7	(0.2-2.3)	
0.8	(0.1-7.3)	
Gestation	at	birth	(wks.)	 <34	
34-37	
38+	
1	
1.6	(0.2-13.4)	
1.1	(0.1-9.0)	
3.3	(0.3-34.4)	
2.5	(0.3-20.6)	
2.2	(0.3-17.3)	
1	
1.4	(0.2-13.0)	
1.3	(0.2-10.8)	
Infant	Weight	(kg)	 2.0-3.0	
3.1-4.0	
>4.0	
1	
0.5	(0.2-1.4)	
0.9	(0.2-2.3)	
1.2	(0.4-3.8)	
1.2	(0.5-2.9)	
1.7	(0.9-4.9)	
0.6	(0.1-2.3)	
0.6	(0.2-1.7)	
0.4	(0.3-2.2)	
BM	colonised	 Yes	
No	
14.2	(4.0-50.8)	
1	
6.9	(2.5-19.1)	
2.0	(0.9-4.2)	
3.3	(1.2-11.0)	
1.0	(0.4-2.5)	
Infant	Sex																																Male	
																																															Female	
1	
0.3	(0.1-1.0)	
1.4	(0.6-3.1)	
1.1	(0.5-2.5)	
0.8	(0.3-2.0)	
0.5	(0.2-1.5)	
GBS=	Group	B	Streptococcus;	CI=95%	confidence	interval;	OR=odds	ratio;	wk=weeks;	kg=kilograms;	
BM=breast	milk	
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4.9.	Serotype	distribution	
The	predominant	maternal	rectovaginal	colonising	GBS	ST	was	GBS	STV	in	
54.9%	of	colonised	mothers.	Infants	were	more	likely	to	be	colonised	with	GBS	STV	
at	birth	(p=0.004),	day	six	(p=0.004)	and	day	60-89	(p=0.009)	than	any	other	GBS	ST.	
At	birth,	infants	were	more	likely	to	be	colonised	with	GBS	STs	III	and	V	if	their	
mothers	were	colonised	with	GBS	STs	III	and	V	(x2=24.4,	p<0.001)	compared	to	
mothers	colonised	with	other	GBS	STs.	(Figure	13).		
Mothers’	breast	milk	was	more	likely	to	be	colonised	with	GBS	STV	(p<0.001)	
at	birth	and	day	60-89	than	any	other	GBS	ST.	At	birth	colostrum	was	more	likely	
colonised	with	GBS	ST	III	(p<0.001)	and	V	(p=0.02)	than	Ia,	or	II	(Figure	13).	
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Figure	13	-	Colonising	serotype	distribution	by	isolation	site	and	time	point	
	
Pie	charts	demonstrating	percentage	by	GBS	serotype	of	maternal	rectovaginal	colonisation	at	
delivery;	breast	milk	and	infant	colonisation	by	time	point;	BM=	breast	milk;	Ia=serotype	Ia,	
Ib=serotype	Ib,	II=serotype	II,	III=serotype	III,	V=serotype	V.	N=750	at	birth;	n=723	at	day	6	and	n=684	
at	day	60-89.		
Maternal colonisation by serotype
Total=237
8.4%  Ia
6.8%  Ib
16.5%  II
10.1%  III
54.9%  V
3.4%  other
Infant colonisation by serotype V2
Total=107
6.5%  Ia
7.5%  Ib
17.8%  II
8.4%  III
58.9%  V
0.9%  other
BM colonisation by serotype V1
Total=60
1.7%  Ia
10.0%  Ib
3.3%  II
15.0%  III
63.3%  V
6.7%  other
BM colonisation by serotype V3
Total=79
3.8%  Ia
5.1%  II
5.1%  III
86.1%  V
Infant colonisation by serotype V1
Total=158
7.6%  Ia
5.1%  Ib
17.1%  II
10.8%  III
57.0%  V
2.5%  other
Infant colonisation by serotype V3
Total=50
20.0%  Ia
10.0%  Ib
24.0%  II
2.0%  III
44.0%  V
BM colonisation by serotype V2
Total=50
4.0%  Ia
6.0%  Ib
10.0%  II
24.0%  III
48.0%  V
8.0%  other
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4.10.	Neonatal	sepsis	
During	the	study	period,	51	infants	(6.8%)	presented	with	signs	of	infection	
(68	per	1000	live	births):	18	with	signs	of	pneumonia,	22	with	signs	of	other	febrile	
illness,	ten	with	skin	infections	and	one	with	signs	of	meningitis.	One	child	
presenting	on	day	six	of	life	with	irritability	and	poor	feeding,	had	a	positive	
cerebrospinal	fluid	(CSF)	culture	for	GBS	and	was	treated	for	21	days	with	ampicillin	
and	gentamicin	(1.3	per	1000	live	births).	This	infant	was	born	to	a	mother	who	had	
GBS	STV	cultured	from	both	rectovaginal	swab	and	breast	milk	at	birth	and	day	six	of	
life	and	the	infant	swab	was	positive	at	birth	and	day	six	for	GBS	STV.		
Nine	infants	died	during	the	study	period.	Based	on	verbal	autopsy,	six	
deaths	were	due	to	pneumonia	(median	age	at	death	7	days	[IQR	2-35]);	three	were	
due	to	sepsis	(median	age	6	days	[IQR	1-48]).	Blood	cultures	were	GBS	negative	in	all	
cases.	One	infant	was	born	to	a	colonised	mother	and	was	also	colonised	with	GBS	at	
the	time	of	birth	but	was	non-colonised	on	day	6.	This	infant	died	of	presumed	
sepsis	on	day	48	of	life.	No	other	infants	who	died	or	their	mothers	were	colonised	
with	GBS	at	time	of	birth	or	day	6	of	life.	All	infants	died	prior	to	the	final	follow-up	
appointment.		There	was	no	bacteriological	confirmation	of	GBS	disease	as	a	cause	
of	death	in	any	case.	
	
4.11.	Discussion	
In	this	longitudinal	study	undertaken	in	Gambian	mothers	and	their	infants,	
the	first	colonisation	study	in	the	Gambia	for	25	years	and	the	first	longitudinal	study	
undertaken	in	this	population,	colonisation	of	Gambian	mothers	and	their	infants	
was	assessed	and	demonstrated	high	prevalence	of	GBS	colonisation	in	mothers	at	
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birth	and	in	their	infants	up	to	89	days	of	life.		In	addition,	infants	were	more	likely	to	
be	colonised	if	GBS	was	isolated	from	their	mother’s	breast	milk.	The	overall	
prevalence	of	maternal	GBS	in	this	population	was	higher	than	in	the	original	study	
by	Suara	et	al	(1992)	at	33%	vs.	22%.(17)22%.(17)	However,	the	previous	study	likely	
under-identified	GBS	colonisation,	as	selective	medium	was	not	used	in	the	
microbiology	laboratory	at	the	time	the	study	was	undertaken	by	Suara	et	al.	The	
prevalence	of	GBS	colonisation	in	this	study	is	similar	to	the	recently	reported	
pooled	prevalence	in	South	African	women	(30.4%).(12)		
Our	finding	that	mothers	with	more	than	one	stillbirth	demonstrated	an	
increased	odds	of	having	a	colonised	infant	are	in	concordance	with	Monari	et	al,	
who	identified	stillbirth	as	a	risk	factor	for	invasive	EO-GBS	disease.(170)	This	
phenomenon	has	also	been	noted	in	non-human	primates	(171),	but	there	are	
currently	little	human	data	on	the	association	between	stillbirth,	GBS	colonisation	
and	invasive	disease.	A	recent	meta-analysis	of	GBS	and	stillbirths	was	unable	to	
identify	a	global	link	between	the	two	due	to	the	scarcity	of	data	and	differences	in	
reporting	methods	and	definitions.(172)		
The	prevalence	of	infant	colonisation	in	this	study	is	similar	to	previous	
studies	in	Europe	(173-176)	but	higher	than	those	from	other	African	countries.(177)	
Selective	media,	known	to	increase	the	yield	of	GBS,	was	used	and	this	could	account	
for	the	differences	between	this	study	and	those	using	less	sensitive	culture	
techniques.	To	our	knowledge	this	is	the	first	longitudinal	study	of	infant	
colonisation	and	demonstrates	that	GBS	colonisation	rates	remain	high	up	to	89	days	
of	life.	The	overwhelming	risk	factor	for	infant	colonisation	at	all	time	points	was	GBS	
colonisation	of	their	mother	at	the	time	of	birth.	Delivery	before	34	weeks	also	
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increased	the	odds	of	GBS	colonisation	at	birth.	Similar	studies	have	indicated	that	
risk	factors	for	infant	colonisation	include	maternal	rectovaginal	colonisation,	
preterm	delivery,	low	birth	weight	and	maternal	urinary	tract	infection	(4,	137,	173,	
176).(4,	137,	173,	176).	However,	unlike	these	studies	low	birth	weight	was	not	
identified	as	a	risk	factor,	probably	because	only	infants	weighing	more	than	2	kg	
were	recruited.		
Several	case	reports	suggest	that	isolation	of	GBS	in	breast	milk	is	implicated	
in	late	onset	GBS	disease.(178,	179)	Our	data	support	this	suggestion,	since	GBS	
colonisation	in	breast	milk	was	also	identified	as	a	risk	factor	for	neonatal	
colonisation	at	delivery	and	for	persistence	of	infant	colonisation	throughout	the	
first	three	months	of	life.	This	is	an	important	finding	in	a	population	such	as	this	
with	high	rates	of	breastfeeding.	It	may	be	that	GBS	enters	the	mammary	glands	
from	a	colonised	infant	following	infant	suckling.	Conversely,	it	is	also	possible	that	
gut	microbiota	may	pass	into	the	breast	via	the	entero-mammary	circulation.(180)	
Whether	it	is	also	a	risk	factor	for	LO-GBS	disease	in	this	population	is	not	clear,	since	
cases	of	LO-GBS	disease	were	not	observed	and	the	study	was	not	powered	to	
measure	clinical	disease	as	an	endpoint.	Conversely,	it	might	be	a	protective	factor	
through	induction	of	immunity.(40)	The	relevance	of	this	finding	requires	further	
study.			
It	is	interesting	to	note	that	risk	factors	for	maternal	colonisation	include	
midwife	delivery	and	increasing	number	of	antenatal	visits.	This	phenomenon	has	
not	been	previously	noted	in	LMIC	where	hygienic	birth	practices	may	be	
compromised.	GBS	has	been	implicated	in	nosocomial	outbreaks	globally	(181,	182),	
although	the	number	of	reported	outbreaks	in	resource-rich	countries	has	greatly	
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reduced	since	the	implementation	of	GBS	screening	programmes.	It	is	conceivable	
that	unclean	birth	practices,	especially	in	times	of	clean	water	shortage,	such	as	the	
hot,	dry	and	wet	seasons,	may	facilitate	the	fecal-oral	spread	of	GBS	between	
colonised	and	non-colonised	mothers	and	their	infants.	It	is	also	possible	that	
increasing	hospital	exposure	by	midwives	may	increase	the	risk	of	nosocomial	
transmission.		
A	large	proportion	of	women	were	colonised	with	GBS	STV,	similar	to	the	
previous	smaller	study	by	Suara	et	al,	which	identified	32	colonised	pregnant	women	
of	whom	12	(30%)	were	colonised	with	GBS	STV.(17)	STV	has	been	identified	as	an	
important	neonatal	and	adult	colonising	and	disease-causing	GBS	ST	globally.(12,	28,	
183)	Additionally,	in	our	cohort,	STV	was	the	predominant	GBS	ST	cultured	in	breast	
milk	and	GBS	STs	Ib	and	V	were	associated	with	longer	median	colonisation	duration	
compared	to	other	GBS	STs.	A	study	of	pregnant	women	from	South	Africa	found	
high	prevalence	of	GBS	colonisation	throughout	pregnancy,	with	GBS	STV	and	III	
colonisation	lasting	longer	than	other	GBS	STs	(STV	mean	duration	8.6	weeks;	95%CI	
6.8-10.4	vs.	STIII	9.2	weeks;	95%	CI	8.1–10.2).(12)	The	difference	in	GBS	ST	
distribution	and	duration	of	colonisation	between	these	studies	may	be	due	to	
population	differences	between	South	Africa	and	the	Gambia.	There	are	no	other	
longitudinal	infant	colonisation	studies	to	compare	with	the	results	of	this	study.	Our	
results	may	also	indicate	differences	in	maternally-derived	antibody	that	might	
prevent	colonisation	of	certain	GBS	STs	in	these	diverse	populations.	In	the	most	
recent	study	from	South	Africa,	the	authors	indicate	that	it	is	the	acquisition	of	a	
new	GBS	ST	that	is	associated	with	EO-GBS	disease	rather	than	the	persistent	GBS	
ST,	possibly	due	to	absence	(or	low	levels)	of	maternal	antibody	to	this	new	GBS	
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ST.(146)	
In	summary,	this	study	has	identified	a	number	of	factors	that	may	affect	
maternal	colonisation	and	transmission	from	mother	to	infant,	such	as	previous	
stillbirths	and	spontaneous	abortions,	increased	hospital	contact	and	season	of	birth.	
It	will	be	important	to	bear	these	factors	in	mind	when	analysing	antibody	data.	
These	data	may	also	have	implications	for	our	understanding	of	the	relationship	
between	GBS	and	stillbirths	and	for	prevention	of	LO-GBS	disease.		
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Chapter	5	–	Optimisation	of	opsonophagocytosis	killing	assay	and	antibody-
mediated	complement	deposition	assay	
As	outlined	in	Chapter	1,	higher	GBS	ST-specific	antibody	concentration	has	
been	associated	with	decreased	risk	of	neonatal	GBS	infection(116).	However,	there	
is	evidence	from	pneumococcal	and	meningococcal	studies	that	functional	antibody	
activity	may	correlate	more	closely	with	protection	from	disease,(184,	185)	as	ELISAs	
give	information	on	antibody	concentration	without	information	on	functional	
activity.	As	antibody	function	is	required	for	bacterial	killing,(148)	it	was	deemed	
important	to	investigate	functional	activity	of	anti-GBS	antibody.	As	outlined	in	
Chapter	1,	the	current	assessment	of	functional	antibody	activity	against	GBS	is	
undertaken	using	opsonophagocytic	killing	assays	(OPkA).	
However,	there	are	many	issues	surrounding	this	assay	in	large-scale	
neonatal	studies	due	to	its	reliance	on	human	cells,	the	labour	intensity	of	the	assay	
and	the	volume	of	serum	required	(in	excess	of	100uL	in	some	cases).	One	of	the	
hypotheses	of	this	study	is	that	higher	concentrations	of	functionally	active	anti-GBS	
antibody	at	birth	and	at	day	60-89	are	inversely	correlated	with	infant	GBS	
colonisation.	
Measurement	of	antibody-mediated	deposition	of	C3b/iC3b	onto	GBS	
bacteria	may	be	a	more	suitable	field	assay	compared	to	the	current	“Gold	
Standard”,	the	OPkA.	Thus,	correlation	with	the	OPkA	against	each	GBS	ST	should	
first	be	established.	In	this	Chapter,	the	optimisation	of	the	OPkA	and	CDA	and	their	
correlation	is	described.	
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5.1.	Optimisation	of	functional	assays		
As	part	of	the	training	and	preparation	for	this	project,	I	spent	two	months	in	
the	GSK	vaccine	research	laboratories	(at	the	time	of	the	study,	Novartis	Vaccine	
Laboratories,	Siena,	Italy),	learning	their	OPkA	methods.	This	was	followed	by	a	
further	six	months	in	the	immunoassay	research	laboratories	at	Public	Health	
England,	Porton	Down	where	I	refined	both	the	OPkA	and	the	CDA	used	to	assess	
functional	antibody	concentrations.		
	
5.2.	Optimisation	of	the	opsonophagocytosis	assay	(OPkA)	
Prior	to	undertaking	the	OPkA	a	number	of	optimisation	steps	were	required.	
These	included:	establishing	a	representative	panel	of	sera	to	test	the	assays;	
defining	the	appropriate	concentration	of	baby	rabbit	complement	for	use	with	each	
GBS	ST;	determining	the	concentration	of	human	IgG-depleted	complement	required	
in	each	assay	and	finally	correlating	the	killing	titres	obtained	with	IgG-depleted	
human	and	rabbit	complement.	The	OPkA	as	described	in	Chapter	3	was	used	to	
determine	a	killing	titre	in	experiments	using	either	baby	rabbit	or	human	
complement.		
5.2.1.	Panel	of	sera	
For	both	optimisation	experiments	a	panel	of	30	sera	was	selected	with:	high	
(defined	as	75-99	centile	for	geometric	mean	(GM)	FI-C’	values,	n=10);	medium	
(defined	as	25-75th	centile	for	GM	FI-C’	values,	n=10)	and	low	(10-25th	centile	for	GM	
FI-C’	values	n=10)	values	for	each	of	the	GBS	STs	Ia,	III	and	V.	(Table	11)	
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Table	11	–	GM	FI-C'	values	used	in	panel	sera	for	OPkA	optimisation	experiments	
GBS	ST	 High	(GM	FI-C’;	
95%	CI)	
n=10	
Medium	(GM	FI-C’;	95%	
CI)		
n=10	
Low	(GM	FI-C’;	95%	
CI)	
n=10	
Ia	 7956	(4218-8607)	 4445	(5324-7622)	 2191(1000-3090)	
III	 9348	(7083-9976)	 3784	(2741-4561)	 2301	(1000-3189)	
V	 9067	(8219-15391)	 4841	(3869-6466)	 2520	(1000-3145)	
	
5.2.2.	Assay	parameters	
Each	OPkA	contained	a	standard	human	reference	serum	(SHRS)	positive	
control	and	three	negative	controls	(without	serum,	without	cells	and	without	
complement).	As	antibody-independent	killing	was	observed	in	the	negative	control	
with	serum	and	complement	but	without	cells,	an	antibody	titre	of	double	the	upper	
limit	of	the	titre	observed	in	this	control	well	was	considered	positive	(>1:30).	Titres	
below	the	limit	of	detection	were	allocated	an	arbitrary	value	of	15.		
5.2.3.	Rabbit	complement	concentration	
The	assay	was	performed	as	described	in	the	methods	section	but	with	
concentrations	of	rabbit	complement	at	1%,	3%,	5%,	10%	and	20%.	The	assay	was	
performed	for	GBS	STs	Ia,	III	and	V	using	SHRS	sera	raised	against	each	of	the	GBS	
STs	used.	Optimal	killing	of	GBS	STs	Ia	and	V	in	the	negative	controls	was	observed	
with	10%	complement	concentration,	whilst	optimal	killing	in	the	GBS	STIII	negative	
controls	was	observed	at	3%.	(Figure	14a)		
GBS	STIa	and	III	had	higher	killing	titres	than	V	at	all	concentrations	of	
complement.	There	was	also	an	increased	OPkA	titre	with	increasing	complement	
concentration	until	a	point	was	reached	when	killing	appeared	to	drop	off	
dramatically	in	the	GBS	STIII	OPkA.	(Figure	14b)	 	
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Figure	14	-	OPkA	titres	in	positive	sera	and	negative	controls	
A.	OPkA	titres	in	the	complement-only	control	wells	(no	serum)	with	each	
concentration	of	rabbit	complement	for	GBS	STs	Ia,	III	and	V.	
	
B.	OPkA	titre	comparing	rabbit	complement	concentrations	with	SHRS	sera	for	GBS	
STs	Ia,	III	and	V	
	
	Bar	graph	shows	effect	of	different	complement	concentrations	on	OPkA	antibody	titres	for	(A)	
Negative	control	of	serum	and	complement	but	no	cells	and	(B)	SHRS	serum	against	the	homologous	
serotype.	STIa=serotype	Ia,	STIII=serotype	III	and	STV	=	serotype	V.	N=5	replicate	wells	for	each	SHRS	
serotype.	
	
5.2.4.	Human	complement	concentration	
The	assay	was	repeated	using	the	same	approach	as	described	in	the	
methods	section	but	with	IgG-depleted	human	plasma	as	the	complement	source	
instead	of	rabbit	complement	and	concentrations	of	at	1%,	3%,	5%,	10%	and	20%.	
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The	assay	was	performed	for	GBS	STs	Ia,	III	and	V	using	SHRS	sera	raised	against	each	
of	the	GBS	STs	used.	Figure	15	demonstrates	an	increased	OPkA	titre	with	increasing	
complement	concentration.	With	GBS	STIII	the	killing	titre	dropped	dramatically	
between	10%	and	20%	of	complement.	When	determining	the	different	
concentrations	of	complement	within	the	assay,	GBS	STs	III	and	V	optimal	killing	was	
observed	with	5%	complement	concentration.	Titres	above	the	upper	limit	of	the	
assay	were	observed	for	GBS	STIa	at	all	concentrations	of	human	complement,	
suggesting	an	enhanced	antibody/complement	independent	killing	mechanism	may	
be	responsible	for	killing	of	this	GBS	ST.		
Figure	15	-	OPkA	comparing	human	complement	concentrations	with	SHRS	for	GBS	
ST	Ia,	III	and	V	
	 	
	Bar	graph	shows	effect	of	different	complement	concentrations	on	OPkA	antibody	titres	for	SHRS	sera	
against	the	homologous	serotype.	STIa=serotype	Ia,	STIII=serotype	III	and	STV	=	serotype	V.	The	upper	
limit	for	the	killing	titre	against	STIa	was	1:12,000	and	greater	than	50%	killing	was	observed	at	all	
complement	concentrations.	N=5	replicates	for	each	of	the	three	SHRS	serotypes	at	each	complement	
concentration.	
	
5.2.5.	Correlation	between	rabbit	and	human	complement	OPkA	
As	the	OPkA	methods	developed	by	GSK	used	baby	rabbit	complement	and	
the	CDA	methods	used	human	complement	it	was	necessary	to	investigate	whether	
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killing	as	measured	by	a	human	complement	OPkA	correlated	with	the	standard	
rabbit	complement	OPkA.		
Overall,	there	was	good	correlation	between	baby	rabbit	and	human	
complement	for	GBS	STIII	(R2=0.79)	and	GBS	STV	(R2=0.77).	However,	there	was	only	
a	weak	correlation	between	the	rabbit	and	human	complement	OPkA	for	GBS	STIa	
(R2=0.02).	Figure	16	illustrates	the	correlations	observed.	
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Figure	16	-	Example	of	the	correlation	between	OPkA	using	human	and	rabbit	
complement	with	A.	GBS	STIII	and	B.	GBS	STV	
A. Rabbit	complement	OPkA	vs.	human	complement	OPkA	against	GBS	STIII	
(n=20)	
			
	
	
B.	Rabbit	complement	OPkA	vs.	human	complement	OPkA	against	GBS	STV	
(n=20)	
	
		
	
Scatter	plots	with	regression	line	using	log	transformed	OPkA	antibody	titres	against	STIII	and	
STV	GBS	of	human	vs.	baby	rabbit	complement,	OPkA	–	opsonophagocytosis	killing	assay,	
STIII	–	serotype	III;	STV-	serotype	V.	rabbit	=	baby	rabbit	complement;	human	=	human	
exogenous	complement.	N=20	for	each	serotype.	
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5.3.Antibody-mediated	complement	deposition	assay	(CDA)	optimisation	
Having	optimised	the	OPkA	the	next	step	was	to	optimise	the	CDA	to	
measure	antibody-mediated	C3b/iC3b	complement	deposition	onto	the	surface	of	
whole	bacteria	(Chapter	2).	The	same	panel	of	sera	outlined	in	5.2.1.	above	was	used	
to	optimise	the	CDA.	There	were	several	steps	in	the	optimisation	process:	agreeing	
the	gating	strategy,	assessment	of	each	of	the	assay	component	effects	on	FI,	
assessment	of	representativeness	of	bacterial	strains	used	and	assay	reproducibility	
(linearity,	interassay	variability,	positive	and	negative	predictive	values,	sensitivity	
and	specificity).	
5.3.1.	Gating	strategy	for	antibody-mediated	complement	deposition	
In	order	to	correctly	position	the	gate	to	determine	antibody-mediated	
C3b/iC3b	deposition	it	was	necessary	to	identify	the	level	of	background	florescence.	
Figure	17	demonstrates	how	this	was	performed	using	bacteria,	conjugate	and	
complement.	A	gate	was	set	around	the	bacterial	population	following	optimisation	
of	the	voltage	in	the	bacteria-only	control	(600	Hz).		
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Figure	17	-	Example	of	gating	strategy	for	bacteria,	conjugate	and	complement	
control	
A.		
	
B.		
	
	Representative	dot	plot	(A)	and	histogram	(B)	from	a	bacteria,	conjugate	and	complement	only	
control	are	shown.	(A)	gating	(R1)	used	to	identify	bacteria	based	on	size	(FS)	and	complexity	(SS);	R1	
is	the	gate	through	which	the	opsonized	bacteria	are	counted;	(B)	histogram	of	bacteria,	conjugate	
and	complement.	FITC=Fluorescein	isothiocyanate.	FITC	indicates	the	florescence	of	the	anti-rabbit	C3c	
FITC	conjugate	bound	to	the	surface	of	GBS	bacteria.	
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5.3.2.	Gating	strategy	for	controls	
As	mentioned	in	the	methods	section,	a	number	of	controls	were	
incorporated	into	the	assay	in	order	to	ensure	accurate	gating.	Figure	18	
demonstrates	examples	of	the	fluorescence	of	each	of	these	controls.	Gates	are	
initially	set	on	the	bacteria-only	population	as	an	internal	negative	control	to	identify	
fluorescence	due	to	conjugate	binding.	These	gates	were	then	applied	to	the	serum	
samples	from	the	Gambian	cohort.		
	
Figure	18	-	Overlay	plot	demonstrating	positive	and	negative	controls	using	CDA	
	
	Representative	histogram	from	a	bacteria,	conjugate	and	complement	only	control	and	standard	
human	reference	sera	(SHRS)	control	are	shown.	Grey	=	bacteria	only,	red	=	bacteria+complement+	
conjugate	control,	dark	blue	=	SHRS	vaccinated	pool	positive	control.	FL	1	Log	=	log10	fluorescence	of	
each	sample.	
	
5.3.3.	The	fluorescence	Intensity		
Following	gating	(as	outlined	above)	a	fluorescence	intensity	value	(FI)	was	
assigned	to	each	sample,	which	was	calculated	by	multiplying	the	number	of	events	
Bacteria	 Bacteria	
+complement	
Bacteria	+	
complement	
+	SHRS	
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in	the	gate	(R1)	by	the	mean	fluorescence.		
For	the	measurement	of	antibody-mediated	C3b/iC3b	deposition	an	arbitrary	
lower	limit	of	quantification	of	2000	FI-C’	was	used	as	at	this	level	error	bars	were	
above	5%	variance.	Any	FI-C’	below	2000	was	given	an	arbitrary	measurement	of	
1000	FI-C’	for	the	analysis.	Where	no	antibody-mediated	C3b/iC3b	deposition	was	
detected,	these	data	were	given	a	value	of	ND	and	excluded	from	analysis.	The	GM	
FI-C’	and	95%	CI	onto	each	GBS	ST	were	calculated	and	the	percentage	of	cord	blood	
and	infant	sera	with	FI-C’	values	above	2000	was	recorded.	
5.3.4.	Gating	strategy	for	interassay	control.	
In	addition	to	the	positive	and	negative	internal	controls	used	in	each	assay,	
each	assay	contained	four	wells	of	pre-activated	zymosan	(1.8	×	106	particles/well;	
CompTech,	USA):	two	wells	with	zymosan	and	conjugate	and	two	wells	with	
zymosan,	conjugate	and	complement	only.	Zymosan	is	used	to	induce	antibody-
independent	complement	deposition	in	the	absence	of	sera.	In	this	assay	zymosan	is	
used	to	assess	inter-assay	variability	over	the	nine	months	duration	of	the	study.	
Data	from	each	day	were	normalised	to	the	C3b/iC3b	bound	to	the	preactivated	
zymosan	control	to	account	for	day-to-day	variation	within	the	assay.	Figure	19	
demonstrates	a	representative	plot	for	a	zymosan	and	complement	control.	Over	
the	course	of	the	study,	the	mean	standard	deviation	of	FI	for	zymozan	controls	was	
8,831	(coefficient	of	variance	(CoV),	31.6%).		
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Table	12	–	Mean	and	standard	deviation	FI	and	coefficient	of	variance	of	zymosan	
by	month	of	study	and	overall	
	Zymosan	 Jan	 Feb	 Mar	 Apr	 May	 Jun	 Jul	 Aug	 Sep	 Overall	
SD	 8934	 8410	 8482	 8980	 9948	 8890	 8991	 8549	 8293	 8831	
Mean	 28999	 27778	 29776	 28888	 24447	 27602	 29993	 28872	 25559	 27990	
Cov	 30.8%	 30.3%	 28.5%	 31.1%	 40.7%	 32.2%	 30.0%	 29.6%	 32.4%	 31.6%	
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Figure	19	-	Scatter	plot	and	histogram	demonstrating	zymosan	gating	based	on	size	
and	complexity	
A.		
	
B.	
	
Representative	dot	plot	and	histogram	from	a	zymosan,	conjugate	and	complement	only	control	are	
shown.	(A)	gating	strategy	used	to	identify	zymosan	based	on	size	(FS)	and	complexity	(SS).	R1	is	the	
gate	through	which	the	opsonized	zymosan	is	counted;	(B)	histogram	of	zymosan,	conjugate	and	
complement	only	control.	FITC=Fluorescein	isothiocyanate.	FITC	indicates	the	florescence	of	the	anti-
rabbit	C3c	FITC	conjugate	bound	to	the	surface	of	zymosan.	
	
5.3.5.	Effect	of	different	assay	components	on	fluorescence	background	
It	was	important	to	assess	the	variability	of	the	different	components	of	the	
assay	during	the	course	of	the	CDA	analysis.	These	components	included	different	
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human	complement	and	conjugate	batches	and	different	batches	of	1%	BSA	in	PBS	
buffer.	Figure	20	demonstrates	the	differences	observed	over	the	nine	months	of	
analysis.	
Figure	20	-	Differences	in	assay	components	during	the	study	
A.	Bacteria	with	1%	BSA	in	PBS	
	
	The	overlay	plot	shows	the	fluorescence	log	(FL	1	log)	of	the	different	bacteria	controls	in	1%	BSA	in	
PBS	used	during	the	experiments.	Solid	black	line	=	March,	solid	grey	line	=	May;	dotted	line	=	July;	
dashed	line	=	September.	
	
B. Conjugate	
	
	Bar	chart	of	different	conjugate	batches	used	during	the	experiments.	Blue	bar	=	conjugate	batch	4,	
used	until	May	2015;	Red	bar	=	conjugate	batch	5,	used	from	May	to	October	2015.	Black	lines	
represent	error	bar	from	duplicate	samples.	Bac	Only	=	bacteria	only;	Bac	+	Conj	=	bacteria	plus	
conjugate;	Bac	+	Comp	=	bacteria	plus	complement;	Bac	+	Conj	+	Comp	=	bacteria	plus	conjugate	plus	
complement.	FI	–	Fluorescence	intensity.	
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The	variability	between	buffer	batches,	complement	batches	and	conjugate	
batches	was	normalised	to	the	C3b/iC3b	bound	to	the	pre-activated	zymosan	control	
to	account	for	batch-to-batch	variation	within	the	assay,	as	outlined	in	5.3.4.	During	
the	course	of	the	nine	months	of	the	study	the	mean	standard	deviation	(SD)	of	the	
FI	was	5509,	CoV	(CoV=SD/mean)	34.3%	for	the	conjugate	control	and	4434	(39%)	
for	the	bacteria	control.	
	
5.3.6.	Comparison	of	two	strains	of	GBS	STIII	in	positive	and	negative	
controls	
The	GBS	isolates	used	in	this	study	were	geographically	diverse	United	
Kingdom	clinical	isolates	from	neonatal	blood	cultures.	GBS	strains	H092040676	
(STIa),	H090820125	(STIb),	H090320548	(STII),	H092120162	(STIII),	and	H091780506	
(STV)	were	kindly	provided	by	Prof	.Androulla	Efstratiou,	Public	Health	England,	
Colindale,	UK.	
In	order	to	determine	if	these	bacteria	were	representative	of	bacteria	used	
in	other	assays	the	CDA	experiment	was	repeated	using	SHRS	and	GBS	STIII	strain	
COH-1	kindly	provided	by	Prof.	Carol	Baker,	Baylor	College	of	Medicine,	Texas,	USA.	
There	was	little	difference	in	the	FI	for	any	of	the	negative	controls	or	in	the	FI-C’	
with	the	SHRS	between	H092120162	and	COH-1	STIII.	(Figure	21)	
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Figure	21	-	Comparison	of	FI-C’	between	two	strains	of	GBS	STIII	
	
Scatter	plot	with	regression	line	comparing	FI-C’	of	USA	GBS	invasive	strain	with	UK	GBS	invasive	
strain.		N=	10	samples.	FI-C’	fluorescence	intensity	minus	complement	control.	USA=	GBS	STIII	strain	
COH-1;	UK=	GBS	STIII	strain	H092120162.	
	
5.3.7.	Assay	reproducibility	
In	order	to	determine	reproducibility	of	the	CDA,	intra-	and	inter-assay	
precision	calculations	were	performed	using	a	panel	of	one	rabbit	and	13	human	
sera	against	a	GBS	STII	strain.	The	CoV	for	the	intra-assay	precision	(three	assays	
performed	on	one	day)	was	22%	and	CoV	was	26%	for	the	inter-assay	precision	(one	
assay	performed	on	three	separate	days).	Linearity	of	the	assay	was	assessed	using	
SHRS.	The	assay	was	highly	linear,	with	a	mean	R2	of	0.96	for	the	five	GBS	STs	tested.	
	
5.4.	Assay	optimisation	with	pilot	sera	
During	a	pilot	phase	to	test	the	experimental	set	up,	100μL	test	serum	was	
provided	from	two	difference	sources:	
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1. A	cohort	of	100	mother-infant	pairs	from	the	Gambia	–	these	sera	
were	from	the	initial	pilot	study	and	were	used	to	optimise	the	CDA	by	
comparing	it	to	the	IBA.	
2. A	cohort	of	60	mother-infant	pairs	with	samples	taken	from	pregnant	
woman	at	30	weeks	gestation,	cord	blood	and	from	infants	at	12,	24	and	52	
weeks	of	age	from	upper	River	Region,	The	Gambia	kindly	made	available	
from	the	Infant	Nutrition	Group	(ING)	at	MRC	–	used	to	determine	the	
concentration	of	antibody	in	mothers	and	their	infants	in	the	Gambia	by	CDA	
and	to	assess	changes	in	GBS	ST-specific	antibody	distribution	since	the	
previous	study	undertaken	in	1996	using	CDA.	
5.4.1.	Comparison	of	IBA	and	CDA	in	the	pilot	Gambian	study	cohort	
Before	I	could	measure	antibody-mediated	C3b/iC3b	deposition	onto	the	
surface	of	whole	bacteria	it	was	necessary	first	to	measure	antibody	binding	to	the	
surface	of	whole	bacteria	without	the	addition	of	complement.	This	is	an	important	
step	in	assay	development	as	antibody	bound	to	the	surface	of	the	bacteria	may	be	
bound	directly	to	surface	proteins	and	not	mediate	C3b/iC3b	deposition.	In	order	to	
determine	the	relationship	between	antibody	bound	to	the	surface	of	whole	
bacteria	and	antibody-mediated	C3b/iC3b	deposition	the	FI-C	of	the	IBA	to	the	FI-C’	
of	the	CDA	was	compared	in	the	first	100	mother-infant	pairs.	With	the	exception	of	
GBS	STIb,	the	GM	FI-C	of	IBA	was	lower	than	GM	FI-C’	of	CDA,	but	this	was	not	
significant.	This	is	likely	due	to	the	different	conjugates	used	between	the	CDA	and	
IBA.	However,	the	correlation	between	IBA	and	CDA	was	>R2=0.7	(p<0.001)	for	all	
GBS	STs.	The	results	of	the	GM	FI-C’	(95%	CI)	of	the	IBA	compared	to	the	CDA	are	
shown	in	Table	13.	
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Table	13	-	GM	(95%	CI)	of	IBA	FI-C	vs.	CDA	FI-C’	against	GBS	ST	Ia,	Ib,	II,	III	and	V	
GBS	ST	 GM	FI-C	IBA	
n=100	
GM	FI-C’	CDA	
n=100	
R2	 P	
Ia	 1851	(1538-
2227)	
2437	(2181-
2723)	
0.70	 0.01	
Ib	 6197	(4111-
9343)	
3732	(2839-
4904)	
0.94	 <0.001	
II	 4363	(2852-
6676)	
8133	(5923-
11168)	
0.90	 <0.001	
III	 4698	(2213-
7183)	
5261	(4140-
6685)	
0.88	 <0.001	
V	 5165	(3519-
7580)	
5799	(4544-
7402)	
0.78	 0.02	
Table	demonstrates	FI-C	and	FI-C’	values	from	the	first	100	cord	samples	as	outlined	in	5.4.	above.		
GM=geometric	mean,	FI-C=fluorescence	intensity	minus	conjugate;	FI-C’=fluorescence	intensity	minus	
complement;	IBA=IgG	surface-binding	assay;	CDA=antibody-mediated	complement	deposition	assay.	
	
Based	on	assay	optimisation	described	in	5.3.	the	CDA	was	used	to	assess	
functionally	active	antibody	against	all	GBS	STs	using	human	complement	at	a	
concentration	of	20%.	
5.4.2.	Changes	in	ST-specific	antibody	distribution	in	the	Gambia	
Longitudinal	data	from	the	mother	infant	cohort	described	in	5.4.	(n=60)	
above	demonstrated	a	high	concentration	of	antibody-mediated	complement	
deposition	against	GBS	STV,	the	predominant	colonising	and	invasive		disease	
causing	GBS	ST	in	the	Gambia.	Further,	the	analysis	demonstrated	measurable	GM	
FI-C’	against	at	least	one	of	the	GBS	STs	tested.	The	analysis	of	infant	sera	also	
demonstrated	a	decline	in	functional	antibody	activity	against	GBS	STV	until	12	
weeks,	followed	by	a	transcient	increase	in	antibody-mediated	C3b/iC3b	deposition	
at	24	weeks	and	subsequent	decline.	One	possibility	is	that	this	indicates	waning	
maternal	antibody	concentrations	followed	by	increasing	infant	antibody	
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concentrations	in	response	to	infant	GBS	colonisation	and	subsequent	early	
challenge.	(Figure	22)	
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Figure	22	-	Antibody-mediated	C3b/iC3b	deposition	onto	GBS	(95%	CI)	in	Gambian	
cord	and	infant	serum	
A	–	Antibody-mediated	C3b/iC3b	deposition	onto	GBS	STs	Ia,	Ib,	II,	III	and	V	in	cord	
blood	
	 	
B.	Antibody-mediated	C3b/iC3b	deposition	onto	GBS	STV	in	maternal	and	infant	
serum	from	30	weeks	gestation	to	1	year	of	life.	
	
	Dot	and	whisker	plot	of	antibody-mediated	C3b/iC3b	deposition	against:	(A)	STIa,	STIb,	STII,	STIII	and	
STV	in	cord	blood	and	(B)	STV	from	30	weeks	gestation	to	1	year	of	life.		Horizontal	lines	represent	
mean	and	95%	confidence	intervals.	N=100	samples.	Yellow	circles	=	maternal	serum	at	30	weeks	
gestation;	black	circles	=	cord	blood;	blue	squares	=	infant	serum	at	12	weeks;	red	triangles	=	infant	
serum	at	24	weeks;	green	triangles	=	infant	serum	at	52	weeks.	FI-C’	=	fluorescence	intensity	minus	
the	bacteria+conjugate+complement	control.	STIa=	serotype	Ia,	STIb	=	serotype	Ib,	STII	=	serotype	II,	
STIII	=	serotype	III	and	STV=serotype	V,	cord=cord	blood.	
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5.5.	Correlation	between	CDA	and	OPkA	and	assay	robustness	
In	order	to	determine	the	correlation	between	the	CDA	and	OPkA	the	
Pearson	correlation	coefficient	was	calculated	for	each	pairwise	comparison	of	
results	from	matched	panel	samples	as	outlined	above	(5.2.1.	(Table	11)).	In	addition	
the	operating	characteristics	of	the	CDA	were	assessed	as	a	‘test’	for	correctly	
classifying	the	paired	OPkA	titre	as	<30	(<50%	killing)	or	≥30	(50%	or	greater	killing	
observed).	For	this	analysis,	OPkA	was	treated	as	the	‘gold	standard’,	and	CDA	
assessed	as	the	predictor	variable	at	threshold	titers	of	≥30.	For	each	pairwise	set	of	
comparisons,	the	sensitivity,	specificity,	positive	predictive	value	(PPV),	negative	
predictive	value	(NPV)	and	positive	and	negative	likelihood	ratios	(LR+	and	LR−)	were	
calculated.	Likelihood	ratios	provide	an	indexed	measure	of	the	accuracy	of	a	
positive	or	negative	test	result	by	combining	the	sensitivity	and	specificity	of	the	test	
into	a	single	statistic.	The	higher	the	LR+	(or	lower	the	LR-),	the	more	likely	it	is	that	
the	test	result	correctly	agrees	with	the	gold	standard.	
The	sensitivity,	specificity	and	predictive	values	were	calculated	using	the	
following	calculations:	
		 OPKA	+	 OPKA	-	 		
CDA	+	 True	positive	(A)	 False	positive	(B)	 (A+B)	
CDA	-	 False	negative	(C)	 True	negative	(D)	 (C+D)	
	 (A+C)	 (B+D)	 	
	
Sensitivity	=	A/(A+C)	
Specificity	=	B/(B+D)	
PPV	=	A/(A+B)	
NPV	=	C/(C+D)	
LR+	=	Sensitivity/(1-specificity)	
LR-	=	(1-sensitivity)/Specificity	
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Because	high	titres	of	antibody-independent	killing	were	observed	against	
GBS	STIa	in	the	OPkA	using	human	complement	and	yet	results	from	the	IBA	and	
CDA	correlated	well	with	rabbit	complement	OPkA,	the	results	from	the	optimised	
OPkA	using	baby	rabbit	complement	were	used	in	the	correlation	analysis	with	the	
CDA.	
5.5.1.	Results	of	correlation	between	CDA	and	OPkA	
A	total	of	90	individual	sera	were	included	in	this	analysis	(30	for	each	of	the	
three	GBS	STs	Ia,	III	and	V	as	described	in	section	5.2.1).	The	correlation	of	the	CDA	
compared	to	the	OPkA	significant	for	GBS	STs	Ia,	III	and	V	(Figure	23).		
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Figure	23	-	Correlation	between	CDA	and	OPkA	
A. CDA	vs.	rabbit	OPkA	GBS	STIa	(n=30)	
	
B.	CDA	vs.	rabbit	OPkA	GBS	STIII	(n=30)	
	
C.	CDA	vs.	rabbit	OPkA	GBS	STV	(n=30)	
	
	Scatter	plots	with	regression	line	of	log	transformed	CDA	and	OPkA	values	obtained	with	a	panel	
of	n=30	sera	for	(A)	STIa,	(B)	STIII,	(C)	STV.	FI-C=fluorescence	intensity	minus	complement	only	
control.	R2	=	Pearson	correlation	coefficient.		
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5.5.2.	CDA	sensitivity,	specificity,	positive	and	negative	predictive	values	
When	sensitivity,	specificity,	PPV	and	NPV	of	the	CDA	was	calculated	(n = 90),	
the	sensitivity	of	the	CDA	was	80.7%	and	specificity	was	90.0%	with	a	weighted	
positive	likelihood	ratio	of	8.07	(2.7-23.8)	indicating	that	overall	the	CDA	is	a	useful	
test	for	predicting	opsonophagocytic	killing.	Table	14	indicates	the	positive	and	
negative	predictive	values,	likelihood	ratios	and	sensitivity	and	specificity	overall	for	
the	CDA.		
Table	14	-	Positive	and	negative	predictive	values,	sensitivity	and	specificity	of	the	
CDA	overall	and	for	GBS	STs	Ia,	III	and	V	
	 Sensitivity	%	
95%	CI	
Specificity	
95%	CI	
PPV	
95%	CI	
NPV	
95%	CI	
LR+	 LR-	
Overall	 80.7	
(67.7-89.5)	
90.0	
(72.3-97.4)	
93.9	
(82.1-
98.4)	
71.1	
(53.9-
84.0)	
8.07	(2.7-
23.8)	
0.2	
(0.1-
0.4)	
STIa	 60.0	(36.0-
80.0)	
89.0	(50.7-
99.0)	
92.3	
(62.1-
99.6)	
50.0	
(25.5-
74.5)	
5.4	(0.8-
35.5)	
0.5	
(0.3-
0.8)	
STIII	 95.2	(74.1-
99.8)	
87.5	(46.7-
99.3)	
95.2	
(74.1-
99.8)	
87.5	
(46.7-
99.3)	
7.6	(1.2-
47.8)	
0.1	
(0.0-
0.4)	
STV	 87.5	(60.4-
97.8)	
92.3	(62.1-
99.6)	
99.3	
(66.0-
99.7)	
85.7	
(56.2-
97.4)	
11.4	(1.7-
75.5)	
0.1	
(0.0-
0.5)	
	
The	sensitivity,	specificity,	positive	and	negative	predictive	values	remained	
high	for	GBS	STs	V	and	III.	For	GBS	STIa	the	sensitivity	was	reduced	compared	to	
other	STs	although	specificity	remained	high.	This	would	indicate	that	for	STIa,	the	
assay	would	be	able	to	correctly	identify	participants	without	antibody-mediated	
complement	deposition	(specificity	89.0%)	but	the	test	would	have	a	high	false	
negative	rate.	This	could	mean	an	underestimate	of	protection	by	categorising	
infants	who	have	antibody	as	being	antibody-negative.		This	is	also	demonstrated	by	
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the	lowest	positive	likelihood	ratio	and	wide	CI	spanning	1	for	STIa	(LR+	5.4	(0.8-
35.5)).	
	
5.6.	Discussion	
This	optimisation	data	demonstrate	a	good	correlation	between	the	OPkA	
using	baby	rabbit	complement	and	the	CDA	for	GBS	STs	Ia,	III	and	V.	Although	I	was	
only	able	to	establish	a	correlation	between	human	and	rabbit	complement	for	GBS	
STs	III	and	V,	the	use	of	human	over	rabbit	complement	is	still	preferred	when	
assessing	functional	antibody	concentrations	as	species-specific	interactions	can	
affect	the	results	obtained.	Baker	et	al	have	used	endogenous	complement	in	their	
OPkA	assays.(83,	84,	186)	However,	adult	sera	may	contain	naturally	acquired	
antibody	against	GBS	that	would	activate	complement	and	interfere	with	the	assay	
results.	The	use	of	IgG-depleted	human	complement	in	the	CDA	reduces	this	risk	and	
is	a	strength	of	the	assay	design.(165)	Other	investigators	have	used	baby	rabbit	sera	
as	a	complement	source(146,	154,	156)	to	overcome	some	of	these	difficulties	as	
baby	rabbit	sera	is	both	readily	available	and	easily	pooled	which	can	aid	
standardisation	of	assays.	In	addition,	baby	rabbit	serum	lacks	the	intrinsic	
bactericidal	activity	seen	in	human	serum.	Rabbit	serum	is	recommended	by	both	
the	WHO	and	the	CDC	as	a	complement	source	when	assessing	human	bactericidal	
responses	to	serogroup	A	and	C	meningococcus	(187)	and	pneumococcus(184,	188).	
However,	baby	rabbit	complement	has	been	reported	to	induce	higher	bactericidal	
titres	against	serogroup	B	(189)	and	C	(190)meningococcal	strains	compared	to	
human	complement.	In	our	study,	there	was	a	good	correlation	between	the	IBA	and	
CDA	suggesting	that	the	responses	with	human	complement	could	be	used	in	
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functional	assays.		
Following	optimisation,	the	CDA	demonstrated	good	inter-and	intra-assay	
variability	and	the	use	of	zymosan	to	control	for	variations	in	the	assay	components	
showed	an	acceptable	CoV,	which	suggests	that	the	assay	is	robust	in	determining	
antibody-mediated	C3b/iC3b	deposition	onto	the	surface	of	GBS.	The	CDA	has	many	
advantages	over	the	OPkA,	including	avoiding	the	need	for	human	cells	and	using	
fixed	whole	bacteria.	These	elements	have	the	advantage	of	making	the	assay	more	
robust	over	time	and	reducing	the	interassay	variability	often	seen	in	OPkA.	
Additionally,	the	CDA	would	have	advantages	over	an	assay	measuring	IgG	bound	to	
the	CPS	as	the	use	of	whole	fixed	bacteria	would	also	allow	measurement	of	
functional	activity	of	IgG	in	a	protein-based	vaccine.	The	CDA	uses	smaller	quantities	
of	serum	(5μL	vs.	30μL	in	the	OPkA),	which	would	be	useful	when	serum	is	at	a	
premium	such	as	in	neonatal	studies.	
The	pilot	study	demonstrated	the	ability	of	the	CDA	to	identify	functional	
antibody	in	sera	up	to	52	weeks	of	age.	Infant	antibody	declined	up	to	six	months	of	
age	but	thereafter	increased.	This	corresponds	to	the	time	of	increase	in	the	
neonatal	adaptive	immune	response	and	may	suggest	early	colonisation	with	GBS	
inducing	antigen-specific	antibody,	as	is	also	seen	in	pneumococcal	colonisation	in	
Gambian	infants.(191)	This	work	was	performed	using	sera	from	women	with	
natural	immunity	to	GBS	rather	than	vaccine-induced	immunity.	Therefore,	the	
Gambian	sera	will	have	antibody	to	both	the	CPS	and	to	proteins	on	the	bacterial	
surface	and	different	results	may	be	obtained	with	sera	obtained	from	indivuduals	
who	are	vaccinated	with	a	CPS-protein	conjugate	vaccine.	
		 	 	 	121	
The	correlation	between	the	CDA	and	the	OPkA	results	from	matched	
samples	both	overall	and	by	GBS	ST	suggests	that	the	CDA	is	robust	in	predicting	
OPkA	and	could	be	a	useful	marker	of	bacterial	killing	in	vitro.		Testing	the	result	by	
GBS	ST	is	important,	as	results	from	other	pathogens,	such	as	meningococcus,	have	
demonstrated	stronger	correlations	between	functional	assays	with	different	
sources	of	complement	and	some	serogroups	are	correlate	better	than	others.(192)	
The	CDA	was	able	to	predict	opsonophagocytic	killing	for	the	three	GBS	STs	tested.	
The	sensitivity	(80.7%)	and	specificity	(90%)	of	the	CDA	overall	were	good.	However,	
some	sensitivity	was	lost	for	GBS	STIa	compared	to	the	other	two	GBS	STs	due	to	
antibody-independent	killing,	which	could	lead	to	an	under-estimation	of	killing	in	
sera	where	functionally	active	antibody	is	present.		
The	PPV	of	the	CDA	was	high	overall	and	for	all	of	the	GBS	STs,	demonstrating	
that	the	test	is	robust	in	predicting	opsonophagocytic	killing.	In	terms	of	evaluating	
killing	ability,	the	risk	of	underestimating	protection	from	killing	with	a	less	sensitive	
assay	is	preferable	to	overestimating	protective	rates.	These	findings	suggest	that	
CDA	could	be	used	as	an	alternative	to	OPkA	to	predict	antibody-mediated	killing	of	
GBS	in	a	Gambian	population.	Taken	together	with	the	results	of	the	pilot	study,	
these	results	indicate	that	the	CDA	may	be	a	useful	assay	to	identify	functionally	
active	anti-GBS	antibody	against	ST	Ia,	Ib,	II,	III	and	V.		
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Chapter	6	–	Serotype-specific	antibody-mediated	complement	deposition	in	cord	
blood	and	infant	sera.	
6.1.	Introduction	
As	outlined	in	Chapter	5,	it	has	been	established	that	the	CDA	can	be	used	to	
predict	opsonophagocytic	killing	for	GBS	STs	Ia,	III	and	V.	The	next	step	is	to	establish	
the	correlation	between	functional	antibody	concentration	and	infant	GBS	
colonisation.	In	order	to	establish	this,	it	was	first	necessary	to	characterise	the	
antibody-mediated	C3b/iC3b	deposition	in	the	cohort,	their	decline	over	time	and	
any	cross-reactivity	between	GBS	STs.	
As	there	are	no	antibody	reference	standards	available	for	assays	
investigating	GBS,	it	was	necessary	to	establish	cross-reactive	and	functional	activity	
of	each	of	the	GBS	ST-specific	antibodies	in	order	to	establish	differences	in	the	
functional	behaviour	of	each	GBS	ST-specific	antibody	against	GBS	in	vitro.	
In	this	Chapter,	antibody-mediated	C3b/iC3b	deposition	onto	the	surface	of	
whole	GBS	bacteria	is	quantified	using	cord	blood	and	infant	sera	obtained	at	60-89	
days	of	age.	Cross-reactivity	between	GBS	ST-specific	antibodies	is	also	assessed	to	
determine	the	dominant	GBS	ST-specific	response	in	cord	blood	and	serum.	
Additionally,	longevity	of	GBS	ST-specific	antibodies	up	to	89	days	of	age	in	infants	is	
determined.	
	
6.2.	Methods	
The	CDA	was	used	to	measure	antibody-mediated	C3b/iC3b	deposition	onto	
the	surface	of	whole	bacteria.	This	method	is	described	in	Chapter	3.	For	the	analysis	
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I	calculated	reverse	cumulative	distribution	curves	according	to	Reed	et	al	
1995.(193)			
To	assess	cross-reactivity	between	antibodies	and	dominant	GBS	ST-specific	
response,	the	percentage	of	subjects	with	GM	FI-C’	values	greater	than	or	equal	to	
the	following	lower	limit	of	quantification	points	was	assessed:	2000	FI-C’,	5,000	FI-
C’,	10,000	FI-C’	and	20,000	FI-C’.	All	results	were	adjusted	for	maternal	and	infant	
factors	that	might	be	associated	with	decreased	cord	antibody	concentrations	such	
as	maternal	malaria,	infant	birth	weight,	sex	and	season	of	birth	(194,	195).	
	
6.3.	Distribution	of	GBS	ST-specific	antibody-mediated	C3b/iC3b	deposition	in	cord	
blood.	
Using	2000	FI-C’	as	a	lower	limit	of	quantification,	405	cord	sera	(54.0%)	had	
C3b/iC3b	deposition	against	at	least	one	GBS	ST.	Figure	24	demonstrates	the	reverse	
cumulative	distribution	of	C3b/iC3b	deposition	onto	GBS	ST	Ia,	Ib,	II,	III	and	V	in	cord	
sera.	
The	predominant	antibody-mediated	C3b/iC3b	deposition	in	cord	sera	was	
against	the	GBS	STs	with	the	highest	prevalence	of	colonisation,	outlined	in	Chapter	
4;	namely	GBS	STs	V	and	II,	followed	by	Ia	and	III	with	relatively	low	levels	of	
antibody-mediated	C3b/iC3b	deposition	onto	Ib.	This	is	in	accordance	with	our	
finding	that	STIb	is	less	prevalent	in	colonisation	samples	than	the	other	four	GBS	
STs.	
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Figure	24	-	Reverse	cumulative	distribution	curve	(RCD)	of	antibody-mediated	
C3b/iC3b	deposition	against	GBS	ST	Ia,	Ib,	II,	III	and	V	GBS	in	cord	sera.	
	
Reverse	cumulative	distribution	curve	of	FI-C’	detected	in	750	cord	sera.		Y-axis	represents	percentile	of	
cord	sera	with	FI-C’	concentration	above	the	lower	limit	of	quantification	for	each	of	the	serotypes:	
STIa=serotype	Ia	(n=487),	STIb=serotype	Ib	(n=442),	STII	=	serotype	II	(n=525),	STIII=serotype	III	
(n=480),	STV=serotype	V	(n=525).	X-axis	is	the	associated	FI-C’	value	for	that	percentile	of	the	
population.	FI-C’	is	the	florescence	of	the	sample	minus	the	complement-only	control.	Vertical	line	
represents	2000	FI-C’	unit	lower	limit	of	quantification	point.	
	
6.4.	Distribution	of	ST-specific	antibody-mediated	C3b/iC3b	deposition	in	infant	
sera	at	day	60-89.	
At	day	60-89,	273	infants	(43.0%	of	infant	sera)	had	concentrations	above	
2000	FI-C’	against	at	least	one	GBS	ST.	Figure	25	shows	the	reverse	cumulative	
distribution	of	antibody-mediated	C3b/iC3b	deposition	obtained	with	infant	sera.	
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The	predominant	GBS	STs	with	highest	antibody-mediated	C3b/iC3b	
deposition	in	infant	sera	were	similar	but	not	identical	to	that	of	cord	sera.	More	
infants	had	antibody-mediated	C3b/iC3b	deposition	against	GBS	STII,	followed	by	V	
and	III	with	low	antibody-mediated	C3b/iC3b	deposition	onto	GBS	STs	Ia	and	Ib.	This	
corresponds	to	the	predominant	colonising	GBS	STs:	V	(57.0%),	II	(17.1%)	and	III	
(10.8%)	(Chapter	4).	
Figure	25	-	Percentage	of	infant	sera	at	day	60-89	with	C3b/iC3b-mediated	
antibody	deposition	against	GBS	ST	Ia,	Ib,	II,	II	and	V	
	
Reverse	cumulative	distribution	curve	of	FI-C’	detected	in	684	infant	sera.		Y-axis	represents	percentile	
of	cord	sera	with	FI-C’	concentration	above	the	lower	limit	of	quantification	for	each	of	the	serotypes:	
STIa=serotype	Ia	(n=301),	STIb=serotype	Ib	(n=282),	STII	=	serotype	II	(n=351),	STIII=serotype	III	
(n=308),	STV=serotype	V	(n=333).	X-axis	is	the	associated	FI-C’	value	for	that	percentile	of	the	
population.	FI-C’	is	the	florescence	of	the	sample	minus	the	complement-only	control.	Vertical	line	
represents	2000	FI-C’	unit	lower	limit	of	quantification	point.	
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6.5.	Differences	in	concentration	of	antibody-mediated	C3b/iC3b	deposition	onto	
GBS	by	ST	in	cord	and	infant	sera	
The	percentage	of	cord	and	infant	sera	with	antibody-mediated	C3b/iC3b	
deposition	above	and	below	the	2000	FI-C’	lower	limit	of	quantification	varied	by	
GBS	ST.	A	larger	proportion	of	cord	sera	had	antibody-mediated	C3b/iC3b	deposition	
against	GBS	ST	V	(77%),	II	(79%),	III	(75%)	and	Ia	(75%)	than	Ib	(63%)	(p<0.001).		
By	day	60-89,	the	number	of	infant	sera	with	FI-C’	above	2000	was	reduced	
compared	to	cord	sera	for	all	GBS	STs:	Ia	(-39.6%),	Ib	(-33.0%),	II	(-34.2%),	III	(-39.1%)	
and	V	(-34.6%).	Table	15	summarises	those	sera	above	2000	FI-C’,	those	where	
fluorescence	was	detected	but	below	2000	FI-C’		and	those	where	no	fluorescence	
was	detected.	
Table	15	-	Number	(%)	of	subjects	with	detectable	antibody-mediated	C3b/iC3b	
deposition	in	cord	and	infant	sera.	
Cord	
N	with	FI-C’=525/750	
	
Infants	at	three	months	
N	with	FI-C’=412/628	
	 FI-C’	 FI-C’	
	 ≥2000	 <2000	 ND	 ≥2000	 <2000	 ND	
Ia	 394	(53)	 93	(12)	
263	
(35)	 238	(38)	 63	(10)	 327	(52)	
Ib	 330	(44)	 112	(15)	
308	
(41)	 220	(35)	 62	(10)	 346	(55)	
II	 415	(55)	 110	(15)	
225	
(30)	 273	(43)	 78	(12)	 277	(44)	
III	 396	(53)	 84	(11)	
270	
(36)	 241	(38)	 67	(11)	 320	(51)	
V	 405	(54)	 120	(16)	
225	
(30)	 265	(42)	 68	(11)	 295	(47)	
N=number;	Ia	=	serotype	Ia;	Ib	=	serotype	Ib;	II=serotype	II;	III=serotype	III;	V=serotype	V;	FI-C’	
florescence	minus	complement	only	control.	ND=	not	detected	
	
The	GM	FI-C’	(95%	CI)	antibody-mediated	C3b/iC3b	deposition	also	varied	
between	GBS	STs	with	highest	GM	FI-C’	against	STV	[FI-C’	3835	(3494-4208)],	
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followed	by	STII	[FI-C’	3754	(3428-4111],	STIII	[FI-C’	3197	(2930-3488)]	then	STIa	[FI-
C’	3318	(3040-3621)]	and	STIb	[FI-C’2736	(2521-2971)].	
Compared	to	other	GBS	STs,	the	GM	FI-C’	for	STIb	was	lower	than	for	STIa	
(p=0.04),	STII	(p<0.001)	and	STV	(p<0.001)	but	not	than	STIII	(p=0.12).	There	were	no	
significant	differences	between	the	GM	FI-C’	C3b/iC3b	concentrations	between	any	
of	the	other	GBS	STs.	Figure	26	summarises	the	GM	FI-C’	and	95%	CI	for	C3b/iC3b	
deposition	in	cord	and	infant	sera.	
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Figure	26	-	Antibody-mediated	C3b/iC3b	deposition	in	cord	and	infant	sera	
	
	Line	and	error	bars	represent	the	GM	FI-C’	and	95%	confidence	interval	for	antibody-mediated	
C3b/iC3b	deposition	onto	the	surface	of	whole	GBS	bacteria	against	serotype	Ia	(STIa),	serotype	Ib	
(STIb),	serotype	II	(STII),	serotype	III	(STIII)	and	serotype	V	(STV).	Student	t-tests	were	used	to	
determine	differences	in	GMC	FI-C’	between	serotypes.	*p=0.04,	***p=0.01,	****p<0.001	in	cord	sera	
n=525	(top	figure)	and	infant	sera	n=412	(bottom	figure).	
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A	multiple	linear	regression	model	was	calculated	to	predict	antibody-
mediated	C3b/iC3b	deposition	based	on	maternal	age,	weight,	parity,	malaria	during	
pregnancy	and	infant	birth	weight,	season	of	birth	and	infant	sex.	A	significant	
regression	equation	was	found	(F8,435)=4.99,	p<0.001,	R2=0.58.	Increasing	antibody-
mediated	C3b/iC3b	deposition	was	associated	with	increasing	birth	weight	(as	a	
surrogate	for	gestational	age)	or	birth	during	the	wet	season	and	decreasing	
antibody	was	associated	with	maternal	malaria	during	pregnancy	and	maternal	
tetanus	vaccination	in	pregnancy	after	taking	account	of	maternal	age,	maternal	
weight,	parity	and	sex	of	baby.	(Table	16)		
Table	16		–	Multivariable	linear	regression	model	of	factors	associated	with	
antibody-mediated	C3b/iC3b	deposition	in	cord	blood	
Variable	 	 Coefficient	 95%	CI	for	
coefficient	
p-value	
Maternal	factors	 	 	 	 	
Age	 	 0.007	 -0.004	to	
0.019	
0.223	
Weight	(kg)	 	 -0.000	 -0.005	to		
0.004	
0.83	
Parity	 	 -0.021	 -0.056		to	
0.015	
0.25	
Malaria	in	
pregnancy	
	 -0.338	 -0.576	to		
		-0.099	
0.006	
Two	tetanus	
vaccinations	in	
pregnancy	
	 -0.197	 -0.330	to	
			-0.064	
0.004	
Infant	factors	 	 	 	 	
Birth	weight	 	 		.1290985	 .0130307				
.2451663	
0.029	
Season	of	birth	 Dry	hot	 .1860007	 .0577072				
.3142943	
0.005	
	 Wet	 .2085752	 .0939361				
.3232143	
<0.001	
Sex	 Female	 -.0194428	 -.1114994				
.0726138	
0.678	
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6.6.	Cross-reactivity	between	GBS	STs	
Although	34%	of	mothers	were	found	to	be	colonised	with	GBS,	antibody-
mediated	C3b/iC3b	deposition	was	detected	in	70%	of	all	cord	samples	and	56%	of	
infant	samples	to	at	least	one	GBS	ST	as	shown	in	Figure	27.		Additionally,	57%	of	
cord	samples	and	44%	of	infant	samples	demonstrated	antibody-mediated	C3b/iC3b	
deposition	against	all	five	GBS	STs	tested.	Cross-reactivity	between	GBS	STs	was	
examined	using	different	lower	limit	of	quantifications	as	described	above.	As	
expected,	at	low	lower	limit	of	quantifications,	a	high	amount	of	cross-reactivity	was	
observed.	However,	at	a	lower	limit	of	quantification	above	10,000	FI-C’	functional	
antibody	against	a	predominant	GBS	ST	was	identified	.	There	was	also	greater	
divergence	between	the	cord	and	infant	sera	values	at	these	higher	FI-C’	values.	
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Figure	27	-	Percentage	of	sera	with	antibody-mediated	C3b/iC3b	deposition	detected	to	at	least	one	GBS	ST	using	different	lower	limits	of	
quantification	
	
	Bar	graph	demonstrating	percentages	of	cord	and	infant	sera	that	show	antibody-mediated	C3b/iC3b	deposition	onto	≥1	GBS	strain	tested	using	a	lower	limit	of	
quantification	FI_C=	value	of	≥2,000	(A),	≥5,000	(B),	≥10,000	(C),	and	≥20,000	(D).	Samples	that	were	assigned	a	not-determined	value	were	classified	as	not	having	
measurable	functional	antibody	levels.	Cord,	n	=525;	infant,	n=412.	
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To	determine	whether	these	different	lower	limit	of	quantifications	affected	
the	ability	of	the	CDA	to	predict	opsonophagocytic	killing,	the	sensitivity,	specificity,	
PPV	and	NPV	of	the	CDA	were	calculated	using	the	lower	limit	of	quantifications	
described	above.	With	increasing	lower	limit	of	quantification	the	sensitivity	of	the	
CDA	declined.	With	lower	limit	of	quantification	above	FI-C’	10,000	the	sensitivity	of	
the	test	dropped	to	below	50%.	Figure	28	illustrates	these	parameters	at	each	of	the	
different	lower	limit	of	quantification.	Based	on	these	results	an	FI-C’=2000	was	
selected	as	the	lower	limit	of	quantification	point	for	the	CDA.	
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Figure	28	-	Sensitivity,	specificity,	PPV	and	NPV	(%)	of	CDA	in	prediction	of	OPkA	titre	using	different	lower	limits	of	quantification	
	
	Bar	chart	presenting	percentage	sensitivity,	specificity,	positive	and	negative	predictive	values	overall,	and	for	STIa,	STIII	and	STV	with	lower	limit	of	quantification:	(A)	FI-C’	
2000,	(B)	FI-C”	5000,	(C)	FI-C’	10,000,	(D)	FI-C’	20,000.	N=30	samples	for	each	serotype	 	
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6.7.	Antibody-mediated	C3b/iC3b	deposition	between	birth	and	day	60-89		
Antibody-mediated	C3b/iC3b	deposition	declined	rapidly	between	birth	and	
day	60-89.	By	day	89	antibody-mediated	C3b/iC3b	deposition	was	reduced	by	50-
71%	dependent	on	GBS	ST.	In	a	chi-squared	analysis	to	determine	if	rate	of	antibody	
decline	was	the	same	for	all	GBS	STs,	the	percentage	decline	in	GM	FI-C’	forGBS		ST	
Ia	(-45%),	II	(-42%)	and	V	(-49%)	antibody	was	markedly	greater	than	the	GM	FI-C’	for	
Ib	(-29%)	and	III	(-30%)	antibody	(X2	(4,	N=525)	=18.6;	p=0.001).	The	results	are	
summarised	in	Figure	29.		
Figure	29	-	GM	FI-C’	antibody	mediated	C3b/iC3b	deposition	at	birth	and	day	60-89	
	
Bars	represent	GM	FI-C’	concentration	with	95%	confidence	interval;	patterned	bars	are	cord	sera,	
solid	bars	are	infant	sera;	FI-C’	fluorescence	minus	complement	control;	Student	t-tests	were	
calculated	using	GMC	FI-C’	in	cord		vs.	infant	serum	in	n=525	serum	samples;	****	p=<0.001	
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6.8.	Discussion	
A	high	proportion	of	cord	(70%)	and	infant	sera	(55%)	demonstrated	
antibody-mediated	C3b/iC3b	deposition	against	at	least	one	GBS	ST.	The	
predominant	antibody–mediated	C3b/iC3b	deposition	were	onto	GBS	ST	V	and	II,	
which	correspond	to	the	predominant	colonising	GBS	STs.	The	low	concentration	of	
antibody-mediated	C3b/iC3b	onto	GBS	STIb	in	cord	and	infant	sera	also	
corresponded	to	the	low	prevalence	of	this	GBS	ST	in	colonised	women	and	infants.	
The	finding	of	higher	antibody-mediated	C3b/iC3b	deposition	compared	to	
colonisation	is	similar	to	a	Thai	study	by	Herbert	et	al.	(2015)	which	demonstrated	
antibody-mediated	C3b/iC3b	deposition	in	91%	of	cord	serum	compared	to	a	GBS	
colonisation	rate	of	12%	in	Thailand.(164)	Similar	to	the	present	Gambian	study,	
antibody-mediated	C3b/iC3b	deposition	corresponded	to	known	carriage	rates	in	
Thailand.	
The	number	of	cord	sera	with	antibody-mediated	C3b/iC3b	deposition	above	
2000	FI-C’	varied	by	GBS	ST	but	antibody-mediated	C3b/iC3b	deposition	onto	the	
surface	of	GBS	STV	was	greater	than	for	other	GBS	STs.	Concordantly,	the	GM	FI-C’	
concentration	was	also	highest	for	GBS	STs	V	and	II	and	lowest	for	Ib	in	cord	sera,	in	
line	with	the	higher	proportion	of	GBS	STs	V	and	II	colonised	women.	In	adjusted	
analysis,	increasing	birth	weight	and	birth	during	the	dry	hot	or	wet	season	but	not	
tetanus	vaccination	were	associated	with	increased	cord	GM	FI-C’	for	all	GBS	STs	in	
cord	blood.	Maternal	malaria	in	pregnancy	was	associated	with	decreased	GM	FI-C’.	
The	results	suggest	high	cross-reactivity	between	the	different	GBS	STs,	
possibly	as	a	result	of	repeated	episodes	of	colonisation	by	different	GBS	STs.	In	
contrast,	the	study	by	Herbert	et	al.	demonstrated	similar	numbers	of	sera	with	
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antibody-mediated	C3b/iC3b	deposition	against	at	least	three	GBS	STs	but	a	much	
lower	percentage	with	antibody-mediated	C3b/iC3b	deposition	against	all	five	GBS	
STs	(7%	vs.	40%	in	our	study).		This	may	be	due	to	differences	in	circulating	GBS	STs	
or	due	to	assay	sensitivity	issues.	Our	finding	of	a	predominant	GBS	ST	at	higher	GM	
FI-C’	values	is	in	keeping	with	studies	from	South	Africa	demonstrating	that	new,	
rather	than	persistent	colonisation	with	GBS	in	pregnant	women	is	associated	with	
higher	antibody	concentrations(146).	It	is	important	to	note	that	our	study	used	
naturally	immune	sera	and	so	the	cross-reactivity	seen	reflects	natural	antibody	and	
results	may	be	different	in	sera	from	vaccinated	women.	
Antibody-mediated	C3b/iC3b	deposition	decline	between	birth	and	day	89	
appears	to	vary	between	GBS	STs	with	the	quickest	declines	shown	for	GBS	STIa,	STII	
and	STV.	Our	results	could	reflect	higher	initial	antibody-mediated	C3b/iC3b	
deposition	for	GBS	STs	II	and	V	compared	to	other	GBS	STs	and	so	a	more	rapid	slope	
of	decline.	The	finding	that	antibody-mediated	C3b/iC3b	deposition	to	different	GBS	
STs	declines	at	different	rates	was	also	reported	in	a	population	of	non-pregnant	
vaccinated	adults	in	the	USA.	In	this	study,	the	rate	of	antibody	decline	between	4	
weeks	and	52	weeks	post-vaccination	was	most	marked	in	GBS	STIII	(-59%),	followed	
by	Ia	(-42%)	and	V	(-38%).	However,	encouragingly,	despite	different	rates	of	
antibody	decline,	this	USA	study	indicated	that	functional	activity	persisted	for	up	to	
two	years	post-vaccination	with	at	least	a	log10	reduction	in	bacteria	CFU/mL.	In	
contrast,	in	our	study	a	decline	in	functional	activity	was	observed	that	varied	
between	GBS	STs	between	birth	and	day	60-89.	This	could	imply	that	different	rates	
of	antibody	decline	would	lead	to	colonisation	with	subsequent	diverse	GBS	STs	at	
different	rates.		
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Chapter	7	-	Association	between	functional	antibody	and	maternal	and	infant	
colonisation	in	a	Gambian	cohort	
7.1.	Introduction	
Anti-capsular	antibody	against	GBS	is	thought	to	be	the	most	important	
protective	mechanism	against	invasive	disease.(115)	Antibody	to	GBS	CPS	passively	
transferred	from	mother	to	infant	via	the	placenta	has	been	shown	to	reduce	the	
risk	of	neonatal	EO-GBS	disease	by	70-90%,	dependent	on	GBS	ST.(116)		
It	is	less	clear,	however,	whether	presence	of	high	levels	of	functional	
antibody	can	reduce	the	likelihood	of	colonisation	from	mother	to	infant	at	birth	and	
in	the	subsequent	first	months	of	life.	Kwatra	et	al	(2015)	demonstrated	that	higher	
OPkA	titres	against	GBS	STs	Ia	and	III	in	early	pregnancy	were	associated	with	
absence	of	maternal	colonisation	with	these	two	GBS	STs	during	later	
pregnancy.(146)	If	naturally-acquired	maternal	anti-CPS	antibody	passed	to	the	
infant	could	be	shown	to	reduce	infant	colonisation	from	both	the	colonising	and	
cross-reactive	GBS	STs,	this	would	significantly	reduce	the	risk	of	infants	developing	
invasive	EO-	or	LO-GBS	disease.	In	turn,	this	proof	of	principle	would	have	important	
implications	for	the	likelihood	of	success	of	GBS	vaccines	given	to	pregnant	women	
in	order	to	prevent	both	infant	colonisation	and	ultimately	invasive	disease.	
Data	in	Chapter	5	and	6	shows	that	the	CDA	is	capable	of	predicting	
opsonophagocytic	killing	in	vitro	and	that	Gambian	mothers	have	relatively	high	
concentrations	of	anti-GBS	functional	antibody	in	cord	blood.	High	levels	of	cross-
reactivity	between	GBS	STs	have	also	been	demonstrated	that	may	be	an	advantage	
in	protection	from	invasive	disease	following	challenge	from	different	GBS	STs.			
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In	this	Chapter	the	relationship	between	functional	antibody	concentration	
against	GBS	STs	Ia,	II,	III	and	V	and	the	infant	risk	of	GBS-acquisition	with	the	
homologous	GBS	ST	up	to	the	age	of	89	days	is	examined	as	is	the	association	
between	functional	antibody	and	postnatal	clearance	of	GBS.	
7.2.	Methods	
The	patient	population,	microbiological	and	molecular	methods	for	collecting	
samples	are	described	in	Chapters	3	and	4.	I	used	the	CDA	as	described	in	Chapters	3	
and	5	to	measure	antibody-mediated	C3b/iC3b	deposition	onto	the	surface	of	GBS	
bacteria	STIa,	II,	III	and	V	by	flow	cytometry.	Results	are	reported	as	GM	FI-C’,	using	a	
lower	limit	of	quantification	of	2000	FI-C’	units	(Chapter	5).	
Potential	differences	in	antibody-mediated	C3b/iC3b	deposition	between	
sera	from	colonised	and	non-colonised	mothers	and	infants	were	evaluated	by	
student's	t	test	after	log	transformation	of	data.	Four	groups		were	compared	
(mother	colonised/infant	non-colonised;	mother	colonised/infant	colonised;	mother	
non-colonised/infant	colonised	and	neither	mother	nor	infant	colonised)	using	
ANOVA	following	log-transformation	of	data.	Comparison	of	log-transformed	
antibody-mediated	C3b/iC3b	deposition	in	serum	at	birth	(cord	blood)	and	at	60-89	
days	was	performed	using	a	paired	t	test.	Logistic	regression	analysis	was	performed	
to	determine	which	variables	were	independently	and	significantly	associated	with	
the	acquisition	of	GBS.	The	correlation	between	bacterial	concentration	and	
functional	GBS	ST-specific	antibody	was	evaluated	using	Deming	linear	regression	
and	95%	CIs	(PRISM,	La	Jolla).	For	all	comparisons,	p	<0.05	was	considered	to	be	
significant.		
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7.3.	Antibody-mediated	C3b/iC3b	deposition	in	cord	blood	and	maternal	
colonisation	at	delivery	
Overall,	525	serum	samples	from	cord	blood	had	detectable	antibody-
mediated	C3b/iC3b	deposition	against	any	GBS	ST.	Colonised	mothers	were	more	
likely	to	present	during	the	wet	season,	be	over	70kg	in	weight,	non-anaemic,	with	
more	than	one	previous	stillbirth,	and	more	than	one	ANC	attendance.	These	
characteristics	are	described	in	Chapter	4.		
Compared	to	mothers	who	were	non-colonised	with	any	GBS	ST	at	delivery,	
mothers	colonised	with	GBS	STs	Ia,	Ib,	II,	III	or	V	had	significantly	lower	GM	FI-C’	
antibody-mediated	C3b/iC3b	deposition	against	the	homologous	colonising	GBS	ST.		
(Figure	30)		
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Figure	30	–	GM-FI-C’	antibody-mediated	C3b/iC3b	deposition	(95%	CI)	in	cord	
blood	onto	GBS	ST	Ia,	Ib,	II,	III	and	V		
	
	Dot	and	whisker	plot	demonstrating	GMC	antibody-mediated	C3b/iC3b	deposition	against	GBS	STIa,	
Ib,	II,	III	and	V	in	cord	blood	(n=525).	GM	FI-C’	[95%	CI]	compared	between	mothers	colonised	with	
homologous	serotype	(coloured	shapes),	non-colonised	mothers	(gray	shapes)	and	mothers	colonised	
with	other	serotypes	(blue	squares).	ANOVA	was	calculated	to	compare	groups	*p<0.05,	
**p<0.01,****P	<	.001.		
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A	multivariable	regression	analysis,	summarised	in	Table	17	showed	that	
mothers	who	were	colonised	with	the	homologous	GBS	ST	at	delivery	had	
significantly	lower	antibody-mediated	C3b/iC3b	deposition	against	GBS	STs	Ia,	II,	III	
and	V	when	adjusted	for	maternal	age,	previous	abortions,	number	of	stillbirths,	
maternal	anaemia,	maternal	weight,	number	of	ANC	visits,	gestation	at	birth	and	
season	of	delivery	compared	to	mothers	who	remained	non-colonised.	This	was	true	
whether	the	mother	was	colonised	with	the	homologous	GBS	ST	or	if	they	were	
colonised	with	another	GBS	ST.	For	GBS	STIb,	there	was	no	association	between	
mothers	colonised	with	the	homologous	GBS	ST	or	another	GBS	ST,	probably	due	to	
the	low	numbers	of	mothers	colonised	with	GBS	STIb.	An	example	of	the	potential	
model	of	functional	antibody	activity	in	relationship	to	the	colonisation	status	of	
both	mothers	and	infants	is	described	in	Figure	31.	
	
Figure	31	-Potential	model	of	functional	antibody	activity	against	homologous	GBS	
ST	
	
	
M-I-=mother/infant	non-colonised;	M+I+	homol	=	mother/infant	pair	both	colonised	with	
homologous	serotype;	M+I-=mother	colonised/infant	non-colonised;	M+I+	heterol	=	mother/infant	
colonised	with	heterologous	serotype;	M-I+=mother	non-colonised/infant	colonised	heterologous	
serotype.
Functional	activity	measured	by	CDA	 Functional	activity			High		Low		Low		Moderate		Low	
M-I-		M+I+	homol		M+I-		M+I+	heterol		M-I+			
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Table	17-	Multiple	regression	model	demonstrating	the	reduction	in	antibody-mediated	C3b/iC3b	deposition	associated	with	maternal	
colonisation	with	homologous	GBS	ST	compared	to	non-colonised	mothers	
	 STIa	
FI-C’,	(95%	CI)	
STIb	
FI-C’,	(95%	CI)	
STII	
FI-C’,	(95%	CI)	
STIII	
FI-C’,	(95%	CI)	
STV	
FI-C’,	(95%	CI)	
Mother	colonised	with	
homologous	GBS	ST	
-6174	(-9273	to	-
3074)****	
-1924	(-6287	to	
2438)	
-5866	(-9106	to	-
2626)****	
-6731	(-9067	to	-
4394)****	
-3982	(-6004	to	-
1959)****	
Mother	colonised	with	another	
GBS	ST	
-5166	(-6466	to	-
3866)****	
-885	(-1931	to	
160)	
-4871	(-6582	to	-
3160)****	
-5476	(-6626	to	-
4326)****	
-4435	(-6574	to	-
2290)****	
All	GM	FI-C’	figures	demonstrate	the	reduction	in	GM	FI-C’	compared	to	mother/infant	group	where	neither	was	colonised.	Model	adjusted	for	maternal	age,	weight,	
anaemia,	gestation	at	delivery,	previous	stillbirths/spontaneous	abortions,	number	of	antenatal	clinic	visits	and	season	at	delivery.****=p<0.0001
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7.4.	Antibody-mediated	C3b/iC3b	deposition	in	cord	blood	and	maternal	and	infant	
colonisation	dynamics	at	delivery	
There	were	186	colonised	infants	at	birth	and	antibody-mediated	C3b/iC3b	
deposition	was	detected	in	525/750	cord	samples.	Infants	were	more	likely	to	be	
colonised	if	born	to	a	colonised	mother,	where	maternal	weight	was	below	70kg,	
mother	had	more	than	one	previous	stillbirth	or	attended	ANC	more	than	once.	
Additionally,	infants	were	more	likely	to	be	colonised	if	born	at	less	than	37	weeks,	
during	the	dry	hot	or	wet	seasons,	with	a	birth	weight	below	3.1kg	or	delivered	by	
midwives.	These	characteristics	are	described	in	Chapter	4.	Due	to	the	low	number	
of	mother/infant	pairs	both	colonised	with	STIb	(n=7)	or	mothers	colonised	with	STIb	
when	infants	remained	non-colonised	(n=7)	It	was	not	possible	to	draw	conclusions	
about	the	relationship	between	antibody-mediated	C3b/iC3b	deposition	and	
colonisation	with	STIb.		
There	was	a	significant	difference	between	mother/infant	both	colonised,	
mother/infant	both	non-colonised,	mother	colonised/infant	non-colonised,	
mother/infant	colonised	with	a	different	GBS	ST,	mother	non-colonised/infant	
colonised	for	GBS	STs	Ia	(F=17.92,	p<0.001),	II	(F=12.09,	p<0.001),	III	(F=23.65,	
p<0.001)	and	V	(F=7.93,	p<0.001)	in	cord	blood.	
7.4.1.	Antibody-mediated	C3b/iC3b	deposition	if	both	mothers	and	infants	were	
colonised	
Antibody-mediated	C3b/iC3b	deposition	was	lower	if	mother/infant	were	
both	colonised	than	if	mother/infant	were	both	non-colonised	with	the	homologous	
GBS	ST	for	Ia,	II,	III	and	V.	Table	18	outlines	the	GM	FI-C’	values	for	each	of	the	
groups.	If	both	mother	and	infant	were	colonised	with	the	homologous	GBS	ST,	GM	
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FI-C’	antibody-mediated	C3b/iC3b	deposition	was	significantly	higher	than	if	
mother/infant	were	colonised	with	different	GBS	STs	for	II	(p=0.002)	and	III	(p=0.04)	
but	not	for	Ia	(p=0.26)	or	V	(p=1).	There	was	no	difference	between	GM	FI-C’	
antibody-mediated	C3b/iC3b	deposition	when	comparing	mother	and	infant	
colonised	pairs	and	those	pairs	where	mother	was	non-colonised	and	infant	was	
colonised	with	the	homologous	GBS	ST	as	the	antibody	measured	(p=1.0	for	all	GBS	
STs)(Figure	32).		
Table	18	-	GM	FI-C’	and	95%	CI	by	GBS	ST	and	mother/infant	colonisation	group	
	 STIa	 STII	 STIII	 STV	
M-I-	 6309		
(5754-7079)	
7079	
(6457-7762)	
6607	(5888-
7244)	
6026		
(5248-6918)	
M+I+	
homologous	
GBS	ST	
1000	
(1000-1000)	
1413	
(1122-1778)	
1288	(1000-
1585)	
3090	
(2455-3802)	
M+I-	 2455		
(1778-3388)	
3020	
(1820-5012)	
2512	(1585-
3802)	
3677	
(3388-6457)	
M-I+		 1202		
(661-1995)	
1445	
(1023-2042)	
1000	(1000-
1000)	
3090		
(1778-5495)	
M+I+	other	
GBS	ST	
2344		
(1995-2512)	
3090	
(2630-3631)	
2399	(2089-
2754)	
3981	
(3162-4786)	
M-I-=neither	mother	nor	infant	colonised;	M+I+	mother	and	infant	colonised;	M+I-=mother	only	
colonised;	M-I+	infant	only	colonised;	ST=serotype	
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7.4.2.	Antibody-mediated	C3b/iC3b	deposition	if	neither	mother	nor	infant	was	
colonised.	
Compared	to	all	other	groups,	GM	FI-C’	antibody-mediated	C3b/iC3b	
deposition	was	significantly	higher	for	all	GBS	STs	if	the	mother/infant	pair	were	
non-colonised	(Figure	32).	In	a	multivariable	regression	analysis,	mother/infant	pairs	
who	remained	non-colonised	had	significantly	higher	GM	FI-C’	antibody-mediated	
C3b/iC3b	deposition	than	when	mother/infant	pairs	were	both	colonised,	when	
adjusted	for	maternal	age,	maternal	weight,	previous	abortions/stillbirths,	maternal	
anaemia,	number	of	ANC	visits,	birth	season	and	gestation	(P<0.0001)(Table	16).	
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Figure	32	–	Antibody-mediated	C3b/iC3b	deposition	comparing	mother	and	infant	
colonisation	groups	
	
Dot	and	whisker	plots	representing	the	mean	and	95%	confidence	intervals	of	log10	FI-C’	values	of	
antibody-mediated	C3b/iC3b	deposition	onto	the	surface	of	whole	GBS	STs	Ia,	Ib,	II,	III	and	V	bacteria	
(n=525).	FI-C’	–	fluorescence	intensity	minus	complement	control;	M-I-	-	neither	mother	nor	infant	
colonised;	M+I+(Ia/Ib/II/III/V)	-	both	mother	and	infant	colonised	with	the	homologous	GBS	ST;	M+I-	-	
mother	colonised	with	homologous	ST,	infant	non-colonised	with	any	ST;	M+I+O	–	mother	and	infant	
colonised	with	different	GBS	ST;	M-I+	-	infant	colonised	with	homologous	ST,	mother	non-colonised	
with	any	ST.	M-I-=neither	mother	nor	infant	colonised;	M+I+	mother	and	infant	colonised;	M+I-
=mother	only	colonised;	M-I+	infant	only	colonised;	ST=serotype.	ANOVA	was	used	to	compare	groups;	
*p<0.05;	***P<0.01;	****p<0.001.	
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7.4.3.	Antibody-mediated	C3b/iC3b	deposition	if	mother	colonised	but	infant	non-
colonised	at	birth	
Compared	to	mother/infant	pairs	who	both	remained	non-colonised	at	
delivery,	mothers	who	were	colonised	but	had	infants	who	were	non-colonised	had	
significantly	lower	GM	FI-C’	antibody-mediated	antibody	deposition	to	GBS	ST	Ia	
(p=0.001),	II	(p=0.001),	III	(p<0.001)	but	not	than	V	(p=1.0).	When	comparing	
mothers	and	infants	who	were	both	colonised	with	mothers	who	were	colonised	but	
whose	infants	were	non-colonised,	there	was	a	trend	towards	higher	GM	FI-C’	
antibody-mediated	C3b/iC3b	deposition	for	all	GBS	STs	but	this	was	not	significant	
(GBS	ST	Ia	p=0.44;	II	p=0.09;	III	p=0.23;	V	p=0.32).	There	was	no	difference	between	
mothers	colonised	and	infants	who	were	non-colonised	compared	to	mothers/infant	
pairs	where	both	were	colonised	with	other	GBS	STs	or	where	infant	was	colonised	
but	mother	was	non-colonised.		
7.4.4.	Antibody-mediated	C3b/iC3b	deposition	if	infant	was	colonised	but	mother	
was	non-colonised	
Compared	to	mother/infant	pairs	who	were	non-colonised	at	birth,	GM	FI-C’	
antibody-mediated	C3b/iC3b	concentration	was	lower	in	infants	who	were	colonised	
when	mothers	were	non-colonised	for	GBS	STs	Ia	(p=0.001)	and	II	(p<0.001)	but	not	
for	III	(p=0.22)	or	V	(p=0.42).	There	was	no	difference	between	any	of	the	other	
groups	and	GM	FI-C’	antibody-mediated	C3b/iC3b	deposition	compared	to	infants	
colonised	in	the	absence	of	maternal	colonisation.	
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7.5.	Using	CDA	and	OPkA	to	estimate	correlates	of	protection	against	colonisation	
There	was	no	correlation	between	log10	GBS	CFU/mL	from	rectovaginal	or	
infant	swabs	and	GM	FI-C’	antibody-mediated	C3b/iC3b	deposition	in	cord	blood	for	
GBS	STs	III	or	V.	There	was	insufficient	data	to	analyse	the	correlation	between	GBS	
STs	Ia	or	Ib	bacterial	concentration	and	antibody-mediated	C3b/iC3b	deposition.	
There	was	a	moderate	correlation	between	GBS	CFU/mL	from	infant	swabs	at	birth	
and	antibody-mediated	C3b/iC3b	deposition	in	cord	blood	for	GBS	STII	(R2=0.36,	
F=9.67,	P=0.006).	In	addition,	plotting	the	bacterial	concentration	in	infant	swabs	
with	the	antibody-mediated	C3b/iC3b	deposition	in	cord	blood	indicated	that	there	
was	a	threshold	above	which	no	bacteria	were	found	by	culture	or	PCR.	These	
thresholds	were	observed	at	log10	FI-C’=3	(3000	FI-C’	units)	for	GBS	STIa,	log10	FI-
C’=3.4	(2951	FI-C’	units)	for	GBS	STIII	and	log10	FI-C’=3.97	(9332	FI-C’	units)	for	GBS	
STV	(Figure	33).		
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Figure	33	-	Infant	bacterial	colonisation	and	functional	antibody	threshold	
	
Scatter	plots	of	log10	GBS	CFU/mL	from	infant	swabs	and	log10	FI-C’	for	GBS	STs	Ia,	Ib,	II,	III	and	V.	
Vertical	red	line	represents	threshold	above	which	there	is	no	bacterial	colonisation	is	seen.	STIa	n=3;	
STII	n=20;	STIII=10;	STV	n=62.CFU/mL	–	colony-forming	units	per	mililitre;	FI-C’	fluorescence	intensity	
minus	C3b/iC3b	only	control;	ST	–	serotype.		
	
Using	the	correlation	coefficients	calculated	in	Chapter	5,	it	was	possible	to	
estimate	the	potential	OPkA	titre	that	corresponded	to	the	observed	threshold	for	
GBS	STs	Ia,	III	and	V.	Table	19	demonstrates	the	log10	and	antilogged	FI-C’	values	for	
each	GBS	ST	and	the	associated	OPkA	titre.	
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Table	19-		Log10	and	antilog	of	FI-C’	and	corresponding	OPkA	titre.	
GBS	ST	 Log10	FI-C’	 FI-C’	 OPkA	titre	
STIa	 3.01	 1000	 1:100	
STIII	 3.47	 2951	 1:400	
STV	 3.97	 9332	 1:3000	
	
Using	the	RCD	curve	calculated	in	Chapter	6,	65%	of	cord	blood	would	have	
OPkA	titres	above	this	level	for	GBS	STIa,	52%	for	GBS	STIII	and	20%	for	GBS	STV.	
Figure	34	demonstrates	the	RCD	curve	for	cord	blood	with	the	associated	FI-C’	
values	corresponding	to	absence	of	infant	bacterial	colonisation.	
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Figure	34	–	Reverse	cumulative	distribution	curve	of	cord	sera	with	associated	FI-C’	
values	corresponding	to	absence	of	infant	colonisation	at	birth	with	that	GBS	ST.
	
Reverse	cumulative	distribution	curve	of	750	cord	serum	samples.		Y	axis	represents	percentile	of	cord	
sera	with	FI-C’	concentration	over	the	lower	limit	of	detection	for	each	of	the	STs.	X-axis	represents	FI-
C’	for	that	population	percentile.	Vertical	line	at	FI-C’=1000	represents	FI-C’	value	associated	with	
absence	of	infant	colonisation	with	GBS	STIa;	Vertical	line	at	FI-C’=2951	represents	FI-C’	value	
associated	with	absence	of	colonisation	with	GBS	STIII;	Vertical	line	at	FI-C’=9332	represents	FI-C’	
value	associate	with	absence	of	colonisation	with	GBS	STIII.	STIa=serotype	Ia	(n=487),	STIb=serotype	Ib	
(n=442),	STII	=	serotype	II	(n=525),	STIII=serotype	III	(n=480),	STV=serotype	V	GBS	(n=525).	FI-C’	is	the	
florescence	of	the	sample	minus	the	complement-only	control.	
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In	order	to	investigate	further	the	relationship	observed	between	bacterial	
concentration	and	functional	cord	antibody	in	the	scatter	diagrams	the	differences	
were	examined	between	cord	sera	containing	very	low	(below	25th	centile);	low	(25th	
to	50th	centile);	median	(50th	to	75th	centile)	and	high	(above	75th	centile)	FI-C’	values	
for	each	of	the	four	GBS	STs	and	this	was	compared	to	infant	colonisation	at	birth	
with	the	homologous	GBS	ST.	Compared	to	those	infants	who	had	very	low	FI-C’	
values,	infants	with	high	homologous	GBS	ST	antibody-mediated	C3b/iC3b	
deposition	were	less	likely	to	be	colonised	with	GBS	STs	Ia	(F=10.3,	p<0.001),	II	
(F=38.15,	p<0.001),	III	(F=9.14,	p=0.01)	and	V	(F=20.18,	p<0.001).	Additionally,	
compared	to	those	infants	with	very	low	FI-C’	in	cord	blood,	infants	with	low	or	
median	FI-C’	were	less	likely	to	be	colonised	with	GBS	STV	(P<0.001).	
Deming	linear	regression	was	then	performed	to	investigate	the	relationship	
between	bacterial	concentration	and	antibody-mediated	C3b/iC3b	deposition	
against	the	homologous	colonising	GBS	ST.	For	each	cord	sample	the	paired	bacterial	
concentration	for	the	homologous	GBS	ST	was	plotted.	The	scatter	plots	in	Figure	35	
demonstrate	a	significant	negative	correlation	between	functional	antibody	
concentration	and		bacterial	concentration	demonstrated	by	negative	slope	and	95%	
CI	that	do	not	span	zero.	This	indicates	that	as	functional	antibody	decreases,	
bacterial	concentration	increases.	Table		20	outlines	the	slopes,	95%	CIs	and	
statistical	significance	value	for	each	of	the	GBS	STs.	
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Figure	35	–	Deming	regression	plots	for	GBS	ST	Ia,	II,	III	and	V	comparing	cord	
serum	with	CFU/mL	from	infant	swabs	at	birth	
	
Deming	regression	of	log10	FI-C’	against	log10	bacterial	concentration	for	STIa,	STII,	STIII	and	STV.	
Log10	bacterial	concentration	on	the	x	axis	(CFU/mL),	log10	FI-C’	on	the	y	axis;	STIa=serotype	Ia,	
STII=serotype	II,	STIII=	serotype	III,	STV=serotype	V.		
	
Table	20	–	Relationship	between	antibody-mediated	C3b/iC3b	deposition	and	
bacterial	concentration	(CFU/mL)	for	GBS	ST	Ia,	II,	III	and	V	
Serotype	 Intercept	(95%	CI)	 Slope	(95%	CI)	 P	
Ia	 3.70	(3.64-3.75)	 -0.09	(-0.15	to	-0.03)	 0.0009	
II	 3.75	(3.7-3.79)	 -0.1	(-0.14	to	-0.07)	 <0.0001	
III	 3.69	(3.65-3.74)	 -0.1	(-0.14	to	-0.05)	 <0.0001	
V	 3.73	(3.68-3.78)	 -0.05	(-0.07	to	-0.03)	 <0.0001	
	
7.6.	Clearance	of	colonisation	and	antibody-mediated	C3b/iC3b	deposition	
To	better	understand	the	role	of	antibody	kinetics	on	bacterial	colonisation,	
four	groups	of	infants	were	compared:	those	who	were	never	colonised,	those	who	
were	intermittently	colonised	(either	at	birth	or	day	6-9	or	day	60-89),	those	
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colonised	at	two	time	points	(either	birth	and	day	6-9,	or	birth	and	day	60-89,	or	day	
6-9	and	day	60-89)	and	those	who	remained	colonised	throughout	the	study	using	
ANOVA.	There	was	insufficient	longitudinal	data	to	assess	the	impact	of	antibody-
mediated	C3b/iC3b	deposition	on	colonisation	with	GBS	STIb.	
7.6.1.	Persistent	colonisation	from	birth	to	day	60-89	
Infants	who	were	persistently	colonised	with	the	same	GBS	ST	from	birth	to	
day	60-89	had	significantly	lower	FI-C’	antibody-mediated	cC3b/iC3b	deposition	
values	than	those	infants	who	remained	non-colonised	for	GBS	ST	II	(p=0.04)	and	V	
(p=0.01).	No	infants	were	persistently	colonised	with	GBS	STIII	and	only	one	infant	
was	persistently	colonised	with	GBS	STIa.	There	was	no	statistical	difference	in	
antibody-mediated	C3b/iC3b	deposition	between	persistently	and	intermittently	
colonised	infants	(GBS	STII	p=0.23;	GBS	STV	p=0.34)(Figure	36).		
7.6.2.	Intermittent	colonisation	between	birth	and	day	60-89.	
Infants	who	were	intermittently	colonised	had	significantly	lower	antibody-
mediated	C3b/iC3b	deposition	for	GBS	STs	Ia	(p=0.005),	II	(p<0.001),	III	(p<0.001)	and	
V	(p=0.02)	compared	to	infants	who	remained	non-colonised	from	birth	to	day	60-
89.	Infants	colonised	on	one	occasion	had	significantly	higher	antibody	
concentrations	for	GBS	STs	II	(p=0.002)	and	V	(P=0.05)	but	not	for	the	other	GBS	STs	
(STIa	p=0.38,	STIII	p=0.31)	compared	to	infants	colonised	on	two	occasions.	There	
was	no	significant	difference	between	infants	colonised	on	two	occasions	and	infants	
who	were	persistently	colonised	(GBS	ST	V	p=0.49,	Ia	p=0.34,	II	p=0.49,	III	p=0.36)	
(Figure	36).	
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Figure	36	-Median	and	standard	deviation	of	antibody-mediated	C3b/iC3b	
deposition	in	cord	blood	comparing	non-colonised,	intermittently	and	persistently	
colonised	infants	
	
Box	and	whisker	plot	with	Tukey	correction	demonstrating	median	antibody-mediated	C3b/iC3b	
deposition	in	non-colonised	infants,	intermittently	colonised	infants	(one	occasion),	infants	colonised	
on	two	occasions	and	persistently	colonised	infants	with	GBS	STIa,	II,	III	and	V.	FI-C’=	fluorescence	
intensity	minus	complement	control,	n=684.	ANOVA	was	calculated	to	determine	differences	between	
the	four	groups,	*p<0.05,	**p<0.03,	***p<0.01,	****p<0.001.	
	
7.7.	Discussion	
This	study	has	demonstrated	an	inverse	correlation	between	maternal	and	
infant	colonisation	and	functional	antibody	in	cord	blood.	The	data	support	the	
notion	that	the	risk	of	a	colonised	mother	giving	birth	to	a	colonised	infant	
diminishes	as	naturally-acquired	antibody	increases.		This	proof	of	concept	supports	
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the	idea	that	vaccinating	mothers	in	pregnancy	against	GBS	could	have	the	same	
effect,	provided	the	vaccine-induced	antibody	levels	are	similar	and	the	antibody	
similarly	functional	in	comparison	with	naturally	acquired	antibody.	
This	study	has	the	advantage	of	measuring	functional	antibody	against	whole	
GBS	bacteria	rather	than	total	anti-CPS	antibody	concentration	and	so	enables	a	
more	detailed	analysis	of	the	physiological	effect	of	antibody	on	bacterial	killing	that	
may	be	important	to	reduce	sustained	bacterial	colonisation	in	the	infant.	
Our	data	show	that	mothers	with	higher	GM	FI-C’	antibody-mediated	
complement	deposition	are	less	likely	to	be	colonised	with	GBS	themselves	than	
mothers	with	lower	GM	FI-C’	antibody-mediated	complement	deposition	in	cord	
blood.		In	turn,	infants	born	to	mothers	with	higher	GM	FI-C’	antibody-mediated	
complement	deposition	are	themselves	less	likely	to	be	colonised	at	birth	or	to	
acquire	GBS	colonisation	during	the	first	weeks	of	life.	This	is	an	important	finding	as	
reducing	maternal	colonisation	has	the	effect	of	reducing	infant	colonisation	and	
therefore	should	impact	on	EO-	and	LO-GBS	disease.		
Apart	from	the	study	presented	in	this	thesis,	there	are	currently	no	data	
available	that	investigate	the	role	of	cord	antibody	in	protecting	infants	
longitudinally	from	colonisation	at	birth	and	up	to	89	days	of	age.	
Interestingly,	our	results	differ	from	previous	studies	that	have	demonstrated	
higher	anti-CPS	IgG	concentrations	in	pregnant	women	who	were	colonised	with	GBS	
than	in	non-colonised	women.		With	the	exception	of	the	study	by	Baker	et	al.	
(1980)(117),	these	studies	measured	antibody	by	ELISA	or	radioactive	binding	assay	
(RABA).	Neither	of	these	assays	tell	us	anything	about	antibody	function,	nor	were	
the	studies	designed	to	assess	whether	antibody	reduces	the	risk	of	colonisation	in	
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the	mother	and	transmission	to	the	infant	at	birth,	as	shown	in	this	study.	Two	
studies	have	used	OPkA	to	measure	antibody	in	longitudinal	cohort	studies	of	
pregnant	women.	The	Baker	study	(111)	which	measured	antibody	via	RABA	and	
OPkA	in	cord	and	maternal	sera	to	GBS	STIII	in	10	colonised	women,	found	that	
although	antibody	measured	by	RABA	was	low	in	non-colonised	women,	irrespective	
of	colonisation	status	most	mothers	had	low	levels	of	functional	antibody	
concentration	with	little	variation	in	antibody	activity	between	28	weeks	gestation	
and	delivery.		The	Baker	study	also	found	that	mothers	colonised	with	GBS	STIII	had	
higher	OPkA	titres	against	GBS	STIII	than	non-colonised	mothers.(117)	This	apparent	
increase	in	functional	antibody	associated	with	colonisation	could	represent	
different	timing	of	acquisition	and	therefore	different	antibody	kinetics	that	would	
not	be	detected	when	sampling	occurred	on	only	one	occasion	using	maternal/cord	
serum	and	vaginal	colonisation	at	birth,	as	was	the	case	with	our	study	design.	A	
much	larger	longitudinal	study	of	507	pregnant	women	by	Kwatra	et	al(146)	
attempted	to	describe	such	kinetics.	Their	study	found	that	women	who	were	never	
colonised	during	pregnancy	had	higher	functional	antibody	measured	by	OPkA	than	
those	women	who	had	new	acquisition	of	colonisation	during	the	study.		Further,	
they	found	that	although		women	who	were	newly	acquired	GBS	during	pregnancy	
had	higher	antibody	measured	by	ELISA	at	that	timepoint	than	non-colonised	
women	there	was	no	an	increase	in	OPkA	titre.	Further,	the	study	identified	that	
women	who	became	colonised	during	pregnancy	had	an	increase	in	both	ELISA	and	
OPkA	titre	between	28	weeks	of	pregnancy	and	delivery.	It	is	likely	that	this	rise	in	
antibody	concentration	and	function	prevents	further	maternal	colonisation	with	
this	GBS	ST.	This	study	was	not	designed	to	follow	up	mothers	longitudinally,	and	
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therefore	cannot	predict	which	mothers	had	been	persistently	colonised	and	those	
that	were	newly	colonised	by	the	time	they	gave	birth.	However,	the	fact	that	
increased	functional	activity	was	seen	in	non-colonised	compared	to	colonised	
mothers	and	an	inverse	relationship	between	cord	functional	antibody	and	transfer	
of	colonisation	between	mother	and	child	also	demonstrates	that	timing	of	
acquisition	is	likely	to	be	important	in	transfer	of	functional	antibody	from	mother	to	
child	and	thus	protection	from	infant	colonisation.	One	could	argue	though	that	
ultimately,	what	matters	for	protection	is	the	amount	of	functional	antibody	
reaching	the	infant	at	the	time	of	birth	and	hence	the	exact	kinetics	of	colonisation	
during	pregnancy	might	be	less	relevant.	The	kinetics	of	vaccine-induced	versus	
naturally-acquired	antibody	might	be	very	different	and	this	requires	further	
exploration	in	future	studies.	
This	study	also	demonstrated	that	compared	to	mother/infants	pairs	who	are	
non-colonised	at	birth,	mother/infant	pairs	where	both	are	colonised	had	
significantly	lower	antibody-mediated	C3b/iC3b	deposition.	The	same	was	true	if	the	
infant	was	colonised	but	not	the	mother.	Interestingly,	if	the	mother/infant	pair	had	
discordant	GBS	STs	then	the	FI-C’	was	higher	than	if	both	mother/infant	were	
colonised	with	the	same	GBS	ST	for	II	and	III	but	not	for	Ia	or	V.	This	is	an	important	
finding	as	it	may	suggest	that	waning	maternal	immunity	with	subsequent	
colonisation	of	a	different	GBS	ST	has	occurred.	Further,	this	data	suggests	that	the	
immune	response	to	the	different	GBS	STs	may	vary	and	it	will	therefore	be	highly	
important	to	analyse	vaccine	responses	to	multiple	GBS	STs	prior	to	Phase	III	vaccine	
trials	if	we	are	to	ensure	protective	titres	are	achieved	for	each	GBS	ST.	
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Where	mothers	are	colonised	but	infants	are	non-colonised	the	GM	FI-C’	was	
lower	than	if	both	mother	and	infant	remain	non-colonised.	However,	there	was	no	
difference	between	mother/infant	colonised	and	mother	colonised/infant	non-
colonised	for	any	GBS	ST.	This	could	again	be	due	to	the	challenge	with	a	new	GBS	ST	
and	a	developing	maternal	immune	response	or	due	to	persistent	colonisation	and	
therefore	waning	immunity.		
This	study	has	demonstrated	that	functional	antibody	above	the	75th	centile	
against	GBS	STs	Ia,	II,	III	and	V	correlates	with	absence	of	bacteria	identified	by	
culture	or	PCR	in	infants.	This	data	suggest	that	there	is	a	potential	threshold	of	
functional	antibody	above	which	the	infant	is	no	longer	colonised.	This	finding	could	
be	very	useful	in	developing	an	assay	that	can	ultimately	be	correlated	with	vaccine	
efficacy	in	prevention	of	neonatal	disease.		
Our	data	demonstrates	that	infants	who	remain	colonised	from	birth	up	to	
day	60-89	have	significantly	lower	FI-C’	values	in	cord	blood	and	rapid	decline	in	
activity	up	to	day	89	of	life.	Infants	who	cleared	colonisation	by	the	end	of	the	first	
week	of	life	had	higher	FI-C’	values	in	cord	blood	than	infants	who	remained	
colonised	for	two	visits	but	cleared	by	the	final	visit.	This	would	suggest	that	higher	
antibody-mediated	C3b/iC3b	deposition	contributes	to	on-going	killing	in	the	infant	
up	to	day	89	of	life.	
To	date,	nearly	all	published	work	has	focused	on	the	role	of	antibody	in	
protecting	infants	from	invasive	disease.(115,	116,	139,	140,	142,	196-203).	These	
studies	are	mostly	cross-sectional	in	nature	and	therefore	cannot	demonstrate	the	
effect	of	maternal	antibody	during	the	entire	period	of	risk	for	EO-	and	LO-GBS	
disease.	There	are	currently	no	published	studies	of	antibody	persistence	in	infants	
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and	our	data	add	a	new	dimension.	Edwards	et	al.	(2012)	demonstrated	OPkA	
activity	in	healthy	adult	sera	up	to	18	months	post-vaccination	with	GBS	STs	Ia	and	III	
CPS-conjugated	vaccines,	although	the	antibody	concentration	declined	rapidly	by	
four-weeks	post-	vaccination.	Baker	et	al.	2002	also	demonstrated	good	functional	
antibody	activity	two	months	after	vaccination	of	pregnant	women.(85)	The	GBS	ST-
specific	kinetics	of	antibody	decline	in	both	infants	and	mothers	are	important	to	
clarify	further,	as	this	will	have	implications	for	the	vaccine	strategy,	for	example	the	
timing	of	vaccination	in	pregnancy	and	the	need	for	further	doses	in	subsequent	
pregnancies.	
Our	data	suggests	that	interventions	such	as	maternal	vaccination	should	
have	an	impact	on	reduction	of	maternal	and	infant	colonisation	at	birth	and	up	to	
day	89	of	life	in	infants.	Estimating	a	threshold	of	protection	from	colonisation	is	
problematic,	as	this	is	only	a	surrogate	for	protection	from	invasive	disease,	but	our	
results	demonstrate	that	it	might	be	possible	to	develop	an	immune	correlate	of	
protection	from	colonisation,	if	well	standardised	assays	were	to	become	available.		
Of	course,	such	potential	correlates	require	verification	in	the	context	of	protection	
from	disease.		
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Chapter	8.	General	Discussion	
Based	on	the	available	published	literature	at	the	time	of	initiating	this	
project,	the	hypothesis	was	formulated	that	maternal	antibody	could	directly	
influence	maternal	and	infant	colonisation	with	GBS	at	birth	and	up	to	89	days	of	
life,	in	line	with	the	estimated	half	life	of	maternal	antibody	in	general.	If	this	
hypothesis	could	be	proven,	it	would	support	the	use	of	colonisation	as	a	surrogate	
marker	of	protection	from	infant	disease.	If	maternal	vaccination	against	GBS	and	
the	resulting	antibody	is	transferred	across	the	placenta,	this	could	prevent	
colonisation	during	the	first	three	months	of	life,	after	which	the	risk	of	an	infant	
developing	invasive	disease	reduces.		
As	a	first	step,	the	prevalence	and	risk	factors	for	maternal	and	infant	
colonisation	with	GBS	at	birth	and	the	factors	associated	with	postnatal	acquisition	
in	a	Gambian	population	were	investigated.	This	step	was	important	in	order	to	
establish	the	current	epidemiological	situation	of	GBS	in	the	Gambia,	given	that	a	
range	of	GBS	STs	needs	to	be	covered	by	a	vaccine.	If	the	GBS	STs	causing	
colonisation	and	disease	in	the	Gambia	were	different	to	those	found	in	other	
countries	then	the	vaccine	candidates	currently	in	development	might	not	be	
effective	in	a	West	African	population.		A	longitudinal	prospective	cohort	study	of	
Gambian	mother/infant	pairs	was	thus	performed	to	measure	the	prevalence	of	
maternal/infant	colonisation,	the	predominant	GBS	STs	and	the	colonisation	
dynamics	from	delivery	and	up	to	day	89	of	life.	These	findings	were	subsequently	
used	to	determine	the	possible	predisposing	factors	to	be	included	in	the	model	to	
explain	the	correlation	between	maternal	antibody	and	infant	colonisation	in	line	
with	our	original	hypothesis.	
		 162	
After	successful	completion	of	the	field	study,	where	microbiological	and	
serological	samples	from	750	mother/infant	pairs	were	obtained,	the	antibody-
mediated	C3b/iC3b	deposition	onto	the	surface	of	whole	GBS	bacteria	was	
determined	in	order	to	measure	the	functional	activity	of	this	maternally-derived	
antibody	in	opsonising	GBS.	As	opsonisation	and	subsequent	phagocytosis	and	killing	
are	key	steps	in	eradicating	GBS	from	the	circulation,	it	is	vital	that	the	functional	
activity	of	the	antibody	is	determined	if	an	effective	correlate	of	protection	is	to	be	
developed.		
Whilst	relatively	well	standardised	OPkA	are	routinely	used	to	measure	killing	
of	pneumococci,	no	universally	accepted,	standardised	OPkA	currently	exists	for	
GBS.	The	CDA	used	in	this	work	has	many	advantages	over	an	OPkA,	including	
avoiding	the	need	for	human	cells	and	the	viable	counts	of	bacteria.	These	elements	
have	been	found	to	make	the	assay	more	robust	and	reduce	the	interassay	
variability	often	seen	in	OPkA	between	different	laboratories.	Additionally,	the	CDA	
could	have	advantages	over	an	assay	measuring	IgG	bound	to	the	CPS,	as	is	the	case	
in	a	CPS	ELISA,	since	the	use	of	whole	fixed	bacteria	would	also	allow	measurement	
of	functional	activity	of	IgG	in	the	context	of	a	protein-based	vaccine.		Given	that	a	
good	correlation	between	OPkA	used	in	industry	and	the	CDA	was	demonstrated	for	
GBS	STs	Ia,	III	and	V,	the	CDA	was	used	for	further	analysis	of	functional	antibody	
activity.		
In	this	final	Chapter	I	will	reflect	on	the	sentinel	findings	of	the	analysis	of	
antibody-mediated	C3b/iC3b	deposition	and	correlation	to	maternal	and	infant	
colonisation	and	implications	for	the	development	of	future	vaccines	in	West	Africa.	
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8.1.	Epidemiology	of	GBS	colonisation	in	the	Gambia	in	2014	
One	of	the	unique	strengths	of	our	cohort	was	the	longitudinal	follow	up	of	
mother/infant	pairs	from	birth	and	up	to	89	days.	This	showed	that	GBS	STV	
remained	the	predominant	GBS	ST	in	the	Gambia	followed	by	GBS	STs	II	and	III	with	
an	overall	colonisation	rate	of	33.7%.	This	is	significantly	higher	than	reported	in	the	
original	Suara	et	al	study	from	1994	(present	study,	33%	colonised	(29.63-36.37)	vs.	
Suara,	22%	colonised	(95%	CI	15.04-28.96);	p=0.007).(17)	Several	possible	
explanations	for	this	difference,	include:		
a)	Advances	in	our	knowledge	of	the	relatively	fastidious	nature	of	the	GBS	bacteria	
have	allowed	the	development	of	special	growth	conditions	that	may	increase	the	
recovery	of	GBS	from	swabs.		Protocols	used	by	the	CDC	and	PHE	recommend	the	
use	of	selective	media	to	reduce	overgrowth	from	the	faster	growing	
enterobacteriaceae	that	inhabit	the	maternal	rectum	and	vagina.(4,	160).	These	
were	not	used	in	the	earlier	study.			
b)	the	original	Suara	study	sampled	only	from	the	vagina.	The	maternal	anatomy	
during	labour	is	such	that	bacteria	can	easily	cross	from	the	rectum	to	the	vagina	and	
it	is	now	recommended	that	rectovaginal	swabs	rather	than	only	vaginal	swabs	be	
taken	to	increase	the	likelihood	of	detecting	GBS	colonisation.(4,	168,	204)		
c)	This	study	used	more	rigorous	culture	and	molecular	techniques	to	identify	GBS	in	
line	with	recommendations	by	the	CDC	and	PHE.	(4,	160)		
Thus,	as	a	consequence,	our	results	are	a	more	robust	estimate	of	the	
colonisation	prevalence	in	Gambian	women	in	2014	compared	to	previous	estimated	
and	are	in	line	with	estimates	from	South	Africa	and	Zimbabwe	where	selective	
media	was	also	used.(12,	25)			
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The	large	number	of	infants	recruited	and	the	thorough	clinical	
characterisation	meant	that	a	number	of	risk	factors	for	colonisation	could	be	
assessed.	In	line	with	other	studies,	premature	infants	(gestation	below	34	weeks)	
were	at	increased	risk	of	GBS	colonisation.(205,	206)	This	could	be	because	of	the	
limited	time	available	for	maternal	antibody	to	cross	the	placenta	in	those	born	
before	34	weeks.	The	reduced	skin	barrier,	permeable	infant	gut	and	immature	
immune	system	also	provide	a	more	favourable	environment	for	bacterial	
colonisation	(and	subsequent	invasion).	Alternatively,	the	fact	that	the	mother	is	
colonised	with	GBS	could	contribute	to	premature	labour	resulting	in	a	GBS-
colonised	premature	infant.(207,	208)	
Interestingly,	it	was	found	that	mothers	and	their	infants	were	more	likely	to	
be	colonised	with	GBS	if	birth	occurred	during	the	dry	hot	or	wet	seasons.	Climate	
has	been	shown	to	affect	human	disease,	both	by	influencing	bacterial	virulence	
factors	and	host	immune	response.(209,	210).	One	study	demonstrated	an	increased	
incidence	of	streptococcal	pyoderma	in	humid	climates(211)	and	a	recent	Spanish	
study	found	an	increased	risk	of	GBS	colonisation	with	temperatures	above	23.5°C	
and	humidity	above	77.3%	(OR	1.38;	95%	CI	1.04–1.82).(212)	Such	a	finding	could	be	
an	important	risk	factor	in	equatorial	countries	such	as	the	Gambia	as	increasing	the	
core	body	temperature	may	increase	the	capacity	of	GBS	to	adhere	to	vaginal	
epithelial	cells.(213)	Additionally,	in	countries	such	as	the	Gambia,	access	to	clean	
water	is	difficult,	especially	during	the	hot	and	wet	seasons	and	hygienic	practices	
may	therefore	be	suboptimal.	Our	analysis	could	not	fully	investigate	this,	as	
information	was	not	collected	on	maternal	behavior	or	hygiene	during	pregnancy	or	
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the	study	follow	up	period,	but	future	research	could	address	these	questions	more	
specifically	than	was	possible	during	this	project.	
An	association	between	GBS	colonisation	and	previous	stillbirth	was	also	
observed.	It	is	known	that	mothers	who	are	GBS	colonised	in	pregnancy	are	at	
increased	risk	of	having	a	GBS-infected	infant,	hence	prophylactic	antibiotics	are	
offered	to	these	women	in	resource	rich	settings,	but	the	association	between	GBS	
and	stillbirth	is	still	unclear.	To	date,	the	associations	are	limited	to	case	reports	and	
case	series.(214-217)	Stillbirth	is	a	significant	public	health	concern	with	rates	of	up	
to	28.3	per	1000	total	births	in	sub-Saharan	Africa	in	2009.(218)	Infections	are	
thought	to	account	for	approximately	10-25%	of	stillbirths	in	LMICs.(219)	Despite	
this	significant	global	burden,	the	issue	of	stillbirth	has	finally	received	some	
international	focus	within	the	development	of	the	post-2015	Sustainable	
Development	Goals.(1)	A	recent	systematic	review	identified	17	studies	describing	
stillbirth	associated	with	GBS	culture.(172)	However,	inconsistent	and	
unstandardised	reporting	and	diagnostic	differences	prevented	assessment	of	the	
results	to	inform	future	maternal	intervention	strategies.	Antenatal	screening	and	
treatment	has	substantially	reduced	the	burden	of	EO-	GBS	disease	in	countries	
where	it	has	been	introduced	but	would	be	unlikely	to	reduce	stillbirths	occurring	
prior	to	screening	at	35	weeks.	However,	if	a	maternal	vaccine	in	pregnancy	were	
introduced,	then	protection	of	the	fetus	and	infant	would	occur	that	would	prevent	
not	only	postpartum	GBS	disease	but	also	GBS-related	stillbirths.	The	findings	of	this	
current	study	strengthen	the	association	between	maternal	GBS	colonisation	and	
stillbirth.	
An	increased	risk	of	infant	colonisation	was	also	demonstrated	if	the	infant	
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received	breast	milk	from	which	GBS	was	cultured.	Isolation	of	GBS	in	breast	milk	
has	been	implicated	in	several	case	reports	of	LO-GBS	disease	(178,	179).	Our	data	
support	this	suggestion,	since	GBS	colonisation	in	breast	milk	was	also	identified	as	a	
risk	factor	for	neonatal	colonisation,	both	at	delivery	and	for	persistence	of	infant	
colonisation	throughout	the	first	three	months	of	life.	This	could	be	due	to	passage	
of	GBS	antenatally	from	mother	to	infant	and	continued	passage	via	breast	milk.	In	
populations	such	as	the	Gambia,	where	breastfeeding	rates	are	high,	this	is	an	
important	finding.	It	may	be	that	GBS	enters	the	mammary	glands	from	a	colonised	
infant	following	infant	suckling,	although	there	is	also	some	suggestion	that	normal	
gut	microbiota	(of	which	GBS	may	be	an	example)	may	pass	into	the	mother’s	breast	
via	the	entero-mammary	circulation(180).	Whether	it	is	also	a	risk	factor	for	LO-GBS	
disease	in	our	population	is	not	clear,	since	no	cases	of	LO-GBS	disease	were	
observed	and	our	study	was	not	powered	to	measure	clinical	disease	as	an	endpoint.	
Conversely,	breastfeeding	might	be	a	protective	factor	through	induction	of	
immunity.(40)	The	relevance	of	this	finding	is	currently	being	examined	in	a	follow	
up	study	to	better	understand	immune	factors	in	breast	milk	that	might	be	
associated	with	infant	colonisation.			
Finally,	delivery	by	a	midwife	was	also	identified	as	a	risk	factor	for	GBS	
colonisation,	compared	to	those	delivered	by	TBA,	which	was	somewhat	surprising.	
No	other	studies	have	highlighted	this	risk	factor,	but	it	is	important	as	improving	
maternal	and	neonatal	outcomes	involves	women	giving	birth	in	hospital	facilities.	
There	is	no	current	satisfactory	explanation	for	this	finding	in	our	population.	
However,	the	constraints	placed	on	hospitals	in	LMICs	could	lead	to	reduced	
hygiene,	especially	when	supply	of	gloves	and	clean	water	is	scarce.	Alternatively,	
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infants	who	are	delivered	by	midwives	may	have	had	more	complicated	births,	
requiring	more	manual	intervention	than	those	delivered	by	TBAs.	Nosocomial	
outbreaks	of	GBS	have	been	reported	in	several	hospitals	globally	(181,	182).	Future	
studies	should	monitor	GBS	colonisation	in	mothers	delivering	with	the	help	of	
midwives	in	hospitals	to	determine	whether	nosocomial	spread	might	be	a	risk	
factor	and	therefore	a	create	a	need	for	hospital-based	interventions.	
Taken	together,	our	data	provide	further	evidence	for	the	significant	risk	
factors	previously	described(205)	but	also	suggest	some	novel	risk	factors	which	
have	significance	and	require	further	investigation.		
	
8.2.	Maternally-derived	functional	antibody	and	colonisation	
Most	of	the	previous	work	examining	maternally-derived	antibody	focused	
on	reducing	the	risk	of	neonatal	invasive	disease	by	attempting	to	establish	a	
concentration	of	antibody	above	which	an	infant	does	not	acquire	disease.	Fewer	
studies	have	focused	on	the	relationship	between	maternal	or	infant	colonisation	
and	antibody.	This	matters	because	maternal	colonisation	is	the	major	risk	factor	for	
infant	disease,	thus	investigating	factors	that	can	reduce	maternal	and/or	
subsequent	infant	colonisation	should	reduce	the	risk	of	invasive	disease.	Using	
prevention	of	colonisation	as	a	potential	correlate	of	protection	has	advantages	in	
that	colonisation	is	common	but	disease	is	rare.	Additionally,	studies	of	H.	
influenzae(220),	S.	pneumoniae(221)	and	N.	meningitidis(222)	demonstrate	that	
increasing	antibody	concentrations	in	serum	are	associated	with	reduced	risk	of	
colonisation	with	these	bacteria.	If	the	same	is	true	of	GBS	colonisation,	then	
increasing	maternally-derived	antibody	through	vaccination	could	interrupt	GBS	
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colonisation	and	subsequent	disease.		However,	the	disadvantage	of	using	
colonisation	as	a	surrogate	is	that	no	account	is	taken	of	the	virulence	and	disease-
causing	potential	between	different	GBS	strains.	Thus	a	correlate	based	on	
colonisation	would	need	to	be	assessed	using	these	strains	in	addition	to	the	more	
frequent	colonising	strains.	
This	study	uniquely	describes	maternally-derived	antibody	and	infant	
colonisation	from	birth	up	to	89	days	of	life.	In	particular,	it	focused	on	the	dynamics	
of	transmission	of	colonisation	and	the	effect	of	antibody	on	these	dynamics	over	a	
89-day	period.	The	data	demonstrate	that	compared	to	all	other	mother/infant	
groups,	the	lowest	functionally	active	antibody	level	is	found	in	mother/infant	
pairs	where	both	are	colonised.	Infants	receiving	the	lowest	concentration	of	
functionally	active	antibody	via	cord	blood	are	also	less	likely	to	clear	GBS	
colonisation	between	birth	and	day	60-89.	Further,	the	results	demonstrate	that	for	
GBS	STs	Ia,	III	and	V,	a	threshold	of	antibody	could	be	identified	above	which	no	
infant	was	GBS-colonised	at	birth.	Taken	together	this	strengthens	the	argument	
that	increasing	maternal	antibody	by	vaccination	may	reduce	transmission	of	GBS	
from	a	colonised	mother	(and	thus	impact	on	EO-GBS	disease)	and,	even	if	GBS	is	
acquired	at	birth,	improves	the	rate	of	clearance	of	colonisation	in	the	baby	(and	
thus	impact	on	LO-GBS	disease).	
Increasing	the	concentrations	of	specific	antibodies	in	infants	through	
maternal	vaccination	has	been	shown	to	protect	infants	from	diseases	such	as	
tetanus,	pertussis	and	influenza.(223-225)		This	is	therefore	likely	to	be	a	useful	
strategy	to	prevent	GBS	disease.	However,	as	outlined	in	the	introduction	to	this	
thesis,	the	large	number	of	pregnant	women	needed	for	a	phase	III	vaccine	trial	to	
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establish	formal	efficacy	is	a	barrier	to	progress	in	this	area.	Therefore,	the	ability	to	
identify	a	reliable	immune	correlate	of	protection	against	GBS	disease	would	
facilitate	vaccine	licensure.(147)	
Identifying	biomarkers	that	correlate	with	protection	against	disease	has	
hastened	the	development	and	introduction	of	new	vaccines	for	pneumococcal	and	
meningococcal	diseases.(184,	226)	The	current	paucity	of	data	relating	to	correlates	
of	protection	against	GBS	disease	has	recently	been	described	in	an	excellent	
review.(143)	The	major	ongoing	difficulty	identified	in	this	and	other	reviews	is	to		
establish	a	strain-specific	threshold	of	protection	from	infant	disease	or	colonisation	
of	mother	or	infant,	in	part	because	there	is	a	lack	of	standardisation	between	assays	
currently	in	use,	which	hampers	interpretation	across	studies.(143)		
The	majority	of	GBS	studies	to	date	have	focused	on	anti-CPS	antibody	
concentration	but	have	not	discussed	the	functional	component	of	the	antibody,	
which	may	be	important	for	clearance	of	the	GBS.	Binding	of	C3b/iC3b	and	
opsonophagocytosis	characterise	the	immune	function	that	is	responsible	for	
protection	and	could	therefore	be	used	as	a	correlate	of	protection	from	GBS	
disease.	ELISAs	quantify	the	antibody	response	but	do	not	provide	information	on	
antibody	function.	It	is	important	to	note	that	the	ELISAs	are	specific	for	the	CPS,	
whilst	OPkA	and	CDA	recognise	both	protein	and	polysaccharide	antigens	on	the	
surface	of	the	bacteria.	There	is	a	need	to	establish	both	concentration	and	function	
of	antibody	in	order	to	determine	a	correlate	of	protection	from	GBS	disease,	which	
can	then	be	correlated	to	the	antibody	concentration	measured	by	ELISA	as	a	useful	
surrogate	of	protection	from	GBS	disease,	which	is	easier	to	measure.	Functional	
assays	may	also	allow	a	better	estimation	of	the	duration	of	protection	following	
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vaccination	than	ELISAs.(184,	185,	227)	The	need	to	assess	functional	antibody	
activity	has	already	been	shown	for	the	assessment	of	vaccines	against	
pneumococcus	and	has	been	used	as	a	route	to	change	future	vaccine	
formulations(228):	although	initial	licensure	of	the	seven-valent	pneumococcal	
vaccine	was	based	on	efficacy	trials,	it	was	accepted	that	efficacy	trials	would	prove	
impractical	for	the	licensure	of	higher	valency	formulations	and	so	the	assessment	of	
opsonophagocytosis	as	a	marker	of	antibody	function	proved	essential	for	defining	
correlates	of	protection	for	subsequent	vaccines.(229)	Our	findings	add	weight	to	
the	need	to	measure	functional	activity	by	demonstrating	that	antibody-mediated	
C3b/iC3b	deposition	reduces	the	risk	of	maternal	and	infant	colonisation	and	
enhances	infant	clearance	of	GBS	colonisation.		
However,	the	field	remains	confused	with	regards	to	the	“right”	assay	to	use:	
the	review	by	Dangor	et	al	(2015)(196)	identified	47	studies	describing	correlates	of	
protection	using	34	different	quantitative	and	12	different	functional	assays.	There	
are	substantial	differences	in	the	methods	of	quantitative	assays;	some	assays	use	
microtitre	plates	coated	with	GBS	CPS,	some	measure	GBS	ST-specific	antibody	in	
monoplex	assays	whilst	others	measure	antibody	in	multiplex	assays.	Some	measure	
IgG	antibody	via	direct	ELISA,	some	via	indirect	ELISA,	some	by	measuring	
competitive	binding.	Equally,	variations	in	the	methods	have	been	observed	for	
functional	antibody	assays:	some	of	the	OPkA	assays	use	multiple	dilutions	whilst	
others	use	a	single	point	dilution	and	read	the	results	from	a	standard	curve;	some	
measure	killing	whilst	others	measure	internalisation	of	the	bacteria	into	the	
phagocyte	but	not	killing.	Further,	the	assays	use	different	technologies	such	as	the	
Luminex	platform	or	flow	cytometry	to	determine	antibody	concentration.	Finally,	
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the	lack	of	standardised	reference	ranges	for	IgG	despite	the	availability	of	reference	
sera	(Prof.	Baker,	Baylor	College	of	Medicine,	Houston,	Texas	and	Biota	
pharmaceuticals	Inc.,	Australia)	makes	the	selection	of	a	threshold	of	protection	
difficult	at	present.	Taken	together,	these	methodological	differences	between	
assays	and	lack	of	reference	sera	make	interpretation	of	results	between	groups	
problematic.	However,	irrespective	of	the	assay	used,	protection	from	invasive	
disease	is	consistently	associated	with	high	maternal	antibody	concentration,	and	
this	study	reports	the	same	effect	on	infant	colonisation	in	a	West	African	setting	for	
the	first	time.	Standardised	methodology	and	an	internationally	accepted	reference	
serum	are	urgently	required	to	define	the	threshold	of	protection	from	maternal	and	
infant	colonisation	and	infant	disease	further	and	is	now	a	recognized	research	
priority.		
Although	the	initial	analysis	of	antibody	did	not	appear	to	demonstrate	an	
absolute	correlation	between	absence	of	colonisation	and	maternally-derived	
functional	antibody,	the	examination	of	sera	with	high	compared	to	low	antibody-
mediated	C3b/iC3b	deposition	revealed	that	at	concentrations	above	the	75th	centile	
for	GBS	STs	Ia,	III	and	V,	infants	were	no	longer	GBS	colonised.	Thresholds	between	
1µL/mL	and	10µL/mL	have	been	postulated	for	protection	from	invasive	disease		
depending	on	GBS	ST.(196)	It	is	not	possible	to	compare	the	results	of	our	CDA	with	
these	ELISA	results	directly,	although	the	two	studies	from	South	Africa	and	this	
study	all	demonstrate	that	increasing	antibody	is	associated	with	risk	reduction	for	
colonisation.	However,	it	will	only	be	through	standardisation	of	the	current	
methods	that	a	more	robust	estimate	will	be	determined.	
		 172	
8.3.	Limiting	factors	
This	study	has	several	limitations.	The	results	are	obviously	limited	by	the	
sensitivity	of	detection	of	GBS	on	selective	media,	estimated	at	85%	(230)	and	by	the	
fact	that	the	GBS	ST	was	identified	by	conventional	PCR.	Thus	it	may	be	that	low	
levels	of	colonisation	in	infants	are	underestimated	where	DNA	was	below	the	limit	
of	detection.		
Only	one	culture-confirmed	case	of	GBS	invasive	disease	was	identified	in	this	
cohort.	This	may	represent	an	underestimation	of	the	burden	of	GBS	disease	in	this	
population.	Several	infants	died	within	the	first	four	hours	of	birth	and	so	were	not	
recruited	or	died	in	the	first	few	days	of	life	following	EO-pneumonia	without	a	
culture-confirmed	diagnosis.	It	is	possible	that	these	infants	may	have	succumbed	to	
EO-GBS	disease.	Whilst	it	is	not	possible	to	correlate	these	deaths	with	GBS,	all	three	
infants	who	died	of	early	onset	pneumonia	had	antibody-mediated	C3b/iC3b	
deposition	below	the	limit	of	detection.	There	are	no	other	data	from	the	Gambia	
regarding	the	burden	of	GBS	disease.	Although	more	information	may	have	been	
gathered	from	a	larger	cohort,	this	study	used	a	sample	size	that	could	be	feasibly		
attained	during	a	single-handed	PhD	project	and	with	an	endpoint	of	colonisation.	
There	is	little	other	evidence	from	the	Gambia	for	GBS	disease.	However,	a	
retrospective	review	of	positive	blood	and	CSF	cultures	from	the	MRC	hospital	over	
eight	years	from	infants	under	89	days	of	age	identified	17	positive	cultures.	This	is	
consistent	with	our	disease	estimate	of	1.3/1000	live	births.(231)		
Sampling	at	four	hours	post-birth	may	indicate	contamination	with	maternal	
secretions	rather	than	established	colonisation	at	birth.	However,	the	fact	that	few	
infants	had	lost	colonisation	by	day	six	in	our	cohort	indicates	that	such	colonisation	
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was	persistent	over	the	first	week	of	life.		
The	low	numbers	of	mother/infant	pairs	colonised	with	GBS	STIb	precludes	
detailed	analysis	of	this	GBS	ST.	This	is	disappointing	as	GBS	STIb	is	an	important	
cause	of	infant	disease	in	the	USA	and	is	one	of	the	GBS	STs	being	targeted	by	the	
current	vaccine	candidates.	However,	the	environment	in	which	this	work	was	
conducted	did	not	allow	acquisition	of	a	large	number	of	women	colonised	with	GBS	
ST1b,	as	it	is	not	a	dominant	GBS	ST	in	The	Gambia.	
The	lack	of	standardised	protocols	available	for	functional	assays	was	also	a	
limitation	of	this	study,	as	it	is	for	others	using	functional	assays	against	GBS.	The	
absence	of	a	standardised	assay	to	assess	functional	antibody	activity	means	that	the	
results	of	our	study	should	be	interpreted	with	caution,	as	it	is	not	possible	to	
compare	some	aspects	with	other	studies	at	present.(147)	There	were	a	number	of	
reagents	used,	which	differ	from	other	studies	that	may	have	affected	our	results.	
IgG-depleted	human	plasma	was	used	as	a	complement	source	for	our	assays	(165)	
because	of	the	possibility	of	increased	immunogenicity	when	using	baby	rabbit	
serum.	There	have	been	different	approaches	to	the	use	of	complement	sources	in	
functional	assays,	with	some	groups	preferring	endogenous	complement	that	has	
not	been	IgG	depleted	(83,	84,	186),	whilst	others	use	baby	rabbit	serum	(146,	154,	
156).	The	use	of	a	pooled	IgG-depleted	human	plasma	may	have	affected	our	results	
compared	to	baby	rabbit	serum,	which	may	give	higher	activity	due	to	the	lack	of	
species-specific	complement	regulatory	protein	activity.	This	may	have	been	why	our	
CoV	was	34%,	which	was	marginally	higher	than	the	30%	CoV	used	in	industrial	
assays	to	assess	OPkA	in	pneumococcus	(184)	or	22%	CoV	in	complement	control	in	
standardised	bactericidal	assays	for	H.	influenza.(228)	It	will	be	vital	going	forward	
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that	assay	standardisation	is	undertaken	in	order	to	demonstrate	reliable	predictions	
of	protection	from	colonisation	and	disease.		
Interestingly,	a	large	amount	of	cross-reactivity	between	serotypes	with	
functionally	active	antibodies	was	observed.	Cross-reactive	antibody	has	been	
shown	to	provide	additional	protection	against	invasive	pneumococcal	disease	(232)	
in	vaccinated	populations	and	closely	related	GBS	STs	may	possibly	behave	in	a	
similar	way.	Our	work	was	performed	using	sera	from	women	with	natural	immunity	
to	GBS	rather	than	vaccine-induced	immunity.	Therefore,	the	sera	from	the	Gambian	
women	will	have	antibody	to	both	the	CPS	and	to	proteins	on	the	bacterial	surface.	
Different	results	may	be	obtained	with	sera	obtained	from	CPS-vaccinated	
individuals.	It	may	also	be	possible	that	the	assay	is	not	sufficiently	sensitive	at	FI-C’	
lower	limit	of	quantification	points	to	detect	GBS	ST-specific	functional	activity	at	
these	concentrations.	I	found	that	the	assay	sensitivity	dropped	with	higher	FI-C’	
limits	of	quantification	and	hence	used	this	lower	limit	of	quantification	for	our	
assay.	In	future,	it	may	be	necessary	to	revise	this	lower	limit	of	quantification,	
especially	once	we	are	able	to	standardise	the	assay	in	direct	comparison	with	other	
functional	assays	such	as	the	OPkA.	
Although	the	overall	sensitivity	and	specificity	of	the	CDA	were	good,	it	is	
important	to	note	that	some	sensitivity	was	lost	for	GBS	STIa	when	comparing	CDA	
to	OPkA	and	compared	to	the	other	two	GBS	STs,	which	could	lead	to	an	under-
estimation	of	killing	in	sera	where	functionally	active	antibody	is	present.(233)	As	
antibody-independent	complement-mediated	killing	varies	by	GBS	ST,	it	will	be	
important	to	undertake	GBS	ST-specific	functional	antibody	studies	when	assessing	
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protection	from	disease	and	colonisation	in	the	future,	as	the	protective	thresholds	
are	likely	to	be	different.	
Finally,	the	assumption	has	been	made	that	the	reduction	in	colonisation	is	
due	to	functional	serum	antibody	concentration.	It	may	be	that	protection	from	
colonisation	at	the	mucosal	surface	is	more	complicated	and	includes	innate	and	
adaptive	factors	associated	with	breast	milk	or	the	infants’	developing	microbiome	
(40).	However,	in	other	vaccine	studies,	increased	serum	antibody	concentration	has	
been	associated	with	decrease	in	infant	colonisation	for	pneumococcus,	
meningococcus	(A,	C,	W,	Y)	and	H.	influenzae	as	outlined	above	and	the	same	may	
be	true	of	GBS.	To	measure	mucosal	immunity	is	extremely	challenging,	as	there	are	
few	methods	available	and	to	assess	this	aspect	was	beyond	the	scope	of	this	study.	
However,	samples		have	been	stored	to	assess	the	microbiome	in	future	work.	
	
8.4.	Future	work		
Work	carried	out	in	this	thesis	has	led	to	a	detailed	characterisation	of	the	
seroepidemiology	of	maternal	and	infant	colonisation	with	GBS	in	the	Gambia.	The	
results	have	gone	some	way	to	establish	a	putative	threshold	of	protection	from	
maternal	and	therefore	infant	colonisation	throughout	the	at-	risk	period	for	EO-	and	
LO-GBS	disease	by	demonstrating	the	inverse	relationship	between	functional	
antibody	concentration	and	maternal	and	infant	colonisation.	The	next	step	would	
include	the	development	of	a	widely	available	panel	of	international	standard	sera	
and	the	standardisation	of	assay	protocols	between	laboratories	and	between	
studies.	The	value	of	standardising	protocols	and	reference	sera	has	already	been	
demonstrated	in	the	evaluation	of	several	vaccines.(188,	234-236)	
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It	may	be	possible	to	achieve	licensure	of	GBS	vaccines	in	the	next	few	years	
if	standardised	protocols	for	an	anti-GBS	CPS	IgG	ELISA	quantification	assay	and	
functional	assays	(OPkA/CDA)	and	freely	available	standardised	reference	sera	are	
developed	between	all	participating	academic	and	commercial	organisations.	This	
will	enable	seroepidemiological	studies	to	reliably	describe	thresholds	of	protection	
against	invasive	GBS	disease.(147)	I	have	recently	initiated	a	large	multinational	
consortium	of	academia,	industry,	WHO	and	regulatory	authorities	to	develop	
standardized	protocols	for	quantitative	and	functional	GBS	assays	which	is	currently	
under	review	with	the	Bill	and	Melinda	Gates	Foundation	and	for	which	I	am	the	
principle	investigator.	Using	colonisation	as	a	surrogate	marker	for	protection	from	
invasive	disease	may	provide	a	useful	adjunct	to	these	studies	and	might	replace	the	
need	for	large	efficacy	trials	in	the	future,	once	validated	in	the	field.	
In	addition	the	use	of	whole	genome	sequencing	of	maternal/infant	strains	
will	allow	us	to	better	understand	the	host-pathogen	interaction	and	will	provide	
more	information	on	difference	virulence	between	colonising	and	disease-causing	
strains.	I	have	recently	begun	a	collaboration	with	the	Wellcome	Trust	Sanger	
Institute	to	undertake	whole	genome	sequencing	of	the	colonising	isolates	isolated	
in	this	study.	
	
8.5.	Concluding	remarks		
In	summary,	I	have	shown	that	antibody-mediated	C3b/iC3b	deposition	is	
inversely	related	to	infant	colonisation	at	birth	and	to	clearance	of	colonisation	up	to	
89	days	of	life.	I	have	identified	that	mothers	are	more	likely	to	transfer	GBS	to	their	
infants	if	functional	cord	antibody	is	low	and	that	infants	are	then	more	likely	to	
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become	colonised	postnatally	themselves.		
I	have	identified	differences	in	functional	antibody	concentration	against	the	
different	GBS	STs	associated	with	disease	and	colonisation.	This	warrants	further	
research	and	may	hold	the	key	to	the	rapid	development	and	implementation	of	
effective	vaccines	for	the	prevention	of	neonatal	GBS	disease,	which	remain	a	major	
goal	to	decrease	morbidity	and	mortality	during	the	most	vulnerable	period	of	life.	
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Appendix	1	–	Ethical	approvals	
	
1 Leading research to save lives and improve health across the Developing World 
 
 
 
 
 
 
 
 
 
 
7 February 2014 
 
 
 
 
Professor Beate Kampmann 
Vaccinology Theme Leader 
MRC Unit, The Gambia 
Fajara 
 
 
 
 
Dear Professor Kampmann 
 
L2014.08v2, Re SCC 1350v3: Group-B streptococci in pregnant women and 
their infants in the Gambia- A fresh look at prevalence, serotypes and antibody 
is required 
 
Thank you for submitting your response letter dated 6 February 2014 addressing the 
issues raised by the SCC at its meeting held on 3 February 2014.  
 
I am pleased to approve your request which will be forwarded to the Ethics Committee 
for consideration at its meeting on 28 February 2014.  
 
With best wishes 
 
Yours sincerely 
 
Professor Umberto D’Alessandro 
Chairman, Scientific Coordinating Committee  
 
 
 
 
 
Additional documents submitted for review:-  
x Consent Form (adult), version 2.0 – 27 January 2014 
x Informed Consent Document (child), version 3.0 – 8 January 2014 
x SCC Application Form: SCC 1350 
 
 
Scientific Coordinating Committee 
MRC Unit: The Gambia, Fajara 
PO Box 273 Banjul, The Gambia 
West Africa 
Switchboard (+220) 4495442/6 Ext 2308 
Fax (+220) 4495919/4496513 
E-mail: scc@mrc.gm 
Intranet: http://mrcportal/Committees/SCC/SitePages/Home.aspx 
Webpage:https://mrcportal.mrc.gm/Committees/SCC/SitePages/Home.aspx 
 
		 195	
	
The Gambia Government/MRC Joint 
C/o MRC Unit: The Gambia, Fajara 
P-0. Box 273, Banjul 
The Gambia, West Africa 
ETHICS COMMITTEE 
Fax: + 2 2 0 - 4 4 9 5 9 1 9 or 4496513 
Tel: +220-4495442-6 Ext 2308 
Email: ethics@mrc.gm 
11 March 2014 
Professor Beate K a m p m a n n 
Vacc ino logy Theme Leader 
MRC Unit, The Gamb i a 
Fajara 
Dear Professor K a m p m a n n 
L2014 .08 , Re SCC 1350v3 : G roup -B s t rep tococc i in p regnan t w om en and the i r 
in fants in the Gam b i a - A f r esh look at p reva l ence , se ro t ypes and an t ibody is 
requ i red 
Thank you for submi t t ing your letters dated 21 January and 6 February 2014 for 
cons iderat ion by the Gamb i a Gove rnmen t /MRC Joint Ethics Commi t t e e at its meet ing 
held on 28 February 2014 . 
We are p leased to approve your request . 
With best w ishes 
Yours s incere ly 
Mr Ma lamin Sonko 
Cha i rman , Gamb i a Gove r nmen t /MRC Joint Ethics Comm i t t ee 
Docum ents subm i t t ed fo r rev iew :-
• Consent Form (adul t ) , vers ion 2.0 - 27 January 2014 
• Informed Consen t Documen t (chi ld) , vers ion 3.0 - 8 January 2014 
• SCC App l i cat ion Fo rm: S C C 1350 
The Gambia Government/MRC Joint Ethics Committee: 
Mr Malamin Sonko. Chairman 
Professor Ousman Syan. Scientific Advisor 
Ms ^affte Jobe. Secretary 
Mrs Tulai Jawara-Ceesay 
Dr Ahmadou l.amin Samateh 
Dr Roddie Cole 
Prof. Umherto D'Alessandro 
Dr Stephen Howie 
Dr Kalifa Bo Jang 
Dr Ramatoulie Sjie 
Dr Momodou L Waggeh 
Dr Siga Falima Jagne 
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Appendix	2	–	Patient	information	sheet	and	consent	forms	
	
Identification code: SOP-CTS-015, version 3.0  
Attachment 2c (Child CT) 
 
 
PARTICIPANT	INFORMATION	SHEET	
Version	3	 	 Date	 08/01/14	
	
Study	Title:	Group-B	streptococci	in	pregnant	women	and	their	infants	in	the	Gambia-	A	fresh	
look	at	prevalence,	serotypes	and	antibody	is	required	
SCC:	 1350v3	 Protocol:	 	
	
Sponsor:		
What	is	informed	consent?		
You	and	your	child	are	invited	to	take	part	in	a	research	study.	Before	you	decide,	you	need	to	
understand	why	the	research	study	is	being	done	and	what	it	will	involve.	Please	take	time	to	read	
the	following	information	or	get	the	information	explained	to	you	in	your	language.	Listen	carefully	
and	feel	free	to	ask	if	there	is	anything	that	is	not	clear	or	you	do	not	understand.	You	may	also	
wish	to	consult	your	spouse,	family	members,	friends	or	others	before	deciding	to	take	part	in	the	
study.	
	
If	you	decide	that	you	and	your	child	join	the	study,	you	will	need	to	sign	or	put	a	thumbprint	on	a	
consent	form	saying	you	agree	for	both	of	you	to	be	in	the	study.	You	will	receive	a	copy	of	the	
signed	consent	form.		
Why	is	this	study	being	done?		
Group-B	Streptococcal	(GBS)	is	a	bacterium	which	is	often	carried	by	healthy	women	and	in	a	very	
small	percentage	can	cause	death	and	sickness	in	their	babies.		The	illness	could	be	prevented	by	
giving	a	vaccine	to	pregnant	women.	The	idea	of	vaccinating	the	mother	is	so	that	she	can	pass	on	
the	protection	(antibody)	during	the	pregnancy	to	the	baby,	 just	 like	we	already	do	with	tetanus	
vaccination.	A	vaccine	is	currently	being	developed	but	we	do	not	yet	know	if	this	vaccine	will	be	
useful	 in	The	Gambia	because	we	do	not	know	which	serotype	of	GBS	are	most	common	 in	The	
Gambia.		
	
This	project	aims	to	understand	what	type	of	GBS	is	most	commonly	carried	by	pregnant	women	in	
The	Gambia	and	what	antibody	Gambian	mothers	already	make	and	transmit	to	their	infants	in	
their	blood	and	breastmilk,	even	without	the	vaccine	being	available.	
The	results	of	the	study	will	be	made	available	to	your	community.	
What	does	this	study	involve?	
If	you	decide	to	take	part,	we	will	ask	you	to	deliver	your	baby	at	Faji	Kunda	Health	Centre.	At	birth	
we	will	ask	you	to	take	swabs	from	your	vagina	and	rectum	when	you	are	in	labour	and	to	take	
swabs	from	your	baby’s	mouth	and	rectum	when	they	have	been	born.	We	will	also	ask	for	a	
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sample	of	cord	blood	to	be	taken	by	our	team	at	the	time	of	birth	and	a	small	sample	of	your	
breastmilk,	which	you	can	express	to	look	for	antibodies.	If	you	are	not	aware	of	your	HIV	status,	
we	need	you	to	take	a	blood	test	to	check	this.	Before	we	do	the	test,	it	will	be	fully	explained	to	
you.	If	you	do	not	want	to	do	an	HIV	test,	we	will	not	force	you	to	take	a	test.	If	you	do	take	the	
test,	you	will	be	told	the	result	and	given	advice	about	the	meaning	of	it.	If	you	are	found	to	be	HIV	
infected,	your	baby	will	not	be	able	to	continue	in	the	study.	You	will	be	referred	to	a	government	
approved	clinic	for	treatment,	and	your	baby	will	also	be	tested	for	the	infection.	The	study	also	
involves	you	agreeing	to	attend	the	Faji	Kunda	Health	Centre	for	an	appointment	at	around	1	week	
and	2-3	months	afterwards.		
We	will	ask	you	to	attend	the	Faji	Kunda	MRC	Clinic	at	around	1	week	to	check	you	and	your	baby’s	
health	and	to	take	swabs	from	your	baby’s	mouth	and	rectum	and	some	breastmilk	from	you.	
We	will	then	ask	you	to	attend	the	Faji	Kunda	MRC	Clinic	again	when	your	baby	is	2-3	months	old	
and	at	the	time	of	the	first	normal	vaccinations.	At	that	time	we	would	take	another	set	of	swabs	
from	your	baby’s	mouth	and	rectum	and	a	small	blood	sample	from	your	baby	and	another	sample	
of	your	breastmilk.	
	
In	case	the	investigator	discovers	that	you	or	your	child	is	sick	and	decides	that	either	of	you	
cannot	participate	in	the	study	because	of	that,	you	(or	your	child)	will	receive	immediate	care	at	
the	study	site	and	then	be	referred	to	the	appropriate	health	facility.		
	
If	the	research	study	needs	to	be	stopped,	you	will	be	informed	and	your	child	will	have	the	normal	
medical	care.	
What	will	happen	to	the	samples	taken	in	this	study?	
We	will	test	the	swabs	we	take	from	you	and	your	baby	to	test	for	GBS	and	other	bacteria.	
We	will	use	the	blood	and	breastmilk	samples	to	test	for	antibodies	to	GBS	that	might	protect	your	
baby	from	infection.	We	might	also	wish	to	save	some	blood	for	tests	of	other	antibodies	against	
bacteria	or	viruses	against	which	vaccines	are	currently	being	developed	and	some	might	be	useful	
also	for	pregnant	women	in	the	future.	The	samples	may	also	be	used	in	laboratories	of	other	
organisation	that	might	include	vaccine	companies	in	order	to	check	our	results.	
What	harm	or	discomfort	can	you	expect	in	the	study?	
We	aim	to	minimise	any	discomfort	you	or	your	baby	may	experience	during	the	study.	Taking	a	
rectovaginal	swab	is	not	painful	and	should	take	only	a	few	seconds.	We	will	ask	you	to	express	a	
small	amount	of	breastmilk	(5ml)	at	each	visit.	
We	will	take	a	blood	test	from	your	baby	at	2-3	months	(less	than	a	teaspoon	full).		
What	benefits	can	you	expect	in	the	study?		
At	the	study	visits	you	will	have	the	opportunity	to	discuss	any	concerns	about	your	baby’s	health.	
We	hope	that	what	we	find	out	in	this	study	will	help	to	stop	babies	in	The	Gambia	and	other	parts	
of	the	world	from	becoming	sick	in	the	future.	
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Will	you	be	compensated	for	your	child’s/ward’s	participation	in	the	study?	
You	will	not	get	paid	for	the	participation	of	yourself	or	your	child	in	the	study,	but	you	will	get	
either	transport	by	MRC	or	get	your	transport	costs	to	the	clinic	for	each	study	visit	reimbursed.	
Are	there	other	products	or	treatment?	
We	are	not	offering	any	treatment.	
What	happens	if	you	refuse	to	participate	in	the	study	or	change	your	mind	later?	
You	are	free	to	let	your	child	and	yourself	participate	or	not	in	the	study	and	you	have	the	right	to	
stop	participating	at	anytime	without	giving	a	reason.	This	will	not	affect	the	medical	care	that	you	
or	your	child	would	normally	receive.	
In	case	you	decide	to	withdraw	yourself	or	your	child’s	participation	during	the	study	we	will	not	
work	on	any	samples	without	your	permission,	but	any	information	already	generated	from	the	
samples	will	be	kept.		
Should	any	new	information	become	available	during	the	study	that	may	affect	your	own	or	your	
child’s	participation,	you	will	be	informed	as	soon	as	possible.	
What	compensation	will	be	available	if	you	or	your	child	are	injured	during	the	study?		
We	will	be	responsible	to	provide	for	treatment	caused	by	the	research	study.	If	medical	treatment	
is	required	as	an	emergency,	please	refer	to	your	health	centre	or	clinic	and	contact	the	field	
worker	who	gave	his/her	telephone	number	to	you	or	contact		[Name]	on	[Phone	number].		
	
How	will	you/your	baby’s	information	be	kept	and	who	will	be	allowed	to	see	it?	
All	 information	that	 is	collected	about	you	and	your	baby	 in	the	course	of	the	study	will	be	kept	
strictly	confidential.	You	and	your	baby’s	personal	 information	will	only	be	available	to	the	study	
team	 members	 and	 might	 be	 seen	 by	 some	 rightful	 persons	 from	 the	 Ethics	 Committee,	
Government	authorities	and	sponsor.	
Who	should	you	contact	if	you	have	questions?	
Please	 feel	 free	 to	 ask	 any	 question	 you	might	 have	 about	 the	 research	 study.	 If	 you	 have	 any	
queries	or	concerns	you	can	contact	Dr	Kirsty	Le	Doare	on	[Phone	number],	and	you	can	always	call	
the	 study	 staff.	We	will	 give	 you	 their	 telephone	numbers	on	a	 card	 for	 you	 to	 keep.	 If	 you	are	
unable	to	attend	the	clinic	on	the	designated	times	then	please	call	the	Sukuta	Health	on	[Phone	
number],	and	inform	the	person	on	duty.	The	field	staff	at	the	MRC	Sukuta	clinic	will	then	try	and	
arrange	for	blood	to	be	collected	at	an	alternative	time.	
Who	has	reviewed	this	study?		
This	study	has	been	reviewed	and	approved	by	a	panel	of	scientists	at	the	Medical	Research	
Council	and	the	Gambia	Government/MRC	Joint	Ethics	Committee,	which	consists	of	scientists	and	
lay	persons	to	protect	the	rights	and	wellbeing	of	you	and	your	baby.	
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CONSENT	/	ASSENT	FORM	
Participant’s	Name		 		
Participant’s	Identification	Number:	|__|__|__|__|__|__|__|__|__|__|	
I,	 	 			OR	 	 	
	 (Printed	name	of	parent)	 (Printed	name	of	guardian)	
	have	read	the	written	information	OR	
	have	had	the	information	explained	to	me	by	study	personnel	in	a	language	that	I	understand	
and	
• confirm	that	my	choice	to	let	my	baby	participate	is	entirely	voluntarily	
• confirm	that	I	have	had	the	opportunity	to	ask	questions	about	this	study	and	I	am	satisfied	
with	the	answers	and	explanations	that	have	been	provided,	
• understand	that	I	grant	access	to	data	about	my	baby	to	authorised	persons	described	in	the	
information	sheet,	
• have	had	time	to	consider	to	let	my	baby	take	part	in	this	study.		
• confirm	that	I	agree	to	have	stored	samples	of	blood	from	my	baby	used	for	future	antibody	
research	
• confirm	that	I	agree	that	samples	taken	from	my	baby	may	be	shipped	to	countries	outside	the	
Gambia	for	future	study	
• 	
Tick	as	appropriate	
I	agree	to	allow	my	child	take	part	in	this	study	 Yes	 	 No	 	
I	agree	to	further	research	on	my	child’s	samples	as	described	in	the	
information	sheet	 Yes	 	 No	 	
Participant/parent/guardian	
signature/thumbprint*	
	 	 	 	
	 	 	 Date	(dd/mmm/yyyy)	 Time	(24hr)	
Printed	name	of	impartial	
witness*	
	
Signature	of	impartial	
witness*	
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	 	 Date	(dd/mmm/yyyy)	 Time	(24hr)	
Printed	Name	of	Person	
obtaining	consent	
	
I	attest	that	I	have	explained	the	study	information	accurately	in	_______________________	to,	
and	was	understood	to	the	best	of	my	knowledge	by,	the	participant/parent/guardian	and	that	
he/she	has	freely	given	consent	to	participate	*in	the	presence	of	the	above	named	impartial	
witness	(where	applicable).		
Signature	of	Person	
obtaining	consent	 	 	 	
	 	 	 Date	(dd/mmm/yyyy)	 Time	(24hr)	
*Only	required	if	the	participant	is	unable	to	read	or	write.	
A	copy	of	this	informed	consent	document	has	been	provided	for	the	participant.	
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CONSENT FORM 
Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
I,   
 (Printed name of participant) 
 have read the written information OR 
 have had the information explained to me by study personnel in a language that I understand and 
• confirm that my choice to participate is entirely voluntarily, 
• confirm that I have had the opportunity to ask questions about this study and I am satisfied with 
the answers and explanations that have been provided, 
• understand that I grant access to data about me to authorised persons described in the 
information sheet, 
• confirm that I agree to samples taken during this study being taken outside of the Gambia for 
further study 
• have received time to consider to take part in this study.  
Tick as appropriate 
I agree to take part in this study Yes  No  
I agree to have an HIV test Yes  No  
I agree to have a rectovaginal swab taken when I am in labour Yes  No  
I agree to further research on my samples as described in the 
information sheet Yes  No  
 
Participant’s signature/ 
thumbprint* 
    
   Date (dd/mmm/yyyy) Time (24hr) 
Printed name of witness*  
 
Printed name of person 
obtaining consent 
 
I attest that I have explained the study information accurately in ______________________ to, 
and was understood to the best of my knowledge by, the participant. He/she has freely given 
consent to participate *in the presence of the above named witness (where applicable).  
Signature of person 
obtaining consent    
   Date (dd/mmm/yyyy) Time (24hr) 
* Only required if the participant is unable to read or write. 
 
		 202	
Appendix	3	–	Case	report	forms	
	
 
SCC: 1350                 
                               
Version 1.0 Date 12th January 2014 
1 
 
 
GAMI Study Visit 1 (Birth) – Case report form (CRF) 
 
***NB/ COMPLETE THIS FORM BEFORE TAKING SWABS AND CORD BLOOD*** 
Study Information 
 
 
Subject ID: 
 
T I___I___I___I 
 
 
 
Today’s
Date: 
 
 
I___I ___I / I___I___I/ I___I___I 
Time of 
visit 
(24h): 
 
I___I ___I : I___I___I 
 
 
Mother’s name: 
 
 Last First  
 
Study mother medical information 
  
(Tick yes or no) 
 
If no give details: 
Was the HIV rapid test done after delivery? 
(NB. There is no need to document HIV test results 
from during the pregnancy or earlier) 
 Yes I___I No I___I  
 
Please document HIV rapid test result 
Yes I___I No I___  
 
 
 SO (negative): 
 
     I___I  
 S1 (HIV1+ve): 
 
     I___I 
 S2 (HIV2 +ve):      I___I 
 
If HIV rapid test indicates a possible +ve status, if not already done so, take mother’s blood for serology 
testing. Send sample to MRC lab as URGENT. Continue to proceed to complete the study visit activities, and 
review serology result at next visit. 
 
  
(Tick yes or no) 
 
 
 
 
 
Was HIV serology testing done after delivery? 
 Yes I___I No I___I 
 
 
 
HIV serology result SO (negative): 
 
     I___I  
 S1 (HIV1+ve): 
 
     I___I 
 S2 (HIV2 +ve):      I___I 
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Study infant medical information 
 
 
 Feeding history 
 
(Tick yes or no) 
 
If no give details: 
 
Is the infant feeding well? 
 
 
Yes I___I No I___I 
 
 
Please indicate the feeding type: 
 
Exclusive breastfeeds I___I Formula milk I___I  
 
Please specify which formula if known………………………. 
 
Mixed breast and bottle feeds I___I 
 
Expressed breast milk (EBM) by bottle I___I 
 
Supplemental water I___I 
 
Other supplemental feed I___I  
  
Please specify………………………………… 
 
 
 
 History of infectious episodes 
 
(Tick yes or no) 
 
 
If yes give details: 
 
Is the umbilical stump red inflamed discharging or 
offensive smelling? 
 
 
Yes I___I No I___I 
 
Is the infant jaundiced?  
Yes I___I No I___I 
 
Symptoms or signs of significant illness or infection 
(Fever, hypothermia, poor feeding, floppiness, 
hypoglycaemia)? 
 
 
Yes I___I No I___I 
 
Any admission to hospital in the past 1 –week? Yes I___I No I___I  
Any episodes of the folllowing?:   
Malaria Yes I___I No I___I  
Septicaemia Yes I___I No I___I  
Pneumonia Yes I___I No I___I  
Meningitis Yes I___I No I___I  
Worms Yes I___I No I___I  
Diarrhoea Yes I___I No I___I  
Otitis media Yes I___I No I___I  
Tonsilitis Yes I___I No I___I  
Upper respiratory tract infection Yes I___I No I___I  
Any intravenous or oral antibiotics therapy? Yes I___I No I___I  
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Study infant anthropometry 
Weight (gms): 
 
 
I___I___ I___I___I 
 
Length (cm): 
 
 
I___I___I . I___I 
Head 
circumference 
(cm): 
 
 
 
I___I___I . I___I 
  
Study infant vital signs 
Respiratory rate 
(breaths per 
minute) I___I___I___I 
 
Heart rate 
(beats per 
minute) 
 
 
 
I___I___I___I 
Oxygen 
saturations  (%): 
 
 
I___I___I___I 
 
Temperature 
(oC) 
 
 
I___I___I . I___I 
 
If the vital signs are abnormal the infant should be reviewed by the study clinician 
Eligibility assessment for continued enrolment 
 
In order to continue to be eligible for inclusion in the study, the mother and infant must meet the inclusion 
criteria and none of the exclusion criteria. 
 Inclusion criteria 
 
Inclusion criteria met? 
(Tick yes or no) 
 
1. 
 
Ability to comply with the study procedures as 
judged by a member of the research team? 
 
 
 
Yes I___I No I___I 
 
 
 
Exclusion criteria 
 
 
Exclusion criteria met? 
(Tick yes or no) 
 
1. 
 
Significant congenital abnormalities?  
 
Yes I___I No I___I 
 
2. 
 
Mother HIV positive on rapid test AND confirmed on 
serology? (Study clinician will inform you of a positive 
test result) 
 
 
Yes I___I No I___I 
 
3. 
 
Symptoms or signs of significant illness or infection 
(Fever, hypothermia, poor feeding, floppy, 
hypoglycaemia)? 
 
 
 
 
Yes I___I No I___I 
 
4. Planning to move from the area within the next 2 months that would mean she cannot attend clinic 
Yes I___I No I___I 
 
5. 
 
Enrollment in other studies requiring blood or breast 
milk sampling? 
 
 
 
Yes I___I No I___I 
 
6. 
 
Any other condition or situation meaning that 
participation would not be in the best interests of the 
infants? 
 
 
 
 
Yes I___I No I___I 
 
7 
 
Any reason that would prevent the study endpoints 
being assessed in the infant effectively as judged by 
the investigator? 
 
 
 
Yes I___I No I___I 
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Do any of the vital signs or examination findings exclude the 
infant from the study according to the criteria above? 
 
 
 
Yes I___I No I___I 
 
If yes, do not proceed to taking 
nasopharyngeal and rectal swabs. If in 
doubt discuss the findings with study 
clinician 
 
  
Individual completing form 
 
 
 
Name:     
 Last First  
 
Signature:     
 
 
Is the subject eligible for continued enrolment? 
 
 
 
Yes I___I No I___I 
 
If yes, proceed to rectal and 
nasopharyngeal swab taking and obtain a 
breast milk sample from the mother 
 
If no, do not proceed to swab the baby & 
discuss with study clinician 
Give an appointment for visit 2 
 
 
 
 
 
 
Is the child aged 1-2days of age? 
 
 
 
Yes I___I No I___I 
 
If no, do NOT proceed to swab the baby.  
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Appendix	4	–	Standard	operating	procedures	for	field	samples	
1. Standard	operating	procedure	3	–	breast	milk	collection	and	processing	
2. Standard	operating	procedure	4	–	collection	of	cord	blood	
3. Standard	operating	procedure	5	–	nasopharyngeal	and	rectal	swab	collection	
4. Standard	operating	procedure	6	–	rectovaginal	swab	collection	
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GAMI Study 
Standard Operating Procedure 3.  
 
SOP Title: Breast Milk Collection and processing 
SOP Version: 02   
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, WT Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from:   
Date effective: 14 November 2013 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), 2-5 mls of 
breast milk will be collected from mothers who have given verbal 
consent to participate in the study.  
2. PURPOSE AND SCOPE 
This standard operating procedure (SOP) describes the process of 
collection of breast milk from mothers who have given consent to 
participate in this longitudinal study.   
 
The aim of breast milk collection is to explore the role of antibody 
in protecting newborn infants from colonisation with Group B 
streptococcus. 
 
This SOP applies to the study nurses, government midwives, and 
study ciinicians involved in this procedure.  
3. ABBREVIATIONS  
MRC Medical Research Council; representing MRC Unit 
The Gambia 
SOP Standard Operating Procedure 
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4. RESPONSIBLE PERSONS  
The study team, including the government midwives identify 
pregnant women at the labour ward of Faji Kunda health centre 
who meet the study inclusion criteria. A study information sheet is 
provided and explained. The woman is advised that full written 
consent will be sought by the study team after she has recovered 
suitably from the delivery should she wish to take part.  
5. PROCEDURE 
5.1. Confirm that written consent is given for breast milk sample to be 
taken and stored.  
 
5.2. Explain the procedure to the mother.  
 
5.3. Make available properly labeled breast milk specimen containers as 
follows: 2 x clear universal containers. (These containers are 
available on the labour ward in pre-prepared packs. All containers 
are marked with a black line to indicated the fill level) 
 
5.4. As the mother to wash her hands and provide sterile cotton wool 
and 0.02% chlorhexidine to the mother.  
 
5.5. Show the mother how to clean the nipple area and areola of the 
breast from which milk will be taken.  
 
5.6. Ask the mother to express milk from each breast into separate 
containers.  
 
5.7. Ask her to manually express her milk. Remove the first 0.5ml that 
will be introduced on a tissue and discarded appropriately.  Ask her 
to directly express into the sterile plastic tube (universal container) 
to collect approximately 5mls and place in a cold box.  
 
5.8. Put a sticker on the laboratory form, the corresponding CRF section 
and the tube. 
 
5.9. Complete the field sample log sheet kept at the clinic. 
 
5.10. Ensure that the specimen remains on wet ice in the cold box and is 
transported to the lab within six hours of collection to the 
designated laboratory staff. Complete the appropriate sample log 
book kept at the laboratory. 
 
5.11. Thank the mother and the attending midwife/midwives. 
 
 
 
6. LABORATORY HANDLING 
  6.1. Store breast milk in the fridge and process at time of delivery.  
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6.2 Following receipt of the completed Breast milk sample from the Faji 
Kunda Health Centre team, take the right breast samples and 
centrifuge for 30 mins at 3200 rpm. Remove the fat layer with a 
scalpel and store separately. 
6.3.  Aliqout Whey into 1mL aliquots and label tubes. 
6.4. Freeze at -70 degrees.  
6.5. Record the freezer location in the Sample log book, sign and date 
the record. 
6.6. Take the left breast and dilute 5mL breastmilk in 5mL sterile 
phosphate buffered saline (PBS)  
6.7. Centrifuge at 805g for 20 minutes at 20°C.  
6.8.  Remove the fat layer with a scalpel.  
6.9.  Wash the cell pellet in 5mL PBS and recentrifuge. Then repeat this 
wash step. 
6.10. Resuspend in 7% fetal bovine serum in PBS. 
6.11. Count cells using a hemocytometer. 
6.12. Freeze immediately at -70°C. 
 
 
 
7. REFERENCES 
SCC 1350 – Feb 2014  
• Study Protocol - Group-B Streptococcal Antibody in Mothers 
and Infants (GAMI) January 2014 
8. ATTACHMENTS 
• Participant Information Sheet and consent form (English), 
version 1.0   
• Breast Milk collection form 
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GAMI Study 
Standard Operating Procedure 4.  
 
SOP Title: Cord blood Collection 
SOP Version: 01    
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from: 
 
SOP by Aderonke Odutola for study protocol SCC 
1173 (Dr Martin Ota, Principal Investigator) 
Date effective: 14 November 2013 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), 5 mls of cord 
blood will be collected during delivery from the newborn of mothers who 
have given verbal consent to participate in the study at the Faji Kunda 
Health centre.  
2. PURPOSE AND SCOPE 
This standard operating procedure (SOP) describes the process of 
collection of cord blood from newborns of mothers who have given 
consent to participate in this longitudinal study.   
 
The aim of cord blood collection is to explore the role of antibody in 
protecting newborn infants from colonisation with Group B streptococcus. 
 
This SOP applies to the study nurses, government midwives, and study 
ciinicians involved in this procedure.  
3. ABBREVIATIONS  
MRC Medical Research Council; representing MRC Unit The 
Gambia 
SOP Standard Operating Procedure 
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4. RESPONSIBLE PERSONS  
The study team, including the government midwives identify pregnant 
women at the labour ward of Faji Kunda health centre who meet the 
study inclusion criteria. A study information sheet is provided and 
explained. The woman is advised that full written consent will be sought 
by the study team after she has recovered suitably from the delivery. 
The cord blood sample will be stored safely, but discarded should she 
decide not to partake in the study. 
5. PROCEDURE 
5.1 Confirm that verbal consent is given for cord blood sample to be taken 
and stored.  
 
5.2 Confirm the delivery is a potentially uncomplicated (not high-risk) case. 
 
5.3 Explain to the pregnant woman in labour what you are about to do and 
remind her the reason for collecting the cord blood. 
 
5.4 Make available properly labeled blood sample tubes as follows: 2 x yellow 
top. (These tubes are available on the labour ward in pre-prepared 
packs. All tubes are marked with a black line to indicated the fill level)  
 
5.5 Make available sterile alcohol swabs and a 10ml syringe with a green 
needle. 
 
5.6 Put on a pair of sterile gloves as soon as delivery of the baby is 
imminent. 
 
5.7 Immediately following the delivery of the baby but before the placenta 
separates, identify the large thin-walled opening of umbilical vein lying 
superiorly. 
 
5.8 Remove any used gloves and put on a pair of new gloves. 
 
5.9 Ensure that the cord is lying low between the mother’s legs to avoid back 
flow of blood. 
 
5.10 Clean cord properly with alcohol swab (or gauze soaked in spirit) and 
allow to dry. This is to avoid contamination e.g. with maternal blood. 
 
5.11 Puncture the umbilical vein close to the positioned clamp (this is to 
allow for repositioning of clamp in the event of significant 
bleeding after venepuncture) on the portion of the cord attached to 
the placenta with a sterile/new needle and syringe and withdraw about 
10mls of blood.  
 
		 212	
	
SOP 02, SCC 1350  MRC (UK) The Gambia 
 
 
Version 2.0 – March 2014  Page 3 of 4 
Confidential, unauthorised copying prohibited 
 
 
5.12 Put blood into tubes up to the black “fill line” in the following order: 
yellow top. 
 
 
 
 
 
 
 
 
 
 
5.13 If significant bleeding from venepuncture site reposition clamp in front of 
the site or asked attending midwife to if other than you.  
 
5.14 Store blood in the provided cool box.  
 
5.15 Transport the cord blood in a cold box (packed with ice-packs) within 6 
hours of collection to the infant immunology laboratory at MRC, Fajara 
 
5.16 Complete the study cord blood collection form completely leaving no 
blank space.  
 
5.17 Thank the mother and the attending midwife/midwives. 
 
6. LABORATORY PROCESSING 
6.1.  Centrifuge at 1000g for 10 minutes.  
6.2.  Aliquot the separated serum into 1mL aliquots. 
6.2a Correctly label each tube and date. 
6.3. Freeze at -70 degrees C. 
6.4. Record the freezer location in the sample log book, sign and date the 
record. 
7. REFERENCES 
 SCC 1350 – Feb 2014  
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• Study Protocol - Group-B	 Streptococcal	 Antibody	 in	 Mothers	 and	
Infants	(GAMI)	 January	2014 
8. ATTACHMENTS 
• Participant Information Sheet and consent form (English), version 
1.0   
• Cord blood collection form 
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GAMI Study 
Standard Operating Procedure 5.  
 
SOP Title: Nasopharyngeal and rectal swab collection 
SOP Version: 01    
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from: 
 
SOP by Dr Brenda Kwambana and approved by Dr 
Martin Antonio 
Date effective: 1 March 2014 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), nasopharyngeal 
and rectal swabs will be taken from infants during the first 3 months of 
life. It	has	been	 suggested	 that	GBS	 initially	 colonizes	 the	 infant’s	oropharyngeal	
mucosa	when	contact	with	maternal	vaginal	 secretions	occur	at	 the	 time	of	birth	
(1). Group-B Streptococcus is an enteric pathogen and it is thought that 
gut translocation is the primary route for invasive disease in the newborn 
period. Although the specific mechanisms are poorly understood, 
attachment to the nasopharyngeal epithelial surface and gut mucosal 
surface is thought to be an essential step in the development of mucosal 
and invasive disease [2,3]. Hence, sampling of the nasopharynx and 
rectum can provide invaluable insights into the epidemiology and 
mechanisms of pathogenicity of GBS.  
 
Purpose	and	Scope	
This standard operating procedure (SOP) describes the process of 
collection of nasopharyngeal and rectal swabs from infants of mothers 
who have given consent to participate in this longitudinal study.   
2. ABBREVIATIONS  
NPS Nasopharyngeal swab 
RS  Rectal Swab 
SOP Standard Operating Procedure 
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STGG Skim milk-tryptone-glucose-glycerol (STGG) 
transport medium 
3. RESPONSIBLE PERSONS  
The study team, including the government midwives identify pregnant 
women at the antenatal clinic or the labour ward of Faji Kunda health 
centre who meet the study inclusion criteria. A study information sheet is 
provided and explained. The study team seeks full written consent after 
the mother has recovered suitably from the delivery. A NPS and RS 
sample is collected within the first 48 hours of life. Two further NPS and 
RS samples are collected during the first 3 months of life. All operators 
must be qualified nurses or healthcare assistants. 
 
4. FIELD PROCEDURE 
 
4.1. Ensure that a clean environment is attained to avoid contaminating 
the sample. 
 
4.2. Prepare sterile gloves, sterile calcium alginate fiber tip swabs and a 
2 vials containing 1ml of STTG medium in each. 
 
4.3. Check that the subject’s ID is included in the list of NPS and RS 
swabs to be taken 
 
4.4. Check that the ID number on the subjects identity card and subject 
study folder and the ID on the NPS and RS form all coincide. If 
there is any discrepancy between the ID on any of the records then 
the field worker should not proceed with the collection of the 
sample, but consult with the field supervisor/coordinator. 
 
4.5. Explain the procedure to the mother 
 
4.6. Use only calcium alginate fiber tip swab 
 
4.7. Put on a pair of sterile gloves 
 
NPS SWAB: 
 
4.8. Position the infant in a supine position (on their back), with the 
infant’s head furthest away from you, and the infant’s legs pointing 
towards you. If a firm flat surface cannot be sought, this can be 
done on the knees of the nurse carrying out the procedure (as 
shown in the figure below). The infant should be briefly swaddled 
for the short period of the procedure. This will allow the infant to be 
kept still, and reduce any discomfort. 
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Figure 1. Collection of NPS from an infant 
 
 
4.9. Measure the distance which the swab should be passed, which is 
about half the distance from the nostril to the ear lobe. 
 
4.10. Tip the infant’s head slightly backward and pass the swab directly 
backwards, parallel to the floor of the nasopharynx. The swab 
should pass without resistance until it reaches the posterior 
pharynx. 
 
4.11. If resistance is encountered, remove the swab and pass through 
the other nostril. 
 
4.12. Once the swab is in place, leave in position for five seconds to 
saturate the tip before removing it slowly. 
 
 
 
Figure 2. Passage of a sterile swab through the nasal cavity to 
the nasopharynx 
 
4.13. Place the tip in a vial containing 1ml of STGG transport media. 
Using a pair of scissors wiped with alcohol, cut off the excess wire 
handle, leaving the tip in the transport media. Then tighten the cap 
and label the vial and place on wet ice.  
 
4.14. Dispose what remains of the wire loop into “sharps” box 
 
4.15. Remove any used gloves and dispose of into a yellow clinical waste 
bag. 
 
4.16. Keep a record of the presence or absence of nasal mucous and 
whether or not the procedure was adequately carried out.  
 
		 217	
	
SOP 04, SCC 1350  MRC (UK) The Gambia 
 
 
Version 1.0 – January 2014  Page 4 of 8 
Confidential, unauthorised copying prohibited 
4.17. Ensure that the specimen is placed in the cool box provided 
(containing 2 ice packs) and is transported to the lab within six 
hours of collection  
 
RS SWAB: 
 
4.18. Position the infant in a supine position (on their back), with the 
infant’s head furthest away from you, and the infant’s legs pointing 
towards you. If a firm flat surface cannot be sought, this can be 
done on the knees of the nurse carrying out the procedure. The 
infant should be briefly swaddled for the short period of the 
procedure. This will allow the infant to be kept still, and reduce any 
discomfort. 
 
 
4.19. Hold the infant’s legs up and pass the swab directly backward so 
that the tip is just inside the rectum (about 0.5cm). The swab 
should pass without resistance. 
 
4.20. If resistance is encountered, remove the swab immediately. 
 
4.21. Once the swab is in place, leave in position for five seconds to 
saturate the tip before removing it slowly. 
 
 
 
Figure 2. Passage of a sterile swab to the rectum 
 
4.22. Place the tip in a vial containing 1ml of STGG transport media. 
Using a pair of scissors wiped with alcohol, cut off the excess wire 
handle, leaving the tip in the transport media. Then tighten the cap 
and label the vial and place on wet ice.  
 
4.23. Dispose what remains of the wire loop into “sharps” box 
 
4.24. Remove any used gloves and dispose of into a yellow clinical waste 
bag. 
 
4.25. Keep a record of the presence or absence of faeces/meconium and 
whether or not the procedure was adequately carried out.  
 
4.26. Ensure that the specimen is placed in the cool box provided 
(containing 2 ice packs) and is transported to the lab within 90 
minutes of collection  
 
 
4.27. Report any problems such as bleeding or excessive pain (crying in 
babies) arising during the procedure to the Research Clinician 
immediately. 
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5. LABORATORY PROCEDURES (AT THE MRC FAJARA) 
5.1. Prepare STGG transport medium as below: 
 
Oxoid tryptone soya broth  3.0g  
Glucose    0.5g  
Oxoid skim milk powder  2.0g  
Glycerol    10.0g(1.25g=1ml)  
Double distilled water   100.0 ml  
 
5.2 Dispense in 1.0 ml amount in Nunc or Nalgene cryotubes and 
autoclave for 10minutes at 121°C.  
 
5.3 Tighten the lids before storage.  
 
5.4 Store at 4-8°C or room temperature.  
 
5.5 NB/ Prior to use vortex to re-suspend the pellet for a minimum of 
10-15 seconds.  
 
5.6 Transfer to Faji Kunda Health Centre team in cool box with 2 ice 
packs for NPS and RS to be taking according to field procedure. 
 
5.7 Following receipt of the completed NPS and RS sample from the 
Faji Kunda Health Centre team, vortex the specimen for 10-20 
seconds. Aliquot 0.5mL of STGG into a separate cryotube. Correctly 
label and date each samples and store in –70°C freezer.  
 
5.8 Record the freezer location on the Sample Collection form and sign 
and date the record. 
 
See appendix 1. for quality control of STGG medium. 
  
		 219	
	
SOP 04, SCC 1350  MRC (UK) The Gambia 
 
 
Version 1.0 – January 2014  Page 7 of 8 
Confidential, unauthorised copying prohibited 
6. APPENDIX 1. 
Quality control of STGG medium  
 
Appearance: 
- The solution should be tan in colour with a precipitate at the bottom 
of the tube. 
 
Sterility: 
- Select at random 1 vial from each batch. Vortex until the precipitate 
is suspended and plate 100 µL each on Sheep Blood agar. Incubate 
overnight at 37 °C in 5% CO2 and examine the plate for any growth. 
There should be no growth whatsoever. If there is any growth, 
discard the batch and prepare fresh medium.  
 
Performance: 
- Vortex a vial to suspend the precipitate and inoculate it with a 
representative vaccine strain of pneumococcus. Freeze at -70°Cfor 48 
hours. Thaw out specimen at room temperature, vortex again, 
subculture 100 µL onto GBA plate and streak. Incubate overnight at 
37°C in 5% CO2. The organism should show good growth.  
 
7. ATTACHMENTS 
• Participant information sheet and consent form (English) 
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GAMI	Study	
Standard	Operating	Procedure	6.		
	
SOP	Title:	 rectovaginal	swab	collection	
SOP	Version:	 01		 	 	
Category:	 Clinical	
Prepared	by:	 Dr	Kirsty	Le	Doare,	Clinical	Research	Fellow	
Signature	and	date:	 	
Reviewed	by:	 Dr	Ed	Clarke,	Head	of	Infant	Immunology	
Signature	and	date:	 	
Amended	from:	
	
SOP	by	Dr	Brenda	Kwambana	and	approved	by	Dr	Martin	
Antonio	
Date	effective:	 1	March	2014	
	
1. BACKGROUND		
According	 to	GAMI	 study	 protocol	 (dated	 14	 Jan	 2014),	 rectovaginal	 swabs	will	 be	 taken	
from	women	 in	 labour.	Group-B	Streptococcus	 is	an	enteric	pathogen	and	colonization	 in	
the	mother	 is	 a	 prerequisite	 for	 transfer	 of	 colonization	 to	 the	 infant.	 Yield	 of	 bacterial	
growth	is	highest	when	combining	rectal	and	vaginal	swabs.	Hence,	sampling	of	the	vagina	
and	rectum	can	provide	invaluable	insights	into	the	epidemiology	of	GBS.		
		
	
Purpose	and	Scope	
This	standard	operating	procedure	(SOP)	describes	the	process	of	collection	of	rectovaginal	
swabs	from	mothers	who	have	given	consent	to	participate	in	this	longitudinal	study.			
2. ABBREVIATIONS		
RVS	 	Rectovaginal	Swab	
SOP	 Standard	Operating	Procedure	
STGG	 Skim	milk-tryptone-glucose-glycerol	(STGG)	transport	medium	
3. RESPONSIBLE	PERSONS		
The	 study	 team,	 including	 the	 government	 midwives	 identify	 pregnant	 women	 at	 the	
antenatal	 clinic	 or	 the	 labour	 ward	 of	 Faji	 Kunda	 health	 centre	 who	 meet	 the	 study	
inclusion	 criteria.	 A	 study	 information	 sheet	 is	 provided	 and	 explained.	 The	 study	 team	
seeks	 full	written	 consent	 after	 the	mother	 has	 recovered	 suitably	 from	 the	 delivery.	 An	
RVS	 sample	 is	 collected	 prior	 to	 delivery.	 All	 operators	 must	 be	 qualified	 nurses	 or	
healthcare	assistants.	
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4. FIELD	PROCEDURE	
	
4.1. Explain	the	procedure	to	the	mother.		
4.2. Check	that	the	subject’s	ID	is	included	in	the	list	of	RVS	swabs	to	be	taken		
4.3. Check	that	the	ID	number	on	the	subjects	identity	card	and	subject	study	folder	
and	the	ID	on	the	RVS	form	all	coincide.	If	there	is	any	discrepancy	between	the	
ID	on	any	of	the	records	then	the	field	worker	should	not	proceed	with	the	
collection	of	the	sample,	but	consult	with	the	field	supervisor/coordinator.	
4.4. Ensure	that	a	clean	environment	is	attained	to	avoid	contaminating	the	sample.	
4.5. Use	only	plain	swab	sticks	for	RVS.		
4.6. Put	on	a	pair	of	sterile	gloves	
4.7. Position	the	mother	in	a	supine	position	(on	her	back),	with	her	head	furthest	
away	from	you	with	her	knees	bent	and	open	(Figure	1).	
Figure	1.	Positioning	a	woman	for	an	RVS	
	
	
4.8. Remove	the	protective	covering	over	the	vaginal	swab	by	peeling	off	the	
protective	wrapping	around	the	swab	stick.		Do	not	let	your	fingers	touch	the	
swab.	
4.9. Pass	the	swab	into	the	lower	vagina	and	leave	for	5	seconds.	Then	remove	
slowly.	See	Figure	2.	Do	not	let	your	gloved	fingers	touch	the	mother’s	skin.	
4.10. Pass	the	tip	of	the	same	swab	into	the	anus	and	leave	for	5	seconds.	Then	
remove	slowly.	There	should	be	no	resistance.	If	there	is	any	resistance,	remove	
the	swab	immediately.	
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Figure	2	–	taking	a	combined	rectovaginal	swab	
	
4.11.		 Place	the	tip	in	a	vial	containing	1ml	of	STGG	transport	media.	Using	a	pair	of	
scissors	wiped	with	alcohol,	cut	off	the	excess	wire	handle,	leaving	the	tip	in	the	
transport	media.	Then	tighten	the	cap	and	label	the	vial	and	place	on	wet	ice.			
4.12.		 Put	the	sticker	on	the	laboratory	form,	the	corresponding	CRF	section	and	the	tube.	
4.13.	 Complete	the	sample	log	sheet	kept	at	the	clinic.	
4.14.		 Ensure	that	the	specimen	remains	on	wet	ice	and	is	transported	to	the	lab	within	six	
hours	of	collection	to	the	designated	staff	at	the	laboratory	and	complete	the	
sample	log	book	kept	at	the	laboratory.	
4.15.		 Dispose	what	remains	of	the	wire	loop	into	“sharps”	box	
4.16. 															Remove	 any	 used	 gloves	 and	 dispose	 of	 into	 a	 yellow	 clinical	 waste	 bag.	
	
4.17. 														Thank	the	mother	for	her	co-operation.	
	 	
1.#Remove&swab&from&
packaging.&Insert&swab&2cm&
into&vagina&(front&passage).&
Do&not&touch&co<on&=p&with&
ﬁngers&
Vagina#
2.#Insert&the&SAME&swab&1cm&
into&anus&(back&passage).&
Anus#
3.#Remove&cap&from&cryotube&
containing&1mL&STGG&
transport&medium&
4.#Place&=p&of&swab&into&cryotube,&
cut&oﬀ&excess&handle&using&
scissors&wiped&with&alcohol,&
leaving&=p&in&the&transport&media.&
Tighten&the&cap&ﬁrmly.&
5.#Carefully&label&cryotubewith&the&study&number,&date&and&=me&of&collec=on.&Place&into&transport&bag&on&wet&ice.&Complete&the&sample&
collec=on&form.&Give&the&cryotube&and&the&sample&collec=on&form&to&the&ﬁeld&worker&immediately&to&place&on&wet&ice.&&
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5. LABORATORY	PROCEDURES	(AT	THE	MRC	FAJARA)	
5.1 Prepare	STGG	transport	medium	as	below:	
	
Oxoid	tryptone	soya	broth	 	 3.0g		
Glucose	 	 	 	 0.5g		
Oxoid	skim	milk	powder		 2.0g		
Glycerol	 	 	 	 10.0g(1.25g=1ml)		
Double	distilled	water		 	 100.0	ml		
	
5.2	 Dispense	in	1.0	ml	amount	in	Nunc	or	Nalgene	cryotubes	and	autoclave	for	
10minutes	at	121°C.		
	
5.3	 Tighten	the	lids	before	storage.		
	
5.4	 Store	at	4-8°C	or	room	temperature.		
	
5.5	 NB/	Prior	to	use	vortex	to	re-suspend	the	pellet	for	a	minimum	of	10-15	seconds.		
	
5.6	 Transfer	to	Faji	Kunda	Health	Centre	team	in	cool	box	with	2	ice	packs	for	RVS	to	be	
taking	according	to	field	procedure.	
	
5.7	 Following	receipt	of	the	completed	RVS	sample	from	the	Faji	Kunda	Health	Centre	
team,	vortex	the	specimen	for	10-20	seconds,	aliquot	0.5mL	of	STGG	from	sample	
into	a	separate	cryovial,	correctly	label	both	tubes	and	store	in	–70°C	freezer.		
	
5.8.		 Record	location	of	sample	in	freezer	and	sign	and	date	the	Sample	Collection	form.	
	
See	appendix	1.	for	quality	control	of	STGG	medium.	
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6. APPENDIX	1.	
Quality	control	of	STGG	medium		
	
Appearance:	
- The	solution	should	be	tan	in	colour	with	a	precipitate	at	the	bottom	of	the	tube.	
	
Sterility:	
- Select	at	random	1	vial	from	each	batch.	Vortex	until	the	precipitate	is	suspended	and	
plate	 100	 μL	 each	 on	 Sheep	Blood	 agar.	 Incubate	 overnight	 at	 37	 °C	 in	 5%	CO2	 and	
examine	the	plate	for	any	growth.	There	should	be	no	growth	whatsoever.	 If	there	 is	
any	growth,	discard	the	batch	and	prepare	fresh	medium.		
	
Performance:	
- Vortex	a	vial	to	suspend	the	precipitate	and	inoculate	it	with	a	representative	vaccine	
strain	 of	 pneumococcus.	 Freeze	 at	 -70°Cfor	 48	 hours.	 Thaw	 out	 specimen	 at	 room	
temperature,	 vortex	 again,	 subculture	 100	 μL	 onto	 GBA	 plate	 and	 streak.	 Incubate	
overnight	at	37°C	in	5%	CO2.	The	organism	should	show	good	growth.		
	
7. APPENDIX	2.	
Sample	processing	
	
To	prepare	100ml	of	nutrient	broth	(Glycerol	broth	16%):	
	
- Nutrient	broth	 	 84ml		
- Glycerol	 	 	 16ml		
	
Mix	 well	 and	 distribute	 in	 5mls	 amounts	 in	 screw-cap	 tubes	 or	 bottles.	 Sterilise	 by	
autoclave	at	115°C	for	20	minutes.	This	medium	should	be	within	the	range	Ph	7.2-7.6	at	
room	temperature.	Put	in	the	fridge	for	longer	storage	
	
To	perform	PCR		
	
- Aliquot	7.5μl	to	each	labelled	PCR	plate	well.	
- Add	2.5μl	 of	 sample	or	 control	 to	 the	appropriate	tubes/wells	(use	2.5μl	UV	 treated	
water	to	negative	control	and	do	not	add	anything	to	the	blank).	
- Place	PCR	tubes	into	the	real-time	instrument	(ABI).	
	
8. ATTACHMENTS	
• Participant	information	sheet	and	consent	form	(English)	
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Summary Objectives: To determine risk factors for GBS colonisation in Gambian mothers
and in their infants from birth to day 60e89 of age.
Methods: Swabs and breastmilk from mothers/infant pairs were collected and cultured on se-
lective agar. Negative samples were analysed for GBS DNA via real-time PCR. Positive isolates
were serotyped using multiplex PCR and gel-agarose electrophoresis.
Results: Seven hundred and fifty women/infant pairs were recruited. 253 women (33.7%) were
GBS-colonised at delivery. The predominant serotypes were: V (55%), II (16%), III (10%), Ia
(8%) and Ib (8%). 186 infants were colonised (24.8%) at birth, 181 (24.1%) at 6 days and 96 at
day 60e89 (14%). Infants born before 34 weeks of gestation and to women with rectovaginal
and breastmilk colonisation at delivery had increased odds of GBS colonisation at birth. Season
of birth was associated with increased odds of persistent infant GBS colonisation (dry season
vs. wet season AOR 2.9; 95% CI 1.6e5.2).
Conclusion: GBS colonisation is common in Gambian women at delivery and in their in-
fants to day 60!89 and is dominated by serotype V. In addition to maternal
* Corresponding author. Centre for International Child Health, Imperial College, Norfolk Place, London W2 1PG, UK. Tel.: þ44 207594
8839; fax: þ44 1189440191.
E-mail addresses: K.mehring-le-doare@ic.ac.uk (K. Le Doare), shjarju@mrc.gm (S. Jarju), sdarboe@mrc.gm (S. Darboe), Fiona.
warburton@phe.gov.uk (F. Warburton), Andrew-gorringe@phe.gov.uk (A. Gorringe), pheath@sgul.ac.uk (P.T. Heath), b.kampmann@ic.ac.
uk (B. Kampmann).
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under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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colonisation, breastmilk and season of birth are important risk factors for infant GBS
colonisation.
Crown Copyright ª 2015 Published by Elsevier Ltd on behalf of The British Infection
Association. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Introduction
Group B Streptococcus (GBS) is a leading cause of neonatal
infection worldwide and transmission occurs mainly from
mother to child during the peripartum period.1 In the Afri-
can setting, information on GBS disease prevalence remains
sparse.2 Under-identification and under-reporting of GBS
cases and deaths appear likely, especially where it is diffi-
cult to access healthcare. Maternal colonisation is the lead-
ing risk factor for both early and late onset GBS disease,1
yet in resource-poor countries little is known about
maternal colonisation rates. Little is also known about
maternal or infant colonising serotypes in African countries
but reports indicate that serotype (ST) V may be important
as both a colonising and invasive disease serotype,3,4 as it
was in the USA in the 1990s.5
The current leading candidate for maternal vaccination
is a trivalent capsular polysaccharide protein conjugate
vaccine containing ST Ia, Ib and III which is based on data on
invasive disease serotypes in the USA, UK6 and South Af-
rica.3 Here, we report the results of a longitudinal prospec-
tive cohort study to investigate the prevalence of colonising
and invasive disease serotypes of Gambian women and their
infants from delivery to three months of age.
Methods
Study design and participants
We undertook a prospective longitudinal cohort study in
two government health centres offering antenatal care to
women in the Fajara area of costal Gambia, a low-income
country with an annual birth rate of 43.1/1000 population,
neonatal sepsis rate of 4.42/1000 live births7 and neonatal
mortality rate of 28/1000 live births.8 The combined birth
rate of these two health centres is approximately 12,500
births annually. The health centres were selected to be
representative of the level of care usually available to
Gambian women.
The eligibility criteria for maternal participation in the
study included all pregnant women over the age of 18 years
who had a negative HIV test and were deemed to be at low
risk for pregnancy complications (no evidence of pre-
eclampsia, cardiomyopathy, maternal gestational diabetes,
placenta praevia, twin pregnancy). Women were invited to
deliver at the health centre and offered a confirmatory HIV
test prior to enrolment. Women found to be HIV positive
were referred for specialist ongoing care. Mothers were
excluded if they were not planning to breastfeed or were
unable to remain in the Fajara area for the first three
months postpartum. Healthy infants over 32 weeks of
gestation assessed using the Ballard score and weighing
over 2.5 kg were included. Infants were excluded if they
had obvious congenital abnormalities or required resusci-
tation at the time of delivery requiring transfer to a
neonatal unit. Mother and infant pairs were recruited to
the study between 1st January 2014 and 31st December
2014 if both mother and infant met the inclusion criteria.
All eligible women and infants were recruited until the pre-
defined sample size was reached. Participants were fol-
lowed up daily at home until day 6 and then asked to return
to clinic when the infant 60!89 days old for final follow up
visit and vaccinations. If an infant died during the study a
verbal autopsy was carried out to assess the potential cause
of death.
Ethics statement
Field workers explained the purpose of the study to eligible
participants in their local language (Mandinka, Wolof, Fula,
Jolla, Mangago) and each participant signed an informed
consent form, or in case of illiteracy, thumb-printed and
the consent form was signed by an impartial witness. The
study was approved by the joint Gambian Government/
Medical Research Council Research Ethics Committee, SCC
1350 V4.
Procedures
Sampling
Rectovaginal swabs were taken from enrolled women
presenting in labour to one of the health centres and cord
blood was taken after delivery but prior to separation of
the placenta. A screening questionnaire was completed
after four hours postpartum and the infant checked for any
abnormalities requiring medical intervention. The ques-
tions included ethnic origin, gravida, parity, maternal
weight, blood pressure, haemoglobin concentration, use
of medication/traditional medicines/antibiotics and vacci-
nation in pregnancy, any illnesses in pregnancy, number of
antenatal attendances, HIV status, education, diet, com-
pound location and presence of cattle at the compound.
Nasopharyngeal and rectal swabs were taken from all
eligible infants at four hours after birth. Mothers were
provided with soap and asked to wash their hands and wipe
their breasts with alcohol wipes before hand expressing
colostrum/milk within the first 12 h after birth, at day 6 and
between days 60 and 89. Nasopharyngeal and rectal swabs
were also taken from infants at day 6 of life and again at
60e89 days of life. Infants who were unwell before day 6
were assessed at home and referred for treatment as
necessary. All sick infants had a blood culture taken on
admission to hospital. At each visit a standardized ques-
tionnaire was completed in the local language documenting
infant anthropometry, feeding, vaccinations, signs and
symptoms of infant illnesses, use of antibiotic/traditional
medicine and vital signs.
2 K. Le Doare et al.
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Laboratory procedures
Copan (for rectal and rectovaginal samples) and Dacron (for
nasopharyngeal samples) swabs were collected in skim-milk
tryptone glucose glycerol (STGG) transport medium, stored
at 4 !C and transported to the Medical Research Council
laboratories, The Gambia within 4 h of collection. On
arrival the samples were vortexed briefly and immediately
frozen at "70 !C until processing.
All swab specimens were inoculated into ToddeHewitt
broth supplemented with colistin and nalidixic acid and
were processed for isolation of GBS using standard labora-
tory procedures.1 Presumptive positive GBS samples were
identified by latex agglutination (Oxoid). Five colonies
from positive samples were harvested into phosphate buff-
ered saline (PBS) and subjected to real-time polymerase
chain reaction (PCR).9 Negative samples were also sub-
jected to confirmation by real-time PCR. All GBS positive
isolates were then serotyped using conventional PCR and
identified using gel PCR and agarose electrophoresis.10
Outcomes
The primary outcome was prevalence of ST-specific GBS
colonisation in mothers and infants at birth, six days and
between days 60e89 using microbiological culture and
molecular techniques. Secondary outcomes were detection
of GBS in breastmilk; infant acquisition and loss of GBS
colonisation during the study follow up period and infant
GBS disease (sample obtained from sterile site), as ascer-
tained by positive microbiological culture and confirmatory
PCR. Swabs were considered negative if no GBS was evident
by culture and PCR and positive if GBS was found on culture
and PCR. If swabs were negative on culture but positive on
PCR, conventional PCR was performed to determine sero-
type. If the second PCR resulted in the identification of a
GBS serotype the samples were deemed positive. If no
serotype was identified or the DNA did not amplify, samples
were deemed negative.
Statistical analysis
Calculated on the basis of the previously observed 24%
colonisation rate,11 the intended sample size was 750
mothers, to provide at least 180 colonised women for sero-
type analysis (95% confidence interval (CI) 150e202 women)
and 90 colonised infants (95% CI 72e107 infants). The sam-
ple size of 180 colonised women was chosen to ensure at
least 10 samples of the least prevalent ST based on histor-
ical data from The Gambia (ST III (6%)),11 in order to allow
longitudinal colonisation analysis.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, Texas) and GraphPad Prism version 6.0
(GraphPad Software Inc, La Jolla, California). Descriptive
statistics included the prevalence of colonisation at indi-
vidual time points expressed as a proportion of the total
number of participants. Odds ratios and 95% confidence
intervals (CI) were calculated to determine risk of maternal
and infant colonisation at birth in a single variable analysis.
Adjusted odds ratios were then calculated using any vari-
ables from the single variable analysis with a p-value <0.2
using a backwards-stepwise procedure.
Analyses of the changes in infant colonisation over time
were undertaken using longitudinal logistical regression.
Adjusted odds ratios were then calculated using any
variables from the single variable analysis with a p-value
<0.2 using a backwards-stepwise procedure. New acquisi-
tion of GBS was defined as detection of a new serotype by
culture or PCR that was not previously present. Clearance
of colonisation was defined as a negative GBS culture or
PCR for a specific serotype following a positive sample at
the previous visit for the same ST. The log-rank test was
used to examine differences in duration of colonisation
between serotypes. Using an expected vertical transmission
rate of 50%1 we calculated observed vs. expected statistics
for risk of infant colonisation by ST. For comparison be-
tween our study and the study conducted in 1994, we calcu-
lated 95% confidence intervals for both studies. P-values
<0.05 were considered significant.
Role of the funding source
The funders had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
All authors had full access to all the data and the
corresponding author had final responsibility for the deci-
sion to submit for publication.
Results
Demographics
Between 15th January 2014 and 31st January 2015 we
recruited a total of 750 mothers and their infants to the
study. All mothers met the inclusion criteria except one,
who was admitted to hospital on day three post-partum
severely unwell and subsequently tested positive for HIV1,
despite a negative test at 20 weeks of gestation. She and
her infant were referred for further management and
samples excluded from further analysis. Of the remaining
eligible women and infants, 722 completed the day 6 visit
(median age at follow up 8 days, IQR 7e9) and 684
completed 60e89 days follow up (median age at follow up
62 days, IQR 60e63). The main reasons for not completing
follow up were: 31 women moved out of area, 20 women
whose partners were not in agreement with continued
study participation, one maternal HIV, nine infant deaths,
five declined for other reasons. Participant flow diagram
and demographic characteristics of mothereinfant pairs
are outlined in Supplementary Fig. 1.
Antibiotic treatment
Over the course of the study, 77 women received antimicro-
bials during pregnancy: 34 for urinary tract infection; 10 for
pneumonia; 14 for vaginal discharge; 9 for malaria and 10 for
non-malarial fever. Of these, 73 women received amoxicillin
(median time prior to delivery 42 days [IQR 18e63 days]); 16
received antimalarial therapy (median 38 [31e41]) and three
received erythromycin. In the three months of follow up, 51
infants required antibiotic therapy: 34 received ampicillin
and gentamicin for presumed neonatal sepsis (median 18
days old [IQR 4e34]); 10 received amoxicillin or cloxacillin
for skin infections (20 days [10e58]); 7 received other
antibiotics (18 days [11e23]). Antibiotic therapy was
included in adjusted analyses and had no impact on
colonisation of mother or infant at any time point.
Risk factors for infant GBS colonisation 3
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Table 1 Mother and infant demographics and odds ratios for maternal GBS colonisation at delivery.
Total Colonised Non-colonised p-value OR (95% CI)
Maternal
age yrs
<20 110 40 70 0.78 1
20e24 262 81 181 0.78 (0.5e1.3)
Mean: 25
(IQR 18e41)
25e29 203 71 132 0.94 (0.6e1.5)
30þ 175 61 114 0.99 (0.6e1.7)
Ethnicity Mandinka 315 115 200 0.38 1
Wolof 108 36 72 0.9 (0.5e1.4)
Fula 126 45 81 1 (0.6e1.5)
Jola 118 33 85 0.7 (0.4e1.0)
Other 81 23 58 0.7 (0.4e1.2)
Missing 2 1 1
Maternal
weight (kg)
<50 27 7 20 0.03* 1
50e70 424 128 296 1.2 (0.5e3.0)
70e90 148 61 87 2.0 (0.8e5.0)
>90 145 56 91 1.8 (0.7e4.4)
Missing 6 3 3
Maternal illness
in pregnancy
Yes 128 45 83 0.32 1
No 504 165 339 1.1 (0.7e1.7)
Missing 118 43 75
Maternal Hb below
10 g/dL
No 99 42 57 0.04* 1
Yes 651 211 440 0.5 (0.3e0.9)
Maternal antibiotics
in pregnancy
No 505 166 339 0.74 1
Yes 128 44 84 1.1 (0.7e1.6)
Missing 117 74 43
Gravida 1 208 67 141 0.44 1
Median: 2 (IQR 1e4) 2e4 370 121 249 1 (0.7e1.5)
5þ 169 63 116 1.3 (0.8e2.0)
Missing 3 1 2
Parity 0e1 212 68 144 0.59 1
Median: 1 (IQR 0e4) 2e4 468 164 304 1.1 (0.8e1.6)
5þ 67 20 47 1.1 (0.7e1.7)
Missing 3 1 2
Living children 0 230 80 150 0.17 1
Median: 1 (IQR 0e3) 1e4 465 155 311 0.9 (0.7e1.3)
5þ 53 17 36 0.9 (0.5e1.7)
Missing 2 2 0
Spontaneous abortion 0 649 213 436 0.09 1
Median 1(IQR 0e2) 1 53 20 33 1.2 (0.7e2.2)
2þ 14 7 7 1.5 (0.8e2.7)
Missing 34 16 18
Stillbirths 0 641 207 434 0.05** 1
1 75 29 46 0.9 (0.4e2.1)
2þ 28 15 13 3.6 (1.2e10.5)
Missing 6 2 4
Number of ANC visits 1 303 85 218 0.01* 1
2þ 447 168 279 1.5 (1.1e2.1)
Attendance by midwife
or TBA
Midwife 436 168 268 0.001* 1
TBA 254 67 187 0.5 (0.4e0.8)
Missing 60 37 23
Birth season Dry cool 280 55 225 0.000* 1
Dry hot 175 85 90 3.9 (2.5e5.9)
Wet 295 113 18 2.5 (1.7e3.7)
Infant sex Male 369 122 247 0.59 1.1 (0.8e1.5)
Female 381 131 250
Birth
weight (kg)
2.5e3 260 73 187 0.04* 1
3.1e4 464 169 295 1.5 (1.1e2.0)
>4.0 26 11 15 1.9 (0.8e4.3)
4 K. Le Doare et al.
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Prevalence and risk factors for maternal
colonisation
The overall prevalence of recto-vaginal GBS colonisation at
delivery was 33.7% (253 women). In single variable analysis
maternal weight >50 kg, maternal haemoglobin <10 g/dL,
more than one previous stillbirth, more than one antenatal
clinic visit, midwife delivery, giving birth during the dry hot
or wet seasons, birth weight over 3 kg and gestation under
34 weeks were associated with increased risk of GBS
colonisation (Table 1). In adjusted analysis, maternal hae-
moglobin <10 g/dL, history of more than one previous still-
birth, attendance at delivery by a midwife rather than a
trained birth attendant and giving birth during the wet or
dry hot season were associated with increased odds of
maternal GBS colonisation at delivery (Table 2).
GBS colonisation dynamics at birth
There were 253 colonised mothers and 186 colonised
infants at birth, of whom 146 were born to colonised
women (57.7%). Table 3 describes the number of colonised
infants at birth, day 6 and at 60!89 days of age according
to colonisation site. Fig. 1a and b demonstrate colonisation
dynamics at each time point.
Compared to mother/infant pairs who were not colon-
ised at birth, mother/infant pairs were more likely to both
be colonised if mother’s weight was below 50 kg, infant was
born at less than 37 weeks of gestation, born during the dry
hot or wet seasons, mothers with more than one previous
stillbirth, mothers attending antenatal clinic more than
once, infants delivered by midwives, infants born with a
birth weight below 3.3 kg or receiving breastmilk colonised
with GBS (Table 4).
In adjusted analysis, compared to mother/infant pairs
who were not colonised at birth, mother/infant pairs were
more likely to both be colonised if birth occurred in the dry
hot or wet seasons, mothers with one or more previous
stillbirths or spontaneous abortions, infants born before 34
weeks of gestation. Compared to mother/infant pairs
where neither was colonised, mother/infant pairs where
the mother was colonised but not the infant were more
likely if the mother had more than one previous stillbirth,
or if the mother gave birth during the wet season. Infant
colonisation in the absence of maternal colonisation
(n Z 40) was associated with gestation before 34
weeks (Table 5).
Most notably, compared to mother/infant pairs at birth
where neither were colonised, infants born to mothers who
had GBS cultured in their breastmilk were more likely to be
colonised with GBS (Table 5).
GBS colonisation dynamics at birth, day 6e9 and
day 60e89
Infants born to colonised mothers had an increased risk of
colonisation at birth and day 6e9 if born during the dry hot
season or if born before 34 weeks of gestation. For all
variables the risk of colonisation decreased over time
(Table 6).
Infants born to non-colonised mothers had an increased
risk of being GBS colonised on day 6e9 and at day 60e89 if
born during the wet season. At birth infants were more
likely to be colonised if breastmilk was colonised and they
remained more likely to be colonised at both 6e9 days and
day 60e89.
Serotype distribution
The predominant maternal rectovaginal colonising serotype
was ST V in 54.9% of colonised mothers. Mothers’ breastmilk
was more likely to be colonised with ST V (p < 0.001) at all
time points than any other serotype. Infants were more
likely to be colonised with ST V at birth (p Z 0.004), day
6e9 (pZ 0.004) and day 60e89 (pZ 0.009) than any other
serotypes. At birth, infants were more likely to be colonised
with ST III and V if their mothers were colonised with ST III
and V (x2 Z 24.4, p < 0.001) compared to mothers colon-
ised with other serotypes. Fig. 2 outlines the percentage
of different serotypes at different time points in infants
and in breastmilk.
Gest. age at
birth (wks.)
<34 56 18 38 0.03* 1
34e37 231 83 148 0.7 (0.4e1.1)
38þ 463 152 311 1.1 (0.7e1.7)
IQR Z inter-quartile range; ANC Z antenatal clinic; TBA Z trained birth attendant. * p-values <0.05 were considered significant.
** p-value Z 0.0475.
Table 2 Multivariable analysis: maternal GBS colonisation
at time of delivery.
AOR (95% CI) p-value
Maternal
weight (kg)
<50 1
50e70 1.0 (0.4e1.6) 0.96
70e90 1.7 (0.6e4.5) 0.30
>90 1.4 (0.3e4.7) 0.68
Number of
ANC visits
1 1
2þ 1.3 (0.9e1.8) 0.16
Maternal Hb below
10 g/dL
No 1
Yes 0.7 (0.4e0.9) 0.04*
Attendance by
midwife or TBA
Midwife 1
TBA 0.6 (0.4e0.9) 0.03*
Previous stillbirths 0 1
1 0.9 (0.4e2.0) 0.86
2þ 5.4 (1.6e18.0) 0.009*
Birth season Dry cool 1
Dry hot 2.0 (1.3e3.1) 0.004*
Wet 1.8 (1.2e2.7) 0.008*
ANC Z antenatal clinic, Hb Z haemoglobin; TBA Z trained
birth attendant. * p-values <0.05 were considered significant.
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Neonatal sepsis
During the study period, 51 infants (6.8%) presented with
signs of infection (68 per 1000 live births): 18 with signs of
pneumonia, 22 with signs of other febrile illness, ten with
skin infections and one with signs of meningitis. One child
presenting on day 6 of life with irritability and poor
feeding, had a positive CSF culture for GBS and was treated
for 21 days with ampicillin and gentamicin (invasive GBS
disease incidence: 1.3 per 1000 live births). This infant was
born to a mother who had ST V cultured from both
rectovaginal swab and breastmilk at birth and day 6 of
life and the infant swab was also positive at birth and day 6
for ST V. The CSF sample was not typed due to laboratory
constraints.
Nine infants died during the study period. Based on
verbal autopsy, six deaths were due to pneumonia (median
age at death 7 days [IQR 2e35]); three due to sepsis
(median age 6 days [1e48]). Blood cultures were negative
in all cases. One infant was born to a colonised mother and
was also colonised with GBS at the time of birth but was not
colonised on day 6. This infant died of presumed sepsis on
day 48 of life. No other infants who died or their mothers
were colonised with GBS at time of birth or day 6 of life. All
infants died prior to the final follow-up appointment. It is
therefore, not possible to determine whether any of these
deaths were due to GBS disease.
Discussion
In this first colonisation study of Gambian mothers and their
infants for 25 years and the first longitudinal study under-
taken in this population, we demonstrate high prevalence
of GBS colonisation in mothers at birth and in their infants
up to 90 days of life. In addition, we demonstrate that
infants were more likely to be colonised if GBS was isolated
from their mother’s breastmilk. The overall prevalence of
maternal GBS in our population is higher than in the original
Table 3 Dynamics of colonisation by site and time point.
Birth n Z 750; 253 colonised mothers (% total)
Mother and infant colonised 146 (19.5% total; 57.7% born to colonised mothers)
Infants colonised, mothers not colonised 40 (5.3)
Total colonised infants 186 (24.8)
Mothers colonised, infants not colonised 107 (14.3)
Neither mother nor infant colonised 457 (60.9)
Site of colonisation at birth (% colonised infants)
Nasopharyngeal and rectal 96 (51.6)
Rectal only 68. (36.6)
Nasopharyngeal only 22 (11.8)
Site of colonisation day 6e9; n Z 722 (% of the 181 colonised infants)
Infant rectal colonisation only 95 (52.5)
Infant nasopharyngeal colonisation only 29 (16.0)
Infant nasopharyngeal and rectal 57 (31.5)
Site of colonisation day 60e89; n Z 684 (% the 94 colonised infants)
Infant rectal colonisation only 57 (60.6)
Infant nasopharyngeal colonisation only 26 (27.7)
Infant nasopharyngeal and rectal 11 (11.7)
Figure 1 a e infant GBS colonisation status over time. Bars
represent percentage of infants colonised at each of the time
p o i n t s ; b l a c k b a r Z b i r t h , g r e y Z d a y 6 a n d
patterned Z three months. b e breastmilk colonisation over
time. Bars represent percentage of infants colonised at each
of the time points; black bar Z birth, grey Z day 6 and
patterned Z three months.
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study by Suara et al. (1992) (Suara 22% colonised (95% CI
15.04e28.96) vs. present study 33.7% colonised
(29.63e36.37); p Z 0.007).11 However, the previous study
likely under-identified GBS colonisation as selective me-
dium was not used. An additional feature that may account
for a lower colonisation rate was the collection of vaginal
but not rectal swabs, which are known to have a higher
yield for GBS.12 The prevalence of GBS colonisation in our
study is similar to the reported pooled prevalence in South
African women (30.4%).3
Our finding that mothers with more than one stillbirth
demonstrated an increased odds of having a colonised
infant are in concordance with Monari et al., who identified
stillbirth as a risk factor for invasive EOGBS disease.13 This
phenomenon has also been noted in non-human primates,14
but there are currently little human data on the association
between stillbirth, GBS colonisation and invasive disease.
Table 4 Characteristics of mother infant pairs according
to colonisation status at birth.
Total MþIþ MþI" M"Iþ M"I" p-value
Maternal
age
0.96
<20 110 23 17 2 68
20e24 262 43 38 19 162
25e29 203 46 25 11 121
30þ 175 34 27 8 106
Ethnicity 0.10
Mandinka 315 63 52 23 177
Wolof 108 23 13 8 64
Fula 126 28 17 2 79
Jola 118 21 12 3 82
Other 81 11 12 4 54
Missing 2 0 1 0 1
Maternal
weight (kg)
0.04*
<50 27 2 5 4 16
50e70 424 74 54 21 275
70e90 148 36 25 3 84
90þ 145 32 23 9 81
Missing 6 3 0 3 0
Mother ill 0.48
Yes 128 24 21 3 80
No 504 97 68 25 314
Missing 118 25 18 12 63
Maternal Hb
<10 g/dL
0.11
No 99 24 18 2 55
Yes 651 122 89 33 403
Maternal
antibiotics
in
pregnancy
No 505 99 92 0 314 0.91
Yes 128 23 24 0 81
Gravida 0.44
1 208 39 28 13 128
2e4 370 67 54 17 232
5þ 169 39 25 10 95
Missing 3 1 0 0 2
Parity 0.94
0e1 212 39 29 13 131
2e4 468 96 68 24 280
5þ 67 10 10 3 44
Missing 3 1 0 0 2
Living
children
0.66
0 230 43 37 14 136
1e4 465 94 61 25 285
5þ 53 7 9 1 36
Missing 2 2 0 0 0
Spontaneous
abortion
0.09
0 649 121 92 31 405
1 53 14 6 4 29
2þ 14 7 1 0 6
Missing 34 11 0 5 18
Table 4 (continued )
Total MþIþ MþI" M"Iþ M"I" p-value
Stillbirths 0.03*
0 641 119 87 32 403
1 75 20 9 6 40
2þ 28 5 10 2 11
Missing 6 2 1 0 3
Number of
ANC visits
0.002*
1 303 58 27 15 203
2þ 447 88 80 25 254
Midwife
delivery
436 108 60 20 248 <0.001*
TBA 254 29 38 12 175
Missing 60 9 9 8 34
Infant sex 0.71
Male 369 72 50 23 224
Female 381 74 57 17 233
Season <0.001*
Dry cool 280 22 33 17 208
Dry hot 175 66 19 3 87
Wet 295 58 55 20 162
Birth
weight (kg)
0.02*
2.5e3 260 44 29 20 167
3.1e4 464 95 74 18 277
>4.0 26 7 4 2 13
Gestation
(weeks)
0.04*
<34 56 13 5 4 34
34e37 231 57 26 12 136
38þ 463 76 76 24 287
Breastmilk
colonised
<0.001*
Yes 64 31 18 7 8
No 600 101 77 31 391
Missing 86 14 12 2 58
MþIþ Z mother and infant colonised; MþI" Z mother colon-
ised, infant not colonised; M"Iþ Z mother not colonised, in-
fant colonised, M"I" Z neither mother nor infant colonised;
TBA Z trained birth attendant; ANC Z antenatal clinic.
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This finding could be important in reducing adverse preg-
nancy outcomes especially following introduction of any
new vaccine.
The prevalence of infant colonisation in our study is
similar to previous studies in Europe15e18 but higher than
those from other most African countries,19 probably due
to the differences in microbiological methods. To our
knowledge this is the first longitudinal study of infant colo-
nisation and demonstrates that GBS colonisation rates
remain high up to three months of life. We demonstrate
that the overwhelming risk factor for infant colonisation
at all time points was having a mother who was GBS colon-
ised at the time of birth. We also established that delivery
before 34 weeks of gestation increased the odds of GBS
colonisation at birth. Similar studies have indicated that
risk factors for infant colonisation include maternal recto-
vaginal colonisation, preterm delivery, low birth weight
and maternal urinary tract infection.1,15,18,20 However, un-
like these studies we did not identify low birth weight as a
risk factor, probably because we only recruited infants
weighing more than 2.5 kg.
Several case reports suggest that isolation of GBS in
breastmilk is implicated in late onset GBS disease.21,22 Our
data suggest that GBS colonisation in breastmilk is a risk
factor for neonatal colonisation, both at delivery and for
persistence of infant colonisation throughout the first three
months of life. This is an important finding in a population
such as this with high rates of breast-feeding. The mecha-
nism for this is not clear; it is possible that GBS enters
the mammary glands following suckling from a colonised in-
fant, although there is also evidence that normal gut micro-
biota may pass into the breast via the entero-mammary
circulation.23 Whether it is also a risk factor for late onset
disease in this population is not known. Conversely, it might
conceivably be a protective factor through induction of im-
munity.24 The relevance of this finding requires further
study.
It is interesting to note that risk factors for maternal
colonisation include midwife delivery and increasing number
of antenatal visits. This phenomenon has not been previ-
ously noted in resource-poor settings where hygienic birth
practices may be compromised. GBS has been implicated in
nosocomial outbreaks in several hospitals globally,25,26
although the number of reported outbreaks in resource-
rich countries has greatly reduced since the implementation
of GBS screening programmes. It is conceivable that unclean
birth practices, especially in times of clean water shortage,
such as the dry hot season or during the wet season may
Table 5 Multivariable analysis of maternal/infant pairs by GBS colonisation status at time of delivery.a
MþIþ
OR (95% CI)
MþI"
OR (95% CI)
M"Iþ
OR (95% CI)
Season
Dry cool 1 1 1
Dry hot 8.3 (3.9e17.6) 1.8 (0.8e3.9) 0.4 (0.1e1.4)
Wet 3.5 (1.8e6.8) 2.3 (1.3e4.3) 1.1 (0.5e2.5)
Breastmilk colonised
Yes 21.0 (8.6e51.3) 11.5 (4.5e29.4) 7.5 (2.0e27.5)
No 1 1 1
Gestation (weeks)
<34 1 1 1
34e37 0.9 (0.9e1.0) 1.0 (0.9e1.1) 0.9 (0.8e1.0)
38þ 0.4 (0.2e1.0) 0.5 (0.3e1.6) 0.9 (0.8e1.0)
Midwife delivery 1 1 1
TBA 0.9 (0.5e1.6) 1.0 (0.6e1.8) 0.6 (0.2e1.3)
Number of antenatal clinic visits
1 1 1 1
2þ 1.1 (0.7e1.9) 1.2 (0.8e2.1) 1.3 (0.6e2.8)
Stillbirths
0 1 1 1
1 2.5 (1.0e8.7) 2.0 (1.0e4.7) 1.4 (0.3e5.9)
2þ 2.4 (0.9e4.1) 2.2 (0.9e2.1) ND
Spontaneous abortion
0 1 1 1
1 0.9 (0.5e1.4) 0.8 (0.3e2.1) 1.0 (0.2e5.5)
2þ 1.2 (1.1e2.3) 0.3 (0.0e2.2) 2.0 ND
Gravida
1 1 1 1
2e4 1.0 (0.9e1.0) 1.1 (0.6e2.0) 1.0 (0.8e1.2)
5þ 1.0 (0.5e2.0) 0.8 (0.4e1.8) 0.8 (0.3e2.3)
MþIþZ mother and infant colonised; MþI"Z mother colonised, infant not colonised; M"IþZ mother not colonised, infant colonised,
M"I" Z neither mother nor infant colonised. 1 Z adjusted odds ratios are compared to this group; TBA Z trained birth attendant.
a M"I" Z base group.
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facilitate the fecal-oral spread of GBS between colonised
and non-colonised mothers and their infants.
A large proportion of women were colonised with ST V,
similar to the previous smaller study by Suara et al., which
identified 32 colonised pregnant women of whom 12 (30%)
were colonised with ST V.11 ST V has been identified as an
important neonatal and adult colonising and disease
causing serotype globally.3,27,28 Additionally, in our cohort,
ST V was the predominant serotype cultured in breastmilk
and ST Ib and V were associated with longer median coloni-
sation duration compared to other serotypes. A study of
pregnant women from South Africa found a high prevalence
of GBS colonisation throughout pregnancy, with ST V and ST
III colonisation lasting longer than other serotypes (ST V
mean duration 8.6 weeks; 95% CI 6.8e10.4 vs. ST III 9.2
weeks; 95% CI 8.1e10.2).3 The difference in serotype distri-
bution and duration of colonisation between these studies
may be due to population differences between South Africa
and the Gambia. There are no other longitudinal infant
colonisation studies with which to compare our results.
Our results may also indicate differences in maternally
derived antibody that might prevent colonisation of certain
serotypes in these diverse populations. In the most recent
study from South Africa, the authors demonstrate that it
is the acquisition of a new serotype that is associated
with EOS rather than the persistent serotype, probably
due to the absence of maternal antibody to this new
serotype.29
Our study has several limitations. First, our results are
limited by the sensitivity of detection of GBS on selective
media, estimated at 85%30 and by the fact that we identi-
fied the serotype by conventional PCR. This may imply that
we have underestimated low levels of colonisation in in-
fants where DNA was below the limit of detection. Second,
we identified only one culture-confirmed case of GBS inva-
sive disease. The low number of positive invasive isolates
Table 6 Single variable analysis of infant GBS colonisation dynamics over time compared to birth.
Birth
OR (95% CI)
Day 6 Day 60e89
OR (95% CI) OR (95% CI)
Mother GBS colonised at delivery
Birth season Dry cool 1 0.2 (0.1e0.6) 0.1 (0.0e0.4)
Dry hot 4.6 (2.2e9.7) 1.9 (1.0e4.1) 0.6 (0.2e1.3)
Wet 1.4 (0.7e2.8) 0.7 (0.3e1.5) 0.3 (0.1e0.7)
Living children 0 1 0.5 (0.3e0.9) 0.2 (0.1e0.4)
1e4 0.9 (0.5e1.6) 0.4 (0.2e0.7) 0.1 (0.0e0.3)
5þ 0.9 (0.3e2.6) 0.6 (0.2e1.8) 0.2 (0.0e0.9)
Gestation at birth (wks.) <34 1 0.4 (0.1e1.4) ND
34e37 0.9 (0.3e2.4) 0.3 (0.1e0.9) 0.2 (0.1e0.7)
38þ 0.4 (0.1e1.0) 0.2 (0.1e0.5) 0.0 (0.0e0.1)
Infant weight (kg) 2.5e3 1 0.5 (0.2e1.0) 0.1 (0.0e0.3)
3.1e4.0 1.2 (0.4e3.8) 0.7 (0.3e0.9) 0.1 (0.1e0.3)
>4.0 0.6 (0.1e2.3) 0.3 (0.1e0.7) 0.1 (0.0e0.6)
BM colonised Yes 0.9 (0.5e1.7) 0.4 (0.2e0.8) 0.3 (0.1e0.7)
No 1 0.4 (0.3e0.6) 0.1 (0.1e0.2)
Infant sex Male 1 0.4 (0.3e0.7) 0.1 (0.1e0.3)
Female 0.7 (0.4e1.2) 0.4 (0.2e0.6) 0.1 (0.1e0.3)
Mother not GBS colonised at delivery
Birth season Dry cool 1 1.4 (0.5e4.3) 0.8 (0.2e2.8)
Dry hot 1 1.3 (0.3e5.3) 4.7 (1.7e13.5)
Wet 2.1 (0.8e6.0) 4.1 (1.6e10.5) 0.2 (0.0e1.9)
Living children 0 1 1.8 (0.5e5.7) 1.7 (0.5e5.6)
1e4 1.0 (0.3e2.9) 2.2 (0.8e5.9) 0.7 (0.2e2.3)
5þ 2.0 (0.1e7.1) 1 0.8 (0.1e7.3)
Gestation at birth (wks.) <34 1 3.3 (0.3e34.4) 1
34e37 1.6 (0.2e13.4) 2.5 (0.3e20.6) 1.4 (0.2e13.0)
38þ 1.1 (0.1e9.0) 2.2 (0.3e17.3) 1.3 (0.2e10.8)
Infant weight (kg) 2.5e3.0 1 1.2 (0.4e3.8) 0.6 (0.1e2.3)
3.1e4.0 0.5 (0.2e1.4) 1.2 (0.5e2.9) 0.6 (0.2e1.7)
>4.0 0.9 (0.2e2.3) 1.7 (0.9e4.9) 0.4 (0.3e2.2)
BM colonised Yes 14.2 (4.0e50.8) 6.9 (2.5e19.1) 3.3 (1.2e11.0)
No 1 2.0 (0.9e4.2) 1.0 (0.4e2.5)
Infant sex Male 1 1.4 (0.6e3.1) 0.8 (0.3e2.0)
Female 0.3 (0.1e1.0) 1.1 (0.5e2.5) 0.5 (0.2e1.5)
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may represent an underestimation of the burden of GBS
disease in this population. Several infants died prior to
recruitment or after recruitment but of early onset pneu-
monia without a culture-positive diagnosis and it is
conceivable that they may have succumbed to early onset
GBS disease. There are no other data from the Gambia
regarding the burden of GBS disease. Although we recog-
nize the limitations of its approach, the only other evi-
dence for GBS disease in the Gambia is shown by a
retrospective review of positive cultures from the MRC
hospital over 8 years that identified 17 positive cultures
from infants under 90 days of age which is consistent
with our disease estimate of 1.3/1000 live births.31 Finally,
sampling at 4 h post-birth may indicate contamination
with maternal secretions rather than established colonisa-
tion at birth. However, the fact that few infants lost colo-
nisation at day 6 indicates that colonisation was persistent
over the first week of life.
GBS capsular polysaccharide-protein conjugate vaccines
are being developed, making the findings of our study
important to ensure that appropriate serotypes are
included in candidates that would be relevant to all African
populations. Information about GBS colonisation and fac-
tors affecting acquisition and duration of colonisation will
Maternal colonisation by serotype
Total=237
8.44%  Ia
6.75%  Ib
16.46%  II
10.13%  III
54.85%  V
3.38%  other
Infant colonisation by serotype V2
Total=107
6.54%  Ia
7.48%  Ib
17.76%  II
8.41%  III
58.88%  V
0.93%  other
BM colonisation by serotype V1
Total=60
1.67%  Ia
10.00%  Ib
3.33%  II
15.00%  III
63.33%  V
6.67%  other
BM colonisation by serotype V3
Total=79
3.80%  Ia
5.06%  II
5.06%  III
86.08%  V
Infant colonisation by serotype V1
Total=158
7.59%  Ia
5.06%  Ib
17.09%  II
10.76%  III
56.96%  V
2.53%  other
Infant colonisation by serotype V3
Total=50
20.00%  Ia
10.00%  Ib
24.00%  II
2.00%  III
44.00%  V
BM colonisation by serotype V2
Total=50
4.00%  Ia
6.00%  Ib
10.00%  II
24.00%  III
48.00%  V
8.00%  other
Figure 2 Colonising serotype distribution by isolation site and time point. Maternal rectovaginal colonisation at delivery; breast-
milk and infant colonisation by time point; BMZ breastmilk; IaZ serotype Ia, IbZ serotype Ib, IIZ serotype II, IIIZ serotype III,
V Z serotype V.
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be helpful in considering strategies for reducing the burden
of infant GBS disease worldwide.
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CONCISE COMMUNICATION
Placental transfer of anti-group B Streptococcus
immunoglobulin G antibody subclasses from
HIV-infected and uninfected women
to their uninfected infants
Kirsty Le Doarea,b,c, Stephen Taylord, Lauren Allend,
Andrew Gorringed, Paul T. Heathb, Beate Kampmanna,c,
Anneke C. Hesselinge and Christine E. Jonesa,b,f
Objectives: Placental antibody transfer is impaired in the context of HIV infection,
which may render HIV-exposed, uninfected infants vulnerable to group B Streptococ-
cus (GBS) disease. The GBS antibody response predominately consists of immunoglo-
bulin G2 (IgG2) antibody. Thus we determined whether concentration and placental
transfer of anti-GBS antibody subclasses was altered in HIV-infected compared with
HIV-uninfected mothers.
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected
and 33 HIV-uninfected mothers and their uninfected infants.
Methods: Sera were analysed using a novel flow cytometric assay that quantified
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST)Ia, STIII and STV GBS bacteria.
Results: IgG2 binding to GBS STIa and V was lower in HIV-infected women compared
with HIV-uninfected women. Moreover, IgG2 binding to GBS STIa was also lower in
HIV-exposed, uninfected infants compared with unexposed infants. However, there
were no statistically significant differences in the transplacental transfer ratio of IgG2 for
anyGBS serotype. The transplacental transfer of total IgGwas reduced for GBS STIII and
V and IgG1 subclass for STIII; placental transfer of all other subclasses was comparable
in HIV-affected and HIV-unaffected pregnancies.
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is
important for functional antibody against the capsular polysaccharide of GBS and
provides confidence that maternal GBS vaccination may result in functional activity in
HIV-infected and uninfected women.
Copyright ! 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Opsonophagocytosis of group B Streptococcus (GBS) is
mediated predominately by the immunoglobulin G2
(IgG2) subclass [1], which is poorly transported across the
placenta compared with IgG1 [2,3]. This may reflect the
lower affinity of IgG2 for the FcRn receptors on
syncytiotrophoblasts of placental cells as compared with
the other subclasses of IgG [4,5]. Studies comparing
maternal and infant antibody concentrations demonstrate
that anti-GBS capsular antibody is transferred across the
placenta with a high degree of efficiency [6]. However,
the proportionally higher concentration of antibody in
infant compared with maternal serum at birth is thought
to be mainly due to excess foetal IgG1 [2]. It has been
demonstrated for GBS serotype (ST) Ia and STIII that not
only is total anti-GBS antibody concentration lower in
GBS-infected infants than in infants without infection
born to colonized mothers [7,8], but that IgG2 is also
lower in infants with GBS infection [9]. Recent studies
have shown that maternal and placental transfer of total
anti-GBS antibody is reduced in the context of maternal
HIV-infection [10,11]. This might explain the greater
reported incidence of early, and especially late onset, GBS
disease observed amongst HIV-exposed, uninfected
infants compared with unexposed infants [12]. A West
African study identified hypergammaglobulinaemia as a
risk factor for reduced placental transfer of IgG subclasses
and this might be a further contributing factor to the
observed excess of GBS morbidity amongst HIV-exposed
infants [13]. Thus, we compared total and subclass anti-
GBS antibody placental transfer in HIV-infected and
HIV-uninfected South African women.
Methods
Samples were collected frommothers and infants enrolled
in a cohort study investigating the influence of maternal
HIV and mycobacterial sensitization on infant immune
responses to Bacillus Calmette-Gue´rin (BCG) vaccina-
tion carried out between 2009 and 2011 [14]. The
demographic details, CD4þ cell count, viral load and
antiretroviral medication have been previously described
[14]. Informed consent was obtained from all mothers
participating in the study. The study was approved by the
Universities of Cape Town (382/2008) and Stellenbosch
(N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/
H0720/178).
Paired sera from 38 HIV-infected and 33 HIV-uninfected
mothers and their uninfected infants were available to
analyse immunoglobulin subclasses. Deposition of total
IgG and IgG1, IgG2, IgG3 and IgG4 anti-GBS antibody
subclasses onto the surface of formaldehyde-fixed GBS
bacteria was measured using a flow cytometric assay
performed in 96-well microtitre plates as previously
described [10]. Mouse monoclonal antibodies: 4E3
antihuman IgG1 H&L, HP6014 antihuman IgG2 fd
gamma, HP6050 antihuman IgG3 hinge heavy chain and
mouse HP6025 antihuman IgG4 Fc (FITC) (Life
Technologies, Carlsbad, California, USA) (1 : 500) in
blocking buffer were added and samples incubated for 20
min at 48C. Assays were analysed using a Beckman
Coulter Cyan flow cytometer equipped with a Cytek 96-
well microtitre plate loader. A fluorescence index (FI) was
calculated for each sample, which involved the multipli-
cation of the percentage of bacteria in the horizontal gate
(%-gated), by the mean fluorescence of that population
(X-mean). The final result for each test was expressed as
the average FI of duplicate test samples minus the average
FI of the bacteria and conjugate-only control. A standard
unit (SU) measurement for each serum sample was then
calculated by comparing to the serum FI response
obtained with the positive control serum for each
serotype which was given an arbitrary value of 1000
(kind gift from Professor Carol Baker, Baylor College of
Medicine, Texas, USA) to give a result in SU/ml.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, College Station, Texas, USA) and
GraphPad Prism version 6.0 (GraphPad Software Inc., La
Jolla, California, USA). The sample size was calculated to
demonstrate a 50% difference in IgG subclass concen-
trations between HIV-exposed and HIV-unexposed
infants with the predefined assumption that antibody
subclass concentrations would be lower in HIV-exposed
infants. Using an a error of 5%, 80% test power and a 95%
confidence interval, the sample size ranged from 10 to 30
in each group. Placental transfer was defined as the ratio of
infant-to-mother GBS IgG concentration at birth.
Missing data were excluded from analysis. We considered
P values less than 0.05 as statistically significant.
Results
The paired sera from 71 mother–infant dyads (38 HIV-
infected mothers and their uninfected infants and 33
HIV-uninfected mothers and their infants) at birth were
available for analysis of total IgG, IgG1 and IgG2 for all
serotypes. For serotypes ST1a and STV, sufficient sera was
available from 60 mother–infant pairs to analyse
subclasses IgG3 and IgG4. Sufficient sera were available
from 40 mother–infant pairs for analysis of IgG3 and
IgG4 for STIII.
Antibody subclass concentrations
Concentrations of anti-GBS IgG1 in mothers and infants
were higher than concentrations of IgG2 for all GBS
serotypes, independent of HIV status (Fig. 1).
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For STIa, HIV-uninfected women had significantly
higher geometric mean concentration (GMC) of subclass
IgG2 and IgG4 than HIV-infected women (IgG2 2.3
[95% confidence interval (CI) 1.6–3.3] vs. 5.9 [4.0–8.9]
SU/ml, P¼ 0.02; IgG4 1.8 [0.9–3.6] vs. 18.6 [6.0–57.8]
SU/ml, P¼ 0.03) but comparable concentrations of IgG1
and IgG3 (Fig. 1). In HIV-unexposed compared with
HIV-exposed, uninfected infants, there was a significantly
higher concentration of IgG2 (P¼ 0.03) and IgG4
(P¼ 0.03). In addition, we noted a trend towards higher
concentrations of anti-STIa IgG1 and lower concen-
tration of IgG3 but this did not reach statistical
significance (Fig. 1).
For STV, HIV-infected women had a trend towards
higher concentrations of IgG1 than HIV-uninfected
women (P¼ 0.049) and HIV-uninfected women had
significantly higher concentrations of IgG2 than HIV-
infected women (P¼ 0.047), although the concentration
of IgG2 was low in both groups. HIV-unexposed infants
had higher concentrations of anti-STV IgG3 antibody
compared with HIV-exposed infants (P¼ 0.039). There
was no statistical difference between HIV-exposed,
uninfected infants and HIV-unexposed infants for any
of the other IgG subclasses (Fig. 1).
There was no significant difference between anti-STIII
IgG subclasses in HIV-infected and HIV-uninfected
women and HIV-exposed, uninfected and HIV-
unexposed infants.
Placental transport of total group B
Streptococcus antibody
Total IgG transplacental antibody transfer ratio (TPR)
was reduced in HIV-infected compared with HIV-
uninfected women for GBS STIII [0.6 (0.3–1.1) vs. 1.3
(0.8–2.3) SU/ml, P¼ 0.04] and STV [1.2 (0.7–1.6) vs.
2.0 (1.1–3.0) SU/ml, P¼ 0.04] but not for STIa. (Table
1). There was no association between CD4þ cell count or
viral load and TPR.
Placental transport of subclasses group B
Streptococcus antibody
TPR of IgG1 was decreased to HIV-exposed infants
compared with HIV-unexposed infants [0.4 (0.1–1.4) vs.
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Fig. 1. Anti-group B Streptococcus subclass distribution in
HIV-infected and HIV-uninfected mothers and their unin-
fected infants at birth. HIV–, HIV uninfected; HIVþ, HIV
infected; IgG, immunoglobulin G; ST, serotype; SU/ml, stan-
dard units per millilitre. Horizontal bars compare groups,
#P<0.05.
Table 1. Geometric mean concentration (GMC) transplacental transfer ratios of total and subclass IgG1, IgG2, IgG3 and IgG4 against GBS STIa,
III and V in HIV-infected and HIV-uninfected mothers to their infants [95% confidence interval (CI)].
STIa STIII STV
HIVþ HIV– P HIVþ HIV– P HIVþ HIV– P
Total 1.1 (0.8–1.6) 1.0 (0.6–1.6) 0.75 0.6 (0.3–1.1) 1.3 (0.8–2.3) 0.04 1.2 (0.7–1.6) 2.0 (1.1–3.0) 0.04
IgG1 1.0 (0.7–1.5) 1.4 (1.0–2.0) 0.44 0.4 (0.1–1.4) 1.3 (0.7–2.5) 0.04 1.0 (0.7–1.4) 1.4 (0.9–2.1) 0.14
IgG2 0.9 (0.5–1.5) 0.7 (0.5–1.2) 0.43 1.1 (0.4–3.2) 0.8 (0.4–1.4) 0.38 0.7 (0.5–1.1) 0.8 (0.6–1.1) 0.59
IgG3 0.3 (0–9) 1.0 (0.3–3.3) 0.5 0.9 (0.6–1.4) 1.3 (0.8–2.1) 0.23
IgG4 0.5 (0.2–1.1) 1.6 (0–4) 0.08 1.2 (0.5–2.9) 0.6 (0.3–1.4) 0.31
GBS, group B Streptococcus; HIV–, HIV-uninfected; HIVþ, HIV infected; IgG, immunoglobulin G; ST, serotype.
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1.3 (0.7–2.5) SU/ml; P¼ 0.04] for STIII but not for STIa
or STV (Table 1). The TPR for IgG2 was unaffected by
maternal HIV infection status for any serotype. There
were no statistical differences between antibody TPR for
any other subclass or any other serotype of GBS between
groups.
Discussion
Our findings demonstrate that whilst total transplacental
transfer ratios are reduced in HIV-infected mothers for
GBS STIII and V, the proportion of individual subclasses
transferred from mother to infant is unaffected by
maternal HIV infection, with the exception of IgG1 to
GBS STIII. Importantly, there was no difference in the
placental transfer of IgG2 that bounds to any of the
GBS serotypes.
HIV-exposed, uninfected infants may be at increased risk
of GBS infection, in particular late onset disease [10,12]
The observation that there is no difference in the
proportion of IgG subclass placental transfer (except for
IgG1 for STIII) may mean that HIV-exposed, uninfected
infants are at increased risk of disease as a result of their
mother’s reduced total antibodies that bind to GBS
bacteria, rather than a selective deficit in IgG2 transfer. It
may alternatively be due to impaired B cell function in the
context of HIV infection that results from poor function
of T helper cellular response and function of antibody in
the context of HIV-infection [15].
The fact that IgG2 surface deposition was lower in HIV-
exposed infants to STIa and in women to STV in HIV-
infected women may indicate reduced antibody function
due toHIV-infection. In this studywewere unable to assess
the opsonophagocytic ability of the antibodywhich would
provide additional information on the functional ability of
antibody to protect from GBS infection. In studies of
pneumococcal vaccination, opsonophagocytosis was
impaired in HIV-infected compared with HIV-uninfected
individuals and the same may be true of GBS [16].
The serotypes we have selected in this study represent
77% of colonizing strains in South African pregnant
women (STIII, 33%; STIa, 39%; STV, 12% [17]). They
also represent 86.1% of early onset GBS disease and 100%
of late onset disease (STIII 57.7% of early onset, 84.4% of
late onset disease; STIa 22.6%/ 13.9%; STV 5.8%/1.9%
[18]). Thus, the serotype-specific antibody observed
corresponds to the predominant colonizing and disease-
causing serotypes in South Africa.
Although patients with HIV disease develop high levels of
total IgG in serum soon after infection [19], the IgG1
subclass is preferentially increased, whereas levels of total
IgG2may be normal or decreased [20].We confirmed the
relatively similar concentration of IgG2 antibody that
binds to GBS STIII in the sera of HIV-infected and HIV-
uninfected women. IgG2 responses to the bacterial
capsular polysaccharide in humans may be driven in part
by IFN-y production [21], whichmay be impaired during
HIV-infection [22]. However, HIV-infected patients in
our cohort showed no selective deficit in IgG2
production. The differences in subclass distribution by
GBS serotype may be as a result of different reactivity of
the different serotypes in our assay. However, comparison
with the larger study demonstrated good correlation
between total antibody concentrations for all serotypes
tested [10].
Maternal HIV infection has been associated with reduced
placental transfer of antibodies against several common
viral and bacterial antigens [23,24]. Additionally, the
finding that HIV-exposed, uninfected infants are more
likely to have sub-protective antibody levels to vaccine
preventable diseases means that these infants are likely to
be more prone to these diseases in early childhood. Our
finding that the placental transfer of IgG2 subclass,
important for the opsonization and killing of GBS, was
not impaired indicates potential for a maternal vaccine to
boost both maternal and infant immunity in areas of high
HIV-prevalence.
Our sample size was limited and we are not able to draw
conclusions on other possible effects of HIV-infection on
placental transfer. Additionally, we cannot comment on
the colonizing serotypes of the mothers. However, the
fact that the antibody against the major GBS serotypes was
detected in all women suggests prior colonization with
GBS. Finally, we cannot comment on protective levels of
antibody in this population, as there were no cases of GBS
disease in our cohort.
In summary, the decreased concentration of serum IgG that
bounds to the surface of GBS in HIV-infected women and
their infants comparedwith non-HIV-infected dyads is not
due to a selective defect in the generation of GBS-specific
IgG2 antibody. Future efforts should address enhancing
protective antibody concentrations through maternal
vaccination against GBS during pregnancy to optimize
IgG2 concentration in the neonate.
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Background:  HIV-exposed  uninfected  infants  have  increased  infection  risk  and  mortality  compared  to
HIV-unexposed  infants.  HIV-exposed  infants  may  be at  increased  risk  of  invasive  GBS  disease  due to
reduced  maternal  antibody  against  GBS.
Methods: We  quantified  antibodies  that  bind  to  the  surface  of  whole  Group  B  Streptococcus  (GBS) of
serotypes  Ia,  Ib,  II, III and  V  using  novel  flow  cytometry  assays  in  South  African  HIV-infected  and  non-
infected  mothers  and  their  uninfected  infants.  Antibody-mediated  complement  C3b/iC3b  deposition  onto
GBS of  these  serotypes  was  also  quantified  by  a novel  flow  cytometry  assay.
Results: Geometric  mean  concentration  (GMC)  of  both  surface-binding  anti-GBS  antibody  and  antibody-
mediated  complement  deposition  onto  GBS  were reduced  in  HIV-infected  women  (n  =  46)  compared  to
HIV-uninfected  women  (n  =  58)  for ST1a  (surface-binding:  19.3  vs 29.3;  p  =  0.003;  complement  depo-
sition:  2.9  vs  5.3  SU/mL;  p  =  0.003),  STIb  (24.9  vs  47.6;  p =  0.003;  2.6  vs 4.9  SU/mL;  p =  0.003),  STII (19.8
vs  50.0;  p = 0.001;  3.1  vs  6.2 SU/mL;  p =  0.001),  STIII  (27.8  vs  60.1;  p  = 0.001;  2.8  vs  5.3  SU/mL;  p =  0.001)
and  STV (121.9  vs  185.6 SU/mL;  p  <  0.001)  and  in  their  infants  for  STIa  (complement  deposition  9.4 vs
27.0  SU/mL;  p = 0.02),  STIb  (13.4  vs  24.5  SU/mL;  p  =  0.02),  STII  (14.6  vs  42.7  SU/mL;  p  = 0.03),  STIII  (26.6 vs
62.7  SU/mL;  p = 0.03) and  STV  (90.4  vs  165.8  SU/mL;  p = 0.04).  Median  transplacental  transfer  of  antibody
from  HIV-infected  women  to their  infants  was reduced  compared  to HIV-uninfected  women  for  GBS
serotypes  II  (0.42  [IQR  0.22–0.59]  vs 1.0  SU/mL  [0.42–1.66];  p < 0.001),  III  (0.54  [0.31–1.03]  vs  0.95  SU/mL
[0.42–3.05],  p  =  0.05)  and V  (0.51  [0.28–0.79]  vs 0.75  SU/mL  [0.26–2.9],  p =  0.04).  The differences  between
infants  remained  significant  at 16  weeks  of age.
Conclusions:  Maternal  HIV  infection  was  associated  with  lower  anti-GBS  surface  binding  antibody  con-
centration  and  antibody-mediated  C3b/iC3b  deposition  onto  GBS  bacteria  of serotypes  Ia, Ib,  II,  III and  V.
This  may  render  these  infants  more  susceptible  to  early  and  late onset  GBS  disease.
Crown  Copyright  © 2014  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The increasing numbers of HIV-exposed infants who remain
uninfected is testament to the success of prevention of mother-to-
child transmission programs in resource-poor settings in the face
! Preliminary data was presented at the European Society of Infectious Diseases
meeting May  2014, Dublin, Ireland.
∗ Corresponding author at: Wellcome Trust/Imperial Centre for Global Health
Research, Department of Paediatrics, Imperial College London, Norfolk Place, London
W2  1PG, UK. Tel.: +44 2075895111; fax: +44 207 5895111.
E-mail address: k.mehring-le-doare@imperial.ac.uk (K. Le Doare).
of a high disease burden [1]. Nevertheless, this group of infants
appears to suffer from increased rates of lower respiratory tract
infection and meningitis compared to HIV-unexposed infants and
up to 4-fold higher mortality in the first year of life [2–4]. Strepto-
coccus agalactiae (group B streptococcus, GBS) is a leading cause of
neonatal pneumonia, sepsis and meningitis in many countries and
five serotypes (Ia, Ib, II, III and V) account for the majority of disease
[5]. Published data show that not only is GBS carriage increased
in HIV-infected pregnant women  compared with HIV-uninfected
mothers [6], but that HIV-exposed, uninfected infants also appear
to have an increased risk of late-onset GBS disease compared to
HIV-unexposed infants [7].
http://dx.doi.org/10.1016/j.vaccine.2014.12.025
0264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Prevention of GBS infection in infants and adults through immu-
nization is a theoretically attainable goal. Maternal transfer of
antibodies is thought to prevent newborn GBS disease [8] and
GBS vaccines offer the potential to prevent disease in low-income
settings where prenatal screening and intrapartum antibiotics are
generally not feasible. A number of studies have demonstrated
an association between the risk of developing invasive GBS dis-
ease in the newborn and maternal anti-capsular antibody levels
[9–12] with opsonophagocytosis the likely effector mechanism
[13–15]. However, maternal HIV status can influence the effi-
ciency of transplacental antibody transfer, resulting in reduced
maternally-derived specific antibody concentration in the infant,
even where the infant is subsequently HIV uninfected [16–19].
Data regarding the persistence of anti-GBS antibodies in popula-
tions with high HIV-prevalence and their function in vitro would
provide insight into their protective potential in different popula-
tions. Thus our objective was to determine the association between
maternal HIV infection status and total IgG binding to the surface of
GBS bacteria of serotypes Ia, Ib, II, II and V and antibody-mediated
deposition of C3b/iC3b onto the surface of these GBS strains as a
potential surrogate for opsonophagocytosis in sera obtained from
mothers and infants.
2. Methods
2.1. Study setting, eligibility and study measures
Samples were collected from mothers and infants enrolled in
a cohort study investigating the influence of maternal HIV and
mycobacterial sensitization on infant immune responses to BCG
vaccination carried out between 2009 and 2011 [20]. In brief, 109
pregnant women presenting to a Community Health Center in
Khayelitsha, Western Cape Province, South Africa who  delivered
a healthy infant over 37 weeks gestation, weighing over 2.5 kg,
knew the result of their HIV test and were willing to provide
written informed consent for themselves and their infants were
recruited to the original study. The subset represented all moth-
ers/infants with available samples. A venous blood sample was
collected from the mother and infant within 24 h of delivery.
All infants had a further venous blood sample collected at 16
weeks. HIV-exposed infants had an HIV polymerase chain reaction
(Amplicor HIV-a DNA kit, version 1.5; Roche Molecular Systems
Inc., Branchburg, NJ) performed at ages 4 and 16 weeks. The study
was approved by the Universities of Cape Town (382/2008) and
Stellenbosch (N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/H0720/178).
In 2009, the HIV prevalence among women attending antenatal
clinics in the area was 31% [21]. During the study period, the Pre-
vention of Mother to Child Transmission program consisted of dual
therapy for mothers and infants, starting with the administration
of zidovudine at 28 or more weeks’ gestation, then zidovudine for 1
month to the infant and a single dose of nevirapine to both mother
and infant. Mothers were eligible for highly active antiretroviral
treatment if their CD4 count was less than 200 cells/!L. Exclu-
sive infant feeding options were encouraged and mothers were
provided with free formula for 6 months if they chose exclusive
formula feeding.
2.2. Laboratory assays
The reproducibility of the assays was assessed between three
different days and between three different operators with a panel
of 18 sera. The assays had a coefficient of variation of less than
30%. Controls used were rabbit polyclonal sera (SSI) raised against
serotypes Ia, Ib, II, III & V, and normal human donor sera.
2.2.1. GBS isolates and growth conditions
Group B Streptococcus isolates used in this study were
H092040676 (Serotype Ia), H090820125 (Serotype Ib),
H090320548 (Serotype II), H092120162 (Serotype III) and
H091780506 (Serotype V), which were kindly provided by
Professor Androulla Efstratiou, Public Health England, Colindale.
Strains are subsequently referred to by their serotype.
GBS isolates used in the antibody surface binding and comple-
ment deposition assays were grown in Todd Hewitt broth at 37 ◦C
with shaking (200 rpm). Once OD600nm 1.0 was reached, cultures
were centrifuged at 3060 × g for 5 min  to pellet the bacteria. The
pellet was  re-suspended in the same volume of phosphate buffered
saline (PBS, pH 7.4, Severn Biotech, UK) containing 2% formalde-
hyde and incubated at room temperature for 1 h. Bacteria were
then washed in PBS by three rounds of centrifugation at 3060 × g
for 5 min  and resuspended. The final cell pellet was resuspended in
1 mL  PBS, which was stored at 4 ◦C before use.
2.2.2. Sample preparation for antibody surface binding assay
Deposition of anti-GBS antibody onto the surface of whole
GBS bacteria was  measured on formaldehyde-fixed GBS using a
flow cytometric assay performed in 96-well microtitration plates.
Briefly, 2 !L of each test serum was  added to 198 !L of serotype Ia,
Ib, II, III or V GBS bacteria at 5.14 × 107 CFU/mL in blocking buffer
(1% BSA in PBS). This was incubated at 25 ◦C for 30 min with shaking
(900 rpm), then pelleted. Supernatant was removed and the pel-
let washed twice with 200 !L of blocking buffer. Alexa Fluor® 488
Goat Anti-Human IgG (H&L) (Life Technologies) (1:500) in blocking
buffer was added and samples incubated for 20 min  at 4 ◦C, before
being washed twice more with blocking buffer.
2.2.3. Sample preparation for antibody-mediated complement
C3b/iC3b deposition assay
Antibody-mediated C3b/iC3b deposition on the surface of whole
GBS bacteria was measured on the surface of formaldehyde-fixed
GBS using a flow cytometric assay performed in 96-well microtitra-
tion plates. Briefly, 35 !L serotype Ia, Ib, II, III and V GBS bacteria at
5.14 × 107 CFU/mL in blocking buffer (1% BSA in PBS) were added
to 10 !L IgG-depleted human complement [22] and 5 !L of each
test serum. Plates were incubated for 7.5 min  at 37 ◦C with shak-
ing (900 rpm) then pelleted. Supernatant was removed and the
pellet washed once with 200 !L blocking buffer. Samples were
resuspended in 200 !L blocking buffer containing 1:500 sheep anti-
human C3c FITC (Abcam) and incubated as for the surface binding
assay.
2.2.4. Sample acquisition
Assays were analyzed using a Beckman Coulter Cyan flow
cytometer equipped with a Cytek 96-well microtitre plate reader.
Protocols were initially set-up to analyze profiles of bacterial events
using bacteria-only control samples and the bacteria identified on
the cytometer by the forward scatter (FS), measuring the size of the
cell, and side scatter (SS), the granularity and internal structural
complexity. An analysis ‘gate’ was  drawn around the population
of interest (single and diplococci) and a relevant histogram plot
created to analyze the fluorescence of the bacterial population.
For each sample, 10,000 individual events were analyzed for flu-
orescence and a horizontal gate was  drawn to include 10% of the
‘no antibody’ control population. A fluorescence index (FI) was
calculated for each sample, which involved the multiplication of
the percentage of bacteria in the horizontal gate (%-gated), by the
mean fluorescence of that population (X-mean). The final result
for each test was expressed as the average FI of duplicate test
samples minus the average FI of the bacteria and conjugate-only
control. A standard unit (SU) measurement for each serum sam-
ple was then calculated by comparing to the serum FI response
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obtained with the positive control serum for each serotype which
was given an arbitrary value of 1000 (kind gift from Professor
Carol Baker, Baylor College of Medicine, Texas) to give a result in
SU/mL.
2.3. Data management and statistical analysis
Sample size was determined for the cohort study; this sub-study
had 80% power (p = 0.05) to investigate differences between anti-
body concentrations in HIV-exposed and HIV-unexposed infants
of at least 30% with the pre-specified hypothesis that the con-
centrations would be lower in HIV-exposed infants. This assay is
currently being formally compared with ELISA and opsonophago-
cytosis uptake assays in another study.
Statistical analyzes were completed using STATA version 12
(StataCorp 2013, La Jolla, CA) and GraphPad Prism version 6.0
(GraphPad Software Inc., La Jolla, CA). Due to the skewed distribu-
tion of the anti-GBS antibody concentrations, log transformations
were required to conform to regression assumptions. A paired t-test
was used to determine any difference in anti-GBS-antibody con-
centrations to each GBS serotype between birth and at 16 weeks.
Comparison of infant anti-GBS antibody concentrations by mater-
nal HIV status was calculated using the Wilcoxon rank sum test.
Correlation of infant anti-GBS antibody concentration to each GBS
serotype at birth and at 16 weeks was assessed using Spearman
correlation. Multiple linear regression was used to ascertain the
relationship between infant anti-GBS antibody concentration to
each GBS serotype and the covariates of maternal age, infant sex
and maternal HIV. In addition, multiple linear regression was used
to explore the relationship between maternal anti-GBS antibody
concentration to each serotype and the covariates maternal age,
maternal HIV status. Placental transfer was defined as the ratio
of infant-to-mother anti-GBS IgG concentration at birth. Missing
data were excluded from analysis. Decline in antibody concentra-
tion between birth and 16 weeks was calculated using ratio of
means.
3. Results
3.1. Participant characteristics
Samples were analyzed from 104 women (46 (44%) HIV-infected
and 58 (56%) HIV-uninfected women) and from 100 infants born to
this group of women (46 (46%) HIV-exposed and 54 (54%) HIV-
unexposed infants). One mother–infant pair was  excluded from
the final analysis because HIV-infection in the infant was  detected
at 4 weeks of age and the infant was referred for rapid initiation
of antiretroviral treatment. All other infants born to HIV-infected
mothers were HIV-uninfected. All infants were born after 37 weeks
gestation. Follow-up samples at 16 weeks were available for 93
infants (93%; 38 HIV-exposed and 55 HIV-unexposed) at a mean
postnatal age of 16.4 weeks (SD = 1.7).
All HIV-infected women chose exclusive formula replacement
feeding. The median (IQR) CD4 count among the HIV-infected
women was 411.5 (293.9–604.0) cells/!L and the median (IQR)
viral load was 800 (357–6000) copies/mL Seven women had CD4
counts of less than 200 cells/!L; three of these were taking
highly active antiretroviral treatment at enrollment and four were
referred to commence highly active antiretroviral treatment fol-
lowing delivery. Further characteristics of the study cohort have
been described previously [20]. At the time of the study, local
GBS disease incidence in Cape Town was reported at 0.67/1000
live births in a population with 24% of these infants being HIV-
uninfected, born to HIV-infected mothers [23].
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Fig. 1. Reverse cumulative distribution curve of maternal anti-GBS IgG surface bind-
ing by serotype concentrations (SU/mL). Curve demonstrates the percentage of the
total population with each antibody concentration for each of the five GBS serotypes.
ST,  serotype; SU/mL, standard units/mL
3.2. Maternal anti-GBS-antibody to GBS serotypes Ia, Ib, II, III and
V
All maternal sera had measurable geometric mean concentra-
tions (GMC) of antibody to at least one serotype. The distribution
of mothers’ antibodies that bound to the surface of GBS serotypes
Ia, Ib, II, III and V is shown in Fig. 1. The predominant surface bind-
ing anti-GBS-antibody was  against serotype V, followed by II, III, Ib
and Ia (Fig. 1).
Women  with HIV infection had significantly lower GMC  anti-
body concentrations to all five serotypes at delivery compared to
HIV-uninfected women (Fig. 2 and Table 1). There were no asso-
ciations between CD4 count and viral load on anti-GBS antibody
concentration by serotype in HIV-infected women.
The concentrations of antibody-mediated complement
C3b/iC3b deposition by GBS serotype are shown in Table 2.
The GMC  of antibody-mediated C3b/iC3b deposition was  signifi-
cantly greater in HIV-uninfected than HIV-infected women  for all
serotypes. The GMC  of antibody-mediated C3b/iC3b deposition
ranged from 4.9 SU/mL (serotype III) to 6.17 SU/mL  (serotype V)
in HIV-uninfected women  and from 2.6 SU/mL (serotype Ib) to
3.4 SU/mL (serotype V) in HIV-infected women.
3.3. Association of maternal HIV infection with placental transfer
of anti-GBS antibody
There was a positive correlation between paired maternal and
infant surface binding antibody concentrations for all serotypes (Ia,
r2 = 0.63, p < 0.001; Ib, r2 = 0.71, p < 0.001; II, r2 = 0.17, p < 0.001; III,
r2 = 0.35, p < 0.001; V, r2 = 0.16, p < 0.001). HIV-infected women had
significant reductions in placental transfer of anti-GBS serotypes II
and V compared with HIV-uninfected women (Table 3). There was
no association between CD4 count or viral load on transplacental
transfer ratios.
3.4. Infant anti-GBS-antibody by serotype at birth to GBS
serotypes Ia, Ib, II, III and V
HIV-exposed uninfected infants had significantly lower GMCs
of anti-GBS surface binding antibodies to all serotypes than unex-
posed infants (Fig. 3 and Table 1). In a multiple regression model
maternal HIV-status remained significant (p < 0.05).
However, there were no significant associations found between
infant anti-GBS-antibody concentrations to each serotype and
maternal age or infant sex.
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Fig. 2. Maternal anti-GBS surface binding IgG to GBS serotypes Ia, Ib, II, III and V concentrations at delivery (SU/mL). ST indicates GBS serotype. HIV indicates human
immunodeficiency virus. Horizontal lines indicate GMC  response.
Table 1
Geometric mean surface binding antibody concentrations (95% confidence intervals) in HIV-infected and HIV-uninfected mothers and their infants at birth and at 16 weeks
of  age.
STIa STIb STII STIII STV
HIV+ mother 19.3 (12.7–29.3) 24.9 (19.6–31.6) 21.8 (13.4–35.7) 27.8 (15.9–48.6) 121.9 (88.0–169.0)
HIV−  mother 37.0 (24.8–55.2) 47.6 (33.3–68.1) 50.0 (28.7–87.0) 60.1 (36.0–100.5) 185.6 (126.4–272.4)
HIV-exposed infants (birth) 9.4 (6.1–14.5) 13.4 (9.6–18.7) 14.6 (8.1–26.3) 26.6 (17.8–39.8) 90.4 (61.16–133.6)
HIV-unexposed infants (birth) 27.0 (16.5–44.3) 24.5 (16.4–36.5) 42.7 (23.4–77.8) 62.7 (38.1–103.1) 165.8 (112.0–245.4)
HIV-exposed infants (16 w) 7.0 (3.8–13.0) 8.7 (6.3–12.1) 17.6 (8.5–36.3) 48.0 (28.3–81.3) 68.54 (38.0–123.6)
HIV-unexposed infants (16 w)  21.6 (13.6–34.2) 14.9 (10.6–21.1) 68.3 (38.8–120.3) 97.4 (63.0–150.7) 180.2 (106.3–305.4)
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected; 16 w,  16 weeks of
age.
Table  2
Geometric mean concentration of antibody-mediated C3b/iC3b deposition (95% confidence intervals) on GBS serotypes Ia, Ib, II, III and V in HIV-infected and HIV-uninfected
mothers and their infants at birth.
STIa p value STIb p value STII p value STIII p value STV p value
HIV+ mother 2.9 (2.3–3.6) 2.6 (1.9–3.2) 3.1 (2.4–3.9) 2.8 (2.2–3.6) 3.4 (2.8–4.2)
HIV−  mother 5.3 (4.6–6.2) 0.003 4.9 (4.2–5.4) 0.003 6.2 (5.6–6.8) 0.001 5.3 (4.5–6.2) 0.001 6.2 (4.9–6.9) <0.0001
HIV-unexposed infants 6.1 (5.9–6.3) 5.9 (4.6–6.2) 6.9 (5.6–7.2) 6.6 (6.4–6.7) 6.3 (5.8–6.9)
HIV-exposed infants 3.8 (3.0–4.8) 0.02 3.1 (3.0–4.1) 0.02 4.2 (3.9–4.9) 0.02 3.9 (3.1–5.0) 0.03 4.2 (3.3–5.4) 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected.
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Table  3
Influence of maternal HIV-infection on transplacental transfer of anti-GBS surface binding antibody to GBS serotypes Ia, Ib, II, III and V.
GBS serotype HIV-infected mothers: infants (IQR) HIV-uninfected mothers: infants (IQR) % Reduction in HIV-infected p value
STIa 0.66 (0.34–0.99) 0.6 (0.39–0.96) 0% 0.86
STIb  0.48 (0.17–0.88) 0.52 (0.32–0.78) 8% 0.48
STII  0.42 (0.22–0.59) 1.0 (0.42–1.66) 58% <0.001
STIII  0.54 (0.31–1.03) 0.95 (0.4–3.05) 43% 0.05
STV  0.51 (0.28–0.79) 0.75 (0.26–2.9) 32% 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; IQR, interquartile range; HIV+, HIV infected, HIV−, HIV
uninfected; 16 w,  16 weeks of age.
Significantly lower GMC  of antibody-mediated C3b/iC3b depo-
sition was noted amongst HIV-exposed infants compared to
HIV-unexposed infants for all serotypes (Table 2). Notably, the GMC
of antibody-mediated C3b/iC3b deposition was higher in infants
than in their mothers for all serotypes.
3.5. Infant anti-GBS antibody at 16 weeks of age
Anti-GBS surface binding antibody GMCs remained significantly
lower at 16 weeks in HIV-exposed uninfected infants compared to
unexposed infants for all serotypes (Table 1). HIV-exposed infants
had significantly slower median rate of antibody decline com-
pared to HIV-unexposed infants at 16 weeks compared to birth to
STII (ratio of decline 1.03 [IQR −0.35 to 4.6] vs 0.21 SU/mL [−0.62
to 0.54], p = 0.04) and STIII (1.53 [−0.21 to 5.36] vs −0.09 SU/mL
(−0.60 to 0.93), p = 0.03) but not to ST1a (−0.12 [IQR −0.64 to
0.13] vs −0.04 [−0.39 to 0.45]), ST1b (−0.52 [−0.65 to 0.46]
vs −0.36 [−0.18 to 0.74]) or STV (−0.40 [−0.61 to 2.9] vs 0.14
[−0.52 to 2.7]).
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Fig. 3. Infant anti-GBS IgG serotype specific antibody concentrations (SU/mL). ST indicates GBS serotype. HIV indicates human immunodeficiency virus. Horizontal lines
indicate  GMC.
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4. Discussion
Our findings demonstrate that total surface binding and func-
tional maternal antibody concentration to each of the GBS
serotypes (Ia, Ib, II, III and V) is lower at delivery in HIV-infected
women compared to their HIV-uninfected peers. Further, for three
of the five serotypes (II, III, V) the transplacental transfer ratio
was significantly lower from HIV-infected women to their unin-
fected infants. It follows therefore that infants born to HIV-infected
women had lower anti-GBS surface binding antibody concentra-
tions at birth for all serotypes; this difference was still evident at
16 weeks of age. The implication of our findings is that HIV-exposed
infants may  be more vulnerable to early and late onset GBS disease
than infants born to HIV-uninfected mothers.
Rectovaginal colonization with GBS is more frequent in HIV-
infected women compared to HIV-uninfected women [6,24].
Maternal colonization is the major risk factor for infant acquisi-
tion at birth and for early onset GBS disease. Thus infants born
to HIV infected mothers may  have both increased susceptibility
and increased exposure. It is generally understood that mater-
nal colonization stimulates maternal immunity; thus the finding
of lower maternal antibody concentrations despite higher colo-
nization rates suggests impairment of anti-GBS-specific antibody
production. This is also seen with polysaccharide-specific antibody
production in HIV-infected adults, such as in pneumococcal dis-
ease [25]. The fact that HIV-infected women have higher rates of
GBS colonization than HIV-uninfected women may  mean that anti-
body production secondary to colonization with GBS is deficient in
the context of maternal HIV-infection increasing the risk of invasive
GBS disease in HIV-exposed infants.
It is difficult to correlate our anti-GBS antibody results with what
is known regarding maternal colonization and infant GBS disease in
this South African population. However, the highest concentrations
of antibodies in women at delivery were to STV and III bacteria. The
latter is consistent with the known predominance of STIII among
carried strains in South African women (37%) but STV is carried by
a minority of women (10%) [24,26]. In our cohort the lowest lev-
els of antibody were to STIa bacteria, which is consistent with an
increased incidence of disease due to this serotype [26]. Our find-
ings may  suggest differences in the immune response to different
colonizing serotypes.
It is likely that lower maternal antibody concentrations and
altered transplacental transfer of antibody in HIV infection play a
role in the increased susceptibility to infectious diseases in infancy
[19,27], but there is a lack of data on the impact of maternal HIV
infection on neonatal infections in general, including GBS infec-
tions [28]. Infant anti-GBS surface binding antibody by serotype
remains lower at 16 weeks in HIV-exposed, uninfected infants,
who might therefore be more vulnerable to late onset GBS disease.
This corresponds to recent data from Cape Town which suggest
that 56% of GBS disease occurred after 7 days of life in a popula-
tion where one in four infants were HIV-exposed [23]. Apart from
the reduced passive immunity provided by maternal antibody in
the context of maternal HIV infection it might be that there are
differences in the immune response to infection of HIV-exposed,
uninfected infants secondary to in utero HIV exposure, as some data
suggest that these infants have altered lymphocyte differentiation
and function despite remaining HIV-uninfected [29,30]. However,
how this corresponds to clinical infection in the neonatal period is
not known.
Our findings are consistent with studies that demonstrate the
higher risk of infectious morbidity and mortality in HIV-exposed
infants compared to HIV-unexposed infants [31–33]. Recent South
African studies demonstrated a high prevalence of neonatal GBS
disease in a population with a high HIV burden [23,24,34]. A Study
from Malawi also demonstrated high rates of early and late onset
GBS infection in a population with high HIV prevalence [35]. In
contrast, one study from the USA did not find evidence of increased
susceptibility to GBS infection in HIV-exposed, uninfected infants
suggesting either regional screening and treatment differences
for both HIV infection and GBS carriage or population-based dif-
ferences in late onset GBS disease that might be unrelated to
HIV-status [36].
Our study has some limitations. Firstly, we  did not assess col-
onization in the mothers participating in the study and thus were
unable to correlate antibody responses to maternal colonization.
Whilst no infant developed early or late onset sepsis or meningitis
during the study, our sample size was also too small to detect this
as a valid endpoint and this was  not the aim of the study.
The use of two novel flow cytometric assays that quantify anti-
body binding to the surface of GBS bacteria and antibody-mediated
C3b/iC3b deposition on the bacterial surface may provide a more
complete assessment of antibody function than the measurement
of anti-polysaccharide IgG alone. However, the response measured
is not wholly serotype-specific as part of the antibody binding is
to cell wall proteins as well as the polysaccharide capsule. Despite
this, we see a serotype-specific response with a clear differentia-
tion between the distribution of antibody binding to the different
serotypes.
The potential of a trivalent maternal GBS vaccine encompass-
ing the major disease-causing serotypes (Ia, Ib, III) [8] to protect
against neonatal disease remains promising. However, it is vital
that ongoing evidence to support its use in vulnerable populations
with high HIV-prevalence is collected in order to support immu-
nization strategies in Sub-Saharan Africa.
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Antibody-Mediated Complement C3b/iC3b Binding to Group B
Streptococcus in Paired Mother and Baby Serum Samples in a Refugee
Population on the Thailand-Myanmar Border
Jenny Herbert,a* Stephen Thomas,a Charlotte Brookes,a Claudia Turner,b,c,d Paul Turner,b,c,d Francois Nosten,b,c Kirsty Le Doare,e,f
Michael Hudson,a Paul T. Heath,f Andrew Gorringe,a Stephen Taylora
Public Health England, Porton Down, Salisbury, United Kingdoma; Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United
Kingdomb; Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailandc;
Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodiad; Wellcome Centre for Global Health Research, Imperial College, London,
United Kingdome; Paediatric Infectious Diseases Research Group & Vaccine Institute, Institute of Infection and Immunity, St. George’s, University of London, London,
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Streptococcus agalactiae (group B streptococcus [GBS]) is the leading cause of neonatal sepsis and meningitis. In this study, we
determined antibody-mediated deposition of complement C3b/iC3b onto the bacterial cell surface of GBS serotypes Ia, Ib, II, III,
and V. This was determined for 520 mother and umbilical cord serum sample pairs obtained at the time of birth from a popula-
tion on the Thailand-Myanmar border. Antibody-mediated deposition of complement C3b/iC3b was detected to at least one se-
rotype in 91% of mothers, despite a known carriage rate in this population of only 12%. Antibody-mediated C3b/iC3b deposi-
tion corresponded to known carriage rates, with the highest levels of complement deposition observed onto the most prevalent
serotype (serotype II) followed by serotypes Ia, III, V, and Ib. Finally, neonates born to mothers carrying serotype II GBS at the
time of birth showed higher antibody-mediated C3b/iC3b deposition against serotype II GBS than neonates born to mothers
with no serotype II carriage. Assessment of antibody-mediated C3b/iC3b deposition against GBSmay provide insights into the
seroepidemiology of anti-GBS antibodies in mothers and infants in different populations.
Group B streptococcus (GBS) (Streptococcus agalactiae) is anatural commensal of the vagina and rectum and is normally
carried asymptomatically (1). However, it is also the leading cause
of neonatal sepsis and meningitis in developed countries and is
associated with a highmortality rate with early-onset disease (0 to
6 days postbirth) and high morbidity in survivors of late-onset
GBSmeningitis (2, 3). Prophylactic treatment with antibiotics has
been introduced in the United States and Australia, greatly reduc-
ing the incidence of early-onset disease in those countries (4, 5).
However, the incidence of late-onset disease (defined as occurring
between 7 and 90 days after birth) has not decreased (5). In late-
onset neonatal sepsis (LONS), GBS may be acquired horizontally
from the community, making it harder to target the source of
infection (6, 7).
Natural antibodies toGBS are transferred frommother to baby
in utero beginning at 17 weeks (passive transport) and by active
transport during the third trimester of pregnancy, and they are
thought to protect the neonate from disease. Several clinical fac-
tors affect the likelihood of developing neonatal sepsis, including
prematurity (8, 9), as premature babies have reduced specific an-
tibodies due to the reduced time for transfer frommother to baby.
Determination of the protective levels of antibody required to
prevent GBS infection in neonates would greatly facilitate the
evaluation and effective use of new vaccines. Effective vaccination
would reduce the long-term costs of treatment of infected neo-
nates; the health care costs of infants that acquire neonatal GBS
infection are estimated to be roughly double those of control ne-
onates matched for age and birth weight (10). Furthermore, effec-
tive vaccination will reduce the likelihood of emergence of antibi-
otic-resistant strains (11).
Functional immunity to GBS has been demonstrated in an
opsonophagocytosis killing assay (OPKA) that measures the anti-
body and complement-dependent uptake and killing of bacteria
by human phagocytes (12, 13). Human vaccine sera with positive
OPKA activity have also been shown to passively protect mice in a
maternal passive protection/infant challenge model (14). OPKA
assays are generally laborious to perform and require large vol-
umes of test sera. Reliance on human donor phagocytes intro-
duces an extra variable, although this has been addressed with the
use of the humanphagocytic cell lineHL60 (15). Additionally, this
HL60-based OPKA has been adapted to measure the uptake of
fluorescently labeled bacteria by flow cytometry, thus removing
the extra plating and counting required for assay analysis (16). A
fluorescence opsonophagocytosis assay (fOPA) was developed
that measures both the uptake of bacteria and the functional re-
spiratory activity of the HL60 cells in a 96-well format (17). How-
ever, OPKA and fOPA require considerable resources to perform
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large studies, and minimizing the sample volume required is im-
portant, particularly for infant studies.
We evaluated the antibody-mediated deposition of comple-
ment C3b/iC3b onto bacteria representing five GBS serotypes
with 534 serum sample pairs frommother and cord blood samples
fromapopulation located on theThailand-Myanmar border (18).
This was evaluated using flow cytometry, and as opsonization of
bacteria by antibody and complement is required for uptake and
killing by phagocytic cells, this may be a surrogate for op-
sonophagocytosis.
MATERIALS AND METHODS
Sample collection. The study population was described by Turner et al.
(18). In brief, mothers enrolled in the study were residents of the Maela
refugee camp located on the Thailand-Myanmar border. Inhabitants were
mostly Karen refugees, with a total population of approximately 43,000.
Around 1,500 deliveries occur in the camp every year, and all antenatal
care is provided by the Shoklo Malaria Research Unit. A total of 549
women were enrolled in the study at 28 to 30 weeks’ gestation. Venous
blood samples were collected from themothers and umbilical cords at the
time of birth. Of the sera collected, a total of 543 serum samples from
mothers and 525 serum samples from umbilical cords were available for
this study. Data were also collected on the GBS carriage status of the
mother at the time of birth, which was assessed by culture of vaginal and
rectal swabs (18).
Study ethics. All women gave informed consent to participate in the
study. Ethical approval was granted by the ethics committee of the Faculty
of Tropical Medicine, Mahidol University, Thailand (MUTM 2009-011-
03) and the Oxford Tropical Research Ethics Committee, Oxford Univer-
sity, United Kingdom (48 08).
GBS isolates and growth conditions. Group B streptococcus isolates
used in this study were geographically diverse United Kingdom clinical
isolates from neonatal blood cultures. H092040676 (serotype Ia),
H090820125 (serotype Ib), H090320548 (serotype II), H092120162 (se-
rotype III), and H091780506 (serotype V) were kindly provided by
Androulla Efstratiou, Public Health England, Colindale. Throughout the
article, strains are referred to by their serotype.
GBS isolates used in the complement deposition assay were grown in
Todd-Hewitt broth at 37°C with shaking (200 rpm). Once an optical
density at 600 nm (OD600) of 1.0 was reached, cultures were centrifuged at
3,060! g for 5min to pellet the bacteria. The pellet was resuspended in the
same volume of phosphate-buffered saline (PBS, pH 7.4; Severn Biotech,
United Kingdom) containing 2% formaldehyde and incubated at room
temperature for 1 h. Bacteria were then washed in PBS by 3 rounds of
centrifugation at 3,060! g for 5min and resuspended. The final cell pellet
was resuspended in 1 ml PBS, which was stored at 4°C before use.
Production of IgG-depleted human complement. Human comple-
ment used in the complement deposition assay was produced as described
previously (19). Briefly, bloodwas collected fromvolunteers into contain-
ers with 50 "g/ml lepirudin (Movianto, United Kingdom). Plasma was
then removed, pooled, and depleted of IgG by protein G Sepharose affin-
ity chromatography. Aliquots were stored at#70°C until use.
Antibody-mediated complement C3b/iC3b deposition assay. Com-
plement deposition assays were performed in 96-well plates, and each test
serum sample was analyzed at a single dilution. To each well, 5 "l sera
(10% final concentration) was added, followed by 10 "l IgG-depleted
human complement (20% final concentration) and 35 "l fixed bacteria
(1.8! 106 CFU/well). The bacteria were resuspended in blocking buffer
(BB) (PBS containing 1% bovine serum albumin [BSA]; Sigma, United
Kingdom). Controls included samples of bacteria only and bacteria and
complement only, which were made to the same volume using BB. Pre-
activated zymosan (1.8 ! 106 particles/well; CompTech, USA) was also
used as a control to normalize for day-to-day variation. The plate was
incubated for 7.5 min at 37°C with shaking at 900 rpm. Plates were then
centrifuged at 3,060 ! g for 5 min, and the supernatant was removed,
ensuring that the bacterial pellet was not disturbed. Pellets were washed
with 200 "l BB and then centrifuged at 3,060 ! g for 5 min, and the
supernatant was removed, ensuring that the bacterial pellet was not dis-
turbed. Each pellet was then resuspended in 200 "l BB containing rabbit
anti-humanC3c conjugated to fluorescein isothiocyanate (FITC) at 1/500
(Abcam, United Kingdom), which binds to both C3b and iC3b, and the
plate was incubated at 4°C for 20 min. The plate was centrifuged at
3,060 ! g for 5 min, and the bacterial pellet was washed twice in BB, as
performed previously. Finally, the pellet was resuspended in 200 "l BB
and kept at 4°C until analysis by flow cytometry.
Data collection and analysis. Samples were analyzed on a CyAn ADP
flowcytometer (BeckmanCoulter, Inc.)with an automatedmicrosampler
system (Cytek Development, Inc.). Data were acquired in a Summit 4.3
(BeckmanCoulter, Inc.), and 5,000 events were obtained for each sample.
This was performed by setting a gate that contained 10% of the events
detected with the control containing bacteria and complement only. A
fluorescence index (FI), which was calculated by multiplying the number
of events in the gate noted above and themean fluorescence intensity, was
assigned to each sample. For each sample, the FI of the control containing
bacteria and complement only was subtracted, giving a final fluorescence
index minus complement-only control (FI#C=) value for each serum
sample, whichwas used as ameasure of antibody-dependent complement
deposition on the bacterial surface. Antibody-independent C3b/iC3b de-
position was similar between strains except for the serotype II isolate,
which showed greater FI values. Data from each day were normalized to
the C3b/iC3b bound to the preactivated zymosan control to account for
day-to-day variation within the assay.
Each serum sample was analyzed in the antibody-mediated comple-
ment deposition assay (CDA) against each of the five GBS serotypes cho-
sen. Each serum sample was analyzed in duplicate, and if the coefficient of
variance (%CV) between the two replicates was $35%, then the serum
was analyzed again. If the repeat FI#complement values were not within
50% of each other, then the serum was subjected to a further repeat anal-
ysis. If the repeats were within 50% of each other, the two C= values were
averaged; this was also the case if the analysis was repeated a third time. If
all three repeats were not within 50% of each other, then the sample was
given a not determined (ND) value for FI#C=. Graphs include all data
except the samples that were assigned ND, unless otherwise stated.
Clinical data analysis and statistics.Clinical data were obtained from
the mothers enrolled in the study and the neonates (18). These data in-
cluded GBS carriage status of the mother, ethnic group, past obstetric
history, recent antibiotic exposure, and any complications occurring dur-
ing birth. Infants were also visited at 7 and 28 days postbirth and at un-
planned sick visits, and the health of the neonate was checked specifically
for signs of neonatal sepsis. All graphs were drawn in GraphPad Prism 6
(GraphPad Software, Inc.). Reverse cumulative distribution curves for
CDA data were prepared as described by Reed et al. (20). The effects of
clinical parameters on antibody-mediated C3b/iC3b deposition were
evaluated using one-way analysis of variance (ANOVA).
RESULTS
Complement deposition assay. The CDA was optimized for in-
cubation times, blocking buffer formulation, IgG-depleted hu-
man plasma concentration, shaking speed, bacterial concentra-
tion, and serum dilution. Reproducibility of the CDA was
measured using a panel of 1 rabbit and 13 human sera against a
serotype II strain. Intra-assay precision (three assays performed
on 1 day) and interassay precision (one assay performed on 3
separate days) returned mean coefficients of variance of 22% and
26%, respectively. Interassay and complement variations over
time were controlled by normalizing all data to the fluorescence
index obtained with activated zymozan-complement controls,
which were included in each assay. Over 67 assays, the mean stan-
dard deviation of FI for the zymozan controls was 8,830 (coeffi-
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cient of variance, 31.6%). Linearity of the assay was assessed using
positive-control human sera (kind gift from Carol Baker), and it
was shown to be highly linear, with a mean R2 of 0.96 for the five
serotypes tested.
Antibody-mediated C3b/iC3b deposition by paired mother
and cord serum samples. Antibody-mediated C3b/iC3b deposi-
tion onto GBS isolates of serotypes Ia, Ib, II, III, and V for each
serum sample was evaluated using high-throughput flow cytom-
etry. A total of 1,045 serum samples were analyzed: 520 from
mothers and 525 associated cord samples (5 sets of twins). Car-
riage and clinical data relating to the mothers and neonates are
reported in Turner et al. (18). The GBS isolates were selected to
represent the two most prevalent serotypes (II and Ia), two sero-
types of medium prevalence (III and V), and one serotype of low
prevalence (Ib) in this region. A value (fluorescence index ob-
tained with test serum minus complement-only control value
[FI!C=]) of C3b/iC3b deposition was assigned to each serum
sample against each serotype tested. Sera with C3b/iC3b deposi-
tion values below the limit of detection of the assay (FI!C=,
"2,000) were assigned a nominal FI!C= value of 1,000 for data
analysis. In addition, sera giving nonreproducible FI!C= values in
duplicate assays were recorded as not determined (ND) and ex-
cluded from the analysis. The number of sera assigned an FI!C=
value of 1,000 or ND varied among the GBS serotypes tested (Ta-
ble 1).
Reverse cumulative distribution curves of antibody-mediated
C3b/iC3b deposition observed against each serotype with mother
and cord serum samples were compared (Fig. 1A). In the 549
mothers originally enrolled in the study, a carriage rate of 12%
(n# 66) was determined using culture- and PCR-based methods
(18). GBS serotype II was themost frequently carried, followed by
serotypes Ia, III, V, and Ib. The level of antibody-mediated C3b/
iC3b deposition observed against each serotype in the whole co-
hort corresponded with the carriage findings, with the highest
number of sera showing measurable C3b/iC3b deposition to se-
rotype II, followed by serotype Ia, serotype III, serotype V, and
serotype Ib.
Reverse cumulative distribution curves were also used to com-
pare the distribution of antibody-mediated C3b/iC3b deposition
in mother and cord serum samples separately for each serotype
(Fig. 1B). Antibody-mediated C3b/iC3b deposition levels for se-
rotypes II and Ia were clearly higher in the cord samples than in
samples from themothers (P# 0.009 andP# 0.037, respectively).
This trend was observed for serotypes III, V, and Ib, but these
differences were not significant (P $ 0.05). The same patterns
were observed when geometric mean C3b/iC3b depositions were
compared for the mother and cord data sets for each serotype
(Fig. 2).
Although GBS carriage was only detected in 12% of mothers,
antibody-mediated C3b/iC3b deposition was above the lower
limit of detection in 97% of cord samples and 92% of mother
samples to at least one serotype tested, as shown in Fig. 3. More-
over, 7% of cord samples and 4% of mother samples contained
antibodies thatmediated C3b/iC3b deposition to all five serotypes
tested. The percentages of individuals with antibody-mediated
C3b/iC3b deposition to !1 strain with FI!C= values of $5,000,
$10,000, and$20,000 are also presented, with fewer individuals
possessing CDA activity at these higher levels. However, there is a
greater divergence between values obtained for mother and cord
samples as the cutoff value is increased.
Association of clinical data with antibody-mediated C3b/
iC3b deposition. In this cohort, no neonates were found to have
early-onset disease (EOD) due to group B streptococcal infection.
Two neonates born to carriage-positive mothers showed signs of
EOD, but GBS was not identified as the causative agent. Thus, it
was not possible to evaluate the level of protective antibody-me-
diated complement deposition required to prevent disease.
The effects of a number of other clinical parameters on levels of
antibody-mediated C3b/iC3b deposition were evaluated by one-
way ANOVA. These included the mother’s age, number of previ-
ous pregnancies, neonate’s gestational age, and use of antibiotics.
None of these parameters had a significant effect (P$ 0.05) on the
functional antibody levels in mother and cord samples in this
study (data not shown). Sera from babies born at "37 weeks’
gestation did not show lower functional antibody levels to any of
the five GBS serotypes tested (data not shown).
GBS carriage was determined for each mother at the time of
birth by culture of vaginal and rectal swabs (18). No carriage data
were obtained from the neonate. For each serotype, antibody-
mediated C3b/iC3b deposition in samples frommothers that car-
ried GBS at the time of birth and their neonates was compared to
that of mothers and neonates where GBS carriage was not de-
tected. The antibody-mediated complement deposition in the
cord samples from neonates with mothers carrying GBS serotype
II was significantly higher (P " 0.001) than that determined in
cord samples taken from neonates born to mothers that did not
carry serotype II GBS (Fig. 4). A similar trend was observed when
comparing sera from mothers who carried serotype Ia GBS and
their neonates with samples from noncarriage mothers, shown in
Fig. 5. This did not reach statistical significance due to the low
number of mothers carrying this serotype. No significant differ-
ences were determined between mother and cord serum samples
against serotypes III, V, and Ib, possibly due to the small number
of mothers carrying these serotypes (18).
DISCUSSION
We developed a flow cytometry assay that measures antibody-
mediated deposition of complement components (C3b/iC3b)
that are required for opsonophagocytosis onto the surface of GBS
serotypes Ia, Ib, II, III, andV.Maternal antibodies toGBS capsular
polysaccharides have been shown to protect infants from early-
onset GBS disease (21, 22), with opsonophagocytic killing the
likely effector mechanism (15, 23). Opsonophagocytosis assays
were developed for a range of bacteria (24–27) and have been
widely used to assess immune responses to pneumococcal vac-
TABLE 1 Antibody-mediated C3b/iC3b deposition values above or
below the lower limit of detection (FI!C=" 2,000) or not determined
due to a variable FI!complement value obtained in repeat analyses
Serotype
FI!C=$ 2,000
(% [n])a
FI!C=" 2,000
(% [n])
FI!C= not determined
(% [n])
Ia 56.6 (605) 34.6 (370) 8.7 (93)
Ib 26.7 (285) 72.2 (771) 1.1 (12)
II 71.2 (760) 22.8 (244) 6.0 (64)
III 38.7 (413) 53.4 (570) 8.0 (85)
V 42.6 (455) 53.6 (572) 3.8 (41)
a n# number of samples analyzed. FI!C= is the fluorescence index value obtained with
the test serum minus the C3b/iC3b fluorescence obtained with the control containing
bacteria and complement only.
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FIG 1 (A) Reverse cumulative distribution (RCD) curves show distribution of antibody-mediated C3b/iC3b deposition levels against GBS serotypes Ia (n !
975), Ib (n ! 1,059), II (n ! 1,007), III (n ! 986), and V (n ! 1,030) in serum samples taken from mothers and umbilical cords. (B) RCD curves show
antibody-mediated C3b/iC3b deposition levels in mother and cord samples separately against GBS serotypes Ia (mother, n! 497; cord, n! 478), Ib (mother,
n! 535; cord, n! 521), II (mother, n! 505; cord, n! 499), III (mother, n! 500; cord, n! 483), and V (mother, n! 518; cord, n! 509). FI-C=, fluorescence
index minus complement only.
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cines where a role in protection was demonstrated (28–30). How-
ever, these assays rely on a source of phagocytic cells, such as fresh
human peripheral blood mononuclear cells (25, 27, 31) or differ-
entiated HL60 cells (29, 30), and day-to-day variability in these
cells can affect assay performance (32). The interaction of com-
plement proteins with a number of pathogens, includingNeisseria
meningitidis (33) andHaemophilus influenzae (34), has been stud-
ied in detail and is key in protecting against disease. Complement
interactions with Streptococcus pneumoniae are thought to be im-
portant, with individuals deficient in classic pathway components
having increased susceptibility to disease (35) and serotypes with
resistance to C3b/iC3b opsonization demonstrating greater inva-
sive capacity (36). The potential role of opsonophagocytosis in
protection fromGBSdiseasewas demonstrated using viable count
assays that use log reduction in CFU determination as a primary
readout (37–39).
FIG 2 Geometric means of antibody-mediated C3b/iC3b deposition levels in
mother and cord samples against serotypes Ia, Ib, II, III, and V GBS (n! the
number of samples included in each group). Data do not include the values
that were not assigned an FI"C= value. Bars represent 95% confidence inter-
vals.
FIG 3 Percentages of mother and cord samples that show antibody-mediated C3b/iC3b binding against !1 GBS strain tested using a cutoff FI"C= value of
#2,000 (A),#5,000 (B),#10,000 (C), and#20,000 (D). Samples that were assigned a not-determined value were classified as not havingmeasurable functional
antibody levels along with the samples assigned an FI"C= value of 1,000. Cord, n! 525; mother, n! 543.
FIG 4 Box plot shows the effect of serotype II carriage on antibody-mediated
C3b/iC3b binding to serotype II GBS in sera frommother and cord pairs taken
frommothers who were carriage positive (serotype II only) versus those from
mothers who were carriage negative. **, P$ 0.001.
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In this study, a complement deposition assay was utilized as a
possible surrogate for OPA. This flow cytometric assay measures
the antibody-dependent deposition of the complement opsonins
C3b/iC3b onto the surface of whole bacteria. This assay uses
smaller volumes of test sera than OPKA and fOPA yet measures
the total antibody-dependent complement deposition mediated
by all anti-polysaccharide and anti-protein antibodies, including
immunoglobulins other than IgG.Use of this single-dilution assay
enables the screening of a large number of samples in a relatively
short time. The assay uses fixed bacteria, which allowed a single
batch of bacteria for each serotype to be used for the study, thus
avoiding assay variability caused by growth-to-growth variation.
A total of 1,068 sera were analyzed against five GBS serotypes
using the CDA, and antibody-mediated C3b/iC3b deposition was
determined in mother and cord pairs from samples taken at the
time of birth. Within this cohort of 549 mothers, none of the
neonates developed GBS disease; therefore, it was not possible to
determine the level of antibody-mediated C3b/iC3b deposition
required to prevent disease. However, sera from neonates born to
GBS serotype II carriage-positivemothers had significantly higher
antibody-mediated complement deposition levels against sero-
type II GBS than sera from those born to mothers who were not
carriers of serotype II. Coupled with the absence of invasive dis-
ease in this population, this may indicate that neonates at risk
(born to carrier mothers) had adequate levels of antibodies to
prevent disease. Greater antibody-mediated C3b/iC3b deposition
in neonates born to carriermothers was also observed for serotype
Ia and was not observed for the other three serotypes tested likely
due to the small numbers of carrier mothers. This phenomenon
was observed previously, with infants born to GBS-colonized
mothers having antibody concentrations to a GBS surface protein
(Sip) that were higher than those found in infants born tomothers
who had no colonization (40).
Antibody-mediated C3b/iC3b deposition above the lower
limit of detection to at least one serotype was observed in 97% of
cord samples and 92% of mother samples, with 7% of cord sam-
ples and 4% of mother samples containing antibodies that medi-
ateC3b/iC3b deposition to all five serotypes tested. As only 12%of
mothers were found to be carriers of GBS at the time of birth, this
prevalence is greater than expected and may indicate that broad
immunity is generated by repeated transient episodes of carriage
of different GBS serotypes. No studies have evaluated the length of
carriage of GBS, which may vary depending on the geographic
region and ethnic population. The high proportion of individuals
with functional anti-GBS antibodies observed in this population
may explain the low incidence of GBS neonatal disease in this
geographic region, with Southeast Asia showing some of the low-
est rates of neonatal GBS disease (18, 41, 42). This requires further
study of invasive disease epidemiology and antibody prevalence.
As only 32/525 infants in the study were!37 weeks’ gestation,
we expected consistently higher geometric mean antibody-medi-
ated C3b/iC3b deposition levels in the cord samples than in sam-
ples from mothers due to the active transfer of IgG in the third
trimester (43, 44). For the two most prevalent serotypes, the cord
samples indeed showed greater complement deposition than the
samples from mothers. However, in the serum samples from
mothers, IgM may also contribute to the complement deposition
observed and would not have been transferred to the neonates,
which may explain why higher neonatal/maternal complement
deposition ratios were not seen for the three least-carried sero-
types.
Serum samples from premature and term neonates were com-
pared in this study, but no difference was seen in complement
deposition mediated by samples from the two groups. Prematu-
rity was previously shown to affect antibody levels that are trans-
ferred from mother to baby (43). However, in this cohort, no
neonates were born severely premature, since mothers were en-
rolled when already 28 to 30 weeks pregnant, and the low number
of neonates born within this group (n " 32) may lack statistical
power. In addition, antibody transfer occurs in the third trimester
(!27 weeks’ gestation), which may be why we saw no difference
between the neonates born prematurely (!37 weeks) and those
born at term.
The antibody-mediated complement deposition assay is a very
useful tool for assessing large numbers of sera against multiple
serotypes/strains. It could potentially be used to assess why there
are different incidences of disease in different ethnic groups and
geographic regions. For instance, in the United States, a 3-fold-
higher risk of GBS infection (late onset) was observed in the Afri-
can American community, with an incidence of 0.42/1,000 live
births versus an incidence of 0.11/1,000 live births in the nonblack
community (6), despite presumably having the same circulating
GBS strains. This has also been observed in southern Israel, where
the Bedouin Arab population has a GBS EOD incidence of 0.07/
1,000 live births, whereas the Jewish population has an incidence
of 0.35/1,000 live births (45). It may be that in these higher-inci-
dence populations, lower concentrations of functional antibodies
are present in mothers, resulting in higher neonatal disease rates.
Disease rates also vary in different geographic regions, with Africa
thought to have the highest incidence of disease, followed by the
Americas, Europe, and Southeast Asia (46). Geographic differ-
ences were also observed in England (0.72/1,000 live births), Scot-
land (0.42/1,000 live births), and Northern Ireland (0.9/1,000 live
births) (9). Currently, little information is available to help under-
stand these differences and why they occur to aid the rational
introduction of a GBS vaccine or other therapy.
This study has opened up the potential to evaluate the levels of
FIG 5 Box plot shows the effect of serotype Ia carriage on antibody-mediated
C3b/iC3b binding to serotype Ia GBS. Comparison of functional antibody
levels was done by comparing the mother and cord pairs taken from mothers
who were carriage positive (serotype Ia only) versus those from mothers who
were carriage negative.
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antibody-mediated complement deposition against different GBS
serotypes in large-scale seroepidemiological studies. Although the
goal of evaluating the antibody-mediated complement deposition
required to prevent disease was not attained in this study, this
research has provided a baseline for future studies. This assay will
enable some of the key unanswered questions, for instance, why
different populations show different incidences of disease, to be
studied. Use of this and other immunoassays in efficacy trials of
new GBS vaccines may identify a correlate of protection that will
facilitate vaccine development and evaluation.
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Invasive  Group-B  streptococcal  (GBS)  disease  is a leading  cause  of  infant  mortality  and  morbidity  world-
wide.  GBS  colonises  the maternal  rectum  and  vagina  and  transmission  of  bacteria  from  a colonized  mother
to her  infant  at birth  is  an  important  risk  factor  for GBS  disease.  GBS  disease  has  also  been  associated
with  case  reports  of  transmission  via  infected  breast  milk  raising  questions  about  mode  of acquisition  and
transmission  of  this  enteric  pathogen  and  the  development  of  neonatal  disease.  However,  most  breast-
fed  infants  remain  unaffected  by  GBS  in  breast  milk.  Mechanisms  associated  with  transmission  of  GBS
in  breast  milk  and  potential  factors  that  may  protect  the  infant  from  transmission  remain  poorly  under-
stood.  Understanding  factors  involved  in protection  or transmission  of  GBS  infection  via breast  milk  is
important  both  for  premature  infants  who  are  a high-risk  group  and  for infants  in  the  developing  world
where  breastfeeding  is  the  only  sustainable  infant  feeding  option.  In this review  we discuss  the  proposed
mechanisms  for GBS  colonization  in breast  milk  on  one  hand  and  its  immune  factors  that  may  protect
from  transmission  of  GBS  from  mother  to infant  on  the  other.  Innate  and  adaptive  immune  factors,  includ-
ing  serotype-specific  antibody  and  their significance  in the  prevention  of infant  disease  are  presented.  We
further report  on  the  role of  human  oligosaccharides  in  protection  from  invasive  GBS  disease.  Advances
in  our  knowledge  about  breast  milk  and  immunity  in  GBS  disease  are  needed  to  fully  appreciate  what
might  mitigate  transmission  from  mother  to  infant  and  protect  neonates  from  this  devastating  disease
and  to contribute  to the  development  of novel  prevention  strategies,  including  maternal  immunization
to  prevent  infant  disease.
©  2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Streptococcus agalactiae (Lancefield Group B streptococcus; GBS)
was first described as a cause of bovine mastitis by Nocard and
Mollereau in 1887 [1]. Lancefield and Hare subsequently identified
GBS in vaginal swabs in 1935 [2] and in 1938 Fry described three
fatal cases in post-partum women [3]. Reports of neonatal disease
from GBS were sporadic until the early 1960s when GBS became
recognized as a leading cause of early neonatal sepsis in the USA
[4]. By the 1970s it had become the dominant pathogen in the early
neonatal period [5]. By the early 1980s GBS had become the most
common cause of neonatal sepsis and meningitis in a number of
developed countries [6–8]. In the past five years, late-onset (LO)
GBS disease has been associated with case reports of transmission
∗ Corresponding author at: Wellcome Trust Centre for Global Health Research,
Norfolk Place, London, UK. Tel.: +44 207594 2063.
E-mail addresses: kirstyledoare@gmail.com, k.mehring-le-doare@imperial.ac.uk
(K. Le Doare), b.kampmann@imperial.ac.uk (B. Kampmann).
via infected breast milk [9] raising questions about mode of acquisi-
tion and transmission of this enteric pathogen and the development
of neonatal disease.
Although GBS is not just a neonatal disease, the disease inci-
dence and severity is highest during the first 90 days of life. Early
onset (EO) GBS disease (disease presenting in the first six days of
life) accounts for approximately 60–70% of all GBS disease. GBS
serotypes Ia, Ib, II, III and V are responsible for most EO disease
[10,11]. In contrast, serotype III predominates in LO disease, which
may be acquired perinatally, nosocomially or from the community.
[12]
In the USA EO disease rates have declined from 1.4 per 1000
live births in 1990 [13] to at 0.28 per 1000 live births in 2012 [14]
mainly attributed to the implementation of universal screening for
GBS rectovaginal colonization in pregnant women and intrapartum
antibiotic prophylaxis. However, the incidence of LO disease has
remained static at between 0.3 and 0.4 per 1000 births since 1990
[14]. This amounts to 28,100 cases and 1865 deaths annually in
the USA [14]. Although the epidemiology of GBS in resource-rich
http://dx.doi.org/10.1016/j.vaccine.2014.04.020
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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countries is well documented, its contribution to the burden of
neonatal infection in low/middle income countries has proved
more difficult to assess. GBS has been reported as the predomi-
nant cause of neonatal sepsis in South Africa and Kenya [15–17]
as well as an important cause of meningitis in Malawi and Kenya,
but Asian studies have reported a much lower incidence [18–20].
A recent systematic review reported that the overall incidence of
GBS in resource-poor settings ranged between 0 and 3.06 per 1000
live births [21].
GBS colonizes the rectum and vagina, and maternal colonization
is a pre-requisite for EO disease and a risk factor for LO [22,23]. In
resource-rich countries an estimated 20–30% of pregnant women
are colonized with GBS [23,24], approximately 50% of their babies
become colonized and 1% progress to develop invasive disease. EO
disease may  occur rapidly; signs of sepsis are evident at birth or
within 12 h in over 90% of cases (98% within the first 12 h) [12].
Despite its rarity, LO disease, mostly presenting as meningitis, has
devastating long term consequences in survivors with up to 50%
suffering severe neurological sequelae [25].
It has been suggested that GBS initially colonizes the infant’s
oropharyngeal mucosa when contact with maternal vaginal secre-
tions occur at the time of birth [26]. Butter and DeMoor
demonstrated GBS in the nose and throat of infants at the same time
as GBS was cultured from the mother’s breast milk [27]. Fileron et al.
reviewed cases of LOGBS disease associated with GBS in breast milk
and found 48 LOGBS disease cases between January 1977 and March
2013 of which four had no other positive culture from mother or
infant other than GBS-contaminated breast milk. [9].
Therefore, there appears to be a dichotomy between cases of
LO disease through infected breast milk and the potential bene-
fits of the components of breast milk which protect the majority of
infants from invasive disease. The underlying mechanisms of GBS
transmission or protection through breast milk, are not fully under-
stood, but are important to elucidate, particularly in the context
of premature infants who are a high risk group and for infants in
the developing world where breastfeeding is the only sustainable
infant feeding option. In this review we focus on the peculiarities
of GBS that may  aid transmission in breast milk and the role of
immune parameters such as antibody in breast milk on the other
hand that may  help protect the breastfed infant from GBS disease.
2. Breast milk as vector of transmission of GBS
2.1. GBS in breast milk
Few studies have identified presence of GBS in breast milk, and
methodological differences make comparisons difficult [28–32].
Low incidence is described in mothers of extremely preterm infants
of 0.4% [31] and term infants of 0.82%. Higher incidence in raw milk
ranged from 3.5% [30] to 10% [29] in donor breast milk. However,
the concurrent incidence of GBS colonization in these mothers and
the effect of intrapartum and postpartum antibiotic treatment were
unknown.
The variety of delivery, treatment and storage methods of breast
milk offers potential for GBS contamination. Human breast milk
may  contain 103 to 109 cfu/mL of GBS at any point, representing a
reservoir of potential infection for the neonatal gut [33]. Breast milk
directly from the mother (either through natural breast feeding or
as expressed breast milk) is given raw and is rarely cultured in cases
of neonatal infection. Expressed breast milk and bank milk may
be frozen, which affects immune components and bank milk may
also be pasteurized. Pasteurization is thought to eradicate impor-
tant viral and bacterial infections [34] but also depletes milk of the
majority of its cellular components and immunoglobulins [35] and
may  increase the bacterial growth rate [36].
Very recently, best practices on the use of breast milk in the
context of prevention of GBS neonatal disease have been proposed,
including the search for GBS in milk at the time of recurrent GBS
neonatal disease and in cases of mastitis in mothers of high-risk
preterm neonates admitted to neonatal intensive care units [37].
For these neonates, microbiological control of raw milk has also
been proposed in the absence of mastitis [37]. However, the best
strategy has yet to be developed as it does not appear that pasteur-
izing maternal milk changes the overall incidence of late onset GBS
disease in preterm infants [38]. In a recent review article of cases
of late onset GBS disease from breast milk, GBS was  found in 0–2%
of raw milk samples and 1.4% of pasteurized milk samples [9].
2.2. Proposed methods of acquisition
Two  main mechanisms of acquisition have been proposed: fol-
lowing colonization of the neonatal oropharynx at the time of
birth, mothers may  develop colonization of the milk ducts through
ascending infection from the neonate, due to the retrograde flow
of milk associated with suckling. The infant is then reinfected as
the concentration of bacteria increases in the breast milk [39]. This
may  occur with or without mastitis depending on additional fac-
tors such as milk stasis and bacterial load [40]. In most of the case
reports of GBS disease associated with breast milk there is no sign
of maternal mastitis, indicating silent maternal duct colonization
[9]. However, recent studies in animal models and discovery of
lactobacilli in breast milk after oral administration suggest that
bacteria from the maternal digestive tract may also colonize the
breast. [41] It has also been suggested that lactic acid bacteria may
transfer from the mother’s gut to breast milk and through the milk
to the infant’s digestive tract [42]. The epidemiological relationship
between neonatal and maternal derived GBS isolates in breast milk
has been confirmed by polymerase chain reaction (PCR) [43]. How-
ever, it is not clear whether the LO disease relates to infected breast
milk or is a result of gut translocation from an already colonized
infant.
GBS may  infect the submucosa of the gastrointestinal tract
either through a defect in the epithelial cell layer, or by concomitant
infectious agents [33]. As neonatal gastric acid secretion is reduced,
more bacteria may  reach the intestinal mucosa. This is supported
by findings that preterm infants fed with contaminated maternal
milk via nasogastric tube have developed GBS disease [44].
3. Breast milk as vehicle of protection from GBS infection
3.1. Innate and adaptive immune properties of breast milk
Breast milk is the main source of non-pathogenic bacteria to the
infant gastrointestinal tract. Intestinal bacteria are one of the most
important stimuli for the development of mucosa-associated lym-
phoid tissue (MALT) in the neonatal small intestine [45] and pro-
duce organic acids that prevent growth of enteric pathogens. Addi-
tionally, breast milk and colostrum contain many components with
antimicrobial and immunomodulatory properties that are believed
to impair translocation of infectious pathogens [46]. Some of these
substances compensate directly for deficiencies in the neonatal
immune system and enhance survival of defense agents, including
secretory IgA (SIgA), lactoferrin, lysozyme, IFN-!; some adapt the
gastrointestinal tract to extrauterine life, i.e. epidermal growth fac-
tor [47]; some prevent inflammation or enhance specific-antibody
production, such as PAF-acetylhydrolase, antioxidants, interleukins
1, 6, 8, and 10, transforming growth factor (TGF), secretory leuko-
cyte protease inhibitors (SLPI), and defensin 1 [46]. Breast milk also
contains substantial amounts of intracellular adhesion molecule
1 and vascular adhesion molecule 1; low quantities of soluble
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S-selectin, l-selectin and CD14, which may  mediate differentia-
tion and growth of B cells [46]. Natural autoantibodies, thought to
be important in the selection of the pre-immune B cell repertoire
and in the development of immune tolerance, are also detected in
colostrum and in breast milk [48]. Recently, the beneficial effects of
human oligosaccharides in prevention of neonatal diarrhoeal and
respiratory tract infections have been highlighted [49,50].
Human breast milk is known to contain factors that can modu-
late toll-like receptor (TLR) signaling, including soluble TLR2, which
can competitively inhibit signaling through membrane TLR2 [51],
as well as a protein that inhibits TLR2-mediated and activates TLR4-
mediated transcriptional responses in human intestinal epithelial
and mononuclear cells by an as-yet-unknown mechanism [52]. It
has been speculated that reduced TLR2 responsiveness at birth may
facilitate the normal establishment of beneficial Gram-positive bifi-
dobacteria intestinal flora. Lipids present in human milk have been
shown to inactivate GBS in vitro, providing additional benefit to
protect from invasive infection at the mucosal surfaces [53].
4. Antibody in breast milk
Neonates have low levels of SIgA and SIgM [54] thus protection
from invasive pathogens at the mucosal surface relies on antibod-
ies in breast milk. As antibody in breast milk is produced following
antigenic stimulation of the maternal MALT and bronchial tree
(bronchomammary pathway) [55], these antibodies are targeted
to many infectious agents encountered by the mother both prior to
birth and during the breastfeeding period.
It is currently hypothesized that SIgA represents the crucial
primary protective component of breast milk [56,57]. SIgA pro-
tects against mucosal pathogens by immobilizing these, preventing
their adherence to epithelial surfaces, or by neutralizing toxins
or virulence factors. SIgA concentration is far higher in colostrum
(12 mg/ml) than in that found in mature milk (1 mg/ml). A breastfed
infant may  ingest around 0.5–1.0 g of SIgA per day [40].
5. The role of SIgA in breast milk
SIgA production is enhanced by Interleukin-6 (IL-6) whilst the
production of secretory components is enhanced by TNF-! and
TGF-" causes class switching towards B cells producing IgA [47],
all of which are present in breast milk.
SIgA antibodies present in breast milk are specific for numerous
enteric and respiratory pathogens. In studies from resource-poor
countries, breast milk-mediated protection against infections with
Vibrio cholerae, Campylobacter,  Shigella, Giardia lamblia and respira-
tory tract infections was significantly related to the content of SIgA
antibody in breast milk against these pathogens [58–60]. This could
support the hypothesis that similar protection could be obtained
from SIgA antibody in breast milk to GBS in a highly breastfed
population. However, maternal SIgA does not appear to enter the
neonatal circulation, [61] except in preterm infants, where inges-
tion of milk rich in IgA to respiratory syncytial virus (RSV) resulted
in increased serum IgA levels during the perinatal period [62], so
its effectiveness is limited to the mucosal surface.
SIgA is more resistant to proteolysis than other immunoglobu-
lins and is therefore able to function in the gastrointestinal tract
[46]. This could account for the finding that the faeces of breast fed
infants contains IgA by the second day of life, compared to 30% of
formula-fed infants, where IgA is only found in faeces by one month
of age [63].
Breast milk contains SIgA antibodies against bacterial-adhesion-
site-like pili [46,64]. SIgA antibody in milk blocks adherence of S.
pneumoniae and Haemophilus influenza to human retropharyngeal
cells [64] and casein in vitro [65]. The neutralizing capacity of milk
anti-poliovirus antibodies has also been reported [66,67].
The effect of third trimester maternal immunization with a sin-
gle dose of licensed quadrivalent meningococcal vaccine on the
potential protection of infants, including by breast milk demon-
strated elevated N. meningitidis-specific IgA antibodies in breast
milk up to six months post partum in vaccinated infants [68].
Similarly, in mothers who received pneumococcal polysaccharide
vaccine (PSV) during the third trimester, the geometric mean con-
centration of IgA in breast milk was significantly higher two months
postpartum than in women  who received conjugate H. influenzae
vaccine in the third trimester and remained higher at seven months
post partum. [69]
6. Group B Streptococcal antibody in breast milk
As described above, high levels of breast milk SIgA could
offer protection to neonates via interference of antibody with
the carbohydrate-mediated attachment of GBS to nasopharyngeal
epithelial cells. Through this mechanism, colonizing organism load
may  be reduced with a consequent reduction in morbidity and
mortality caused by GBS in the neonatal period [70].
In transition milk, low or moderate IgA antibodies to CPS type III
GBS, were detected in approximately 63% of a cohort of 70 Swedish
women [71]. In a study of IgG antibody concentration in transition
milk in 46 women  from the USA, Weisman and Dobson [70] found
concentrations of IgG to types Ia, II or III which were approximately
10% of those in maternal serum. Edwards et al. measured IgG and
IgA in breast milk to type III GBS in 18 women with high and low
antibody titers and found measurable levels of antibody in both
groups up to 2 months post-delivery [72]. Detectable levels of CPS
serotype III antibody in breast milk in women  correlated with con-
currently high levels in their serum. Whilst no studies demonstrate
a correlation between GBS-antibody levels in breast milk and infant
colonization, Berardi et al. report that GBS-positive breast milk is
associated with heavy infant colonization [73].
To determine the effect of maternal immunization with GBS
CPS-II and CPS-III antibody on postnatal protection from disease
a rodent model has been used, where increased survival in pups
exposed postnatally to breast milk with high titers of antibody
compared to low titers was  shown, supporting the beneficial added
effect of breast milk antibody following vaccination [74,75].
7. Human oligosaccharides
Oligosaccharides prevent cell adherence for S. pneumoniae [76]
and Escherichia coli (E. coli) [77]. Additionally, E. coli and Campy-
lobacter jejuni toxin can be neutralized by oligosaccharides [49,78]
and milk glycoconjugates prevent cell adherence of Vibrio cholera
and E. coli [79,80]. Taken together, these studies suggest that the
transfer of human milk oligosaccharides delivers real protection to
infants against many bacterial and viral infections.
GBS type Ib and II polysaccharides are of interest as they are vir-
tually identical to certain oligosaccharides present in human milk
[75,81,82] which raises the possibility of cross-reactivity with other
human glycoconjugates [83]. The results from murine models sug-
gest that these oligosaccharides may  act as receptor analogues that
anchor the bacteria in the mucosal layer and prevent cell adhesion
in the epithelial layer, thus preventing invasive disease.
8. Conclusion
Most neonatal infections occur via mucosal membranes in
the respiratory, gastrointestinal, and urinary tracts, yet there is
only limited protection at these vast mucosal surfaces during the
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neonatal period. Breast milk provides considerable amounts of
specific SIgA antibodies that are produced as a result of microbial
and food antigens the mother has previously encountered. Such
SIgA antibodies from breast milk provide protection to the neonate
at the mucosal surface. Breast milk additionally contains high
concentrations of non-specific protective molecules, such as lacto-
ferrin that has bactericidal, viricidal, and fungicidal properties.
Milk oligosaccharides might block adherence of microorganism at
the mucosal surface by functioning as receptor analogues.
There is increasing data from recent publications that enhanced
protection against diarrhea, respiratory tract infections, otitis
media and H. influenzae infections, as well as wheezing illness
may  persist for years after breastfeeding. However, the role
of breast milk antibody in protection from neonatal GBS dis-
ease remains poorly understood. Current research is evaluating
transport, persistence and function of GBS antibodies and other
immune-constituents in breast milk. These studies aim to identify
protective factors involved in the passive transfer of immune com-
ponents in breast milk and associated protection from colonization
and infant disease. Additionally, research correlating neonatal col-
onization with antibody levels in breast milk would provide insight
into possibly protective factors from disease.
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Streptococcus  agalactiae  (group  B streptococcus  (GBS)),  remains  the  leading  cause  of neonatal  sepsis  and
meningitis  in many  countries  and an  important  cause  of  disease  in  pregnant  women,  immunocompro-
mised  adults  and  the  elderly.  Intrapartum  antibiotic  strategies  have  reduced  the incidence  of  early-onset
neonatal  GBS  where  applied,  but  have  had no  impact  on  late onset  GBS  infection  and  only  a  limited  impact
on disease  in  pregnant  women.  In low/middle  income  settings,  the  disease  burden  remains  uncertain
although  in  several  countries  of Southern  Africa  appears  comparable  to  that  of  high-income  countries.
Disease  may  be rapidly  fulminating  and  cases  therefore  missed  before  appropriate  samples  are  obtained.
This  may  lead  to  significant  underestimation  of  the  true  burden  and  be a particular  issue  in  many  African
and  Asian  countries;  comprehensive  epidemiological  data from  such  countries  are  urgently  required.
The  available  data  suggest  that  the  serotype  distribution  of  GBS  isolates  is  similar  in Africa,  Western
Pacific,  Europe,  the  Americas  and  the  Eastern  Mediterranean  regions  and  has  not  changed  over the  past
30 years.  Five  serotypes  (Ia, Ib,  II, III,  V) account  for the  majority  of  disease;  conjugate  vaccines  including
some  or all  of these  serotypes  therefore  hold  great  promise  for  preventing  this  important  disease.
© 2013 Elsevier Ltd. All rights reserved.
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1. Historical trends
Streptococcus agalactiae (Lancefield group B streptococcus; GBS)
was first described as a cause of bovine mastitis by Nocard and
Mollereau in 1887 [1]. Lancefield and Hare subsequently identified
GBS in vaginal swabs in 1935 [2] and in 1938 Fry described three
fatal cases in post-partum women. This was notable because all
∗ Corresponding author at: Vaccine Institute and Paediatric Infectious Diseases
Research Group, St George’s, University of London, London SW17 0RE, UK.
Tel.:  +44 20 87255980.
E-mail address: pheath@sgul.ac.uk (P.T. Heath).
previous severe streptococcal infections in that setting had been
attributed to group A streptococcus [3]. Reports of neonatal disease
from GBS were sporadic until the early 1960s when GBS became
recognized as a leading cause of early neonatal sepsis in the USA
[4,5]. By the 1970s it had become the dominant pathogen in the
early neonatal period [6,7]. A similar (but slightly later) time trend
was noted for GBS meningitis in the UK [8]. By the early 1980s
GBS had become the most common cause of neonatal sepsis and
meningitis in a number of developed countries [9–11].
Human isolates of GBS express a capsular polysaccharide (CPS),
a major virulence factor that helps the microorganism evade host
defense mechanisms [4]. Isolates of GBS can be divided into ten CPS
serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII, IX) each antigenically and
0264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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structurally unique. In 1974, Baker and Barrett demonstrated that
whilst all GBS serotypes were capable of causing neonatal infection,
type III isolates were significantly increased amongst infants with
GBS meningitis [12].
Bisharat et al.’s work on GBS multilocus sequence typing (MLST)
using a global collection of isolates demonstrated that capsular
serotype does not strictly follow sequence type (ST) and that a sin-
gle, bovine-derived ST (ST-17), appears to be overrepresented in
neonatal disease [13]. Further work from the USA [14] and the UK
[15] determined that ST-17 in types II and III GBS are closely related
to ancestral bovine isolates. This sequence type appears to be asso-
ciated with neonatal disease, irrespective of the capsular serotype,
but not with adult disease [15].
2. Infants
2.1. Early and Late onset infections
GBS disease is not restricted to newborns, but its greatest
impact, both in terms of severity and incidence, is in the neona-
tal period and up to the first 90 days of life. Early onset (EO) GBS
disease is usually defined as infection presenting in the first six days
of life and accounts for approximately 60–70% of all GBS disease.
GBS serotypes Ia, II, III and V are responsible for most EO disease
[16–18]. Maternal carriage of GBS in the gastrointestinal and/or
genital tracts is a pre-requisite for EO disease, vertical transmis-
sion occurring during or just prior to birth. In developed countries
an estimated 20–30% of pregnant women are colonized with GBS
[19,20], approximately 50% of their babies become colonized and
1% progress to develop invasive disease. Disease may  occur rapidly;
signs are evident at birth or within 12 h in over 90% of cases (98%
within the first 12 h) and presentation is typically with pneumonia
or sepsis [21].
In contrast, late-onset (LO) disease is caused predominantly by
serotype III, is acquired perinatally, nosocomially or from commu-
nity sources, and in up to 50% of cases presents with meningitis
[16,21–23]. Cases occurring later in infancy than 90 days are also
described, but rare, and generally associated with extreme prema-
turity [24–28].
2.2. The burden of infant GBS disease – high income countries
The burden of GBS disease can be defined in terms of its
incidence, morbidity and mortality. Multistate, population-based,
active surveillance in the USA in 1990 identified an EO disease rate
of 1.4 per 1000 live births and a LO rate of 0.4 per 1000 births [26].
This equated to 7600 cases and 310 deaths per year in the USA.
Both EO and LOGBS disease occurred at significantly higher rates
amongst African-American compared to Caucasian infants, as well
as amongst low-birthweight or preterm infants [26,27].
In the UK, a multi-center study carried out between 1977 and
1978 recorded an incidence of invasive GBS disease in infants < 2
months of age of 0.3 cases per 1000 live births [29]. Through the
late 1990s studies from different centers in England reported inci-
dence figures ranging from 0.6 to 1.2 cases per 1000 live births
[30–32]. In 2000–2001, national surveillance was  enhanced; the
overall incidence was 0.72 per 1000 live births (95% confidence
interval 0.66–0.78), 0.47 per 1000 (0.42–0.52) for EO disease and
0.25 per 1000 (0.21–0.28) for LO disease [21]. Regional variation
was marked; the incidence in Scotland was 0.42 per 1000 whilst
in Northern Ireland it was 0.9 per 1000 live births. As with other
studies, infants of low birthweight (<1500 g) were shown to have
the highest rates of GBS disease [21].
National population-based surveillance studies have defined
the incidence <3 months of age in a number of developed
countries including Portugal (2001–2005, 0.54/1000) [11], Finland
(1985–1994, 0.76/1000) [10] and Germany (2001–2003, 0.47/1000)
[9]. Hospital based surveillance studies (which may  be biased
towards higher risk pregnancies) have generally yielded higher
incidences such as in Australasia (EOGBS (<48 h of age): 2/1000 in
1991–1993, 1.3/1000 in 1993–1995, 0.5/1000 in 1995–1997) [33]
and Spain (EOGBS (<3 days of age): 1.1/1000, 1996–1997; 0.7/1000,
2000–2001) [34]. Edmonds et al. recently conducted a systematic
review to define the current global incidence of GBS disease in
infants under 3 months [35]. The analysis was confined to data
since the year 2000 and estimated an overall incidence of 0.53
(0.44–0.62) in the European region, 0.67 (range 0.54–0.80) in the
Americas and 0.15 (range −0.03 to 0.07) in Australasia. IAP was fre-
quent in developed countries and associated with lower incidence
figures; those countries reporting no use of IAP had a 2.2-fold higher
incidence of EOGBS compared with those reporting any use.
GBS disease is also associated with significant morbidity and
mortality. GBS meningitis, in particular, results in long term
neurodevelopmental impairment. Bedford et al. described 5-year
neurodevelopmental outcomes following an acute episode of
neonatal meningitis in 98 children, of whom 13% had severe, 17%
moderate and 18% mild disability at 5 years. Overall 50% of those
with GBS meningitis had neurodevelopmental impairment at 5
years of age [36]. A recent small series from the USA has shown sim-
ilar rates of sequalae (up to 44% with moderate–severe impairment)
[37].
Case fatality rates for GBS disease are estimated at between 9%
in Oxford (1990–1996) [30] and 15% in London (1990–1999) [38],
with a UK national figure of 10% in 2000–2001 [21]. In the USA
between 1993 and 1998 the quoted case fatality rates for EO and
LO disease were 4.7% and 2.8% respectively [39]. Case fatality rates
were significantly higher in premature infants (<33 weeks gesta-
tion) 15.2% vs. 6.4% for term infants (>37 weeks gestation), relative
risk of 6.7 in EOGBS (21, 39). Other national studies have revealed
case fatality rates of 6.6% in Portugal [11], 4.3% in Germany [9] and
8% in Finland [10]. Overall current case fatality rates by region as
estimated in the Edmond meta-analysis are 0.07 (range 0.04–0.1)
in Europe and 0.11 (0.06–0.16) in the Americas [35].
2.3. Risk factors
Numerous maternal, obstetric and neonatal factors have been
associated with or identified as risk factors for maternal GBS col-
onization, transmission of GBS from mother to baby, neonatal
GBS colonization or neonatal disease with GBS (both EO and LO).
Although some of these have provided useful insights into the
pathophysiology of perinatal GBS disease, many of them are inter-
related, studies have produced contradictory results and relatively
few factors are sufficiently robust or clinically relevant enough to
guide prevention strategies.
The gastrointestinal tract is the primary reservoir of GBS and
the source of vaginal colonization in women. Local hygiene or sex-
ual practices can increase the risk for vaginal colonization. Other
factors associated with maternal colonization include ethnicity
(women of Black race), use of tampons or intrauterine devices, obe-
sity, absence of lactobacilli in the gastrointestinal flora and preterm
delivery [40–42]. GBS bacteriuria during pregnancy is associated
with heavy colonization, a further risk factor for perinatal trans-
mission [43,44]. Mothers with GBS bacteriuria demonstrate a
higher incidence of adverse obstetric outcomes: habitual abortion,
intrauterine growth restriction, preterm labour, chorioamnionitis
and premature rupture of membranes [43].
Factors associated with an increased risk of neonatal coloniza-
tion include maternal colonization, male sex, Black race, prolonged
rupture of membranes, prematurity, low levels of maternal anti-
GBS antibodies and intrapartum fever. In one analysis, infants born
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to GBS-colonized women had a 29-fold increased risk for EO disease
compared to infants born to women who were not colonized [45].
In one case control study, prematurity (odds ratio 10.4, 95% confi-
dence interval 3.9–27.6), rupture of the membranes more than 18 h
before delivery (25.8, 10.2–64.8), rupture of the membranes before
the onset of labour (11.1, 4.8–25.9), and intrapartum fever (10.0,
2.4–40.8) were all significant risk factors for EOGBS [46]. Infants
born to mothers less than 20 years of age or of Black/Hispanic race
[27], with heavy genital GBS colonization [47], low levels of anti-
GBS capsular antibodies [48] or with a previous infant with EOGBS
disease [49] are all associated with a higher risk of EO disease.
Risk factors for LO disease are less well documented. Male sex,
Black race, maternal colonization and having a twin with LO dis-
ease are all associated with an increased risk for LOGBS disease
[22,27,28,50,51]. LO disease has been noted in children born to HIV-
infected mothers [52]. More recently it has become clear that the
major risk factor for LO disease is extreme prematurity [25–28].
2.4. Intrapartum antibiotics (IAP)
National strategies for targeting pregnant women  for IAP
include either risk-based [53] or screening based strategies
[54–56]. Following the publication of recommendations for both
risk-based and screening-based approaches, the incidence of
EOGBS disease in the USA decreased by almost 70% between 1996
and 1998 [39]. Death certificate analysis also documented a steeper
decline in EO deaths temporally associated with prevention imple-
mentation, without similarly steep declines in other causes of
deaths including LO deaths [57]. In an attempt to assess the relative
effectiveness of the two  strategies the CDC conducted a retrospec-
tive cohort study [58]. Adjusting for confounders, women who were
screened for GBS prenatally had a 50% reduced risk of delivering a
baby with GBS disease than did those exposed to the risk-based
strategy. In one study from the USA between 2002 and 2010 the
incidence of EO disease declined from 3.5 to 2.6 per 1000 admis-
sions, whilst LO disease has increased from 0.8 to 1.1 per 1000
admissions [59].
However, even strict and universal implementation of guide-
lines does not eliminate EOGBS disease; it can occur despite
administration of IAP, in infants of mothers who were negative on
screening, and where no risk factors are evident in labour [60–62].
In 2005 it was estimated that 1425 cases of EOGBS occurred in the
USA despite widespread use of IAP [63,64]. Most significantly, IAP
has no impact on LOGBS infection where the burden of disease is
substantial [64]. The majority of GBS meningitis occurs after the
first week of life so this particular burden remains; in the USA GBS
is now the most common cause of bacterial meningitis in children
less than 5 years of age [63].
2.5. Low and middle income countries
Although the epidemiology of GBS in the developed world is
well documented, its contribution to the burden of neonatal infec-
tion in low/middle income countries has proved more difficult to
assess. GBS has been reported as the predominant cause of neonatal
sepsis in southern Africa and Kenya [65–67] as well as an impor-
tant cause of meningitis in Malawi and Kenya, but Asian studies
have reported a much lower incidence [68–70]. In contrast, colo-
nization studies from these countries have reported only limited
variation in maternal GBS colonization rates, similar to those of
high income countries (Middle East/North Africa, 22%; Asia/Pacific,
19%; Sub-Saharan Africa, 19%; India/Pakistan, 12%; and Americas,
14%) [71].
Two systematic reviews of GBS incidence have attempted to
shed some light on this. Edmonds et al. showed that studies repor-
ting use of any IAP had a lower incidence of EO disease, but found
only one study from a middle-income country (South Africa) that
reported IAP use and no low-income countries reported IAP use.
Only 7 low-income countries reported data on GBS disease inci-
dence, only 3 for EOGBS disease (Kenya, Bangladesh, Malawi). The
mean incidence of EO disease was 0.43 (95% CI 0.37–0.49). Inci-
dence was highest in studies from Africa (0.53, 95% CI 0.15–0.92])
whilst studies from Southeast Asia reported the lowest incidence
(0.11, 95% CI 0.012–0.220). The incidence of LO disease was again
highest in Africa (0.71, 95% CI 0.38–1.04). The case fatality ratio
was three times higher in low-income countries (12.6%, 95% CI
10.8–14.9) than in high-income countries (4.6%, 2.1–9.1) [35].
Similar findings were reported by Dagnew et al., who  conducted
a systematic review and meta-analysis of GBS  disease focusing
on low and middle-income settings. They reported that the over-
all incidence of GBS in resource-poor settings ranged between 0
and 3.06 per 1000 live births [72]. Differences in incidence were
observed both between and within geographic regions. Variation
was greatest across sub-Saharan Africa, with studies from Nigeria
and the Gambia reporting lower incidence rates (0–0.17 per 1000
live births [73,74]) than studies from southern Africa (1.80–3.06 per
1000 live births [75,76]). Variation was evident across studies from
Latin America (0.39–1.15 per 1000 live births [77,78]), whereas
studies from Asia and the Middle East reported a lower GBS inci-
dence (0–0.26 per 1000 live births [68–70,79–83]). Reported case
fatality rates (median, 20%; range, 10–60%) also varied within and
between geographic regions [72].
Potential explanations for the variations highlighted in these
reviews include fundamental differences in disease epidemiology
due to differences in maternal GBS colonization, differences in
strain virulence [84], maternal and infant anti-GBS antibody levels
[74] or genetic susceptibilities. However, under-identification and
under-reporting of cases and deaths appears very likely in some
study settings, especially where it is difficult to access healthcare.
A substantial proportion of births in sub-Saharan Africa (42–65%),
India (53%) and Bangladesh (85%) for example, occur outside health
institutions. In contrast, South Africa, which reports one of the high-
est incidences, also has a high proportion of hospital-based births
(89%) [35]. Darmstadt et al. attempted to increase case ascertain-
ment by capturing births in the community. Of 919 community
assessments that resulted in a hospital referral only 54% complied
within two days and compliance was lower in infants aged 0–6
days. Of 259 neonatal deaths, 62% were never assessed by a health
worker and 59% occurred within the 1st two  days of life, consistent
with the time period of greatest risk for the development of GBS
sepsis [68].
Differences in microbiological and sampling techniques may
also contribute to differences in reported incidences [85]. Edmond
et al. searched articles for relevant indicators of this, such as the
proportion of specimens collected on the first day of illness or on
the day of birth or care-seeking and referral on day one of life, but
no data were available. Further, they sought to quantify labora-
tory techniques by searching for information on specimen volume,
transport conditions and culture techniques, but data were dis-
parate and could not be pooled [35]. Dagnew et al. also examined
methods of GBS sample isolation and identification. Thirteen stud-
ies, including all studies from South and Southeast Asia and the
Middle East used manual culture methods to isolate and identify
GBS and seven used automated methods (BACTEC system). GBS
incidence rates were shown to be higher amongst studies using
automated culture methods: 0.80–3.06 vs. 0–0.39/1000, suggesting
this as a further explanation [72].
2.6. GBS serotypes
In the USA and Europe, invasive GBS-serotypes are predomi-
nantly Ia, Ib, II, III and V [48,86–88] whilst a Gambian study reported
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to GBS-colonized women had a 29-fold increased risk for EO disease
compared to infants born to women who were not colonized [45].
In one case control study, prematurity (odds ratio 10.4, 95% confi-
dence interval 3.9–27.6), rupture of the membranes more than 18 h
before delivery (25.8, 10.2–64.8), rupture of the membranes before
the onset of labour (11.1, 4.8–25.9), and intrapartum fever (10.0,
2.4–40.8) were all significant risk factors for EOGBS [46]. Infants
born to mothers less than 20 years of age or of Black/Hispanic race
[27], with heavy genital GBS colonization [47], low levels of anti-
GBS capsular antibodies [48] or with a previous infant with EOGBS
disease [49] are all associated with a higher risk of EO disease.
Risk factors for LO disease are less well documented. Male sex,
Black race, maternal colonization and having a twin with LO dis-
ease are all associated with an increased risk for LOGBS disease
[22,27,28,50,51]. LO disease has been noted in children born to HIV-
infected mothers [52]. More recently it has become clear that the
major risk factor for LO disease is extreme prematurity [25–28].
2.4. Intrapartum antibiotics (IAP)
National strategies for targeting pregnant women  for IAP
include either risk-based [53] or screening based strategies
[54–56]. Following the publication of recommendations for both
risk-based and screening-based approaches, the incidence of
EOGBS disease in the USA decreased by almost 70% between 1996
and 1998 [39]. Death certificate analysis also documented a steeper
decline in EO deaths temporally associated with prevention imple-
mentation, without similarly steep declines in other causes of
deaths including LO deaths [57]. In an attempt to assess the relative
effectiveness of the two  strategies the CDC conducted a retrospec-
tive cohort study [58]. Adjusting for confounders, women who were
screened for GBS prenatally had a 50% reduced risk of delivering a
baby with GBS disease than did those exposed to the risk-based
strategy. In one study from the USA between 2002 and 2010 the
incidence of EO disease declined from 3.5 to 2.6 per 1000 admis-
sions, whilst LO disease has increased from 0.8 to 1.1 per 1000
admissions [59].
However, even strict and universal implementation of guide-
lines does not eliminate EOGBS disease; it can occur despite
administration of IAP, in infants of mothers who were negative on
screening, and where no risk factors are evident in labour [60–62].
In 2005 it was estimated that 1425 cases of EOGBS occurred in the
USA despite widespread use of IAP [63,64]. Most significantly, IAP
has no impact on LOGBS infection where the burden of disease is
substantial [64]. The majority of GBS meningitis occurs after the
first week of life so this particular burden remains; in the USA GBS
is now the most common cause of bacterial meningitis in children
less than 5 years of age [63].
2.5. Low and middle income countries
Although the epidemiology of GBS in the developed world is
well documented, its contribution to the burden of neonatal infec-
tion in low/middle income countries has proved more difficult to
assess. GBS has been reported as the predominant cause of neonatal
sepsis in southern Africa and Kenya [65–67] as well as an impor-
tant cause of meningitis in Malawi and Kenya, but Asian studies
have reported a much lower incidence [68–70]. In contrast, colo-
nization studies from these countries have reported only limited
variation in maternal GBS colonization rates, similar to those of
high income countries (Middle East/North Africa, 22%; Asia/Pacific,
19%; Sub-Saharan Africa, 19%; India/Pakistan, 12%; and Americas,
14%) [71].
Two systematic reviews of GBS incidence have attempted to
shed some light on this. Edmonds et al. showed that studies repor-
ting use of any IAP had a lower incidence of EO disease, but found
only one study from a middle-income country (South Africa) that
reported IAP use and no low-income countries reported IAP use.
Only 7 low-income countries reported data on GBS disease inci-
dence, only 3 for EOGBS disease (Kenya, Bangladesh, Malawi). The
mean incidence of EO disease was 0.43 (95% CI 0.37–0.49). Inci-
dence was highest in studies from Africa (0.53, 95% CI 0.15–0.92])
whilst studies from Southeast Asia reported the lowest incidence
(0.11, 95% CI 0.012–0.220). The incidence of LO disease was again
highest in Africa (0.71, 95% CI 0.38–1.04). The case fatality ratio
was three times higher in low-income countries (12.6%, 95% CI
10.8–14.9) than in high-income countries (4.6%, 2.1–9.1) [35].
Similar findings were reported by Dagnew et al., who  conducted
a systematic review and meta-analysis of GBS  disease focusing
on low and middle-income settings. They reported that the over-
all incidence of GBS in resource-poor settings ranged between 0
and 3.06 per 1000 live births [72]. Differences in incidence were
observed both between and within geographic regions. Variation
was greatest across sub-Saharan Africa, with studies from Nigeria
and the Gambia reporting lower incidence rates (0–0.17 per 1000
live births [73,74]) than studies from southern Africa (1.80–3.06 per
1000 live births [75,76]). Variation was evident across studies from
Latin America (0.39–1.15 per 1000 live births [77,78]), whereas
studies from Asia and the Middle East reported a lower GBS inci-
dence (0–0.26 per 1000 live births [68–70,79–83]). Reported case
fatality rates (median, 20%; range, 10–60%) also varied within and
between geographic regions [72].
Potential explanations for the variations highlighted in these
reviews include fundamental differences in disease epidemiology
due to differences in maternal GBS colonization, differences in
strain virulence [84], maternal and infant anti-GBS antibody levels
[74] or genetic susceptibilities. However, under-identification and
under-reporting of cases and deaths appears very likely in some
study settings, especially where it is difficult to access healthcare.
A substantial proportion of births in sub-Saharan Africa (42–65%),
India (53%) and Bangladesh (85%) for example, occur outside health
institutions. In contrast, South Africa, which reports one of the high-
est incidences, also has a high proportion of hospital-based births
(89%) [35]. Darmstadt et al. attempted to increase case ascertain-
ment by capturing births in the community. Of 919 community
assessments that resulted in a hospital referral only 54% complied
within two days and compliance was lower in infants aged 0–6
days. Of 259 neonatal deaths, 62% were never assessed by a health
worker and 59% occurred within the 1st two  days of life, consistent
with the time period of greatest risk for the development of GBS
sepsis [68].
Differences in microbiological and sampling techniques may
also contribute to differences in reported incidences [85]. Edmond
et al. searched articles for relevant indicators of this, such as the
proportion of specimens collected on the first day of illness or on
the day of birth or care-seeking and referral on day one of life, but
no data were available. Further, they sought to quantify labora-
tory techniques by searching for information on specimen volume,
transport conditions and culture techniques, but data were dis-
parate and could not be pooled [35]. Dagnew et al. also examined
methods of GBS sample isolation and identification. Thirteen stud-
ies, including all studies from South and Southeast Asia and the
Middle East used manual culture methods to isolate and identify
GBS and seven used automated methods (BACTEC system). GBS
incidence rates were shown to be higher amongst studies using
automated culture methods: 0.80–3.06 vs. 0–0.39/1000, suggesting
this as a further explanation [72].
2.6. GBS serotypes
In the USA and Europe, invasive GBS-serotypes are predomi-
nantly Ia, Ib, II, III and V [48,86–88] whilst a Gambian study reported
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serotype-V predominance [84]. The recent global review of invasive
isolates showed that serotype III was the most frequently identi-
fied serotype in all regions with available data (48.9%), followed by
serotypes Ia (22.9%), V (9.1%), Ib (7.0%) and II (6.2%). There was lit-
tle change in ST distribution over the last 30 years [35]. There was
however, little data from low/middle income countries.
3. Pregnancy-associated GBS disease
The incidence of pregnancy-associated GBS disease in the USA
initially declined after the introduction of IAP strategies (0.29 per
1000 live births in 1993 vs. 0.11–0.14 per 1000 live births in 2005)
[87]. In a recent study the incidence was shown to be 0.02/1000
in non-pregnant women vs. 0.49/1000 (range 0.36–0.64) in post-
partum women [89]. This study highlighted that the majority of
pregnancy-associated disease actually occurred in the postpartum
period. The authors found that pregnant women had a relative
risk for GBS disease of 5.0 (95% CI, 2.9–8.7) compared with non-
pregnant women. The median age at onset was 28 years and half
of the cases were associated with infection of the upper genital
tract, placenta, or amniotic sac. Other manifestations included bac-
teremia without focus (31%), endometritis without foetal death
(8%), chorioamnionitis without foetal death (4%), pneumonia (2%),
and puerperal sepsis (2%). Amongst those for whom pregnancy out-
come was known (368/409, 90%), 61% had a spontaneous abortion
or stillborn infant, 30% had infants without apparent illness, 5% had
live-born infants who developed clinical infections, and 4% had
induced abortions. Most pregnancy-related cases (330/409, 81%)
occurred in the absence of additional underlying conditions; 79
occurred with at least one additional underlying condition or risk
factor including smoking, asthma, diabetes, obesity and alcohol or
drug abuse [89]. The serotypes causing maternal GBS appear to be
similar to those that cause EOGBS [90,91].
4. GBS in non-pregnant adults
Amongst adults, older age, black race, and underlying medical
conditions are associated with higher rates of invasive GBS dis-
ease [92–101]. Common presentations of GBS disease in adults
include skin and/or soft-tissue infection, bacteremia without focus,
pneumonia, and osteomyelitis; serious clinical syndromes, such
as meningitis and endocarditis are rare but are often associated
with considerable morbidity and mortality [93–97,100,101]. The
case fatality rate is markedly higher amongst adults than amongst
neonates [94–98,100]. In contrast to neonates and pregnant
women, disease incidence amongst non-pregnant adults increased
significantly in the USA between 1990 and 2007 [102]. Amongst
persons aged 15–64 years, incidence increased from 3.6 per 100 000
population in 1999 to 7.3 per 100 000 in 2007, a relative increase of
48% (95% CI, 32–65%); amongst those 65 years or older, incidence
increased from 21.5 per 100 000 to 26.0 per 100 000, a relative
increase of 20% (95% CI, 8–35%). These values translate to a 32% (95%
CI, 22–43%) increase in the overall incidence of adult disease, which
increased from 6.0 per 100 000 in 1999 to 7.9 per 100 000 in 2005.
The case-fatality rate decreased from 23.7% in 1990 to 7.5% in 2007
[102]. The proportion with known outcome that died was  highest
in the oldest age groups. Seasonal variability was evident, with dis-
tinct peaks occurring each year during the later summer months. In
contrast to pregnant women and neonates, in adult cases, serotype
V predominated, accounting for 31% of cases, followed by serotypes
Ia (24%), II (12%), and III (12%) [63]. Recently, however, a Portuguese
study found that serotype Ia was responsible for the majority of
invasive infections in all age groups [103].
The underlying medical conditions associated with invasive GBS
disease in non-pregnant adults include diabetes mellitus (41%),
heart disease (36%), and malignancy (17%). In one series, nearly
88% of adult cases had at least 1 underlying condition [100]. In
the USA between 1998 and 2007, the proportion of patients with
underlying diabetes increased significantly (from 36.5% to 44.4%),
although the proportion of patients with cancer, heart failure, and
atherosclerotic cardiovascular disease remained relatively stable
[101].
5. Discussion
GBS is the leading cause of neonatal sepsis and meningitis in
developed countries. It is also a recognized and increasing cause
of disease in adults in such countries, especially pregnant women,
the elderly and the immunocompromised. In resource-poor sett-
ings, however, the neonatal burden is less clear, although in some
countries may  be higher than in developed countries. The disease is
often rapidly fulminating and many cases may  be missed because
of difficulties with obtaining samples before babies die. This issue
is especially important in African and Asian countries. A failure to
diagnose cases in the community, sick babies that then fail to reach
healthcare facilities, inadequate culture methods, and widespread
antibiotic usage may  all lead to an underestimation of the GBS
burden. More high-quality studies are urgently needed in these
settings.
Comprehensive data on disease burden will enable appropri-
ate preventative strategies to be devised and implemented. GBS
vaccines in particular, hold great promise as they have the poten-
tial to prevent all neonatal GBS disease, early and late onset, to
avoid the issues around screening and intrapartum antibiotic use
and are likely to be the most cost effective approach of all. Available
data suggest that a conjugate vaccine incorporating five serotypes
may  prevent over 85% of global GBS disease in infants under three
months. Vaccine development is eagerly awaited.
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